

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number  
**WO 2005/019258 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/47** (74) Agent: CARPENTER, David A.; MS 49, 1 DNA Way, South San Francisco, CA 94080 (US).
- (21) International Application Number: PCT/US2004/025788 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 10 August 2004 (10.08.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/493,546 11 August 2003 (11.08.2003) US
- (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, Ca 94080-4990 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ABBAS, Alexander [US/US]; 6087 Ocean View Drive, Oakland, Ca 94618-1844 (US). CLARK, Hilary [US/US]; 1504 Noe St., San Francisco, Ca 94131 (US). OUYANG, Wenjun [CN/US]; 1057 Galley Lane, Foster City, CA 94404 (US). WILLIAMS, P. Mickey [US/US]; 509 Alto Avenue, Half Moon Bay, CA 94019 (US). WOOD, William L. [US/US]; 15060 Montebello Rd., Cupertino, CA 95014 (US). WU, Thomas D. [US/US]; 41 Nevada Street, San Francisco, CA 94110 (US).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GIL, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/019258 A2

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

(57) Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

WO 2005/019258

PCT/US2004/025788

**COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES**PRIORITY

5           This application claims priority to U.S. Provisional Application No.: 60/493,546 filed August 11, 2003, to which U.S. Provisional Applications claim priority under 35 U.S.C. §119, the entire disclosure of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

10           The present invention relates to compositions and methods useful for the diagnosis and treatment of immune related diseases.

BACKGROUND OF THE INVENTION

15           Immune related and inflammatory diseases are the manifestation or consequence of fairly complex, often multiple interconnected biological pathways which in normal physiology are critical to respond to insult or injury, initiate repair from insult or injury, and mount innate and acquired defense against foreign organisms. Disease or pathology occurs when these normal physiological pathways cause additional insult or injury either as directly related to the intensity of the response, as a consequence of abnormal regulation or excessive stimulation, as a reaction to self, or as a combination of these.

20           Though the genesis of these diseases often involves multistep pathways and often multiple different biological systems/pathways, intervention at critical points in one or more of these pathways can have an ameliorative or therapeutic effect. Therapeutic intervention can occur by either antagonism of a detrimental process/pathway or stimulation of a beneficial process/pathway.

25           Many immune related diseases are known and have been extensively studied. Such diseases include immune-mediated inflammatory diseases, non-immune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, *etc.*

30           T lymphocytes (T cells) are an important component of a mammalian immune response. T cells recognize antigens which are associated with a self-molecule encoded by genes within the major histocompatibility complex (MHC). The antigen may be displayed together with MHC molecules on the surface of antigen presenting cells, virus infected cells, cancer cells, grafts, *etc.* The T cell system eliminates these altered cells which pose a health threat to the host mammal. T cells include helper T cells and cytotoxic T cells. Helper T cells proliferate extensively following recognition of an antigen-MHC complex on an antigen presenting cell. Helper T cells also secrete a variety of cytokines, *i.e.*, lymphokines, which play a central role in the activation of B cells, cytotoxic T cells and a variety of other cells which participate  
35           in the immune response.

          CD4 T helper cells play central role in regulating immune system. Under different pathogenic challenges, naive CD4 T cells can differentiate to two different subsets. T helper 1 (Th1) cells produce IFN-gamma, TNF-alpha and LT. Th1 cells and cytokines they produced are important for cellular immunity and critical for clearance of intracellular pathogen invasions. IFN-gamma produced by Th1 cells also helps  
40           antibody isotype switch to IgG2a, while the cytokines produced by Th1 cells activate macrophages and

WO 2005/019258

PCT/US2004/025788

promote CTL reaction. In contrast, T helper 2 (Th2) CD4 cells mainly mediate humoral immunity. Th2 cells secrete IL-4, IL-5, IL-6, and IL-13. These cytokines play central in role in promotion of eosinophil development and mast cell activation. Th2 cells also help in B cell development antibody isotype switching to IgE and IgA. Th2 cells and their cytokines are critical for helminthes clearance.

5 Although Th1 and Th2 cells are necessary for the immune system to fight with various pathogenic invasion, unregulated Th1 and Th2 differentiation could play a role in autoimmune diseases. For example, uncontrolled Th2 differentiation has been demonstrated to be involved in immediate hypersensitivity, allergic reaction and asthma. Th1 cells have been shown to present in diabetes, MS, psoriasis, and lupus. Currently, IL-12 and IL-4 have been identified to be the key cytokines initiating the development of the Th1  
10 and Th2 cells, respectively. Upon binding to its receptor, IL-12 activates Stat4, which then forms a homodimer, migrates into the nucleus and initiates down stream transcription events for Th1 development. IL-4 activates a different Stat molecule, Stat6, which induces transcription factor GATA3 expression. GATA-3 will then promote downstream differentiation of Th2 cells. The differentiation of Th1 and Th2 cells are a dynamic process, at each stage, there are different molecular events happening and different gene  
15 expression profiles. For example, at the early stage naive T cells are sensitive to environment stimuli, such as cytokines and costimulatory signals. If they receive the Th2 priming signal, they will quickly shut down the expression of the IL-12 receptor b2 chain expression and block further Th1 development. However, at the late stage of Th1 development, applying Th2 differentiation cytokines will fail to switch cells to a Th2 type. In this experiment, we mapped the gene expression profiles during the whole process of Th1 and Th2  
20 development. We isolated naive CD4 T cells from normal human donors. Th1 cells were generated by stimulation of T cells with anti-CD3 and CD-28 plus IL-12, and anti-IL-4 antibody. Th2 cells were generated by similar TCR stimulation plus IL-4, anti-IL12, and anti-IFN-g antibodies. The undifferentiated T cells were generated by TCR stimulation, and neutralizing antibodies for IL-12, IL-4 and IFN-gamma. T cells were expanded on day 3 of primary activation with 5 volumes of fresh media. The fully differentiated  
25 Th1 and Th2 cells were then restimulated by anti-CD3 and anti-CD28. RNA was purified at different stages of T cell development, and RNA isolated for gene chip based expression analysis. Comparing gene expression profiles enabled us to identified genes preferentially expressed in Th1 or Th2 cell at different stages. These genes could play very important roles in the initiation of Th1/Th2 differentiation, maintenance of Th1/Th2 phenotype, activation of Th1/Th2 cells, and effector functions, such as cytokine production, of  
30 Th1/Th2 cells. These genes could also serve as molecular markers to identify and target specific Th1 and Th2 subsets. Thus, these genes are potential therapeutic targets for many autoimmune diseases.

Autoimmune related diseases could be treated by suppressing the immune response. Using neutralizing antibodies that inhibit molecules having immune stimulatory activity would be beneficial in the treatment of immune-mediated and inflammatory diseases. Molecules which inhibit the immune response  
35 can be utilized (proteins directly or via the use of antibody agonists) to inhibit the immune response and thus ameliorate immune related disease.

Despite the above identified advances in T cell research, there is a great need for additional diagnostic and therapeutic agents capable of detecting the presence of a T cell mediated disorders in a mammal and for effectively reducing these disorders. Accordingly, it is an objective of the present invention  
40 to identify polypeptides that are overexpressed in activated T cells as compared to resting T cells, and to use

**WO 2005/019258****PCT/US2004/025788**

those polypeptides, and their encoding nucleic acids, to produce compositions of matter useful in the therapeutic treatment and diagnostic detection of T cell mediated disorders in mammals.



WO 2005/019258

PCT/US2004/025788

# SUMMARY OF THE INVENTION

## A. Embodiments

The present invention concerns compositions and methods useful for the diagnosis and treatment of immune related disease in mammals, including humans. The present invention is based on the identification of proteins (including agonist and antagonist antibodies) which are a result of stimulation of the immune response in mammals. Immune related diseases can be treated by suppressing or enhancing the immune response. Molecules that enhance the immune response stimulate or potentiate the immune response to an antigen. Molecules which stimulate the immune response can be used therapeutically where enhancement of the immune response would be beneficial. Alternatively, molecules that suppress the immune response attenuate or reduce the immune response to an antigen (*e.g.*, neutralizing antibodies) can be used therapeutically where attenuation of the immune response would be beneficial (*e.g.*, inflammation). Accordingly, the PRO polypeptides, agonists and antagonists thereof are also useful to prepare medicines and medicaments for the treatment of immune-related and inflammatory diseases. In a specific aspect, such medicines and medicaments comprise a therapeutically effective amount of a PRO polypeptide, agonist or antagonist thereof with a pharmaceutically acceptable carrier. Preferably, the admixture is sterile.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprises contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native sequence PRO polypeptide. In a specific aspect, the PRO agonist or antagonist is an anti-PRO antibody.

In another embodiment, the invention concerns a composition of matter comprising a PRO polypeptide or an agonist or antagonist antibody which binds the polypeptide in admixture with a carrier or excipient. In one aspect, the composition comprises a therapeutically effective amount of the polypeptide or antibody. In another aspect, when the composition comprises an immune stimulating molecule, the composition is useful for: (a) increasing infiltration of inflammatory cells into a tissue of a mammal in need thereof, (b) stimulating or enhancing an immune response in a mammal in need thereof, (c) increasing the proliferation of T-lymphocytes in a mammal in need thereof in response to an antigen, (d) stimulating the activity of T-lymphocytes or (e) increasing the vascular permeability. In a further aspect, when the composition comprises an immune inhibiting molecule, the composition is useful for: (a) decreasing infiltration of inflammatory cells into a tissue of a mammal in need thereof, (b) inhibiting or reducing an immune response in a mammal in need thereof, (c) decreasing the activity of T-lymphocytes or (d) decreasing the proliferation of T-lymphocytes in a mammal in need thereof in response to an antigen. In another aspect, the composition comprises a further active ingredient, which may, for example, be a further antibody or a cytotoxic or chemotherapeutic agent. Preferably, the composition is sterile.

In another embodiment, the invention concerns a method of treating an immune related disorder in a mammal in need thereof, comprising administering to the mammal an effective amount of a PRO polypeptide, an agonist thereof, or an antagonist thereto. In a preferred aspect, the immune related disorder is selected from the group consisting of: systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune

WO 2005/019258

PCT/US2004/025788

thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, hepatobiliary diseases such as infectious, autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel disease, gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis, allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria, immunologic diseases of the lung such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, transplantation associated diseases including graft rejection and graft -versus-host-disease.

In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody. In one aspect, the present invention concerns an isolated antibody which binds a PRO polypeptide. In another aspect, the antibody mimics the activity of a PRO polypeptide (an agonist antibody) or conversely the antibody inhibits or neutralizes the activity of a PRO polypeptide (an antagonist antibody). In another aspect, the antibody is a monoclonal antibody, which preferably has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues. The antibody may be labeled and may be immobilized on a solid support. In a further aspect, the antibody is an antibody fragment, a monoclonal antibody, a single-chain antibody, or an anti-idiotypic antibody.

In yet another embodiment, the present invention provides a composition comprising an anti-PRO antibody in admixture with a pharmaceutically acceptable carrier. In one aspect, the composition comprises a therapeutically effective amount of the antibody. Preferably, the composition is sterile. The composition may be administered in the form of a liquid pharmaceutical formulation, which may be preserved to achieve extended storage stability. Alternatively, the antibody is a monoclonal antibody, an antibody fragment, a humanized antibody, or a single-chain antibody.

In a further embodiment, the invention concerns an article of manufacture, comprising:

- (a) a composition of matter comprising a PRO polypeptide or agonist or antagonist thereof;
- (b) a container containing said composition; and
- (c) a label affixed to said container, or a package insert included in said container referring to the use of said PRO polypeptide or agonist or antagonist thereof in the treatment of an immune related disease. The composition may comprise a therapeutically effective amount of the PRO polypeptide or the agonist or antagonist thereof.

In yet another embodiment, the present invention concerns a method of diagnosing an immune related disease in a mammal, comprising detecting the level of expression of a gene encoding a PRO polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample as compared to the control sample indicates the presence of immune related disease in the mammal from which the test tissue cells were obtained.

In another embodiment, the present invention concerns a method of diagnosing an immune disease

WO 2005/019258

PCT/US2004/025788

in a mammal, comprising (a) contacting an anti-PRO antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and a PRO polypeptide, in the test sample; wherein the formation of said complex is indicative of the presence or absence of said disease. The detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A larger quantity of complexes formed in the test sample indicates the presence or absence of an immune disease in the mammal from which the test tissue cells were obtained. The antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. The test sample is usually obtained from an individual suspected of having a deficiency or abnormality of the immune system.

In another embodiment, the invention provides a method for determining the presence of a PRO polypeptide in a sample comprising exposing a test sample of cells suspected of containing the PRO polypeptide to an anti-PRO antibody and determining the binding of said antibody to said cell sample. In a specific aspect, the sample comprises a cell suspected of containing the PRO polypeptide and the antibody binds to the cell. The antibody is preferably detectably labeled and/or bound to a solid support.

In another embodiment, the present invention concerns an immune-related disease diagnostic kit, comprising an anti-PRO antibody and a carrier in suitable packaging. The kit preferably contains instructions for using the antibody to detect the presence of the PRO polypeptide. Preferably the carrier is pharmaceutically acceptable.

In another embodiment, the present invention concerns a diagnostic kit, containing an anti-PRO antibody in suitable packaging. The kit preferably contains instructions for using the antibody to detect the PRO polypeptide.

In another embodiment, the invention provides a method of diagnosing an immune-related disease in a mammal which comprises detecting the presence or absence of a PRO polypeptide in a test sample of tissue cells obtained from said mammal, wherein the presence or absence of the PRO polypeptide in said test sample is indicative of the presence of an immune-related disease in said mammal.

In another embodiment, the present invention concerns a method for identifying an agonist of a PRO polypeptide comprising:

(a) contacting cells and a test compound to be screened under conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and

(b) determining the induction of said cellular response to determine if the test compound is an effective agonist, wherein the induction of said cellular response is indicative of said test compound being an effective agonist.

In another embodiment, the invention concerns a method for identifying a compound capable of inhibiting the activity of a PRO polypeptide comprising contacting a candidate compound with a PRO polypeptide under conditions and for a time sufficient to allow these two components to interact and determining whether the activity of the PRO polypeptide is inhibited. In a specific aspect, either the candidate compound or the PRO polypeptide is immobilized on a solid support. In another aspect, the non-immobilized component carries a detectable label. In a preferred aspect, this method comprises the steps of:

(a) contacting cells and a test compound to be screened in the presence of a PRO polypeptide under

WO 2005/019258

PCT/US2004/025788

conditions suitable for the induction of a cellular response normally induced by a PRO polypeptide; and

- (b) determining the induction of said cellular response to determine if the test compound is an effective antagonist.

In another embodiment, the invention provides a method for identifying a compound that inhibits the expression of a PRO polypeptide in cells that normally express the polypeptide, wherein the method comprises contacting the cells with a test compound and determining whether the expression of the PRO polypeptide is inhibited. In a preferred aspect, this method comprises the steps of:

- (a) contacting cells and a test compound to be screened under conditions suitable for allowing expression of the PRO polypeptide; and

- (b) determining the inhibition of expression of said polypeptide.

In yet another embodiment, the present invention concerns a method for treating an immune-related disorder in a mammal that suffers therefrom comprising administering to the mammal a nucleic acid molecule that codes for either (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide or (c) an antagonist of a PRO polypeptide, wherein said agonist or antagonist may be an anti-PRO antibody. In a preferred embodiment, the mammal is human. In another preferred embodiment, the nucleic acid is administered via *ex vivo* gene therapy. In a further preferred embodiment, the nucleic acid is comprised within a vector, more preferably an adenoviral, adeno-associated viral, lentiviral or retroviral vector.

In yet another aspect, the invention provides a recombinant viral particle comprising a viral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide, or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein the viral vector is in association with viral structural proteins. Preferably, the signal sequence is from a mammal, such as from a native PRO polypeptide.

In a still further embodiment, the invention concerns an *ex vivo* producer cell comprising a nucleic acid construct that expresses retroviral structural proteins and also comprises a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein said producer cell packages the retroviral vector in association with the structural proteins to produce recombinant retroviral particles.

In a still further embodiment, the invention provides a method of increasing the activity of T-lymphocytes in a mammal comprising administering to said mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein the activity of T-lymphocytes in the mammal is increased.

In a still further embodiment, the invention provides a method of decreasing the activity of T-lymphocytes in a mammal comprising administering to said mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein the activity of T-lymphocytes in the mammal is decreased.

In a still further embodiment, the invention provides a method of increasing the proliferation of T-lymphocytes in a mammal comprising administering to said mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein the proliferation of T-lymphocytes in the mammal is increased.

WO 2005/019258

PCT/US2004/025788

In a still further embodiment, the invention provides a method of decreasing the proliferation of T-lymphocytes in a mammal comprising administering to said mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein the proliferation of T-lymphocytes in the mammal is decreased.

5           B.       Additional Embodiments

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions  
10       suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a  
15       Fc region of an immunoglobulin.

In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

In yet other embodiments, the invention provides oligonucleotide probes useful for isolating  
20       genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.

In other embodiments, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least  
25       about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid  
30       sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity,  
35       alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-  
40       length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

WO 2005/019258

PCT/US2004/025788

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a

WO 2005/019258

PCT/US2004/025788

PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60  
5 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160  
10 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500  
15 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide  
20 sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise  
25 a binding site for an anti-PRO antibody.

In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences herein above identified.

In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino  
30 acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity,  
35 alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about  
40 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a

WO 2005/019258

PCT/US2004/025788

PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

5 In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid  
10 sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity,  
15 alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs as disclosed herein.

In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal  
20 signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as herein before described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

25 Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

30 In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring  
35 a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

In a still further embodiment, the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

40 Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an



WO 2005/019258

PCT/US2004/025788

agonist or antagonist thereof as herein before described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.

5

#### BRIEF DESCRIPTION OF THE DRAWINGS

SEQ ID NOs 1-6464 show the nucleic acids of the invention and their encoded PRO polypeptides. Also included, for convenience is a List of Figures attached hereto as Appendix A, in which each Figure number corresponds to the same number SEQ ID NO: in the sequence listing. For example, Figure 1 equals SEQ ID NO:1 of the sequence listing.

10

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### I. Definitions

The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein.

25

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (*e.g.*, an extracellular domain sequence), naturally-occurring variant forms (*e.g.*, alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

30

The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide

40

ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a

WO 2005/019258

PCT/US2004/025788

PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this

method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X," "Y" and "Z" each represent different hypothetical amino acid residues.

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the

WO 2005/019258

PCT/US2004/025788

length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

"PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.

"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code

WO 2005/019258

PCT/US2004/025788

for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides.

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic

WO 2005/019258

PCT/US2004/025788

acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.

In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the

specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

5           The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

          Nucleic acid is "operably linked" when it is placed into a functional relationship with another  
10   nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and,  
15   in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

          The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody  
20   compositions with polypeptidic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

25           "Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The  
30   higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

35           "Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM  
40   sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl,



WO 2005/019258

PCT/US2004/025788

0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

"Active" or "activity" for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules

WO 2005/019258

PCT/US2004/025788

specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (Zapata et al., *Protein Eng.* 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')<sub>2</sub> fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen-

binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

5 The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

10 The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: 15 IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired 20 structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) in the same polypeptide chain (V<sub>H</sub>-V<sub>L</sub>). By using a linker that is too short to allow pairing between the two 25 domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials 30 which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE 35 under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

The term "immune related disease" means a disease in which a component of the immune system of a mammal causes, mediates or otherwise contributes to a morbidity in the mammal. Also included are diseases in which stimulation or intervention of the immune response has an ameliorative effect on progression of the disease. Included within this term are immune-mediated inflammatory diseases, non-immune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, *etc.*

The term "T cell mediated disease" means a disease in which T cells directly or indirectly mediate or otherwise contribute to a morbidity in a mammal. The T cell mediated disease may be associated with cell mediated effects, lymphokine mediated effects, *etc.*, and even effects associated with B cells if the B cells are stimulated, for example, by the lymphokines secreted by T cells.

Examples of immune-related and inflammatory diseases, some of which are immune or T cell mediated, which can be treated according to the invention include systemic lupus erythematosus, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis), demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis,

WO 2005/019258

PCT/US2004/025788

granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel disease (ulcerative colitis: Crohn's disease), gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis, allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria, immunologic diseases of the lung such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, transplantation associated diseases including graft rejection and graft -versus-host-disease. Infectious diseases including viral diseases such as AIDS (HIV infection), hepatitis A, B, C, D, and E, herpes, *etc.*, bacterial infections, fungal infections, protozoal infections and parasitic infections.

The term "effective amount" is a concentration or amount of a PRO polypeptide and/or agonist/antagonist which results in achieving a particular stated purpose. An "effective amount" of a PRO polypeptide or agonist or antagonist thereof may be determined empirically. Furthermore, a "therapeutically effective amount" is a concentration or amount of a PRO polypeptide and/or agonist/antagonist which is effective for achieving a stated therapeutic effect. This amount may also be determined empirically.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (*e.g.*,  $I^{131}$ ,  $I^{125}$ ,  $Y^{90}$  and  $Re^{186}$ ), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include adriamycin, doxorubicin, epirubicin, 5-fluorouracil, cytosine arabinoside ("Ara-C"), cyclophosphamide, thiotepa, busulfan, cytoxin, taxoids, *e.g.*, paclitaxel (Taxol, Bristol-Myers Squibb Oncology, Princeton, NJ), and doxetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France), toxotere, methotrexate, cisplatin, melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycins, esperamicins (see U.S. Pat. No. 4,675,187), melphalan and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors such as tamoxifen and onapristone.

A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, especially cancer cell overexpressing any of the genes identified herein, either *in vitro* or *in vivo*. Thus, the growth inhibitory agent is one which significantly reduces the percentage of cells overexpressing such genes in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in *The Molecular Basis of Cancer*, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogens, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13.

The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and

WO 2005/019258

PCT/US2004/025788

traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; 5 fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- $\alpha$  and - $\beta$ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- $\beta$ ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- $\alpha$  and TGF- $\beta$ ; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon- $\alpha$ , - $\beta$ , and - $\gamma$ ; colony stimulating factors (CSFs) such as 10 macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 $\alpha$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; a tumor necrosis factor such as TNF- $\alpha$  or TNF- $\beta$ ; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

15 As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (*i.e.*, is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin 20 molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

As used herein, the term "inflammatory cells" designates cells that enhance the inflammatory 25 response such as mononuclear cells, eosinophils, macrophages, and polymorphonuclear neutrophils (PMN).

WO 2005/019258

PCT/US2004/025788

**Table 1**

```

/*
5  *
  * C-C increased from 12 to 15
  * Z is average of EQ
  * B is average of ND
  * match with stop is _M; stop-stop = 0; J (joker) match = 0
10 */
#define _M      -8      /* value of a match with a stop */

int      _day[26][26] = {
/*      A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
15 /* A */      { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2,-1, 0,_M, 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, 0},
/* B */      { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2, 2,_M,-1, 1, 0, 0, 0,-2,-5, 0,-3, 1},
/* C */      {-2,-4,15,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4,_M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5},
/* D */      { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3, 2,_M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 2},
/* E */      { 0, 2,-5, 3, 4,-5, 0, 1,-2, 0, 0,-3,-2, 1,_M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 3},
20 /* F */      {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2, 0,-4,_M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5},
/* G */      { 1, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3, 0,_M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, 0},
/* H */      {-1, 1,-3, 1, 1,-2,-2, 6,-2, 0, 0,-2,-2, 2,_M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, 2},
/* I */      {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2, 2,-2,_M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2},
/* J */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
25 /* K */      {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3, 0, 1,_M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, 0},
/* L */      {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6, 4,-3,_M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2},
/* M */      {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4, 6,-2,_M,-2,-1, 0,-2,-1, 0, 2,-4, 0,-2,-1},
/* N */      { 0, 2,-4, 2, 1,-4, 0, 2,-2, 0, 1,-3,-2, 2,_M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, 1},
/* O */      {_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M, 0,_M,_M,_M,_M,_M,_M,_M,_M,_M,_M},
30 /* P */      { 1,-1,-3,-1,-1,-5,-1, 0,-2, 0,-1,-3,-2,-1,_M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0},
/* Q */      { 0, 1,-5, 2, 2,-5,-1, 3,-2, 0, 1,-2,-1, 1,_M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, 3},
/* R */      {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3, 0, 0,_M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, 0},
/* S */      { 1, 0, 0, 0, 0,-3, 1,-1,-1, 0, 0,-3,-2, 1,_M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, 0},
/* T */      { 1, 0,-2, 0, 0,-3, 0,-1, 0, 0, 0,-1,-1, 0,_M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, 0},
35 /* U */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */      { 0,-2,-2,-2,-2,-1,-1,-2, 4, 0,-2, 2, 2,-2,_M,-1,-2,-2,-1, 0, 0, 4,-6, 0,-2,-2},
/* W */      {-6,-5,-8,-7,-7, 0,-7,-3,-5, 0,-3,-2,-4,-4,_M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6},
/* X */      { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,_M, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */      {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2,_M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4},
40 /* Z */      { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1,_M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
};

```

45

50

55

WO 2005/019258

PCT/US2004/025788

# **Table 1 (cont')**

```

/*
*/
#include <stdio.h>
5  #include <ctype.h>

#define MAXJMP      16      /* max jumps in a diag */
#define MAXGAP      24      /* don't continue to penalize gaps larger than this */
#define JMPS        1024    /* max jmps in an path */
10  #define MX        4      /* save if there's at least MX-1 bases since last jmp */

#define DMAT         3      /* value of matching bases */
#define DMIS         0      /* penalty for mismatched bases */
#define DINS0        8      /* penalty for a gap */
15  #define DINS1        1    /* penalty per base */
#define PINS0        8      /* penalty for a gap */
#define PINS1        4      /* penalty per residue */

struct jmp {
20      short          n[MAXJMP]; /* size of jmp (neg for dely) */
      unsigned short  x[MAXJMP]; /* base no. of jmp in seq x */
}; /* limits seq to 2^16 -1 */

struct diag {
25      int            score;      /* score at last jmp */
      long            offset;     /* offset of prev block */
      short           ijmp;       /* current jmp index */
      struct jmp      jp;         /* list of jmps */
};

30  struct path {
      int             spc;        /* number of leading spaces */
      short           n[JMPS]; /* size of jmp (gap) */
      int             x[JMPS]; /* loc of jmp (last elem before gap) */
35  };

char      *ofile; /* output file name */
char      *namex[2]; /* seq names: getseqs() */
char      *prog; /* prog name for err msgs */
40  char      *seqx[2]; /* seqs: getseqs() */
int       dmax; /* best diag: nw() */
int       dmax0; /* final diag */
int       dna; /* set if dna: main() */
int       endgaps; /* set if penalizing end gaps */
45  int       gapx, gapy; /* total gaps in seqs */
int       len0, len1; /* seq lens */
int       ngapx, ngapy; /* total size of gaps */
int       smax; /* max score: nw() */
int       *xbm; /* bitmap for matching */
50  long      offset; /* current offset in jmp file */
struct     diag  *dx; /* holds diagonals */
struct     path  pp[2]; /* holds path for seqs */

char      *calloc(), *malloc(), *index(), *strcpy();
55  char      *getseq(), *g_calloc();

```

60



WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

/* Needleman-Wunsch alignment program
*
* usage: progs file1 file2
5  * where file1 and file2 are two dna or two protein sequences.
* The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ';', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
10 * Output is in the file "align.out"
*
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/
15 #include "nw.h"
#include "day.h"

static  _dbval[26] = {
20     1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};

static  _pbval[26] = {
25     1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
    1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
    1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)
30     main
    int      ac;
    char     *av[ ];
{
    prog = av[0];
35     if (ac != 3) {
        fprintf(stderr, "usage: %s file1 file2\n", prog);
        fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
        fprintf(stderr, "The sequences can be in upper- or lower-case\n");
        fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
40         fprintf(stderr, "Output is in the file \"align.out\"\n");
        exit(1);
    }
    namex[0] = av[1];
    namex[1] = av[2];
45     seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
    xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                                /* 1 to penalize endgaps */
50     ofile = "align.out";                      /* output file */

    nw();                                        /* fill in the matrix, get the possible jumps */
    readjumps();                               /* get the actual jumps */
    print();                                   /* print stats, alignment */
55     cleanup(0);                             /* unlink any tmp files */
}
60

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

/* do the alignment, return best score: main()
 * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
 * pro: PAM 250 values
5  * When scores are equal, we prefer mismatches to any gap, prefer
 * a new gap to extending an ongoing gap, and prefer a gap in seqx
 * to a gap in seq y.
 */
nw()
10  nw
    {
        char          *px, *py;          /* seqs and ptrs */
        int           *ndely, *dely;      /* keep track of dely */
        int           ndelx, delx;        /* keep track of delx */
15  int             *tmp;                /* for swapping row0, row1 */
        int           mis;                /* score for each type */
        int           ins0, ins1;         /* insertion penalties */
        register      id;                 /* diagonal index */
        register      ij;                 /* jmp index */
20  register          *col0, *col1;        /* score for curr, last row */
        register      xx, yy;            /* index into seqs */

        dx = (struct diag *)g_calloc("to get diags", len0+len1+1, sizeof(struct diag));

25  ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
        dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
        col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
        col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
        ins0 = (dna)? DINS0 : PINS0;
30  ins1 = (dna)? DINS1 : PINS1;

        smax = -10000;
        if (endgaps) {
            for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
35  col0[yy] = dely[yy] = col0[yy-1] - ins1;
                ndely[yy] = yy;
            }
            col0[0] = 0;          /* Waterman Bull Math Biol 84 */
40  }
        else
            for (yy = 1; yy <= len1; yy++)
                dely[yy] = -ins0;

        /* fill in match matrix
        */
45  for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
            /* initialize first entry in col
            */
            if (endgaps) {
50  if (xx == 1)
                    col1[0] = delx = -(ins0+ins1);
                else
                    col1[0] = delx = col0[0] - ins1;
                ndelx = xx;
55  }
            else {
                col1[0] = 0;
                delx = -ins0;
                ndelx = 0;
60  }

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

...nw

```

5      for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
        mis = col0[yy-1];
        if (dna)
            mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
        else
            mis += _day[*px-'A'][*py-'A'];

10      /* update penalty for del in x seq;
        * favor new del over ongong del
        * ignore MAXGAP if weighting endgaps
        */
        if (endgaps || ndely[yy] < MAXGAP) {
15            if (col0[yy] - ins0 >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else {
                dely[yy] -= ins1;
                ndely[yy]++;
20            }
        } else {
            if (col0[yy] - (ins0+ins1) >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
25            } else
                ndely[yy]++;
        }

30      /* update penalty for del in y seq;
        * favor new del over ongong del
        */
        if (endgaps || ndelx < MAXGAP) {
            if (col1[yy-1] - ins0 >= delx) {
35                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
            } else {
                delx -= ins1;
                ndelx++;
40            }
        } else {
            if (col1[yy-1] - (ins0+ins1) >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
45            } else
                ndelx++;
        }

50      /* pick the maximum score; we're favoring
        * mis over any del and delx over dely
        */

```

55

60

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

...nw

```

id = xx - yy + len1 - 1;
if (mis >= delx && mis >= dely[yy])
    col1[yy] = mis;
else if (delx >= dely[yy]) {
    col1[yy] = delx;
    ij = dx[id].ijmp;
    if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
10    && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
        dx[id].ijmp++;
        if (++ij >= MAXJMP) {
            writejms(id);
            ij = dx[id].ijmp = 0;
15            dx[id].offset = offset;
            offset += sizeof(struct jmp) + sizeof(offset);
        }
        dx[id].jp.n[ij] = ndelx;
        dx[id].jp.x[ij] = xx;
        dx[id].score = delx;
    }
    else {
        col1[yy] = dely[yy];
        ij = dx[id].ijmp;
25        if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
            && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
30                writejms(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
        }
        dx[id].jp.n[ij] = -ndely[yy];
        dx[id].jp.x[ij] = xx;
        dx[id].score = dely[yy];
    }
40    if (xx == len0 && yy < len1) {
        /* last col
        */
        if (endgaps)
            col1[yy] -= ins0+ins1*(len1-yy);
45        if (col1[yy] > smax) {
            smax = col1[yy];
            dmax = id;
        }
    }
50    if (endgaps && xx < len0)
        col1[yy-1] -= ins0+ins1*(len0-xx);
    if (col1[yy-1] > smax) {
        smax = col1[yy-1];
55        dmax = id;
    }
    tmp = col0; col0 = col1; col1 = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
60 (void) free((char *)col0);
(void) free((char *)col1);
}

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

/*
 *
 * print() -- only routine visible outside this module
5  *
 * static:
 * getmat() -- trace back best path, count matches: print()
 * pr_align() -- print alignment of described in array p[ ]; print()
 * dumpblock() -- dump a block of lines with numbers, stars: pr_align()
10 * nums() -- put out a number line: dumpblock()
 * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
 * stars() -- put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */
15
#include "nw.h"

#define SPC      3
#define P_LINE   256    /* maximum output line */
20 #define P_SPC   3      /* space between name or num and seq */

extern  _day[26][26];
int     olen;           /* set output line length */
FILE    *fx;            /* output file */
25

print()
{
    print
    {
        int     lx, ly, firstgap, lastgap;    /* overlap */
30
        if ((fx = fopen(ofile, "w")) == 0) {
            fprintf(stderr, "%s: can't write %s\n", prog, ofile);
            cleanup(1);
        }
35
        fprintf(fx, "<first sequence: %s (length = %d)\n", namex[0], len0);
        fprintf(fx, "<second sequence: %s (length = %d)\n", namex[1], len1);
        olen = 60;
        lx = len0;
        ly = len1;
40
        firstgap = lastgap = 0;
        if (dmax < len1 - 1) {    /* leading gap in x */
            pp[0].spc = firstgap = len1 - dmax - 1;
            ly -= pp[0].spc;
        }
45
        else if (dmax > len1 - 1) {    /* leading gap in y */
            pp[1].spc = firstgap = dmax - (len1 - 1);
            lx -= pp[1].spc;
        }
        if (dmax0 < len0 - 1) {    /* trailing gap in x */
50
            lastgap = len0 - dmax0 - 1;
            lx -= lastgap;
        }
        else if (dmax0 > len0 - 1) {    /* trailing gap in y */
55
            lastgap = dmax0 - (len0 - 1);
            ly -= lastgap;
        }
        getmat(lx, ly, firstgap, lastgap);
        pr_align();
60
    }
}

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

/*
 * trace back the best path, count matches
 */
5  static
   getmat(lx, ly, firstgap, lastgap)                                getmat
       int      lx, ly;                                           /* "core" (minus endgaps) */
       int      firstgap, lastgap;                                /* leading trailing overlap */
   {
10      int      nm, i0, i1, siz0, siz1;
       char      outx[32];
       double     pct;
       register   n0, n1;
       register char *p0, *p1;
15
       /* get total matches, score
        */
       i0 = i1 = siz0 = siz1 = 0;
       p0 = seqx[0] + pp[1].spc;
20      p1 = seqx[1] + pp[0].spc;
       n0 = pp[1].spc + 1;
       n1 = pp[0].spc + 1;

       nm = 0;
25      while ( *p0 && *p1 ) {
           if (siz0) {
               p1++;
               n1++;
               siz0--;
30           }
           else if (siz1) {
               p0++;
               n0++;
               siz1--;
35           }
           else {
               if (xbm[*p0-'A']&xbm[*p1-'A'])
                   nm++;
               if (n0++ == pp[0].x[i0])
                   siz0 = pp[0].n[i0++];
40               if (n1++ == pp[1].x[i1])
                   siz1 = pp[1].n[i1++];
               p0++;
               p1++;
45           }
       }

       /* pct homology:
        * if penalizing endgaps, base is the shorter seq
50      * else, knock off overhangs and take shorter core
        */
       if (endgaps)
           lx = (len0 < len1)? len0 : len1;
       else
55         lx = (lx < ly)? lx : ly;
       pct = 100.*((double)nm/((double)lx);
       fprintf(fx, "\n");
       fprintf(fx, "<%d match%s in an overlap of %d: %.2f percent similarity\n",
60         nm, (nm == 1)? "" : "es", lx, pct);

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

    fprintf(fx, "<gaps in first sequence: %d", gapx);
    if (gapx) {
5         (void) sprintf(outh, " (%d %s%s)",
            ngapx, (dna)? "base":"residue", (ngapx == 1)? "" : "s");
            fprintf(fx, "%s", outh);

    fprintf(fx, ", gaps in second sequence: %d", gapy);
10    if (gapy) {
        (void) sprintf(outh, " (%d %s%s)",
            ngapy, (dna)? "base":"residue", (ngapy == 1)? "" : "s");
            fprintf(fx, "%s", outh);
    }
15    if (dna)
        fprintf(fx,
            "\n<score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
            smax, DMAT, DMIS, DINS0, DINS1);
    else
20        fprintf(fx,
            "\n<score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
            smax, PINS0, PINS1);
    if (endgaps)
        fprintf(fx,
25        "<endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
            firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s",
            lastgap, (dna)? "base" : "residue", (lastgap == 1)? "" : "s");
    else
        fprintf(fx, "<endgaps not penalized\n");
30 }
    static      nm;          /* matches in core -- for checking */
    static      lmax;        /* lengths of stripped file names */
    static      ij[2];       /* jmp index for a path */
    static      nc[2];       /* number at start of current line */
35    static      ni[2];       /* current elem number -- for gapping */
    static      siz[2];
    static char *ps[2];      /* ptr to current element */
    static char *po[2];      /* ptr to next output char slot */
    static char out[2][P_LINE]; /* output line */
40    static char star[P_LINE]; /* set by stars() */

    /*
     * print alignment of described in struct path pp[ ]
     */
45    static
    pr_align()
    {
        int      nn;         /* char count */
        int      more;
50        register i;

        for (i = 0, lmax = 0; i < 2; i++) {
            nn = stripname(namex[i]);
            if (nn > lmax)
55                lmax = nn;

            nc[i] = 1;
            ni[i] = 1;
            siz[i] = ij[i] = 0;
60            ps[i] = seqx[i];
            po[i] = out[i];
        }

```

...getmat

pr\_align

**Table 1 (cont')**

```

5      for (nn = nm = 0, more = 1; more; ) {
        for (i = more = 0; i < 2; i++) {
            /*
            * do we have more of this sequence?
            */
            if (!*ps[i])
10                continue;

            more++;

            if (pp[i].spc) { /* leading space */
                *po[i]++ = ' ';
                pp[i].spc--;
15            }
            else if (siz[i]) { /* in a gap */
                *po[i]++ = '-';
                siz[i]--;
20            }
            else { /* we're putting a seq element
                    */
                *po[i] = *ps[i];
                if (islower(*ps[i]))
25                    *ps[i] = toupper(*ps[i]);

                po[i]++;
                ps[i]++;

                /*
                * are we at next gap for this seq?
                */
                if (ni[i] == pp[i].x[ij[i]]) {
                    /*
                    * we need to merge all gaps
                    * at this location
                    */
                    siz[i] = pp[i].n[ij[i]]++;
                    while (ni[i] == pp[i].x[ij[i]])
40                        siz[i] += pp[i].n[ij[i]]++;
                }
                ni[i]++;
            }
        }
        if (++nn == olen || !more && nn) {
45            dumpblock();
            for (i = 0; i < 2; i++)
                po[i] = out[i];
            nn = 0;
        }
50    }

    /*
    * dump a block of lines, including numbers, stars: pr_align()
    */
55    static
    dumpblock()
    {
        register i;
        for (i = 0; i < 2; i++)
            *po[i]-- = '\0';
60    }

```

**...pr\_align**



WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**
**...dumpblock**

```

5      (void) putc('\n', fx);
      for (i = 0; i < 2; i++) {
          if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
              if (i == 0)
                  nums(i);
              if (i == 0 && *out[1])
10                 stars();
              putline(i);
              if (i == 0 && *out[1])
                  fprintf(fx, star);
              if (i == 1)
15                 nums(i);
          }
      }
  }

20  /*
   * put out a number line: dumpblock()
   */
   static
   nums(ix)
25  {
      int      ix;      /* index in out[ ] holding seq line */

      char      nline[P_LINE];
      register  i, j;
      register  char *pn, *px, *py;
30
      for (pn = nline, i = 0; i < lmax+P_SPC; i++, pn++)
          *pn = ' ';
      for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
          if (*py == ' ' || *py == '-')
35             *pn = ' ';
          else {
              if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                  j = (i < 0)? -i : i;
                  for (px = pn; j; j /= 10, px--)
40                     *px = j%10 + '0';
                  if (i < 0)
                      *px = '-';
              }
              else
45                 *pn = ' ';
              i++;
          }
      }
      *pn = '\0';
      nc[ix] = i;
      for (pn = nline; *pn; pn++)
          (void) putc(*pn, fx);
      (void) putc('\n', fx);
55  }

  /*
   * put out a line (name, [num], seq, [num]): dumpblock()
   */
   static
60  putline(ix)
      int      ix;
      {

```

**nums**
**putline**

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')****...putline**

```

5      int          i;
      register char *px;

      for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax+P_SPC; i++)
10         (void) putc(' ', fx);

      /* these count from 1:
      * ni[ ] is current element (from 1)
      * nc[ ] is number at start of current line
      */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px&0x7F, fx);
      (void) putc('\n', fx);
20 }

/*
 * put a line of stars (seqs always in out[0], out[1]): dumpblock()
 */
25 static
stars()
{
    int          i;
30    register char *p0, *p1, cx, *px;

    if (!*out[0] || (*out[0] == ' ' && *(po[0]) == ' ') ||
        !*out[1] || (*out[1] == ' ' && *(po[1]) == ' '))
        return;
35    px = star;
    for (i = lmax+P_SPC; i; i--)
        *px++ = ' ';

    for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
40        if (isalpha(*p0) && isalpha(*p1)) {

            if (xbm[*p0-'A'] & xbm[*p1-'A']) {
                cx = '*';
                nm++;
45            }
            else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
                cx = '.';
            else
                cx = ' ';
50        }
        else
            cx = ' ';
        *px++ = cx;
55    }
    *px++ = '\n';
    *px = '\0';
}
60

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```
/*
 * strip path or prefix from pn, return len: pr_align()
 */
5  static
  stripname(pn)
    stripname
      char    *pn;      /* file name (may be path) */
10  {
      register char    *px, *py;

      py = 0;
      for (px = pn; *px; px++)
        if (*px == '/')
15        py = px + 1;
      if (py)
        (void) strcpy(pn, py);
      return(strlen(pn));
20  }
```

25

30

35

40

45

50

55

60

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
5  * g_calloc() -- calloc() with error checkin
 * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
10 #include <sys/file.h>

char    *jname = "/tmp/homgXXXXXX";          /* tmp file for jumps */
FILE    *fj;

15 int    cleanup();                          /* cleanup tmp file */
long    lseek();

/*
 * remove any tmp file if we blow
20 */
cleanup(i)
    int    i;
{
    if (fj)
25     (void) unlink(jname);
    exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
30 char    *
getseq(file, len)
35     char    *file;    /* file name */
    int    *len;    /* seq len */
{
    char    line[1024], *pseq;
40     register char    *px, *py;
    int    natgc, tlen;
    FILE    *fp;

    if ((fp = fopen(file, "r")) == 0) {
45         fprintf(stderr, "%s: can't read %s\n", prog, file);
        exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
50         if (*line == ';' || *line == '<' || *line == '>')
            continue;
        for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
55     }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
        exit(1);
    }
60     pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')****...getseq**

```

5      py = pseq + 4;
      *len = tlen;
      rewind(fp);

      while (fgets(line, 1024, fp)) {
          if (*line == ';' || *line == '<' || *line == '>')
              continue;
10         for (px = line; *px != '\n'; px++) {
              if (isupper(*px))
                  *py++ = *px;
              else if (islower(*px))
                  *py++ = toupper(*px);
15             if (index("ATGCU", *(py-1)))
                 natgc++;
          }
      }
      *py++ = '\0';
      *py = '\0';
      (void) fclose(fp);
      dna = natgc > (tlen/3);
      return(pseq+4);
25 }

char *
g_alloc(msg, nx, sz)
      char *msg;          /* program, calling routine */
      int nx, sz;         /* number and size of elements */
30 {
      char *px, *calloc();

      if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
          if (*msg) {
35             fprintf(stderr, "%s: g_alloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
             exit(1);
          }
      }
      return(px);
40 }

/*
 * get final jmps from dx[ ] or tmp file, set pp[ ], reset dmax: main()
 */
45 readjmps()
{
    readjmps
    {
        int fd = -1;
        int siz, i0, i1;
50        register i, j, xx;

        if (fj) {
            (void) fclose(fj);
            if ((fd = open(jname, O_RDONLY, 0)) < 0) {
55                fprintf(stderr, "%s: can't open() %s\n", prog, jname);
                cleanup(1);
            }
        }
        for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; i++) {
60            while (1) {
                for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)
                    ;
            }
        }
    }
}

```

**g\_alloc**

**Table 1 (cont')****...readjumps**

```

5         if (j < 0 && dx[dmax].offset && fj) {
            (void) lseek(fd, dx[dmax].offset, 0);
            (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
            (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
            dx[dmax].ijmp = MAXJMP-1;
        }
10        else
            break;
    }
    if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1);
15    }
    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz;
20        if (siz < 0) { /* gap in second seq */
            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1
            */
25            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy -= siz;
        /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
30            i1++;
        }
        else if (siz > 0) { /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
35            gapx++;
            ngapx += siz;
        /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
40            i0++;
        }
    }
    else
        break;
}

45    /* reverse the order of jumps
    */
    for (j = 0, i0--; j < i0; j++, i0--) {
        i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
50        i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
    }
    for (j = 0, i1--; j < i1; j++, i1--) {
        i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
        i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
55    }
    if (fd >= 0)
        (void) close(fd);
    if (fj) {
        (void) unlink(jname);
60        fj = 0;
        offset = 0;
    }
}

```

WO 2005/019258

PCT/US2004/025788

**Table 1 (cont')**

```
5  /*
   * write a filled jmp struct offset of the prev one (if any): nw()
   */
   writejumps(ix)
       writejumps
           int    ix;
10  {
       char    *mktemp();

       if (!fj) {
           if (mktemp(jname) < 0) {
15               fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);
               cleanup(1);
           }
           if ((fj = fopen(jname, "w")) == 0) {
               fprintf(stderr, "%s: can't write %s\n", prog, jname);
20               exit(1);
           }
       }
       (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
       (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
   }
```

WO 2005/019258

PCT/US2004/025788

**Table 2**

PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXYYYYYYY	(Length = 12 amino acids)

5    % amino acid sequence identity =  
 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =  
 5 divided by 15 = 33.3%

**Table 3**

PRO	XXXXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXXYYYYYYYZZYZ	(Length = 15 amino acids)

10    % amino acid sequence identity =  
 (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =  
 15    5 divided by 10 = 50%

**Table 4**

PRO-DNA	NNNNNNNNNNNNNN	(Length = 14 nucleotides)
Comparison DNA	NNNNNNLLLLLLLL	(Length = 16 nucleotides)

20    % nucleic acid sequence identity =  
 (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =  
 25    6 divided by 14 = 42.9%

**Table 5**

PRO-DNA	NNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLLVV	(Length = 9 nucleotides)

30    % nucleic acid sequence identity =  
 (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =  
 4 divided by 12 = 33.3%

## 35    II. Compositions and Methods of the Invention

### A.    Full-Length PRO Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples  
 40 below. However, for sake of simplicity, in the present specification the protein encoded by the full length



native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.

As disclosed in the Examples below, various cDNA clones have been disclosed. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

#### B. PRO Polypeptide Variants

In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the native full-length sequence PRO or in various domains of the PRO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally, the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.

PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO

polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

**Table 6**

	Original Residue	Exemplary Substitutions	Preferred Substitutions
10	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
15	Cys (C)	ser	ser
	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
20	Ile (I)	leu; val; met; ala; phe; norleucine	leu
	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
25	Pro (P)	ala	ala
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
30	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- 40 (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., *Nucl. Acids Res.*, 13:4331 (1986); Zoller et al., *Nucl. Acids Res.*, 10:6487 (1987)], cassette mutagenesis

WO 2005/019258

PCT/US2004/025788

[Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

### C. Modifications of PRO

Covalent modifications of PRO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparaginy residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the

WO 2005/019258

PCT/US2004/025788

DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an alpha-tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1,

WO 2005/019258

PCT/US2004/025788

CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

#### D. Preparation of PRO

The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.

##### 1. Isolation of DNA Encoding PRO

DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., *supra*; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if

necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

5 Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity  
10 of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example,  $\text{CaCl}_2$ ,  $\text{CaPO}_4$ , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The  
15 calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host  
20 system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming  
25 mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli*  
30 strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710  
35 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110  
40 strain 1A2, which has the complete genotype *tonA* ; *E. coli* W3110 strain 9E4, which has the complete

genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan<sup>r</sup>*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan<sup>r</sup>*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Flier et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylophilic, 269 (1982).

Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is

WO 2005/019258

PCT/US2004/025788

inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard  
5 ligation techniques which are known to the skilled artisan.

The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector. The  
10 signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646  
15 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast,  
20 and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g.,  
25 ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR  
30 activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose  
35 promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)].  
40



Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., *J. Biol. Chem.*, 255:2073 (1980)] or other glycolytic enzymes  
5 [Hess et al., *J. Adv. Enzyme Reg.*, 7:149 (1968); Holland, *Biochemistry*, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of  
10 transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters  
15 obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters  
20 are compatible with the host cell systems.

Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use  
25 an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or  
30 nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in  
35 recombinant vertebrate cell culture are described in Gething et al., *Nature*, 293:620-625 (1981); Mantei et al., *Nature*, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by  
40 conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, *Proc.*

Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope.

#### 5. Purification of Polypeptide

Forms of PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced.

#### E. Tissue Distribution

The location of tissues expressing the PRO can be identified by determining mRNA expression in various human tissues. The location of such genes provides information about which tissues are most likely to be affected by the stimulating and inhibiting activities of the PRO polypeptides. The location of a gene in a specific tissue also provides sample tissue for the activity blocking assays discussed below.

As noted before, gene expression in various tissues may be measured by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, *Proc. Natl. Acad. Sci. USA*, 77:5201-5205 [1980]), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.

Gene expression in various tissues, alternatively, may be measured by immunological methods,

such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence of a PRO polypeptide or against a synthetic peptide based on the DNA sequences encoding the PRO polypeptide or against an exogenous sequence fused to a DNA encoding a PRO polypeptide and encoding a specific antibody epitope. General techniques for generating antibodies, and special protocols for Northern blotting and *in situ* hybridization are provided below.

#### F. Antibody Binding Studies

The activity of the PRO polypeptides can be further verified by antibody binding studies, in which the ability of anti-PRO antibodies to inhibit the effect of the PRO polypeptides, respectively, on tissue cells is tested. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies, the preparation of which will be described hereinbelow.

Antibody binding studies may be carried out in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, *Monoclonal Antibodies: A Manual of Techniques*, pp.147-158 (CRC Press, Inc., 1987).

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of target protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, *e.g.*, US Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

#### G. Cell-Based Assays

Cell-based assays and animal models for immune related diseases can be used to further understand the relationship between the genes and polypeptides identified herein and the development and pathogenesis of immune related disease.

In a different approach, cells of a cell type known to be involved in a particular immune related disease are transfected with the cDNAs described herein, and the ability of these cDNAs to stimulate or inhibit immune function is analyzed. Suitable cells can be transfected with the desired gene, and monitored for immune function activity. Such transfected cell lines can then be used to test the ability of poly- or monoclonal antibodies or antibody compositions to inhibit or stimulate immune function, for example to

WO 2005/019258

PCT/US2004/025788

modulate T-cell proliferation or inflammatory cell infiltration. Cells transfected with the coding sequences of the genes identified herein can further be used to identify drug candidates for the treatment of immune related diseases.

In addition, primary cultures derived from transgenic animals (as described below) can be used in the cell-based assays herein, although stable cell lines are preferred. Techniques to derive continuous cell lines from transgenic animals are well known in the art (see, *e.g.*, Small *et al.*, *Mol. Cell. Biol.* 5: 642-648 [1985]).

One suitable cell based assay is the mixed lymphocyte reaction (MLR). *Current Protocols in Immunology*, unit 3.12; edited by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W Strober, National Institutes of Health, Published by John Wiley & Sons, Inc. In this assay, the ability of a test compound to stimulate or inhibit the proliferation of activated T cells is assayed. A suspension of responder T cells is cultured with allogeneic stimulator cells and the proliferation of T cells is measured by uptake of tritiated thymidine. This assay is a general measure of T cell reactivity. Since the majority of T cells respond to and produce IL-2 upon activation, differences in responsiveness in this assay in part reflect differences in IL-2 production by the responding cells. The MLR results can be verified by a standard lymphokine (IL-2) detection assay. *Current Protocols in Immunology*, above, 3.15, 6.3.

A proliferative T cell response in an MLR assay may be due to direct mitogenic properties of an assayed molecule or to external antigen induced activation. Additional verification of the T cell stimulatory activity of the PRO polypeptides can be obtained by a costimulation assay. T cell activation requires an antigen specific signal mediated through the T-cell receptor (TCR) and a costimulatory signal mediated through a second ligand binding interaction, for example, the B7 (CD80, CD86)/CD28 binding interaction. CD28 crosslinking increases lymphokine secretion by activated T cells. T cell activation has both negative and positive controls through the binding of ligands which have a negative or positive effect. CD28 and CTLA-4 are related glycoproteins in the Ig superfamily which bind to B7. CD28 binding to B7 has a positive costimulation effect of T cell activation; conversely, CTLA-4 binding to B7 has a T cell deactivating effect. Chambers, C. A. and Allison, J. P., *Curr. Opin. Immunol.* (1997) 9:396. Schwartz, R. H., *Cell* (1992) 71:1065; Linsey, P. S. and Ledbetter, J. A., *Annu. Rev. Immunol.* (1993) 11:191; June, C. H. *et al*, *Immunol. Today* (1994) 15:321; Jenkins, M. K., *Immunity* (1994) 1:405. In a costimulation assay, the PRO polypeptides are assayed for T cell costimulatory or inhibitory activity.

Direct use of a stimulating compound as in the invention has been validated in experiments with 4-1BB glycoprotein, a member of the tumor necrosis factor receptor family, which binds to a ligand (4-1BBL) expressed on primed T cells and signals T cell activation and growth. Alderson, M. E. *et al.*, *J. Immunol.* (1994) 24:2219.

The use of an agonist stimulating compound has also been validated experimentally. Activation of 4-1BB by treatment with an agonist anti-4-1BB antibody enhances eradication of tumors. Hellstrom, I. and Hellstrom, K. E., *Crit. Rev. Immunol.* (1998) 18:1. Immunoadjuvant therapy for treatment of tumors, described in more detail below, is another example of the use of the stimulating compounds of the invention.

Alternatively, an immune stimulating or enhancing effect can also be achieved by administration of a PRO which has vascular permeability enhancing properties. Enhanced vascular permeability would be

beneficial to disorders which can be attenuated by local infiltration of immune cells (*e.g.*, monocytes, eosinophils, PMNs) and inflammation.

On the other hand, PRO polypeptides, as well as other compounds of the invention, which are direct inhibitors of T cell proliferation/activation, lymphokine secretion, and/or vascular permeability can be directly used to suppress the immune response. These compounds are useful to reduce the degree of the immune response and to treat immune related diseases characterized by a hyperactive, superoptimal, or autoimmune response. This use of the compounds of the invention has been validated by the experiments described above in which CTLA-4 binding to receptor B7 deactivates T cells. The direct inhibitory compounds of the invention function in an analogous manner. The use of compound which suppress vascular permeability would be expected to reduce inflammation. Such uses would be beneficial in treating conditions associated with excessive inflammation.

Alternatively, compounds, *e.g.*, antibodies, which bind to stimulating PRO polypeptides and block the stimulating effect of these molecules produce a net inhibitory effect and can be used to suppress the T cell mediated immune response by inhibiting T cell proliferation/activation and/or lymphokine secretion. Blocking the stimulating effect of the polypeptides suppresses the immune response of the mammal. This use has been validated in experiments using an anti-IL2 antibody. In these experiments, the antibody binds to IL2 and blocks binding of IL2 to its receptor thereby achieving a T cell inhibitory effect.

#### H. Animal Models

The results of the cell based *in vitro* assays can be further verified using *in vivo* animal models and assays for T-cell function. A variety of well known animal models can be used to further understand the role of the genes identified herein in the development and pathogenesis of immune related disease, and to test the efficacy of candidate therapeutic agents, including antibodies, and other antagonists of the native polypeptides, including small molecule antagonists. The *in vivo* nature of such models makes them predictive of responses in human patients. Animal models of immune related diseases include both non-recombinant and recombinant (transgenic) animals. Non-recombinant animal models include, for example, rodent, *e.g.*, murine models. Such models can be generated by introducing cells into syngeneic mice using standard techniques, *e.g.*, subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, *etc.*

Graft-versus-host disease occurs when immunocompetent cells are transplanted into immunosuppressed or tolerant patients. The donor cells recognize and respond to host antigens. The response can vary from life threatening severe inflammation to mild cases of diarrhea and weight loss. Graft-versus-host disease models provide a means of assessing T cell reactivity against MHC antigens and minor transplant antigens. A suitable procedure is described in detail in Current Protocols in Immunology, above, unit 4.3.

An animal model for skin allograft rejection is a means of testing the ability of T cells to mediate *in vivo* tissue destruction and a measure of their role in transplant rejection. The most common and accepted models use murine tail-skin grafts. Repeated experiments have shown that skin allograft rejection is mediated by T cells, helper T cells and killer-effector T cells, and not antibodies. Auchincloss, H. Jr. and Sachs, D. H., *Fundamental Immunology*, 2nd ed., W. E. Paul ed., Raven Press, NY, 1989, 889-992. A suitable procedure is described in detail in *Current Protocols in Immunology*, above, unit 4.4. Other

transplant rejection models which can be used to test the compounds of the invention are the allogeneic heart transplant models described by Tanabe, M. *et al*, *Transplantation* (1994) 58:23 and Tinubu, S. A. *et al*, *J. Immunol.* (1994) 4330-4338.

Animal models for delayed type hypersensitivity provides an assay of cell mediated immune function as well. Delayed type hypersensitivity reactions are a T cell mediated *in vivo* immune response characterized by inflammation which does not reach a peak until after a period of time has elapsed after challenge with an antigen. These reactions also occur in tissue specific autoimmune diseases such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE, a model for MS). A suitable procedure is described in detail in *Current Protocols in Immunology*, above, unit 4.5.

EAE is a T cell mediated autoimmune disease characterized by T cell and mononuclear cell inflammation and subsequent demyelination of axons in the central nervous system. EAE is generally considered to be a relevant animal model for MS in humans. Bolton, C., *Multiple Sclerosis* (1995) 1:143. Both acute and relapsing-remitting models have been developed. The compounds of the invention can be tested for T cell stimulatory or inhibitory activity against immune mediated demyelinating disease using the protocol described in *Current Protocols in Immunology*, above, units 15.1 and 15.2. See also the models for myelin disease in which oligodendrocytes or Schwann cells are grafted into the central nervous system as described in Duncan, I. D. *et al*, *Molec. Med. Today* (1997) 554-561.

Contact hypersensitivity is a simple delayed type hypersensitivity *in vivo* assay of cell mediated immune function. In this procedure, cutaneous exposure to exogenous haptens which gives rise to a delayed type hypersensitivity reaction which is measured and quantitated. Contact sensitivity involves an initial sensitizing phase followed by an elicitation phase. The elicitation phase occurs when the T lymphocytes encounter an antigen to which they have had previous contact. Swelling and inflammation occur, making this an excellent model of human allergic contact dermatitis. A suitable procedure is described in detail in *Current Protocols in Immunology*, Eds. J. E. Cologan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, John Wiley & Sons, Inc., 1994, unit 4.2. See also Grabbe, S. and Schwarz, T., *Immun. Today* 19 (1): 37-44 (1998).

An animal model for arthritis is collagen-induced arthritis. This model shares clinical, histological and immunological characteristics of human autoimmune rheumatoid arthritis and is an acceptable model for human autoimmune arthritis. Mouse and rat models are characterized by synovitis, erosion of cartilage and subchondral bone. The compounds of the invention can be tested for activity against autoimmune arthritis using the protocols described in *Current Protocols in Immunology*, above, units 15.5. See also the model using a monoclonal antibody to CD18 and VLA-4 integrins described in Issekutz, A.C. *et al*, *Immunology* (1996) 88:569.

A model of asthma has been described in which antigen-induced airway hyper-reactivity, pulmonary eosinophilia and inflammation are induced by sensitizing an animal with ovalbumin and then challenging the animal with the same protein delivered by aerosol. Several animal models (guinea pig, rat, non-human primate) show symptoms similar to atopic asthma in humans upon challenge with aerosol antigens. Murine models have many of the features of human asthma. Suitable procedures to test the compounds of the invention for activity and effectiveness in the treatment of asthma are described by Wolyniec, W. W. *et al*, *Am. J. Respir. Cell Mol. Biol.* (1998) 18:777 and the references cited therein.

Additionally, the compounds of the invention can be tested on animal models for psoriasis like diseases. Evidence suggests a T cell pathogenesis for psoriasis. The compounds of the invention can be tested in the scid/scid mouse model described by Schon, M. P. *et al*, *Nat. Med.* (1997) 3:183, in which the mice demonstrate histopathologic skin lesions resembling psoriasis. Another suitable model is the human skin/scid mouse chimera prepared as described by Nickoloff, B. J. *et al*, *Am. J. Path.* (1995) 146:580.

Recombinant (transgenic) animal models can be engineered by introducing the coding portion of the genes identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals. Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, *e.g.*, baboons, chimpanzees and monkeys. Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (Hoppe and Wanger, U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (*e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci. USA* 82, 6148-615 [1985]); gene targeting in embryonic stem cells (Thompson *et al.*, *Cell* 56, 313-321 [1989]); electroporation of embryos (Lo, *Mol. Cel. Biol.* 3, 1803-1814 [1983]); sperm-mediated gene transfer (Lavitrano *et al.*, *Cell* 57, 717-73 [1989]). For review, see, for example, U.S. Patent No. 4,736,866.

For the purpose of the present invention, transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals"). The transgene can be integrated either as a single transgene, or in concatamers, *e.g.*, head-to-head or head-to-tail tandems. Selective introduction of a transgene into a particular cell type is also possible by following, for example, the technique of Lasko *et al.*, *Proc. Natl. Acad. Sci. USA* 89, 6232-636 (1992).

The expression of the transgene in transgenic animals can be monitored by standard techniques. For example, Southern blot analysis or PCR amplification can be used to verify the integration of the transgene. The level of mRNA expression can then be analyzed using techniques such as *in situ* hybridization, Northern blot analysis, PCR, or immunocytochemistry.

The animals may be further examined for signs of immune disease pathology, for example by histological examination to determine infiltration of immune cells into specific tissues. Blocking experiments can also be performed in which the transgenic animals are treated with the compounds of the invention to determine the extent of the T cell proliferation stimulation or inhibition of the compounds. In these experiments, blocking antibodies which bind to the PRO polypeptide, prepared as described above, are administered to the animal and the effect on immune function is determined.

Alternatively, "knock out" animals can be constructed which have a defective or altered gene encoding a polypeptide identified herein, as a result of homologous recombination between the endogenous gene encoding the polypeptide and altered genomic DNA encoding the same polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding a particular polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques. A portion of the genomic DNA encoding a particular polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see *e.g.*, Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced DNA

has homologously recombined with the endogenous DNA are selected [see *e.g.*, Li *et al.*, *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras [see *e.g.*, Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the polypeptide.

#### I. ImmunoAdjuvant Therapy

In one embodiment, the immunostimulating compounds of the invention can be used in immunoadjuvant therapy for the treatment of tumors (cancer). It is now well established that T cells recognize human tumor specific antigens. One group of tumor antigens, encoded by the MAGE, BAGE and GAGE families of genes, are silent in all adult normal tissues, but are expressed in significant amounts in tumors, such as melanomas, lung tumors, head and neck tumors, and bladder carcinomas DeSmet *et al.*, (1996) *Proc. Natl. Acad. Sci. USA*, 93:7149. It has been shown that costimulation of T cells induces tumor regression and an antitumor response both *in vitro* and *in vivo*. Melero, I. *et al.*, *Nature Medicine* (1997) 3:682; Kwon, E. D. *et al.*, *Proc. Natl. Acad. Sci. USA* (1997) 94: 8099; Lynch, D. H. *et al.*, *Nature Medicine* (1997) 3:625; Finn, O. J. and Lotze, M. T., *J. Immunol.* (1998) 21:114. The stimulatory compounds of the invention can be administered as adjuvants, alone or together with a growth regulating agent, cytotoxic agent or chemotherapeutic agent, to stimulate T cell proliferation/activation and an antitumor response to tumor antigens. The growth regulating, cytotoxic, or chemotherapeutic agent may be administered in conventional amounts using known administration regimes. Immunostimulating activity by the compounds of the invention allows reduced amounts of the growth regulating, cytotoxic, or chemotherapeutic agents thereby potentially lowering the toxicity to the patient.

#### J. Screening Assays for Drug Candidates

Screening assays for drug candidates are designed to identify compounds that bind to or complex with the polypeptides encoded by the genes identified herein or a biologically active fragment thereof, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds, including peptides, preferably soluble peptides, (poly)peptide-immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art. All assays are common in that they call for contacting the drug candidate with a polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to



WO 2005/019258

PCT/US2004/025788

interact.

In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, *e.g.*, on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the polypeptide and drying. Alternatively, an immobilized antibody, *e.g.*, a monoclonal antibody, specific for the polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, *e.g.*, the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, *e.g.*, by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labelled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular protein encoded by a gene identified herein, its interaction with that protein can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers [Fields and Song, *Nature (London)* 340, 245-246 (1989); Chien *et al.*, *Proc. Natl. Acad. Sci. USA* 88, 9578-9582 (1991)] as disclosed by Chevray and Nathans, *Proc. Natl. Acad. Sci. USA* 89, 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, while the other one functioning as the transcription activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER<sup>TM</sup>) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

In order to find compounds that interfere with the interaction of a gene identified herein and other intra- or extracellular components can be tested, a reaction mixture is usually prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a test compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described above.

WO 2005/019258

PCT/US2004/025788

The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

#### K. Compositions and Methods for the Treatment of Immune Related Diseases

The compositions useful in the treatment of immune related diseases include, without limitation, proteins, antibodies, small organic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, triple helix molecules, *etc.* that inhibit or stimulate immune function, for example, T cell proliferation/activation, lymphokine release, or immune cell infiltration.

For example, antisense RNA and RNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation initiation site, *e.g.*, between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, *e.g.*, Rossi, *Current Biology* 4, 469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, *e.g.*, PCT publication No. WO 97/33551, *supra*.

These molecules can be identified by any or any combination of the screening assays discussed above and/or by any other screening techniques well known for those skilled in the art.

#### L. Anti-PRO Antibodies

The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

##### 1. Polyclonal Antibodies

The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections.

The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized.

Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

##### 2. Monoclonal Antibodies

WO 2005/019258

PCT/US2004/025788

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., *supra*] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Human and Humanized Antibodies

The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding  
5 subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by  
10 corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The  
15 humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These  
20 non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric  
25 antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage  
30 display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous  
35 immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10, 779-783 (1992); Lonberg *et al.*, Nature 368 856-859 (1994);

Morrison, Nature 368, 812-13 (1994); Fishwild *et al.*, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

The antibodies may also be affinity matured using known selection and/or mutagenesis methods as described above. Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')<sub>2</sub> bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan *et al.*, Science 229:81 (1985) describe a procedure wherein intact antibodies are

proteolytically cleaved to generate F(ab')<sub>2</sub> fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is  
5 mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Fab' fragments may be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby *et al.*, J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')<sub>2</sub> molecule. Each Fab' fragment was separately secreted from *E. coli* and  
10 subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.*, J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)  
20 has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary V<sub>L</sub> and V<sub>H</sub> domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber *et al.*, J. Immunol. 152:5368 (1994). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt *et al.*, J. Immunol. 147:60 (1991).

Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein. Alternatively, an anti-PRO polypeptide arm may be combined with an arm which binds to a  
30 triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as  
35 EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).

##### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been  
40 proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of

HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 6. Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, J. Exp. Med., **176**: 1191-1195 (1992) and Shopes, J. Immunol., **148**: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.* Cancer Research, **53**: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.*, Anti-Cancer Drug Design, **3**: 219-230 (1989).

#### 7. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, **238**: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient,



WO 2005/019258

PCT/US2004/025788

followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).

#### 8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., **257**: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, J. National Cancer Inst., **81**(19): 1484 (1989).

#### M. Pharmaceutical Compositions

The active PRO molecules of the invention (e.g., PRO polypeptides, anti-PRO antibodies, and/or variants of each) as well as other molecules identified by the screening assays disclosed above, can be administered for the treatment of immune related diseases, in the form of pharmaceutical compositions.

Therapeutic formulations of the active PRO molecule, preferably a polypeptide or antibody of the invention, are prepared for storage by mixing the active molecule having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or polyethylene glycol (PEG).

Compounds identified by the screening assays disclosed herein can be formulated in an analogous manner, using standard techniques well known in the art.

Lipofections or liposomes can also be used to deliver the PRO molecule into cells. Where antibody fragments are used, the smallest inhibitory fragment which specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable region sequences of an antibody, peptide

molecules can be designed which retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology (see, *e.g.*, Marasco *et al.*, *Proc. Natl. Acad. Sci. USA* 90, 7889-7893 [1993]).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise a cytotoxic agent, cytokine or growth inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active PRO molecules may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations of the PRO molecules may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$ -ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

#### N. Methods of Treatment

It is contemplated that the polypeptides, antibodies and other active compounds of the present invention may be used to treat various immune related diseases and conditions, such as T cell mediated diseases, including those characterized by infiltration of inflammatory cells into a tissue, stimulation of T-cell proliferation, inhibition of T-cell proliferation, increased or decreased vascular permeability or the inhibition thereof.

Exemplary conditions or disorders to be treated with the polypeptides, antibodies and other compounds of the invention, include, but are not limited to systemic lupus erythematosus, rheumatoid

arthritis, juvenile chronic arthritis, osteoarthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated  
5 thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease (glomerulonephritis, tubulointerstitial nephritis), demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, idiopathic demyelinating polyneuropathy or Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy, hepatobiliary diseases such as infectious hepatitis (hepatitis A, B, C, D, E  
10 and other non-hepatotropic viruses), autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel disease (ulcerative colitis: Crohn's disease), gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis, allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria, immunologic  
15 diseases of the lung such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, transplantation associated diseases including graft rejection and graft -versus-host-disease.

In systemic lupus erythematosus, the central mediator of disease is the production of auto-reactive antibodies to self proteins/tissues and the subsequent generation of immune-mediated inflammation. Antibodies either directly or indirectly mediate tissue injury. Though T lymphocytes have not been shown  
20 to be directly involved in tissue damage, T lymphocytes are required for the development of auto-reactive antibodies. The genesis of the disease is thus T lymphocyte dependent. Multiple organs and systems are affected clinically including kidney, lung, musculoskeletal system, mucocutaneous, eye, central nervous system, cardiovascular system, gastrointestinal tract, bone marrow and blood.

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that mainly  
25 involves the synovial membrane of multiple joints with resultant injury to the articular cartilage. The pathogenesis is T lymphocyte dependent and is associated with the production of rheumatoid factors, auto-antibodies directed against self IgG, with the resultant formation of immune complexes that attain high levels in joint fluid and blood. These complexes in the joint may induce the marked infiltrate of lymphocytes and monocytes into the synovium and subsequent marked synovial changes; the joint  
30 space/fluid if infiltrated by similar cells with the addition of numerous neutrophils. Tissues affected are primarily the joints, often in symmetrical pattern. However, extra-articular disease also occurs in two major forms. One form is the development of extra-articular lesions with ongoing progressive joint disease and typical lesions of pulmonary fibrosis, vasculitis, and cutaneous ulcers. The second form of extra-articular disease is the so called Felty's syndrome which occurs late in the RA disease course, sometimes after joint  
35 disease has become quiescent, and involves the presence of neutropenia, thrombocytopenia and splenomegaly. This can be accompanied by vasculitis in multiple organs with formations of infarcts, skin ulcers and gangrene. Patients often also develop rheumatoid nodules in the subcutis tissue overlying affected joints; the nodules late stage have necrotic centers surrounded by a mixed inflammatory cell infiltrate. Other manifestations which can occur in RA include: pericarditis, pleuritis, coronary arteritis,  
40 interstitial pneumonitis with pulmonary fibrosis, keratoconjunctivitis sicca, and rheumatoid nodules.

WO 2005/019258

PCT/US2004/025788

Juvenile chronic arthritis is a chronic idiopathic inflammatory disease which begins often at less than 16 years of age. Its phenotype has some similarities to RA; some patients which are rheumatoid factor positive are classified as juvenile rheumatoid arthritis. The disease is sub-classified into three major categories: pauciarticular, polyarticular, and systemic. The arthritis can be severe and is typically destructive and leads to joint ankylosis and retarded growth. Other manifestations can include chronic anterior uveitis and systemic amyloidosis.

Spondyloarthropathies are a group of disorders with some common clinical features and the common association with the expression of HLA-B27 gene product. The disorders include: ankylosing spondylitis, Reiter's syndrome (reactive arthritis), arthritis associated with inflammatory bowel disease, spondylitis associated with psoriasis, juvenile onset spondyloarthropathy and undifferentiated spondyloarthropathy. Distinguishing features include sacroileitis with or without spondylitis; inflammatory asymmetric arthritis; association with HLA-B27 (a serologically defined allele of the HLA-B locus of class I MHC); ocular inflammation, and absence of autoantibodies associated with other rheumatoid disease. The cell most implicated as key to induction of the disease is the CD8+ T lymphocyte, a cell which targets antigen presented by class I MHC molecules. CD8+ T cells may react against the class I MHC allele HLA-B27 as if it were a foreign peptide expressed by MHC class I molecules. It has been hypothesized that an epitope of HLA-B27 may mimic a bacterial or other microbial antigenic epitope and thus induce a CD8+ T cells response.

Systemic sclerosis (scleroderma) has an unknown etiology. A hallmark of the disease is induration of the skin; likely this is induced by an active inflammatory process. Scleroderma can be localized or systemic; vascular lesions are common and endothelial cell injury in the microvasculature is an early and important event in the development of systemic sclerosis; the vascular injury may be immune mediated. An immunologic basis is implied by the presence of mononuclear cell infiltrates in the cutaneous lesions and the presence of anti-nuclear antibodies in many patients. ICAM-1 is often upregulated on the cell surface of fibroblasts in skin lesions suggesting that T cell interaction with these cells may have a role in the pathogenesis of the disease. Other organs involved include: the gastrointestinal tract: smooth muscle atrophy and fibrosis resulting in abnormal peristalsis/motility; kidney: concentric subendothelial intimal proliferation affecting small arcuate and interlobular arteries with resultant reduced renal cortical blood flow, results in proteinuria, azotemia and hypertension; skeletal muscle: atrophy, interstitial fibrosis; inflammation; lung: interstitial pneumonitis and interstitial fibrosis; and heart: contraction band necrosis, scarring/fibrosis.

Idiopathic inflammatory myopathies including dermatomyositis, polymyositis and others are disorders of chronic muscle inflammation of unknown etiology resulting in muscle weakness. Muscle injury/inflammation is often symmetric and progressive. Autoantibodies are associated with most forms. These myositis-specific autoantibodies are directed against and inhibit the function of components, proteins and RNA's, involved in protein synthesis.

Sjögren's syndrome is due to immune-mediated inflammation and subsequent functional destruction of the tear glands and salivary glands. The disease can be associated with or accompanied by inflammatory connective tissue diseases. The disease is associated with autoantibody production against Ro and La antigens, both of which are small RNA-protein complexes. Lesions result in keratoconjunctivitis sicca,

WO 2005/019258

PCT/US2004/025788

xerostomia, with other manifestations or associations including biliary cirrhosis, peripheral or sensory neuropathy, and palpable purpura.

Systemic vasculitis are diseases in which the primary lesion is inflammation and subsequent damage to blood vessels which results in ischemia/necrosis/degeneration to tissues supplied by the affected vessels and eventual end-organ dysfunction in some cases. Vasculitides can also occur as a secondary lesion or sequelae to other immune-inflammatory mediated diseases such as rheumatoid arthritis, systemic sclerosis, *etc.*, particularly in diseases also associated with the formation of immune complexes. Diseases in the primary systemic vasculitis group include: systemic necrotizing vasculitis: polyarteritis nodosa, allergic angiitis and granulomatosis, polyangiitis; Wegener's granulomatosis; lymphomatoid granulomatosis; and giant cell arteritis. Miscellaneous vasculitides include: mucocutaneous lymph node syndrome (MLNS or Kawasaki's disease), isolated CNS vasculitis, Behet's disease, thromboangiitis obliterans (Buerger's disease) and cutaneous necrotizing venulitis. The pathogenic mechanism of most of the types of vasculitis listed is believed to be primarily due to the deposition of immunoglobulin complexes in the vessel wall and subsequent induction of an inflammatory response either via ADCC, complement activation, or both.

Sarcoidosis is a condition of unknown etiology which is characterized by the presence of epithelioid granulomas in nearly any tissue in the body; involvement of the lung is most common. The pathogenesis involves the persistence of activated macrophages and lymphoid cells at sites of the disease with subsequent chronic sequelae resultant from the release of locally and systemically active products released by these cell types.

Autoimmune hemolytic anemia including autoimmune hemolytic anemia, immune pancytopenia, and paroxysmal nocturnal hemoglobinuria is a result of production of antibodies that react with antigens expressed on the surface of red blood cells (and in some cases other blood cells including platelets as well) and is a reflection of the removal of those antibody coated cells via complement mediated lysis and/or ADCC/Fc-receptor-mediated mechanisms.

In autoimmune thrombocytopenia including thrombocytopenic purpura, and immune-mediated thrombocytopenia in other clinical settings, platelet destruction/removal occurs as a result of either antibody or complement attaching to platelets and subsequent removal by complement lysis, ADCC or FC-receptor mediated mechanisms.

Thyroiditis including Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, and atrophic thyroiditis, are the result of an autoimmune response against thyroid antigens with production of antibodies that react with proteins present in and often specific for the thyroid gland. Experimental models exist including spontaneous models: rats (BUF and BB rats) and chickens (obese chicken strain); inducible models: immunization of animals with either thyroglobulin, thyroid microsomal antigen (thyroid peroxidase).

Type I diabetes mellitus or insulin-dependent diabetes is the autoimmune destruction of pancreatic islet  $\beta$  cells; this destruction is mediated by auto-antibodies and auto-reactive T cells. Antibodies to insulin or the insulin receptor can also produce the phenotype of insulin-non-responsiveness.

Immune mediated renal diseases, including glomerulonephritis and tubulointerstitial nephritis, are the result of antibody or T lymphocyte mediated injury to renal tissue either directly as a result of the production of autoreactive antibodies or T cells against renal antigens or indirectly as a result of the

WO 2005/019258

PCT/US2004/025788

deposition of antibodies and/or immune complexes in the kidney that are reactive against other, non-renal antigens. Thus other immune-mediated diseases that result in the formation of immune-complexes can also induce immune mediated renal disease as an indirect sequelae. Both direct and indirect immune mechanisms result in inflammatory response that produces/induces lesion development in renal tissues with resultant organ function impairment and in some cases progression to renal failure. Both humoral and cellular immune mechanisms can be involved in the pathogenesis of lesions.

Demyelinating diseases of the central and peripheral nervous systems, including Multiple Sclerosis; idiopathic demyelinating polyneuropathy or Guillain-Barré syndrome; and Chronic Inflammatory Demyelinating Polyneuropathy, are believed to have an autoimmune basis and result in nerve demyelination as a result of damage caused to oligodendrocytes or to myelin directly. In MS there is evidence to suggest that disease induction and progression is dependent on T lymphocytes. Multiple Sclerosis is a demyelinating disease that is T lymphocyte-dependent and has either a relapsing-remitting course or a chronic progressive course. The etiology is unknown; however, viral infections, genetic predisposition, environment, and autoimmunity all contribute. Lesions contain infiltrates of predominantly T lymphocyte mediated, microglial cells and infiltrating macrophages; CD4+ T lymphocytes are the predominant cell type at lesions. The mechanism of oligodendrocyte cell death and subsequent demyelination is not known but is likely T lymphocyte driven.

Inflammatory and Fibrotic Lung Disease, including Eosinophilic Pneumonias; Idiopathic Pulmonary Fibrosis, and Hypersensitivity Pneumonitis may involve a dysregulated immune-inflammatory response. Inhibition of that response would be of therapeutic benefit.

Autoimmune or Immune-mediated Skin Disease including Bullous Skin Diseases, Erythema Multiforme, and Contact Dermatitis are mediated by auto-antibodies, the genesis of which is T lymphocyte-dependent.

Psoriasis is a T lymphocyte-mediated inflammatory disease. Lesions contain infiltrates of T lymphocytes, macrophages and antigen processing cells, and some neutrophils.

Allergic diseases, including asthma; allergic rhinitis; atopic dermatitis; food hypersensitivity; and urticaria are T lymphocyte dependent. These diseases are predominantly mediated by T lymphocyte induced inflammation, IgE mediated-inflammation or a combination of both.

Transplantation associated diseases, including Graft rejection and Graft-Versus-Host-Disease (GVHD) are T lymphocyte-dependent; inhibition of T lymphocyte function is ameliorative.

Other diseases in which intervention of the immune and/or inflammatory response have benefit are infectious disease including but not limited to viral infection (including but not limited to AIDS, hepatitis A, B, C, D, E and herpes) bacterial infection, fungal infections, and protozoal and parasitic infections (molecules (or derivatives/agonists) which stimulate the MLR can be utilized therapeutically to enhance the immune response to infectious agents), diseases of immunodeficiency (molecules/derivatives/agonists) which stimulate the MLR can be utilized therapeutically to enhance the immune response for conditions of inherited, acquired, infectious induced (as in HIV infection), or iatrogenic (*i.e.*, as from chemotherapy) immunodeficiency, and neoplasia.

It has been demonstrated that some human cancer patients develop an antibody and/or T lymphocyte response to antigens on neoplastic cells. It has also been shown in animal models of neoplasia

WO 2005/019258

PCT/US2004/025788

that enhancement of the immune response can result in rejection or regression of that particular neoplasm. Molecules that enhance the T lymphocyte response in the MLR have utility *in vivo* in enhancing the immune response against neoplasia. Molecules which enhance the T lymphocyte proliferative response in the MLR (or small molecule agonists or antibodies that affected the same receptor in an agonistic fashion) can be used therapeutically to treat cancer. Molecules that inhibit the lymphocyte response in the MLR also function *in vivo* during neoplasia to suppress the immune response to a neoplasm; such molecules can either be expressed by the neoplastic cells themselves or their expression can be induced by the neoplasm in other cells. Antagonism of such inhibitory molecules (either with antibody, small molecule antagonists or other means) enhances immune-mediated tumor rejection.

Additionally, inhibition of molecules with proinflammatory properties may have therapeutic benefit in reperfusion injury; stroke; myocardial infarction; atherosclerosis; acute lung injury; hemorrhagic shock; burn; sepsis/septic shock; acute tubular necrosis; endometriosis; degenerative joint disease and pancreatitis.

The compounds of the present invention, *e.g.*, polypeptides or antibodies, are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation (intranasal, intrapulmonary) routes. Intravenous or inhaled administration of polypeptides and antibodies is preferred.

In immunoadjuvant therapy, other therapeutic regimens, such administration of an anti-cancer agent, may be combined with the administration of the proteins, antibodies or compounds of the instant invention. For example, the patient to be treated with a the immunoadjuvant of the invention may also receive an anti-cancer agent (chemotherapeutic agent) or radiation therapy. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in *Chemotherapy Service* Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of the immunoadjuvant or may be given simultaneously therewith. Additionally, an anti-estrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) may be given in dosages known for such molecules.

It may be desirable to also administer antibodies against other immune disease associated or tumor associated antigens, such as antibodies which bind to CD20, CD11a, CD18, ErbB2, EGFR, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more antibodies binding the same or two or more different antigens disclosed herein may be coadministered to the patient. Sometimes, it may be beneficial to also administer one or more cytokines to the patient. In one embodiment, the PRO polypeptides are coadministered with a growth inhibitory agent. For example, the growth inhibitory agent may be administered first, followed by a PRO polypeptide. However, simultaneous administration or administration first is also contemplated. Suitable dosages for the growth inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth inhibitory agent and the PRO polypeptide.

For the treatment or reduction in the severity of immune related disease, the appropriate dosage of an a compound of the invention will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the agent is administered for preventive or therapeutic purposes,

previous therapy, the patient's clinical history and response to the compound, and the discretion of the attending physician. The compound is suitably administered to the patient at one time or over a series of treatments.

For example, depending on the type and severity of the disease, about 1 µg/kg to 15 mg/kg (*e.g.*, 0.1-20 mg/kg) of polypeptide or antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

O. Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing materials (*e.g.*, comprising a PRO molecule) useful for the diagnosis or treatment of the disorders described above is provided. The article of manufacture comprises a container and an instruction. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for diagnosing or treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is usually a polypeptide or an antibody of the invention. An instruction or label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

P. Diagnosis and Prognosis of Immune Related Disease

Cell surface proteins, such as proteins which are overexpressed in certain immune related diseases, are excellent targets for drug candidates or disease treatment. The same proteins along with secreted proteins encoded by the genes amplified in immune related disease states find additional use in the diagnosis and prognosis of these diseases. For example, antibodies directed against the protein products of genes amplified in multiple sclerosis, rheumatoid arthritis, or another immune related disease, can be used as diagnostics or prognostics.

For example, antibodies, including antibody fragments, can be used to qualitatively or quantitatively detect the expression of proteins encoded by amplified or overexpressed genes ("marker gene products"). The antibody preferably is equipped with a detectable, *e.g.*, fluorescent label, and binding can be monitored by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. These techniques are particularly suitable, if the overexpressed gene encodes a cell surface protein. Such binding assays are performed essentially as described above.

*In situ* detection of antibody binding to the marker gene products can be performed, for example, by immunofluorescence or immunoelectron microscopy. For this purpose, a histological specimen is removed from the patient, and a labeled antibody is applied to it, preferably by overlaying the antibody on a biological



WO 2005/019258

PCT/US2004/025788

sample. This procedure also allows for determining the distribution of the marker gene product in the tissue examined. It will be apparent for those skilled in the art that a wide variety of histological methods are readily available for *in situ* detection.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

#### EXAMPLE 1: Microarray analysis of stimulated T-cells

Nucleic acid microarrays, often containing thousands of gene sequences, are useful for identifying differentially expressed genes in diseased tissues as compared to their normal counterparts. Using nucleic acid microarrays, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The cDNA probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is configured such that the sequence and position of each member of the array is known. For example, a selection of genes known to be expressed in certain disease states may be arrayed on a solid support. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. If the hybridization signal of a probe from a test (for example, activated CD4+ T cells) sample is greater than hybridization signal of a probe from a control (for example, non-stimulated CD4 + T cells) sample, the gene or genes overexpressed in the test tissue are identified. The implication of this result is that an overexpressed protein in a test tissue is useful not only as a diagnostic marker for the presence of a disease condition, but also as a therapeutic target for treatment of a disease condition.

The methodology of hybridization of nucleic acids and microarray technology is well known in the art. In one example, the specific preparation of nucleic acids for hybridization and probes, slides, and hybridization conditions are all detailed in PCT Patent Application Serial No. PCT/US01/10482, filed on March 30, 2001 and which is herein incorporated by reference.

When CD4+ T cells mature from thymus and enter into the peripheral lymph system, they usually maintain their naive phenotype before encountering antigens specific for their T cell receptor [Sprent et al., *Annu Rev Immunol.* (2002); 20:551-79]. The binding to specific antigens presented by APC, causes T cell activation. Depending on the environment and cytokine stimulation, CD4+ T cells differentiate into a Th1 or Th2 phenotype and become effector or memory cells [Sprent et al., *Annu Rev Immunol.* (2002); 20:551-79 and Murphy et al., *Nat Rev Immunol.* (2002) Dec;2(12):933-44]. This process is known as primary activation. Having undergone primary activation, CD4+ T cells become effector or memory cells, they maintain their phenotype as Th1 or Th2. Once these cells encounter antigen again, they undergo secondary activation, but this time the response to antigen will be quicker than the primary activation and results in the

WO 2005/019258

PCT/US2004/025788

production of effector cytokines as determined by the primary activation [Sprent et al., *Annu Rev Immunol.* (2002); 20:551-79 and Murphy et al., *Annu Rev Immunol.* 2000;18:451-94].

Studies have found during the primary and secondary activation of CD4 + T cells the expression of certain genes is variable [Rogge et al., *Nature Genetics.* 25, 96 - 101 (2000) and Ouyang et al., *Proc Natl Acad Sci U S A.* (1999) Mar 30;96(7):3888-93]. The present study represents a model to identify differentially expressed genes during the primary and secondary activation response *in vitro*.

For primary activation conditions, naïve T cells were activated by anti-CD3, anti-CD28 and specific cytokines (experimental conditions are described below). This primary activation was termed condition (a). RNA isolated from cells in this condition can provide information about what genes are differentially regulated during the primary activation, and what cytokines affect gene expression during Th1 and Th2 development. After primary activation, the CD4+ T cells were maintained in culture for a week. However, as the previous activation and cytokine treatment has been imprinted into these cells and they have become either effector or memory cells. During this period, because there are no APCs or antigens, the CD4+ T cells enter a resting stage. This resting stage, termed condition (b) (with experimental conditions described below), provides information about the differences between naïve vs. memory cells, and resting memory Th1 vs. resting memory Th2 cells. The resting memory Th1 and Th2 cells then undergo secondary activation under condition (c) and condition (d), with both conditions being described below. These conditions provide information about the differences between activated naïve and activated memory T cells, and the differences between activated memory Th1 vs. activated memory Th2 cells. This study demonstrates differential gene expression during different stages of CD4 T cell activation and differentiation. As we know, many autoimmune diseases are caused by memory Th1 and Th2 cells. The data now provide us opportunity to find markers to identify these cells and specifically target these cells as a new therapeutic approach.

In this experiment, CD4+ T cells were purified from a single donor using the RosetteSep™ protocol (Stem Cell Technologies, Vancouver BC) which contains anti-CD8, anti-CD16, anti-CD19, anti-CD36 and anti-CD56 antibodies used to produce a population of isolated CD4 + T cells with the modification to the protocol of using 1.3 ml reagent/25ml blood. The isolated CD4+ T cells were washed by PBS (0.5% BSA) twice and counted. Naïve CD4+ T cells were further isolated by Miltenyi CD45RO beads (Miltenyi Biotec) through the autoMACS™ depletion program and the purity of the cells was determined by FACS analysis. Experiments proceeded only with >90% cell pure CD4+ T cells. At this point RNA was extracted from  $50 \times 10^6$  CD4+ T cells for use as a baseline control. The remainder of the cells were stimulated by plate bound anti-CD3 and anti-CD28 at  $20 \times 10^6$  cells / 6 ml T cell media / well of a 6 well plate.

On Day 1, to induce Th1 differentiation, IL-12 (1 ng/ml) and anti-IL-4 (1µ/ml) were added. For Th2 differentiation, IL-4 (5 ng/ml), anti-IL-12 (0.5 µg/ml), and anti-IFN-γ were added. For Th0 cells, anti-IL-12 (0.5 µg/ml), anti-IL-4 (1µg/ml) and anti-IFN-γ (0.1 µg/ml) were added. All reagents were from R&D Systems (R & D Systems Inc. Minneapolis, MN).

On Day 2, cells from one well per condition were harvested for RNA purification to obtain a 48hr time point (condition (a)). On Day 3, the cells were expanded 4 fold by removing the media used for differentiation, and adding fresh media plus IL-2 and cultured for 4 days. On Day 7, the cells were washed

and counted, and the cytokine profiles were examined by intracellular cytokine staining and ELISA to determine if differentiation was complete. Half of the cells were harvested and RNA purified to determine the expression of genes in the resting state (condition (b)). IL-4 and IFN-gamma producing cells were enriched for by using the Miltenyi™ cytokine assay kit. The isolated IL-4 or IFN-gamma producing cells were expanded for two more weeks by using similar conditions as above.

On Day 21, cells were harvested and subject to intracellular cytokine staining and ELISA for cytokine production analysis. The remainder of the cells were re-stimulated by anti-CD3 and anti-CD28 (secondary activation). Cells were harvested at 12 hr (condition (c)) and 48 hr (condition (d)) for RNA purification. From the different conditions, RNA was extracted and analysis run on Affimax (Affymetrix Inc. Santa Clara, CA) microarray chips. Non-stimulated cells harvested immediately after purification, were subjected to the same analysis. Genes were compared whose expression was upregulated or downregulated at the different activated conditions vs. resting cells.

Below are the results of these experiments, demonstrating that various PRO polypeptides of the present invention are significantly upregulated or downregulated in isolated stimulated CD4+ T helper cells as compared to unstimulated CD4+ T helper cells or isolated resting CD4+ T helper cells. As Th1 and Th2 cells play a role in normal immune defense during infection, and play a role in immune disorders, this data demonstrate that the PRO polypeptides of the present invention are useful not only as diagnostic markers for the presence of one or more immune disorders, but also serve as therapeutic targets for the treatment of those immune disorders.

SEQ ID NOs 1-6464 show nucleic acids and their encoded proteins show differential expression at (condition (c)) or (condition (d)) vs. unstimulated cells as a normal control, cells that have undergone primary activation, or primary activated cells that had been in resting for 7 days. SEQ ID NO:2955, SEQ ID NO:2855, SEQ ID NO:3487, SEQ ID NO:3088, SEQ ID NO:1319, SEQ ID NO:1629, SEQ ID NO:1733, SEQ ID NO:1561, and SEQ ID NO:1699 are highly overexpressed at (condition (c)) or (condition (d)) vs. unstimulated cells as a normal control, cells that have undergone primary activation, or primary activated cells that had been in resting for 7 days.

#### EXAMPLE 2: Use of PRO as a hybridization probe

The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.

DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.

Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.

### EXAMPLE 3: Expression of PRO in *E. coli*

This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

5       The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR  
10       amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene.

15       The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

20       Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

25       PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal  
30       chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110 fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium  
35       citrate•2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

40       *E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step

results in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 4: Expression of PRO in mammalian cells

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10 µg pRK5-PRO DNA is mixed with about 1 µg DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500 µl of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl<sub>2</sub>. To this mixture is added, dropwise, 500 µl of 50

WO 2005/019258

PCT/US2004/025788

mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 µCi/ml <sup>35</sup>S-cysteine and 200 µCi/ml <sup>35</sup>S-methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Sompariyac et al., *Proc. Natl. Acad. Sci.*, 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 µg pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 µg/ml bovine insulin and 0.1 µg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as CaPO<sub>4</sub> or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as <sup>35</sup>S-methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 promoter/enhancer containing vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 promoter/enhancer containing vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be concentrated and purified by any selected method, such as by Ni<sup>2+</sup>-chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g.

WO 2005/019258

PCT/US2004/025788

extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect® (Quiagen), Dosper® or Eugene® (Boehringer Mannheim). The cells are grown as described in Lucas et al., supra. Approximately  $3 \times 10^7$  cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mL of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 µm filtered PS20 with 5% 0.2 µm diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with  $3 \times 10^5$  cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at  $1.2 \times 10^6$  cells/mL. On day 0, pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22 µm filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration

WO 2005/019258

PCT/US2004/025788

buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ l of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 5: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 6: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO in Baculovirus-infected insect cells.

The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold<sup>TM</sup> virus DNA (Pharmingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as



described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO can then be purified, for example, by  $\text{Ni}^{2+}$ -chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by  
5 Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM  $\text{MgCl}_2$ ; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45  $\mu\text{m}$  filter. A  $\text{Ni}^{2+}$ -NTA agarose column (commercially available from Qiagen) is prepared  
10 with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline  $A_{280}$  with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching  $A_{280}$  baseline again, the column is developed with a 0 to 500  
15 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with  $\text{Ni}^{2+}$ -NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

20 Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 7: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.

Techniques for producing the monoclonal antibodies are known in the art and are described, for  
25 instance, in Goding, supra. Immunogens that may be employed include purified PRO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms.  
30 Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO antibodies.

35 After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT

WO 2005/019258

PCT/US2004/025788

(hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### EXAMPLE 8: Purification of PRO Polypeptides Using Specific Antibodies

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

#### EXAMPLE 9: Drug Screening

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or

fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable  
5 or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can  
10 affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or  
15 fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September  
20 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture  
25 the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

#### 30 EXAMPLE 10: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or  
35 stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of a PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must  
40 be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful

WO 2005/019258

PCT/US2004/025788

information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, 5 Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by 10 generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made 15 available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since 20 the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications 25 of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

**WO 2005/019258**

**PCT/US2004/025788**

**APPENDIX A**

## List of Figures

- Figure 1: DNA344243, U25789, 200012\_x.at  
Figure 2: PRO94991  
Figure 3: DNA326466, NP\_004530.1, 200027.at  
Figure 4: PRO60800  
Figure 5: DNA326324, NP\_000972.1, 200029.at  
Figure 6: PRO4738  
Figure 7: DNA344244, NP\_006324.1, 200056.s.at  
Figure 8: PRO61385  
Figure 9: DNA304680, NP\_031381.2, 200064.at  
Figure 10: PRO71106  
Figure 11: DNA325222, NP\_000967.1, 200088\_x.at  
Figure 12: PRO62236  
Figure 13: DNA270963, NP\_003326.1, 1294.at  
Figure 14: PRO59293  
Figure 15: DNA188207, NP\_005371.1, 37005.at  
Figure 16: PRO21719  
Figure 17: DNA333633, NP\_055697.1, 38149.at  
Figure 18: PRO88275  
Figure 19: DNA254127, NP\_008925.1, 38241.at  
Figure 20: PRO49242  
Figure 21A-B: DNA329908, BAA13246.1, 38892.at  
Figure 22: PRO85225  
Figure 23: DNA327523, NP\_004916.1, 39248.at  
Figure 24: PRO38028  
Figure 25: DNA328357, 1452321.2, 39582.at  
Figure 26: PRO84217  
Figure 27A-B: DNA273398, NP\_056383.1, 41577.at  
Figure 28: PRO61398  
Figure 29: DNA327526, NP\_065727.2, 45288.at  
Figure 30: PRO83574  
Figure 31: DNA344245, AF177331, 47069.at  
Figure 32: PRO94992  
Figure 33A-B: DNA335121, NP\_066300.1, 47550.at  
Figure 34: PRO89524  
Figure 35: DNA344246, NP\_009093.1, 50221.at  
Figure 36: PRO94993  
Figure 37A-B: DNA226870, NP\_000782.1, 48808.at  
Figure 38: PRO37333  
Figure 39A-B: DNA194778, NP\_055545.1, 200617.at  
Figure 40: PRO24056  
Figure 41: DNA287245, NP\_004175.1, 200628.s.at  
Figure 42: PRO69520  
Figure 43: DNA287245, NM\_004184, 200629.at  
Figure 44: PRO69520  
Figure 45: DNA327532, NP\_002056.2, 200648.s.at  
Figure 46: PRO71134  
Figure 47: DNA226063, X05130, 200656.s.at  
Figure 48: PRO36526  
Figure 49: DNA274759, NP\_005611.1, 200660.at  
Figure 50: PRO62529  
Figure 51: DNA324276, NP\_000985.1, 200674.s.at  
Figure 52: PRO80959  
Figure 53: DNA304669, NP\_002119.1, 200679\_x.at  
Figure 54: PRO71096  
Figure 55A-B: DNA344247, 7684654.2, 200690.at  
Figure 56: PRO94994  
Figure 57: DNA344248, NP\_004125.3, 200691.s.at  
Figure 58: PRO94995  
Figure 59: DNA344249, NM\_004134, 200692.s.at  
Figure 60: PRO94996  
Figure 61: DNA324897, NP\_006845.1, 200700.s.at  
Figure 62: PRO12468  
Figure 63: DNA328375, NP\_002071.1, 200708.at  
Figure 64: PRO80880  
Figure 65: DNA327114, NP\_006004.1, 200725\_x.at  
Figure 66: PRO62466  
Figure 67: DNA323943, NP\_001021.1, 200741.s.at  
Figure 68: PRO80676  
Figure 69: DNA344250, NP\_000382.3, 200742.s.at  
Figure 70: PRO94997  
Figure 71: DNA304659, NP\_002023.1, 200748.s.at  
Figure 72: PRO71086  
Figure 73: DNA344251, 7762050.6, 200749.at  
Figure 74: PRO94998  
Figure 75: DNA287207, NP\_006316.1, 200750.s.at  
Figure 76: PRO39268  
Figure 77A-B: DNA344252, NP\_001377.1, 200762.at  
Figure 78: PRO62709  
Figure 79: DNA225584, NP\_001145.1, 200782.at  
Figure 80: PRO36047  
Figure 81: DNA226262, NP\_005554.1, 200783.s.at  
Figure 82: PRO36725  
Figure 83: DNA324060, NP\_002530.1, 200790.at  
Figure 84: PRO80773  
Figure 85: DNA287211, NP\_002147.1, 200806.s.at  
Figure 86: PRO69492  
Figure 87: DNA287211, NM\_002156, 200807.s.at  
Figure 88: PRO69492  
Figure 89: DNA325222, NM\_000976, 200809\_x.at  
Figure 90: PRO62236  
Figure 91: DNA269874, NP\_001271.1, 200810.s.at  
Figure 92: PRO58272  
Figure 93: DNA269874, NM\_001280, 200811.at  
Figure 94: PRO58272  
Figure 95: DNA227795, NP\_006420.1, 200812.at  
Figure 96: PRO38258  
Figure 97: DNA189687, NP\_000843.1, 200824.at  
Figure 98: PRO25845  
Figure 99A-B: DNA255281, NP\_006380.1, 200825.s.at  
Figure 100: PRO50357  
Figure 101: DNA88165, M14221, 200838.at  
Figure 102: PRO2678  
Figure 103: DNA196817, L16510, 200839.s.at  
Figure 104: PRO3344  
Figure 105: DNA326615, NP\_000971.1, 200869.at  
Figure 106: PRO82971  
Figure 107: DNA226112, NP\_002769.1, 200871.s.at

WO 2005/019258

PCT/US2004/025788

Figure 108: PRO36575  
Figure 109: DNA254537, NP\_002957.1, 200872.at  
Figure 110: PRO49642  
Figure 111: DNA254572, NP\_006576.1, 200873.s.at  
Figure 112: PRO49675  
Figure 113: DNA271030, NP\_006383.1, 200875.s.at  
Figure 114: PRO59358  
Figure 115: DNA324107, NP\_006421.1, 200877.at  
Figure 116: PRO80814  
Figure 117: DNA328379, BC015869, 200878.at  
Figure 118: PRO84234  
Figure 119: DNA329099, 1164406.9, 200880.at  
Figure 120: PRO60127  
Figure 121: DNA271847, NP\_001530.1, 200881.s.at  
Figure 122: PRO60127  
Figure 123: DNA226124, NP\_003135.1, 200890.s.at  
Figure 124: PRO36587  
Figure 125: DNA325584, NP\_002005.1, 200894.s.at  
Figure 126: PRO59262  
Figure 127: DNA325584, NM\_002014, 200895.s.at  
Figure 128: PRO59262  
Figure 129: DNA272961, NP\_004485.1, 200896.x.at  
Figure 130: PRO61041  
Figure 131A-B: DNA329018, NP\_057165.2, 200897.s.at  
Figure 132: PRO84693  
Figure 133: DNA328380, X64879, 200904.at  
Figure 134A-B: DNA329018, NM\_016081, 200907.s.at  
Figure 135: PRO84693  
Figure 136: DNA304665, NP\_000995.1, 200909.s.at  
Figure 137: PRO71092  
Figure 138: DNA272974, NP\_005989.1, 200910.at  
Figure 139: PRO61054  
Figure 140: DNA272695, NP\_001722.1, 200920.s.at  
Figure 141: PRO60817  
Figure 142: DNA272695, NM\_001731, 200921.s.at  
Figure 143: PRO60817  
Figure 144A-B: DNA270430, NP\_054706.1, 200931.s.at  
Figure 145: PRO58810  
Figure 146: DNA325153, NP\_150644.1, 200936.at  
Figure 147: PRO22907  
Figure 148: DNA329925, NP\_001528.1, 200942.s.at  
Figure 149: PRO85239  
Figure 150A-B: DNA287217, NP\_001750.1, 200951.s.at  
Figure 151: PRO36766  
Figure 152A-B: DNA287217, NM\_001759, 200952.s.at  
Figure 153: PRO36766  
Figure 154A-B: DNA226303, D13639, 200953.s.at  
Figure 155: PRO36766  
Figure 156: DNA324149, NP\_000984.1, 200963.x.at  
Figure 157: PRO11197  
Figure 158A-C: DNA344253, NP\_002304.2, 200965.s.at  
Figure 159: PRO94999  
Figure 160: DNA344254, AL137335, 200992.at  
Figure 161: DNA325778, NP\_006816.2, 200998.s.at  
Figure 162: PRO82248  
Figure 163: DNA325778, NM\_006825, 200999.s.at  
Figure 164: PRO82248  
Figure 165: DNA275408, NP\_001596.1, 201000.at  
Figure 166: PRO63068  
Figure 167: DNA328387, NP\_001760.1, 201005.at  
Figure 168: PRO4769  
Figure 169: DNA304713, NP\_006463.2, 201008.s.at  
Figure 170: PRO71139  
Figure 171: DNA304713, NM\_006472, 201009.s.at  
Figure 172: PRO71139  
Figure 173: DNA304713, S73591, 201010.s.at  
Figure 174: PRO71139  
Figure 175: DNA89242, NP\_000691.1, 201012.at  
Figure 176: PRO2907  
Figure 177: DNA328388, NP\_006443.1, 201014.s.at  
Figure 178: PRO84240  
Figure 179A-B: DNA344255, 1327792.5, 201016.at  
Figure 180: PRO95001  
Figure 181: DNA328389, NP\_006861.1, 201022.s.at  
Figure 182: PRO84241  
Figure 183: DNA344256, NP\_005633.2, 201023.at  
Figure 184: PRO95002  
Figure 185A-B: DNA329101, NP\_056988.2, 201024.x.at  
Figure 186: PRO84751  
Figure 187: DNA196628, NP\_005318.1, 201036.s.at  
Figure 188: PRO25105  
Figure 189: DNA328391, NP\_004408.1, 201041.s.at  
Figure 190: PRO84242  
Figure 191: DNA344257, NP\_006296.1, 201043.s.at  
Figure 192: PRO95003  
Figure 193: DNA103208, NP\_004090.3, 201061.s.at  
Figure 194: PRO4538  
Figure 195: DNA344258, NP\_003810.1, 201064.s.at  
Figure 196: PRO62717  
Figure 197: DNA344259, NP\_001907.2, 201066.at  
Figure 198: PRO95004  
Figure 199: DNA151675, NP\_004791.1, 201078.at  
Figure 200: PRO11975  
Figure 201: DNA274743, NP\_002850.1, 201087.at  
Figure 202: PRO62517  
Figure 203: DNA254725, NP\_002257.1, 201088.at  
Figure 204: PRO49824  
Figure 205: DNA304719, NP\_002296.1, 201105.at  
Figure 206: PRO71145  
Figure 207: DNA344260, NP\_003312.2, 201113.at  
Figure 208: PRO95005  
Figure 209: DNA326273, NP\_001961.1, 201123.s.at  
Figure 210: PRO82678  
Figure 211: DNA271185, NP\_002397.1, 201126.s.at  
Figure 212: PRO59502

WO 2005/019258

PCT/US2004/025788

Figure 213: DNA344261, NP\_062543.1, 201132.at  
 Figure 214: PRO95006  
 Figure 215A-B: DNA227128, NP\_055634.1, 201133.s.at  
 Figure 216: PRO37591  
 Figure 217: DNA329104, NP\_004085.1, 201144.s.at  
 Figure 218: PRO69550  
 Figure 219: DNA344262, NP\_000959.2, 201154.x.at  
 Figure 220: PRO95007  
 Figure 221A-B: DNA326365, NP\_066565.1, 201158.at  
 Figure 222: PRO82761  
 Figure 223: DNA334099, NP\_003642.2, 201161.s.at  
 Figure 224: PRO85244  
 Figure 225: DNA151802, NP\_003661.1, 201169.s.at  
 Figure 226: PRO12890  
 Figure 227: DNA151802, NM\_003670, 201170.s.at  
 Figure 228: PRO12890  
 Figure 229: DNA329091, NP\_003936.1, 201171.at  
 Figure 230: PRO11997  
 Figure 231: DNA323783, NP\_006591.1, 201173.x.at  
 Figure 232: PRO80535  
 Figure 233A-B: DNA344263, NP\_003477.2, 201195.s.at  
 Figure 234: PRO49192  
 Figure 235: DNA328400, NP\_003842.1, 201200.at  
 Figure 236: PRO1409  
 Figure 237: DNA103488, NP\_002583.1, 201202.at  
 Figure 238: PRO4815  
 Figure 239: DNA344264, NP\_005023.2, 201215.at  
 Figure 240: PRO83378  
 Figure 241: DNA326974, NP\_000958.1, 201217.x.at  
 Figure 242: PRO83285  
 Figure 243: DNA327544, NP\_002865.1, 201222.s.at  
 Figure 244: PRO70357  
 Figure 245: DNA344265, NP\_006754.1, 201235.s.at  
 Figure 246: PRO80725  
 Figure 247: DNA275049, NP\_004930.1, 201241.at  
 Figure 248: PRO62770  
 Figure 249: DNA226615, NP\_001668.1, 201242.s.at  
 Figure 250: PRO37078  
 Figure 251: DNA226615, NM\_001677, 201243.s.at  
 Figure 252: PRO37078  
 Figure 253: DNA287331, NP\_002645.1, 201251.at  
 Figure 254: PRO69595  
 Figure 255: DNA324525, NP\_000997.1, 201257.x.at  
 Figure 256: PRO81179  
 Figure 257: DNA227416, NP\_006745.1, 201259.s.at  
 Figure 258: PRO37879  
 Figure 259: DNA227416, NM\_006754, 201260.s.at  
 Figure 260: PRO37879  
 Figure 261: DNA270950, NP\_003182.1, 201263.at  
 Figure 262: PRO59281  
 Figure 263: DNA97290, NP\_002503.1, 201268.at  
 Figure 264: PRO3637  
 Figure 265: DNA344266, AF267863, 201276.at  
 Figure 266: PRO95008  
 Figure 267: DNA328405, NP\_112556.1, 201277.s.at  
 Figure 268: PRO84252  
 Figure 269: DNA331290, NP\_038474.1, 201285.at  
 Figure 270: PRO86391  
 Figure 271: DNA270526, NP\_001166.1, 201288.at  
 Figure 272: PRO58903  
 Figure 273A-B: DNA327545, NP\_001058.2, 201291.s.at  
 Figure 274: PRO82731  
 Figure 275A-B: DNA327545, NM\_001067, 201292.at  
 Figure 276: PRO82731  
 Figure 277A-B: DNA344267, NM\_134264, 201294.s.at  
 Figure 278: PRO95009  
 Figure 279A-B: DNA226778, AL110269, 201295.s.at  
 Figure 280: PRO37241  
 Figure 281: DNA333423, NP\_001144.1, 201301.s.at  
 Figure 282: PRO61325  
 Figure 283: DNA333423, NM\_001153, 201302.at  
 Figure 284: PRO61325  
 Figure 285: DNA329106, NP\_003013.1, 201311.s.at  
 Figure 286: PRO83360  
 Figure 287: DNA329106, NM\_003022, 201312.s.at  
 Figure 288: PRO83360  
 Figure 289: DNA255078, NP\_006426.1, 201315.x.at  
 Figure 290: PRO50165  
 Figure 291: DNA274745, NP\_006815.1, 201323.at  
 Figure 292: PRO62518  
 Figure 293: DNA150781, NP\_001414.1, 201324.at  
 Figure 294: PRO12467  
 Figure 295: DNA150781, NM\_001423, 201325.s.at  
 Figure 296: PRO12467  
 Figure 297: DNA329002, NP\_001753.1, 201326.at  
 Figure 298: PRO4912  
 Figure 299: DNA329002, NM\_001762, 201327.s.at  
 Figure 300: PRO4912  
 Figure 301A-C: DNA271656, NP\_056128.1, 201334.s.at  
 Figure 302: PRO59943  
 Figure 303: DNA329107, NP\_008818.3, 201367.s.at  
 Figure 304: PRO84754  
 Figure 305A-B: DNA329108, 1383643.16, 201368.at  
 Figure 306: PRO84755  
 Figure 307: DNA329107, NM\_006887, 201369.s.at  
 Figure 308: PRO84754  
 Figure 309: DNA329218, NP\_055227.1, 201381.x.at  
 Figure 310: PRO84829  
 Figure 311: DNA344268, NP\_002800.2, 201388.at  
 Figure 312: PRO63269  
 Figure 313: DNA326116, NP\_057376.1, 201391.at  
 Figure 314: PRO82542  
 Figure 315: DNA331447, NP\_006614.2, 201397.at  
 Figure 316: PRO85247  
 Figure 317: DNA328410, NP\_004519.1, 201403.s.at  
 Figure 318: PRO60174  
 Figure 319: DNA327072, NP\_066357.1, 201406.at



WO 2005/019258

PCT/US2004/025788

Figure 320: PRO10723  
 Figure 321: DNA344269, NP\_077007.1, 201420.s.at  
 Figure 322: PRO95010  
 Figure 323: DNA272286, NP\_001743.1, 201432.at  
 Figure 324: PRO60544  
 Figure 325A-C: DNA88140, NP\_004360.1, 201438.at  
 Figure 326: PRO2670  
 Figure 327: DNA344270, NP\_071505.1, 201450.s.at  
 Figure 328: PRO95011  
 Figure 329: DNA326736, NP\_006657.1, 201459.at  
 Figure 330: PRO83076  
 Figure 331: DNA226359, NP\_002219.1, 201464.x.at  
 Figure 332: PRO36822  
 Figure 333: DNA226359, NM\_002228, 201466.s.at  
 Figure 334: PRO36822  
 Figure 335: DNA328414, NP\_003891.1, 201471.s.at  
 Figure 336: PRO81346  
 Figure 337: DNA103320, NP\_002220.1, 201473.at  
 Figure 338: PRO4650  
 Figure 339: DNA325704, NP\_004981.2, 201475.x.at  
 Figure 340: PRO82188  
 Figure 341: DNA327551, NP\_001024.1, 201476.s.at  
 Figure 342: PRO59289  
 Figure 343: DNA327551, NM\_001033, 201477.s.at  
 Figure 344: PRO59289  
 Figure 345: DNA254783, NP\_001354.1, 201478.s.at  
 Figure 346: PRO49881  
 Figure 347: DNA254783, NM\_001363, 201479.at  
 Figure 348: PRO49881  
 Figure 349: DNA329940, NP\_001805.1, 201487.at  
 Figure 350: PRO2679  
 Figure 351: DNA304459, NP\_005720.1, 201489.at  
 Figure 352: PRO37073  
 Figure 353: DNA304459, NM\_005729, 201490.s.at  
 Figure 354: PRO37073  
 Figure 355: DNA325920, NP\_036243.1, 201491.at  
 Figure 356: PRO82373  
 Figure 357: DNA253807, NP\_065390.1, 201502.s.at  
 Figure 358: PRO49210  
 Figure 359: DNA329941, NP\_001543.1, 201508.at  
 Figure 360: PRO85249  
 Figure 361: DNA323741, NP\_003123.1, 201516.at  
 Figure 362: PRO80498  
 Figure 363: DNA344271, NP\_073719.1, 201522.x.at  
 Figure 364: PRO62659  
 Figure 365: DNA328418, NP\_003398.1, 201531.at  
 Figure 366: PRO84261  
 Figure 367: DNA329943, NP\_009037.1, 201534.s.at  
 Figure 368: PRO85251  
 Figure 369: DNA329943, NM\_007106, 201535.at  
 Figure 370: PRO85251  
 Figure 371: DNA329553, NP\_064535.1, 201543.s.at  
 Figure 372: PRO38313  
 Figure 373: DNA344272, NP\_004121.2, 201554.x.at  
 Figure 374: PRO95012  
 Figure 375: DNA272171, NP\_002379.2, 201555.at

Figure 376: PRO60438  
 Figure 377: DNA226291, NP\_055047.1, 201557.at  
 Figure 378: PRO36754  
 Figure 379A-B: DNA290226, NP\_039234.1, 201559.s.at  
 Figure 380: PRO70317  
 Figure 381A-B: DNA290226, NM\_013943, 201560.at  
 Figure 382: PRO70317  
 Figure 383: DNA227478, NP\_002157.1, 201565.s.at  
 Figure 384: PRO37941  
 Figure 385: DNA150986, D13891, 201566.x.at  
 Figure 386: PRO0  
 Figure 387: DNA344273, M75715, 201573.s.at  
 Figure 388: PRO95013  
 Figure 389A-B: DNA270995, NP\_004721.1, 201574.at  
 Figure 390: PRO59324  
 Figure 391: DNA227071, NP\_000260.1, 201577.at  
 Figure 392: PRO37534  
 Figure 393A-B: DNA329944, AB032988, 201581.at  
 Figure 394: DNA227013, NP\_001560.1, 201587.s.at  
 Figure 395: PRO37476  
 Figure 396: DNA150990, NP\_003632.1, 201601.x.at  
 Figure 397: PRO12570  
 Figure 398: DNA290280, NP\_004359.1, 201605.x.at  
 Figure 399: PRO70425  
 Figure 400: DNA329947, NP\_536806.1, 201613.s.at  
 Figure 401: PRO37674  
 Figure 402: DNA188207, NM\_005380, 201621.at  
 Figure 403: PRO21719  
 Figure 404: DNA329114, NP\_001340.1, 201623.s.at  
 Figure 405: PRO84759  
 Figure 406: DNA329114, NM\_001349, 201624.at  
 Figure 407: PRO84759  
 Figure 408: DNA344274, 7698185.18, 201626.at  
 Figure 409: PRO95014  
 Figure 410A-D: DNA344275, U96876, 201627.s.at  
 Figure 411: DNA344276, NM\_004300, 201629.s.at  
 Figure 412: PRO89350  
 Figure 413: DNA329115, NP\_434702.1, 201631.s.at  
 Figure 414: PRO84760  
 Figure 415: DNA326193, NP\_085056.1, 201634.s.at  
 Figure 416: PRO82609  
 Figure 417: DNA287240, NP\_004326.1, 201641.at  
 Figure 418: PRO29371  
 Figure 419: DNA88410, NP\_005525.1, 201642.at  
 Figure 420: PRO2778  
 Figure 421A-B: DNA220748, NP\_000201.1, 201656.at  
 Figure 422: PRO34726  
 Figure 423: DNA328423, NP\_003245.1, 201666.at  
 Figure 424: PRO2121  
 Figure 425: DNA344277, NP\_683877.1, 201676.x.at  
 Figure 426: PRO81959  
 Figure 427: DNA324742, NP\_001751.1, 201700.at  
 Figure 428: PRO81367  
 Figure 429: DNA270883, NP\_001061.1, 201714.at  
 Figure 430: PRO59218

WO 2005/019258

PCT/US2004/025788

Figure 431A-B: DNA151806, NP\_001422.1, 201718.s\_at  
 Figure 432: PRO12768  
 Figure 433A-B: DNA151806, NM\_001431, 201719.s\_at  
 Figure 434: PRO12768  
 Figure 435: DNA273759, NP\_006014.1, 201725.at  
 Figure 436: PRO61721  
 Figure 437: DNA344278, NP\_005618.2, 201739.at  
 Figure 438: PRO86741  
 Figure 439: DNA326373, NP\_008855.1, 201742.x.at  
 Figure 440: PRO82769  
 Figure 441A-B: DNA344279, 345309.13, 201749.at  
 Figure 442: PRO95015  
 Figure 443: DNA287167, NP\_006627.1, 201761.at  
 Figure 444: PRO59136  
 Figure 445A-B: DNA150444, NP\_055589.1, 201778.s\_at  
 Figure 446: PRO12253  
 Figure 447A-B: DNA103387, NP\_002287.1, 201795.at  
 Figure 448: PRO4716  
 Figure 449A-B: DNA272263, NP\_006286.1, 201797.s\_at  
 Figure 450: PRO70138  
 Figure 451: DNA151017, NP\_004835.1, 201810.s\_at  
 Figure 452: PRO12841  
 Figure 453: DNA151017, NM\_004844, 201811.x.at  
 Figure 454: PRO12841  
 Figure 455: DNA324015, NP\_006326.1, 201821.s\_at  
 Figure 456: PRO80735  
 Figure 457: DNA329952, NP\_005854.2, 201830.s\_at  
 Figure 458: PRO85256  
 Figure 459: DNA304710, NP\_001531.1, 201841.s\_at  
 Figure 460: PRO71136  
 Figure 461: DNA88450, NP\_000226.1, 201847.at  
 Figure 462: PRO2795  
 Figure 463: DNA254350, NP\_004043.2, 201849.at  
 Figure 464: PRO49461  
 Figure 465: DNA150725, NP\_001738.1, 201850.at  
 Figure 466: PRO12792  
 Figure 467: DNA329118, NP\_068660.1, 201853.s\_at  
 Figure 468: PRO83123  
 Figure 469A-B: DNA103553, NP\_000167.1, 201865.x.at  
 Figure 470: PRO4880  
 Figure 471: DNA272066, NP\_002931.1, 201872.s\_at  
 Figure 472: PRO60337  
 Figure 473A-B: DNA331295, NP\_002710.1, 201877.s\_at  
 Figure 474: PRO86394  
 Figure 475: DNA150805, NP\_055703.1, 201889.at  
 Figure 476: PRO11583  
 Figure 477: DNA344280, BC028932, 201890.at  
 Figure 478: DNA329956, NP\_000875.1, 201892.s\_at  
 Figure 479: PRO85260  
 Figure 480: DNA328431, NP\_001817.1, 201897.s\_at  
 Figure 481: PRO45093  
 Figure 482: DNA324310, NP\_003356.1, 201903.at  
 Figure 483: PRO80988  
 Figure 484: DNA305191, NP\_000999.1, 201909.at  
 Figure 485: PRO71295  
 Figure 486: DNA275385, NP\_002085.1, 201912.s\_at  
 Figure 487: PRO63048  
 Figure 488: DNA254978, NP\_060625.1, 201917.s\_at  
 Figure 489: PRO50067  
 Figure 490: DNA103328, NP\_005406.2, 201920.at  
 Figure 491: PRO4658  
 Figure 492: DNA329057, NP\_004116.2, 201921.at  
 Figure 493: PRO84719  
 Figure 494: DNA227112, NP\_006397.1, 201923.at  
 Figure 495: PRO37575  
 Figure 496: DNA83046, NP\_000565.1, 201925.s\_at  
 Figure 497: PRO2569  
 Figure 498: DNA83046, NM\_000574, 201926.s\_at  
 Figure 499: PRO2569  
 Figure 500A-B: DNA344281, NP\_005906.2, 201930.at  
 Figure 501: PRO62927  
 Figure 502: DNA329119, NP\_004633.1, 201938.at  
 Figure 503: PRO4550  
 Figure 504A-B: DNA329120, NP\_002560.1, 201945.at  
 Figure 505: PRO2752  
 Figure 506: DNA274167, NP\_006422.1, 201946.s\_at  
 Figure 507: PRO62097  
 Figure 508: DNA274167, NM\_006431, 201947.s\_at  
 Figure 509: PRO62097  
 Figure 510A-B: DNA327563, NP\_066945.1, 201963.at  
 Figure 511: PRO83592  
 Figure 512: DNA344282, NP\_002624.2, 201968.s\_at  
 Figure 513: PRO95016  
 Figure 514: DNA344283, NP\_751896.1, 201970.s\_at  
 Figure 515: PRO95017  
 Figure 516: DNA344284, NP\_002393.1, 202016.at  
 Figure 517: PRO95018  
 Figure 518: DNA328437, NP\_005792.1, 202021.x.at  
 Figure 519: PRO84271  
 Figure 520: DNA300776, NP\_000990.1, 202029.x.at  
 Figure 521: PRO70900  
 Figure 522: DNA344285, NP\_005521.1, 202069.s\_at  
 Figure 523: PRO83596  
 Figure 524: DNA226116, NP\_002990.1, 202071.at  
 Figure 525: PRO36579  
 Figure 526: DNA344286, AF070533, 202073.at  
 Figure 527: PRO95019  
 Figure 528: DNA289522, NP\_004994.1, 202077.at  
 Figure 529: PRO70276  
 Figure 530A-B: DNA270923, NP\_004808.1, 202085.at  
 Figure 531: PRO59256  
 Figure 532: DNA327568, NP\_002453.1, 202086.at  
 Figure 533: PRO57922  
 Figure 534: DNA271404, NP\_001542.1, 202105.at  
 Figure 535: PRO59703  
 Figure 536: DNA328440, NP\_004517.1, 202107.s\_at

WO 2005/019258

PCT/US2004/025788

Figure 537: PRO84274  
 Figure 538: DNA344287, NP\_003822.2, 202129.s\_at  
 Figure 539: PRO95020  
 Figure 540: DNA324895, NP\_006294.2, 202138.x\_at  
 Figure 541: PRO81501  
 Figure 542A-B: DNA304479, NP\_057124.2, 202194.at  
 Figure 543: PRO733  
 Figure 544: DNA329121, NP\_079471.1, 202241.at  
 Figure 545: PRO84763  
 Figure 546: DNA325711, NP\_000066.1, 202246.s\_at  
 Figure 547: PRO4873  
 Figure 548: DNA294794, NP\_002861.1, 202252.at  
 Figure 549: PRO70754  
 Figure 550: DNA256533, NP\_006105.1, 202264.s\_at  
 Figure 551: PRO51565  
 Figure 552: DNA150808, NP\_002044.1, 202269.x\_at  
 Figure 553: PRO12478  
 Figure 554: DNA150808, NM\_002053, 202270.at  
 Figure 555: PRO12478  
 Figure 556: DNA304716, NP\_510867.1, 202284.s\_at  
 Figure 557: PRO71142  
 Figure 558: DNA328274, NP\_055706.1, 202290.at  
 Figure 559: PRO12912  
 Figure 560: DNA331450, NP\_004381.2, 202295.s\_at  
 Figure 561: PRO2682  
 Figure 562: DNA344288, NP\_000584.2, 202307.s\_at  
 Figure 563: PRO36996  
 Figure 564A-B: DNA329970, NP\_000910.2, 202336.s\_at  
 Figure 565: PRO85272  
 Figure 566: DNA325115, NP\_001435.1, 202345.s\_at  
 Figure 567: PRO81689  
 Figure 568: DNA344289, NP\_002807.1, 202352.s\_at  
 Figure 569: PRO58880  
 Figure 570A-B: DNA254188, NP\_004913.1, 202361.at  
 Figure 571: PRO49300  
 Figure 572: DNA331297, NP\_005953.2, 202364.at  
 Figure 573: PRO86396  
 Figure 574A-B: DNA227353, NP\_055637.1, 202375.at  
 Figure 575: PRO37816  
 Figure 576: DNA344290, 1096863.3, 202377.at  
 Figure 577: PRO95021  
 Figure 578: DNA103246, NP\_059996.1, 202378.s\_at  
 Figure 579: PRO4576  
 Figure 580: DNA328449, NP\_005462.1, 202382.s\_at  
 Figure 581: PRO60304  
 Figure 582: DNA150514, NP\_065203.1, 202418.at  
 Figure 583: PRO12304  
 Figure 584A-C: DNA270933, NP\_006757.1, 202423.at  
 Figure 585: PRO59265  
 Figure 586A-B: DNA335104, NP\_000935.1, 202429.s\_at  
 Figure 587: PRO49644  
 Figure 588: DNA227121, NP\_066928.1, 202430.s\_at  
 Figure 589: PRO37584  
 Figure 590: DNA66487, NP\_002458.1, 202431.s\_at  
 Figure 591: PRO1213  
 Figure 592A-B: DNA327576, NP\_000095.1, 202435.s\_at  
 Figure 593: PRO83600  
 Figure 594A-B: DNA327576, NM\_000104, 202436.s\_at  
 Figure 595: PRO83600  
 Figure 596A-D: DNA270871, U56438, 202437.s\_at  
 Figure 597A-B: DNA344291, 7685287.117, 202438.x\_at  
 Figure 598: PRO2328  
 Figure 599A-B: DNA335104, NM\_000944, 202457.s\_at  
 Figure 600: PRO49644  
 Figure 601A-B: DNA329973, NP\_055461.1, 202459.s\_at  
 Figure 602: PRO82824  
 Figure 603A-B: DNA269642, NP\_004557.1, 202464.s\_at  
 Figure 604: PRO58054  
 Figure 605: DNA227921, NP\_003789.1, 202468.s\_at  
 Figure 606: PRO38384  
 Figure 607A-B: DNA329122, NP\_067675.1, 202478.at  
 Figure 608: PRO84764  
 Figure 609A-B: DNA329122, NM\_021643, 202479.s\_at  
 Figure 610: PRO84764  
 Figure 611: DNA329123, NP\_002873.1, 202483.s\_at  
 Figure 612: PRO84765  
 Figure 613: DNA344292, NP\_003918.1, 202484.s\_at  
 Figure 614: PRO95022  
 Figure 615: DNA324925, NP\_036544.1, 202487.s\_at  
 Figure 616: PRO61812  
 Figure 617A-B: DNA103449, NP\_008862.1, 202498.s\_at  
 Figure 618: PRO4776  
 Figure 619: DNA328451, NP\_000007.1, 202502.at  
 Figure 620: PRO62139  
 Figure 621: DNA234442, NP\_055551.1, 202503.s\_at  
 Figure 622: PRO38852  
 Figure 623A-B: DNA277809, NP\_055582.1, 202523.s\_at  
 Figure 624: PRO64556  
 Figure 625A-B: DNA277809, NM\_014767, 202524.s\_at  
 Figure 626: PRO64556  
 Figure 627A-B: DNA226870, NM\_000791, 202534.x\_at  
 Figure 628: PRO37333  
 Figure 629: DNA328453, NP\_003752.2, 202546.at  
 Figure 630: PRO84281  
 Figure 631A-B: DNA344293, NP\_008879.2, 202557.at  
 Figure 632: PRO95023  
 Figure 633: DNA344294, NP\_004166.1, 202567.at  
 Figure 634: PRO83257  
 Figure 635: DNA325587, NP\_068772.1, 202580.x\_at

WO 2005/019258

PCT/US2004/025788

Figure 636: PRO82083  
Figure 637: DNA329979, NP\_001062.1, 202589.at  
Figure 638: PRO82821  
Figure 639: DNA326078, NP\_057725.1, 202593.s.at  
Figure 640: PRO38464  
Figure 641: DNA329125, NP\_056159.1, 202594.at  
Figure 642: PRO84767  
Figure 643: DNA329125, NM\_015344, 202595.s.at  
Figure 644: PRO84767  
Figure 645: DNA274881, NP\_001896.1, 202613.at  
Figure 646: PRO62626  
Figure 647A-B: DNA329980, 1134366.16, 202615.at  
Figure 648: PRO85278  
Figure 649A-C: DNA344295, NP\_036427.1, 202624.s.at  
Figure 650: PRO95024  
Figure 651A-B: DNA344296, 441144.12, 202625.at  
Figure 652: PRO95025  
Figure 653: DNA103245, NP\_002341.1, 202626.s.at  
Figure 654: PRO4575  
Figure 655: DNA329126, NP\_005025.1, 202635.s.at  
Figure 656: PRO84768  
Figure 657: DNA59763, NP\_000192.1, 202638.s.at  
Figure 658: PRO1960  
Figure 659: DNA289528, NP\_004302.1, 202641.at  
Figure 660: PRO70286  
Figure 661A-B: DNA344297, NP\_006281.1, 202643.s.at  
Figure 662: PRO12904  
Figure 663A-B: DNA344298, NM\_006290, 202644.s.at  
Figure 664: PRO12904  
Figure 665: DNA254129, NP\_006001.1, 202655.at  
Figure 666: PRO49244  
Figure 667A-B: DNA333747, 099914.40, 202663.at  
Figure 668: PRO88372  
Figure 669: DNA344299, NP\_001665.1, 202672.s.at  
Figure 670: PRO95026  
Figure 671: DNA272801, NP\_004483.1, 202678.at  
Figure 672: PRO60906  
Figure 673: DNA335588, NP\_003801.1, 202687.s.at  
Figure 674: PRO1096  
Figure 675: DNA335588, NM\_003810, 202688.at  
Figure 676: PRO1096  
Figure 677: DNA344300, NP\_008869.1, 202690.s.at  
Figure 678: PRO41946  
Figure 679A-B: DNA150467, NP\_055513.1, 202699.s.at  
Figure 680: PRO12272  
Figure 681: DNA330776, NP\_005740.1, 202704.at  
Figure 682: PRO58014  
Figure 683: DNA326000, NP\_004692.1, 202705.at  
Figure 684: PRO82442  
Figure 685A-B: DNA328459, NP\_004332.2, 202715.at  
Figure 686: PRO84285  
Figure 687A-B: DNA270254, NP\_002006.2, 202724.s.at  
Figure 688: PRO58642  
Figure 689: DNA331298, NP\_055271.2, 202730.s.at  
Figure 690: PRO81909  
Figure 691: DNA344301, NM\_145341, 202731.at  
Figure 692: PRO95027  
Figure 693A-B: DNA344302, BC035058, 202741.at  
Figure 694: PRO95028  
Figure 695: DNA271973, NP\_002722.1, 202742.s.at  
Figure 696: PRO60248  
Figure 697: DNA344303, BC040437, 202746.at  
Figure 698: PRO1189  
Figure 699: DNA327192, NP\_004858.1, 202747.s.at  
Figure 700: PRO1189  
Figure 701: DNA227164, Y12478, 202749.at  
Figure 702: PRO37627  
Figure 703A-C: DNA329129, NP\_009134.1, 202759.s.at  
Figure 704: PRO84288  
Figure 705A-B: DNA344304, NM\_147150, 202760.s.at  
Figure 706: PRO95029  
Figure 707A-B: DNA256782, AL080133, 202761.s.at  
Figure 708: PRO51715  
Figure 709A-B: DNA328464, 977954.20, 202769.at  
Figure 710: PRO84290  
Figure 711: DNA226578, NP\_004345.1, 202770.s.at  
Figure 712: PRO37041  
Figure 713: DNA273346, NP\_055316.1, 202779.s.at  
Figure 714: PRO61349  
Figure 715: DNA275337, NP\_037365.1, 202786.at  
Figure 716: PRO63011  
Figure 717: DNA344305, 345245.28, 202789.at  
Figure 718: PRO95030  
Figure 719: DNA329986, NP\_006454.1, 202811.at  
Figure 720: PRO61895  
Figure 721: DNA328465, NP\_005639.1, 202824.s.at  
Figure 722: PRO84291  
Figure 723: DNA269828, NP\_006691.1, 202837.at  
Figure 724: PRO58230  
Figure 725: DNA329988, NP\_036460.1, 202842.s.at  
Figure 726: PRO1471  
Figure 727: DNA329988, NM\_012328, 202843.at  
Figure 728: PRO1471  
Figure 729: DNA328466, NP\_004554.1, 202847.at  
Figure 730: PRO84292  
Figure 731: DNA227063, NP\_002849.1, 202850.at  
Figure 732: PRO37526  
Figure 733: DNA103394, NP\_004198.1, 202855.s.at  
Figure 734: PRO4722  
Figure 735: DNA103394, NM\_004207, 202856.s.at  
Figure 736: PRO4722  
Figure 737: DNA344306, NP\_000575.1, 202859.x.at  
Figure 738: PRO74  
Figure 739: DNA275144, NP\_000128.1, 202862.at  
Figure 740: PRO62852

WO 2005/019258

PCT/US2004/025788

Figure 741: DNA328467, NP\_003104.2, 202864.s\_at  
Figure 742: PRO84293  
Figure 743: DNA287289, NP\_058132.1, 202869.at  
Figure 744: PRO69559  
Figure 745: DNA273060, NP\_001246.1, 202870.s\_at  
Figure 746: PRO61125  
Figure 747: DNA325334, NP\_061931.1, 202887.s\_at  
Figure 748: PRO81877  
Figure 749A-B: DNA333705, NP\_004070.3, 202901.x\_at  
Figure 750: PRO88334  
Figure 751A-B: DNA333705, NM\_004079, 202902.s\_at  
Figure 752: PRO88334  
Figure 753: DNA332688, NP\_510966.1, 202910.s\_at  
Figure 754: PRO2030  
Figure 755A-B: DNA275066, NP\_000170.1, 202911.at  
Figure 756: PRO62786  
Figure 757: DNA83008, NP\_001115.1, 202912.at  
Figure 758: PRO2032  
Figure 759A-B: DNA344307, 7762119.3, 202934.at  
Figure 760: PRO95031  
Figure 761: DNA344308, NP\_056518.2, 202937.x\_at  
Figure 762: PRO95032  
Figure 763: DNA304681, NP\_066552.1, 202941.at  
Figure 764: PRO71107  
Figure 765: DNA269481, NP\_001976.1, 202942.at  
Figure 766: PRO57901  
Figure 767: DNA273320, NP\_008950.1, 202954.at  
Figure 768: PRO61327  
Figure 769: DNA344309, X73427, 202988.s\_at  
Figure 770: PRO95033  
Figure 771: DNA329136, NP\_057475.1, 203023.at  
Figure 772: PRO84772  
Figure 773: DNA270174, NP\_000092.1, 203028.s\_at  
Figure 774: PRO58563  
Figure 775A-B: DNA83163, U66702, 203029.s\_at  
Figure 776: PRO2611  
Figure 777A-B: DNA344310, NP\_055566.1, 203037.s\_at  
Figure 778: PRO95034  
Figure 779A-B: DNA344311, NP\_002835.2, 203038.at  
Figure 780: PRO95035  
Figure 781A-B: DNA304464, NP\_055733.1, 203044.at  
Figure 782: PRO71042  
Figure 783A-B: DNA328358, NP\_005981.1, 203047.at  
Figure 784: PRO84218  
Figure 785A-B: DNA227821, NP\_055666.1, 203068.at  
Figure 786: PRO38284  
Figure 787: DNA329137, NP\_005892.1, 203077.s\_at  
Figure 788: PRO12879  
Figure 789A-B: DNA339385, NP\_055568.1, 203082.at  
Figure 790: PRO91190  
Figure 791: DNA344312, 1386457.26, 203086.at  
Figure 792: PRO95036  
Figure 793: DNA329138, NP\_004511.1, 203087.s\_at  
Figure 794: PRO84773  
Figure 795: DNA344313, AF026030, 203092.at  
Figure 796: PRO95037  
Figure 797A-B: DNA227949, NP\_055062.1, 203096.s\_at  
Figure 798: PRO38412  
Figure 799: DNA329992, NP\_002399.1, 203102.s\_at  
Figure 800: PRO59267  
Figure 801: DNA272867, NP\_003960.1, 203109.at  
Figure 802: PRO60960  
Figure 803: DNA150430, NP\_006387.1, 203114.at  
Figure 804: PRO12770  
Figure 805: DNA329994, NP\_004707.2, 203118.at  
Figure 806: PRO85286  
Figure 807: DNA287417, NP\_077003.1, 203119.at  
Figure 808: PRO69674  
Figure 809A-B: DNA226395, NP\_000312.1, 203132.at  
Figure 810: PRO36858  
Figure 811A-B: DNA344314, NP\_620309.1, 203140.at  
Figure 812: PRO12790  
Figure 813: DNA269433, NP\_005877.1, 203163.at  
Figure 814: PRO57856  
Figure 815: DNA340116, NP\_000146.2, 203179.at  
Figure 816: PRO91615  
Figure 817A-B: DNA331303, NP\_003129.1, 203182.s\_at  
Figure 818: PRO86399  
Figure 819: DNA304720, NP\_062427.1, 203186.s\_at  
Figure 820: PRO71146  
Figure 821A-B: DNA270861, NP\_001371.1, 203187.at  
Figure 822: PRO59198  
Figure 823A-B: DNA344315, AAL56659.1, 203194.s\_at  
Figure 824: PRO95038  
Figure 825: DNA329997, NP\_031396.1, 203209.at  
Figure 826: PRO61115  
Figure 827A-B: DNA328481, NP\_057240.1, 203211.s\_at  
Figure 828: PRO84307  
Figure 829: DNA327588, 995529.4, 203213.at  
Figure 830: PRO83607  
Figure 831: DNA334914, NP\_001777.1, 203214.x\_at  
Figure 832: PRO58324  
Figure 833A-C: DNA274481, NP\_000323.1, 203231.s\_at  
Figure 834: PRO62384  
Figure 835A-C: DNA274481, NM\_000332, 203232.s\_at  
Figure 836: PRO62384  
Figure 837: DNA76514, NP\_000409.1, 203233.at  
Figure 838: PRO2540  
Figure 839: DNA334781, NP\_006448.1, 203242.s\_at  
Figure 840: PRO89234  
Figure 841: DNA334781, NM\_006457, 203243.s\_at  
Figure 842: PRO89234  
Figure 843: DNA330000, NP\_036277.1, 203270.at

WO 2005/019258

PCT/US2004/025788

Figure 844: PRO85289  
 Figure 845: DNA270963, NM\_003335, 203281.s\_at  
 Figure 846: PRO59293  
 Figure 847: DNA225675, NP\_005561.1, 203293.s\_at  
 Figure 848: PRO36138  
 Figure 849: DNA225675, NM\_005570, 203294.s\_at  
 Figure 850: PRO36138  
 Figure 851: DNA328489, NP\_006511.1, 203303.at  
 Figure 852: PRO84314  
 Figure 853: DNA344316, NP\_733796.1, 203313.s\_at  
 Figure 854: PRO95039  
 Figure 855: DNA271740, NP\_003085.1, 203316.s\_at  
 Figure 856: PRO60024  
 Figure 857A-B: DNA330003, NP\_005532.1, 203331.s\_at  
 Figure 858: PRO85291  
 Figure 859A-B: DNA330003, NM\_005541, 203332.s\_at  
 Figure 860: PRO85291  
 Figure 861: DNA330004, NP\_055785.2, 203333.at  
 Figure 862: PRO85292  
 Figure 863: DNA324514, NP\_002349.1, 203362.s\_at  
 Figure 864: PRO81169  
 Figure 865: DNA328493, NP\_008957.1, 203367.at  
 Figure 866: PRO84317  
 Figure 867: DNA151022, NP\_001336.1, 203385.at  
 Figure 868: PRO12096  
 Figure 869A-B: DNA344317, 232388.2, 203386.at  
 Figure 870: PRO95040  
 Figure 871A-B: DNA340155, NP\_055647.1, 203387.s\_at  
 Figure 872: PRO91654  
 Figure 873: DNA331200, NP\_004304.1, 203388.at  
 Figure 874: PRO86322  
 Figure 875: DNA88324, M65128, 203391.at  
 Figure 876: PRO2748  
 Figure 877A-B: DNA254616, NP\_004473.1, 203397.s\_at  
 Figure 878: PRO49718  
 Figure 879: DNA270134, NP\_000098.1, 203409.at  
 Figure 880: PRO58523  
 Figure 881: DNA344318, NP\_733821.1, 203411.s\_at  
 Figure 882: PRO95041  
 Figure 883: DNA28759, NP\_006150.1, 203413.at  
 Figure 884: PRO2520  
 Figure 885A-B: DNA256807, NP\_057339.1, 203420.at  
 Figure 886: PRO51738  
 Figure 887: DNA327808, NP\_002961.1, 203455.s\_at  
 Figure 888: PRO83769  
 Figure 889: DNA269591, NP\_002655.1, 203471.s\_at  
 Figure 890: PRO58004  
 Figure 891: DNA150959, NP\_005813.1, 203498.at  
 Figure 892: PRO11599  
 Figure 893A-C: DNA331461, NP\_005493.2, 203504.s\_at  
 Figure 894: PRO86511

Figure 895A-C: DNA328498, AF285167, 203505.at  
 Figure 896: PRO84320  
 Figure 897A-B: DNA333708, NP\_001057.1, 203508.at  
 Figure 898: PRO21928  
 Figure 899A-B: DNA331462, NP\_003096.1, 203509.at  
 Figure 900: PRO86512  
 Figure 901: DNA344319, 474053.9, 203510.at  
 Figure 902: PRO95042  
 Figure 903A-C: DNA344320, BAB47469.2, 203513.at  
 Figure 904: PRO95043  
 Figure 905: DNA272911, NP\_006545.1, 203517.at  
 Figure 906: PRO60997  
 Figure 907A-D: DNA333617, NP\_000072.1, 203518.at  
 Figure 908: PRO88260  
 Figure 909A-B: DNA272399, NP\_001197.1, 203542.s\_at  
 Figure 910: PRO60653  
 Figure 911A-B: DNA272399, NM\_001206, 203543.s\_at  
 Figure 912: PRO60653  
 Figure 913: DNA344321, NP\_003464.1, 203544.s\_at  
 Figure 914: PRO62698  
 Figure 915: DNA324684, NP\_004210.1, 203554.x\_at  
 Figure 916: PRO81319  
 Figure 917A-B: DNA339392, NP\_055758.1, 203556.at  
 Figure 918: PRO91197  
 Figure 919: DNA327594, NP\_003869.1, 203560.at  
 Figure 920: PRO83611  
 Figure 921: DNA332919, NP\_005094.1, 203562.at  
 Figure 922: PRO60597  
 Figure 923: DNA344322, NP\_006346.1, 203567.s\_at  
 Figure 924: PRO85303  
 Figure 925A-B: DNA340123, NP\_003602.1, 203569.s\_at  
 Figure 926: PRO91622  
 Figure 927: DNA329033, NP\_005375.1, 203574.at  
 Figure 928: PRO84700  
 Figure 929: DNA344323, NP\_054763.2, 203583.at  
 Figure 930: PRO95044  
 Figure 931A-B: DNA270323, NP\_036552.1, 203595.s\_at  
 Figure 932: PRO58710  
 Figure 933A-B: DNA344324, NP\_733936.1, 203608.at  
 Figure 934: PRO95045  
 Figure 935: DNA344325, NM\_006355, 203610.s\_at  
 Figure 936: PRO85303  
 Figure 937: DNA287246, NP\_004044.2, 203612.at  
 Figure 938: PRO69521  
 Figure 939: DNA344326, NP\_002681.1, 203616.at  
 Figure 940: PRO95046  
 Figure 941: DNA330018, NP\_064528.1, 203622.s\_at  
 Figure 942: PRO85304  
 Figure 943A-B: DNA270264, DNA270264, 203633.at  
 Figure 944A-B: DNA327597, NP\_075261.1, 203639.s\_at

WO 2005/019258

PCT/US2004/025788

Figure 945: PRO83613  
Figure 946: DNA254642, NP\_004100.1, 203646\_at  
Figure 947: PRO49743  
Figure 948: DNA328507, NP\_006395.1, 203650\_at  
Figure 949: PRO4761  
Figure 950: DNA151752, NP\_002124.1, 203665\_at  
Figure 951: PRO12886  
Figure 952: DNA88352, NP\_002067.1, 203676\_at  
Figure 953: PRO2759  
Figure 954A-B: DNA227646, NP\_000288.1, 203688\_at  
Figure 955: PRO38109  
Figure 956A-B: DNA330021, NP\_001940.1, 203692\_s\_at  
Figure 957: PRO85306  
Figure 958A-B: DNA330021, NM\_001949, 203693\_s\_at  
Figure 959: PRO85306  
Figure 960A-B: DNA344327, NP\_002591.1, 203708\_at  
Figure 961: PRO10691  
Figure 962A-C: DNA331467, NP\_002213.1, 203710\_at  
Figure 963: PRO86516  
Figure 964: DNA329144, NM\_014878, 203712\_at  
Figure 965: PRO84779  
Figure 966: DNA324183, NP\_001926.2, 203716\_s\_at  
Figure 967: PRO80881  
Figure 968: DNA330023, NP\_001915.1, 203725\_at  
Figure 969: PRO85308  
Figure 970A-B: DNA344328, NP\_003613.1, 203736\_s\_at  
Figure 971: PRO95047  
Figure 972A-B: DNA325369, NP\_055877.2, 203737\_s\_at  
Figure 973: PRO81905  
Figure 974: DNA344329, AL834427, 203738\_at  
Figure 975A-B: DNA274324, NP\_006517.1, 203739\_at  
Figure 976: PRO62242  
Figure 977A-B: DNA150748, NP\_001105.1, 203741\_s\_at  
Figure 978: PRO12446  
Figure 979: DNA344330, 197185.7, 203745\_at  
Figure 980: PRO58198  
Figure 981A-B: DNA325972, NP\_001202.3, 203755\_at  
Figure 982: PRO82417  
Figure 983: DNA328509, NP\_006739.1, 203761\_at  
Figure 984: PRO57996  
Figure 985: DNA344331, NP\_057092.1, 203762\_s\_at  
Figure 986: PRO95049  
Figure 987: DNA344332, NM\_016008, 203763\_at  
Figure 988: PRO95050  
Figure 989: DNA330025, NP\_055565.2, 203764\_at  
Figure 990: PRO85310  
Figure 991: DNA330027, NP\_036578.1, 203787\_at  
Figure 992: PRO85312  
Figure 993: DNA274125, NP\_071739.1, 203830\_at  
Figure 994: PRO62061  
Figure 995A-B: DNA331113, NP\_005914.1, 203836\_s\_at  
Figure 996: PRO60244  
Figure 997A-B: DNA344333, U67156, 203837\_at  
Figure 998: PRO60244  
Figure 999A-B: DNA344334, 435717.6, 203843\_at  
Figure 1000: PRO95051  
Figure 1001A-B: DNA325529, NP\_536739.1, 203853\_s\_at  
Figure 1002: PRO82037  
Figure 1003: DNA275339, NP\_005685.1, 203880\_at  
Figure 1004: PRO63012  
Figure 1005: DNA328513, NM\_016283, 203893\_at  
Figure 1006: PRO37815  
Figure 1007: DNA151820, NP\_000851.1, 203914\_x\_at  
Figure 1008: PRO12194  
Figure 1009: DNA82376, NP\_002407.1, 203915\_at  
Figure 1010: PRO1723  
Figure 1011: DNA344335, NP\_004258.2, 203921\_at  
Figure 1012: PRO77044  
Figure 1013: DNA271676, NP\_002052.1, 203925\_at  
Figure 1014: PRO59961  
Figure 1015: DNA344336, NP\_002940.2, 203931\_s\_at  
Figure 1016: PRO95052  
Figure 1017: DNA88035, NP\_002517.1, 203939\_at  
Figure 1018: PRO2135  
Figure 1019: DNA327606, NP\_001163.1, 203945\_at  
Figure 1020: PRO57873  
Figure 1021: DNA327606, NM\_001172, 203946\_s\_at  
Figure 1022: PRO57873  
Figure 1023: DNA344337, NP\_005186.2, 203973\_s\_at  
Figure 1024: PRO95053  
Figure 1025: DNA227239, NP\_003497.1, 203987\_at  
Figure 1026: PRO37702  
Figure 1027: DNA344338, NP\_004471.1, 203988\_s\_at  
Figure 1028: PRO95054  
Figure 1029: DNA226133, NP\_001983.1, 203989\_x\_at  
Figure 1030: PRO36596  
Figure 1031A-B: DNA333574, NP\_002820.2, 203997\_at  
Figure 1032: PRO88221  
Figure 1033A-B: DNA344339, BC010502, 204009\_s\_at  
Figure 1034: PRO95055  
Figure 1035: DNA328516, NP\_005833.1, 204011\_at  
Figure 1036: PRO12323  
Figure 1037: DNA344340, NP\_001385.1, 204014\_at  
Figure 1038: PRO49185  
Figure 1039: DNA329145, NM\_057158, 204015\_s\_at  
Figure 1040: PRO84780  
Figure 1041: DNA330033, NP\_056492.1, 204019\_s\_at  
Figure 1042: PRO85318  
Figure 1043: DNA328271, NP\_008988.2, 204026\_s\_at  
Figure 1044: PRO81868  
Figure 1045: DNA344341, NP\_055390.1, 204030\_s\_at  
Figure 1046: PRO95056  
Figure 1047: DNA344342, 7698646.3, 204057\_at

WO 2005/019258

PCT/US2004/025788

Figure 1048: PRO95057  
 Figure 1049A-B: DNA336315, NP\_005035.1, 204060.s\_at  
 Figure 1050: PRO90466  
 Figure 1051: DNA226737, NP\_004576.1, 204070.at  
 Figure 1052: PRO37200  
 Figure 1053A-C: DNA333515, NP\_075463.1, 204072.s\_at  
 Figure 1054: PRO88167  
 Figure 1055: DNA344343, NP\_003586.1, 204079.at  
 Figure 1056: PRO61375  
 Figure 1057: DNA344344, NP\_006186.1, 204082.at  
 Figure 1058: PRO22518  
 Figure 1059: DNA270476, NP\_003591.1, 204092.s\_at  
 Figure 1060: PRO58855  
 Figure 1061: DNA216689, NP\_002975.1, 204103.at  
 Figure 1062: PRO34276  
 Figure 1063: DNA328522, NP\_001769.2, 204118.at  
 Figure 1064: PRO2696  
 Figure 1065: DNA304489, NP\_003495.1, 204126.s\_at  
 Figure 1066: PRO71058  
 Figure 1067: DNA325824, NP\_002906.1, 204128.s\_at  
 Figure 1068: PRO82290  
 Figure 1069: DNA103333, NP\_055705.1, 204135.at  
 Figure 1070: PRO4663  
 Figure 1071: DNA344345, NP\_006470.1, 204146.at  
 Figure 1072: PRO61659  
 Figure 1073A-B: DNA344346, 7698815.10, 204156.at  
 Figure 1074: PRO95058  
 Figure 1075: DNA330040, NP\_523240.1, 204159.at  
 Figure 1076: PRO59546  
 Figure 1077: DNA273694, NP\_006092.1, 204162.at  
 Figure 1078: PRO61661  
 Figure 1079A-B: DNA254376, NP\_055778.1, 204166.at  
 Figure 1080: PRO49486  
 Figure 1081: DNA272655, NP\_001818.1, 204170.s\_at  
 Figure 1082: PRO60781  
 Figure 1083: DNA330041, NP\_000088.2, 204172.at  
 Figure 1084: PRO85324  
 Figure 1085: DNA328529, NP\_001620.2, 204174.at  
 Figure 1086: PRO49814  
 Figure 1087: DNA226380, NP\_001765.1, 204192.at  
 Figure 1088: PRO4695  
 Figure 1089A-B: DNA290230, NP\_004341.1, 204197.s\_at  
 Figure 1090: PRO70325  
 Figure 1091: DNA151798, NP\_001797.1, 204203.at  
 Figure 1092: PRO12186  
 Figure 1093: DNA271778, NP\_068594.1, 204205.at  
 Figure 1094: PRO60062  
 Figure 1095: DNA333754, NP\_004868.1, 204220.at  
 Figure 1096: PRO88379  
 Figure 1097: DNA150812, NP\_006842.1, 204222.s\_at  
 Figure 1098: PRO12481  
 Figure 1099A-B: DNA287273, NP\_006435.1,

204240.s\_at  
 Figure 1100: PRO69545  
 Figure 1101: DNA330043, NP\_001789.2, 204252.at  
 Figure 1102: PRO85326  
 Figure 1103A-B: DNA103527, NP\_000367.1, 204254.s\_at  
 Figure 1104: PRO4854  
 Figure 1105A-B: DNA103527, NM\_000376, 204255.s\_at  
 Figure 1106: PRO4854  
 Figure 1107: DNA228132, NP\_076995.1, 204256.at  
 Figure 1108: PRO38595  
 Figure 1109: DNA273802, NP\_066950.1, 204285.s\_at  
 Figure 1110: PRO61763  
 Figure 1111: DNA273802, NM\_021127, 204286.s\_at  
 Figure 1112: PRO61763  
 Figure 1113: DNA344347, NP\_002916.1, 204319.s\_at  
 Figure 1114: PRO63255  
 Figure 1115: DNA330136, X76717, 204326.x\_at  
 Figure 1116: PRO82583  
 Figure 1117: DNA327613, NP\_005971.1, 204351.at  
 Figure 1118: PRO83622  
 Figure 1119A-D: DNA339387, NP\_055625.2, 204373.s\_at  
 Figure 1120: PRO91192  
 Figure 1121: DNA344348, NP\_004477.2, 204384.at  
 Figure 1122: PRO95059  
 Figure 1123: DNA334269, NP\_000231.1, 204388.s\_at  
 Figure 1124: PRO59228  
 Figure 1125: DNA334269, NM\_000240, 204389.at  
 Figure 1126: PRO59228  
 Figure 1127: DNA344349, NP\_002241.1, 204401.at  
 Figure 1128: PRO4787  
 Figure 1129: DNA255402, NP\_055288.1, 204405.x\_at  
 Figure 1130: PRO50469  
 Figure 1131A-B: DNA254135, NP\_060066.1, 204411.at  
 Figure 1132: PRO49250  
 Figure 1133: DNA327616, NP\_075011.1, 204415.at  
 Figure 1134: PRO83624  
 Figure 1135: DNA327617, NP\_006811.1, 204439.at  
 Figure 1136: PRO83625  
 Figure 1137A-B: DNA330049, NP\_004514.2, 204444.at  
 Figure 1138: PRO85330  
 Figure 1139: DNA270496, NP\_001316.1, 204459.at  
 Figure 1140: PRO58875  
 Figure 1141: DNA331075, NP\_000601.2, 204489.s\_at  
 Figure 1142: PRO86231  
 Figure 1143: DNA331075, NM\_000610, 204490.s\_at  
 Figure 1144: PRO86231  
 Figure 1145A-C: DNA344350, 418805.19, 204491.at  
 Figure 1146: PRO95060  
 Figure 1147: DNA194652, NP\_001187.1, 204493.at  
 Figure 1148: PRO23974  
 Figure 1149A-B: DNA331311, NP\_056054.1,



WO 2005/019258

PCT/US2004/025788

204500.s.at  
 Figure 1150: PRO86405  
 Figure 1151: DNA297387, NP\_003494.1, 204510.at  
 Figure 1152: PRO58394  
 Figure 1153: DNA330051, NP\_003431.1, 204523.at  
 Figure 1154: PRO85332  
 Figure 1155A-B: DNA272298, NP\_055544.1, 204529.s.at  
 Figure 1156: PRO60555  
 Figure 1157: DNA82362, NP\_001556.1, 204533.at  
 Figure 1158: PRO1718  
 Figure 1159: DNA225993, NP\_000646.1, 204563.at  
 Figure 1160: PRO36456  
 Figure 1161: DNA151910, NP\_004906.2, 204567.s.at  
 Figure 1162: PRO12754  
 Figure 1163: DNA328266, NP\_005993.1, 204616.at  
 Figure 1164: PRO12125  
 Figure 1165: DNA344351, NP\_006177.1, 204621.s.at  
 Figure 1166: PRO12850  
 Figure 1167: DNA344352, NM\_173173, 204622.x.at  
 Figure 1168: PRO95061  
 Figure 1169: DNA226079, NP\_001602.1, 204638.at  
 Figure 1170: PRO36542  
 Figure 1171: DNA226699, NP\_000013.1, 204639.at  
 Figure 1172: PRO37162  
 Figure 1173: DNA254470, NP\_002488.1, 204641.at  
 Figure 1174: PRO49578  
 Figure 1175A-B: DNA227097, NP\_000101.1, 204646.at  
 Figure 1176: PRO37560  
 Figure 1177: DNA52729, M21121, 204655.at  
 Figure 1178: PRO91  
 Figure 1179: DNA344353, M11867, 204670.x.at  
 Figure 1180: PRO95062  
 Figure 1181: DNA327521, NP\_002192.2, 204698.at  
 Figure 1182: PRO58320  
 Figure 1183: DNA271179, NP\_004280.3, 204702.s.at  
 Figure 1184: PRO59497  
 Figure 1185A-B: DNA344354, NP\_612565.1, 204709.s.at  
 Figure 1186: PRO95063  
 Figure 1187A-B: DNA335768, NP\_000121.1, 204714.s.at  
 Figure 1188: PRO90077  
 Figure 1189A-B: DNA273690, NP\_055602.1, 204720.s.at  
 Figure 1190: PRO61657  
 Figure 1191: DNA328698, NP\_006144.1, 204725.s.at  
 Figure 1192: PRO12168  
 Figure 1193A-B: DNA83176, NP\_003234.1, 204731.at  
 Figure 1194: PRO2620  
 Figure 1195A-B: DNA344355, NP\_006193.1, 204735.at  
 Figure 1196: PRO95064  
 Figure 1197A-B: DNA325192, NP\_038203.1, 204744.s.at

Figure 1198: PRO81753  
 Figure 1199: DNA330057, NP\_005941.1, 204745.x.at  
 Figure 1200: PRO85337  
 Figure 1201: DNA287178, NP\_001540.1, 204747.at  
 Figure 1202: PRO69467  
 Figure 1203A-B: DNA226070, NP\_000954.1, 204748.at  
 Figure 1204: PRO36533  
 Figure 1205: DNA330058, NP\_004529.2, 204749.at  
 Figure 1206: PRO85338  
 Figure 1207A-B: DNA270601, NP\_002117.1, 204753.s.at  
 Figure 1208: PRO58973  
 Figure 1209: DNA329153, NP\_001259.1, 204759.at  
 Figure 1210: PRO84786  
 Figure 1211: DNA328541, NP\_004503.1, 204773.at  
 Figure 1212: PRO4843  
 Figure 1213: DNA328542, NP\_055025.1, 204774.at  
 Figure 1214: PRO2577  
 Figure 1215: DNA227033, NP\_002362.1, 204777.s.at  
 Figure 1216: PRO37496  
 Figure 1217: DNA332667, NP\_000034.1, 204780.s.at  
 Figure 1218: PRO1207  
 Figure 1219: DNA344356, NM\_152877, 204781.s.at  
 Figure 1220: PRO95065  
 Figure 1221: DNA344357, NP\_000865.2, 204786.s.at  
 Figure 1222: PRO1011  
 Figure 1223: DNA253585, NP\_004409.1, 204794.at  
 Figure 1224: PRO49183  
 Figure 1225A-B: DNA329907, NP\_036423.1, 204817.at  
 Figure 1226: PRO85224  
 Figure 1227: DNA254127, NM\_006994, 204820.s.at  
 Figure 1228: PRO49242  
 Figure 1229: DNA254127, U90548, 204821.at  
 Figure 1230: PRO49242  
 Figure 1231A-B: DNA269878, M86699, 204822.at  
 Figure 1232: PRO58276  
 Figure 1233: DNA255289, NP\_055606.1, 204825.at  
 Figure 1234: PRO50363  
 Figure 1235: DNA344358, NP\_002175.2, 204863.s.at  
 Figure 1236: PRO85478  
 Figure 1237: DNA344359, NM\_175767, 204864.s.at  
 Figure 1238: PRO95066  
 Figure 1239: DNA333633, NM\_014882, 204882.at  
 Figure 1240: PRO88275  
 Figure 1241: DNA330065, NP\_055079.2, 204887.s.at  
 Figure 1242: PRO85345  
 Figure 1243: DNA226195, NP\_000949.1, 204896.s.at  
 Figure 1244: PRO36658  
 Figure 1245: DNA344360, 334072.2, 204897.at  
 Figure 1246: PRO95067  
 Figure 1247: DNA329157, NP\_004271.1, 204905.s.at  
 Figure 1248: PRO62861  
 Figure 1249A-B: DNA344361, NP\_001549.1, 204912.at

WO 2005/019258

PCT/US2004/025788

Figure 1250: PRO2536  
 Figure 1251: DNA228014, NP\_002153.1, 204949.at  
 Figure 1252: PRO38477  
 Figure 1253: DNA150427, NP\_005599.1, 204960.at  
 Figure 1254: PRO12243  
 Figure 1255: DNA330067, NP\_001800.1, 204962.s.at  
 Figure 1256: PRO60368  
 Figure 1257: DNA287399, NP\_058197.1, 204972.at  
 Figure 1258: PRO69656  
 Figure 1259: DNA329158, NP\_077013.1, 204985.s.at  
 Figure 1260: PRO84788  
 Figure 1261: DNA272427, NP\_004799.1, 205005.s.at  
 Figure 1262: PRO60679  
 Figure 1263: DNA272427, NM\_004808, 205006.s.at  
 Figure 1264: PRO60679  
 Figure 1265: DNA344362, NP\_000666.2, 205013.s.at  
 Figure 1266: PRO4938  
 Figure 1267: DNA329534, NP\_004615.2, 205019.s.at  
 Figure 1268: PRO2904  
 Figure 1269: DNA272312, NP\_005188.1, 205022.s.at  
 Figure 1270: PRO60569  
 Figure 1271: DNA330069, NP\_002866.2, 205024.s.at  
 Figure 1272: PRO85348  
 Figure 1273: DNA328297, NP\_477097.1, 205034.at  
 Figure 1274: PRO59418  
 Figure 1275: DNA324992, NP\_597680.1, 205047.s.at  
 Figure 1276: PRO81586  
 Figure 1277: DNA328551, NP\_003823.1, 205048.s.at  
 Figure 1278: PRO84351  
 Figure 1279A-B: DNA83118, NP\_000213.1, 205051.s.at  
 Figure 1280: PRO2598  
 Figure 1281: DNA254214, NP\_001689.1, 205052.at  
 Figure 1282: PRO49326  
 Figure 1283A-B: DNA220750, NP\_002199.2, 205055.at  
 Figure 1284: PRO34728  
 Figure 1285: DNA329025, NP\_006199.1, 205066.s.at  
 Figure 1286: PRO4860  
 Figure 1287: DNA327632, NP\_001302.1, 205081.at  
 Figure 1288: PRO83635  
 Figure 1289A-B: DNA344363, NP\_005482.1, 205088.at  
 Figure 1290: PRO95068  
 Figure 1291: DNA344364, 331306.1, 205098.at  
 Figure 1292: PRO4949  
 Figure 1293: DNA226177, NP\_001286.1, 205099.s.at  
 Figure 1294: PRO36640  
 Figure 1295: DNA192060, NP\_002974.1, 205114.s.at  
 Figure 1296: PRO21960  
 Figure 1297: DNA344365, NP\_008924.1, 205129.at  
 Figure 1298: PRO95069  
 Figure 1299: DNA299899, NP\_002148.1, 205133.s.at  
 Figure 1300: PRO62760  
 Figure 1301: DNA328554, NP\_038202.1, 205147.x.at  
 Figure 1302: PRO84354

Figure 1303A-B: DNA329160, NP\_002821.1, 205171.at  
 Figure 1304: PRO84789  
 Figure 1305: DNA328810, NP\_001770.1, 205173.x.at  
 Figure 1306: PRO2557  
 Figure 1307: DNA344366, NP\_004476.1, 205184.at  
 Figure 1308: PRO59080  
 Figure 1309: DNA272443, NP\_055531.1, 205213.at  
 Figure 1310: PRO60693  
 Figure 1311: DNA273535, NP\_004217.1, 205214.at  
 Figure 1312: PRO61515  
 Figure 1313: DNA188333, NP\_006410.1, 205242.at  
 Figure 1314: PRO21708  
 Figure 1315: DNA227447, NP\_003193.1, 205254.x.at  
 Figure 1316: PRO37910  
 Figure 1317: DNA227447, NM\_003202, 205255.x.at  
 Figure 1318: PRO37910  
 Figure 1319A-B: DNA188301, NP\_002300.1, 205266.at  
 Figure 1320: PRO21834  
 Figure 1321: DNA332739, NP\_006226.1, 205267.at  
 Figure 1322: PRO87518  
 Figure 1323: DNA227173, NP\_001456.1, 205285.s.at  
 Figure 1324: PRO37636  
 Figure 1325A-B: DNA331483, NM\_003672, 205288.at  
 Figure 1326: PRO86528  
 Figure 1327: DNA43320, DNA43320, 205289.at  
 Figure 1328: PRO313  
 Figure 1329: DNA219011, NP\_001191.1, 205290.s.at  
 Figure 1330: PRO34479  
 Figure 1331A-B: DNA331484, NP\_000869.1, 205291.at  
 Figure 1332: PRO3276  
 Figure 1333: DNA327019, NP\_001406.1, 205321.at  
 Figure 1334: PRO83323  
 Figure 1335A-B: DNA269546, NP\_055612.1, 205340.at  
 Figure 1336: PRO57962  
 Figure 1337: DNA326497, NM\_000156, 205354.at  
 Figure 1338: PRO58046  
 Figure 1339: DNA336844, NP\_003857.1, 205376.at  
 Figure 1340: PRO90913  
 Figure 1341A-C: DNA332571, NP\_065209.1, 205390.s.at  
 Figure 1342: PRO12143  
 Figure 1343: DNA325568, NP\_001265.1, 205393.s.at  
 Figure 1344: PRO12187  
 Figure 1345: DNA325568, NM\_001274, 205394.at  
 Figure 1346: PRO12187  
 Figure 1347: DNA151830, NP\_005893.1, 205397.x.at  
 Figure 1348: PRO62998  
 Figure 1349: DNA151830, NM\_005902, 205398.s.at  
 Figure 1350: PRO62998  
 Figure 1351: DNA329010, NP\_004942.1, 205419.at  
 Figure 1352: PRO23370

WO 2005/019258

PCT/US2004/025788

Figure 1353: DNA335207, NP\_057531.2, 205429.s.at  
Figure 1354: PRO89594  
Figure 1355: DNA287337, NP\_002096.1, 205436.s.at  
Figure 1356: PRO69600  
Figure 1357: DNA272221, NP\_037431.1, 205449.at  
Figure 1358: PRO60483  
Figure 1359: DNA88194, NP\_000724.1, 205456.at  
Figure 1360: PRO2220  
Figure 1361: DNA188355, NP\_004582.1, 205476.at  
Figure 1362: PRO21885  
Figure 1363: DNA287224, NP\_005092.1, 205483.s.at  
Figure 1364: PRO69503  
Figure 1365: DNA330084, NP\_055265.1, 205484.at  
Figure 1366: PRO9895  
Figure 1367A-E: DNA334058, NP\_000531.1, 205485.at  
Figure 1368: PRO88622  
Figure 1369: DNA225959, NP\_006135.1, 205488.at  
Figure 1370: PRO36422  
Figure 1371: DNA226043, NP\_006424.2, 205495.s.at  
Figure 1372: PRO36506  
Figure 1373A-B: DNA344367, NP\_005392.1, 205503.at  
Figure 1374: PRO24022  
Figure 1375: DNA344368, NP\_001481.2, 205505.at  
Figure 1376: PRO95070  
Figure 1377: DNA328566, NP\_060446.1, 205511.at  
Figure 1378: PRO84363  
Figure 1379A-B: DNA334718, NP\_004923.1, 205532.s.at  
Figure 1380: PRO2196  
Figure 1381: DNA344369, NP\_036581.1, 205542.at  
Figure 1382: PRO28528  
Figure 1383: DNA344370, NP\_006797.3, 205548.s.at  
Figure 1384: PRO95071  
Figure 1385: DNA331486, NM\_002534, 205552.s.at  
Figure 1386: PRO69559  
Figure 1387: DNA256257, NP\_055213.1, 205569.at  
Figure 1388: PRO51301  
Figure 1389A-B: DNA227714, NP\_000852.1, 205579.at  
Figure 1390: PRO38177  
Figure 1391A-B: DNA327643, NP\_055712.1, 205594.at  
Figure 1392: PRO83644  
Figure 1393: DNA344371, NP\_073576.1, 205596.s.at  
Figure 1394: PRO95072  
Figure 1395: DNA329013, NP\_005649.1, 205599.at  
Figure 1396: PRO20128  
Figure 1397: DNA90631, NP\_000747.1, 205630.at  
Figure 1398: PRO2519  
Figure 1399: DNA88076, NP\_001628.1, 205639.at  
Figure 1400: PRO2640  
Figure 1401: DNA344372, NP\_003780.1, 205641.s.at  
Figure 1402: PRO95073  
Figure 1403A-B: DNA196641, NP\_002340.1, 205668.at  
Figure 1404: PRO25114  
Figure 1405: DNA344373, NP\_076992.1, 205673.s.at  
Figure 1406: PRO95074  
Figure 1407: DNA328570, NP\_004040.1, 205681.at  
Figure 1408: PRO37843  
Figure 1409: DNA327644, NP\_060395.2, 205684.s.at  
Figure 1410: PRO83645  
Figure 1411: DNA344374, NP\_061989.1, 205687.at  
Figure 1412: PRO95075  
Figure 1413: DNA226234, NP\_001766.1, 205692.s.at  
Figure 1414: PRO36697  
Figure 1415: DNA150621, NP\_036595.1, 205704.s.at  
Figure 1416: PRO12374  
Figure 1417: DNA331817, NP\_055154.3, 205707.at  
Figure 1418: PRO86240  
Figure 1419: DNA220761, NP\_000880.1, 205718.at  
Figure 1420: PRO34739  
Figure 1421: DNA326483, NP\_060346.1, 205748.s.at  
Figure 1422: PRO82861  
Figure 1423: DNA331318, NP\_003636.1, 205768.s.at  
Figure 1424: PRO51139  
Figure 1425: DNA331318, NM\_003645, 205769.at  
Figure 1426: PRO51139  
Figure 1427: DNA330091, NP\_057461.1, 205771.s.at  
Figure 1428: PRO85362  
Figure 1429: DNA344375, NP\_002176.2, 205798.at  
Figure 1430: PRO95076  
Figure 1431A-B: DNA344376, NP\_733772.1, 205801.s.at  
Figure 1432: PRO95077  
Figure 1433: DNA194766, NP\_079504.1, 205804.s.at  
Figure 1434: PRO24046  
Figure 1435: DNA344377, NP\_064512.1, 205807.s.at  
Figure 1436: PRO95078  
Figure 1437: DNA103440, NP\_031386.1, 205821.at  
Figure 1438: PRO4767  
Figure 1439: DNA75526, NP\_001758.1, 205831.at  
Figure 1440: PRO2013  
Figure 1441A-B: DNA328574, NP\_004963.1, 205841.at  
Figure 1442: PRO84368  
Figure 1443A-B: DNA328574, NM\_004972, 205842.s.at  
Figure 1444: PRO84368  
Figure 1445A-B: DNA220746, NP\_000876.1, 205884.at  
Figure 1446: PRO34724  
Figure 1447: DNA330095, NP\_004732.1, 205895.s.at  
Figure 1448: PRO85366  
Figure 1449: DNA328576, NP\_001328.1, 205898.at  
Figure 1450: PRO4940  
Figure 1451: DNA103307, NP\_000238.1, 205904.at  
Figure 1452: PRO4637  
Figure 1453A-B: DNA339322, NP\_003408.1, 205917.at

WO 2005/019258

PCT/US2004/025788

Figure 1454: PRO91128  
 Figure 1455A-B: DNA255292, NP\_056374.1, 205933.at  
 Figure 1456: PRO50365  
 Figure 1457A-B: DNA270867, NP\_006217.1, 205934.at  
 Figure 1458: PRO59203  
 Figure 1459: DNA329047, NP\_006390.1, 205965.at  
 Figure 1460: PRO58425  
 Figure 1461: DNA196439, NP\_003865.1, 205988.at  
 Figure 1462: PRO24934  
 Figure 1463A-B: DNA227747, NP\_005798.1, 206007.at  
 Figure 1464: PRO38210  
 Figure 1465: DNA103281, NP\_002899.1, 206036.s.at  
 Figure 1466: PRO4611  
 Figure 1467: DNA344378, NP\_073715.1, 206042.x.at  
 Figure 1468: PRO95079  
 Figure 1469: DNA275181, NP\_003081.1, 206055.s.at  
 Figure 1470: PRO62882  
 Figure 1471: DNA330096, NP\_057051.1, 206060.s.at  
 Figure 1472: PRO37163  
 Figure 1473A-B: DNA344379, NP\_006246.2, 206099.at  
 Figure 1474: PRO95080  
 Figure 1475: DNA83063, NP\_004429.1, 206114.at  
 Figure 1476: PRO2068  
 Figure 1477A-B: DNA151420, NP\_004421.1, 206115.at  
 Figure 1478: PRO12876  
 Figure 1479: DNA329006, NP\_003142.1, 206118.at  
 Figure 1480: PRO12865  
 Figure 1481: DNA331657, NP\_001707.1, 206126.at  
 Figure 1482: PRO23970  
 Figure 1483: DNA344380, NP\_004953.1, 206159.at  
 Figure 1484: PRO2562  
 Figure 1485: DNA329005, NP\_003028.1, 206181.at  
 Figure 1486: PRO12612  
 Figure 1487A-B: DNA344381, NP\_055604.1, 206188.at  
 Figure 1488: PRO95081  
 Figure 1489A-B: DNA274141, NP\_006460.2, 206245.s.at  
 Figure 1490: PRO62077  
 Figure 1491: DNA334388, NP\_055141.2, 206324.s.at  
 Figure 1492: PRO88904  
 Figure 1493: DNA88224, NP\_001829.1, 206337.at  
 Figure 1494: PRO2236  
 Figure 1495: DNA336220, NM\_006123, 206342.x.at  
 Figure 1496: PRO91049  
 Figure 1497: DNA227700, NP\_004769.1, 206361.at  
 Figure 1498: PRO38163  
 Figure 1499: DNA227208, NP\_005351.2, 206363.at  
 Figure 1500: PRO37671  
 Figure 1501A-B: DNA330100, NP\_055690.1, 206364.at

Figure 1502: PRO85369  
 Figure 1503: DNA329169, NP\_002986.1, 206365.at  
 Figure 1504: PRO1610  
 Figure 1505: DNA329169, NM\_002995, 206366.x.at  
 Figure 1506: PRO1610  
 Figure 1507A-B: DNA335332, NP\_002640.2, 206369.s.at  
 Figure 1508: PRO89706  
 Figure 1509A-E: DNA333253, NP\_066267.1, 206385.s.at  
 Figure 1510: PRO87958  
 Figure 1511: DNA326727, NP\_001527.1, 206445.s.at  
 Figure 1512: PRO83069  
 Figure 1513: DNA153751, NP\_005942.1, 206461.x.at  
 Figure 1514: PRO12925  
 Figure 1515: DNA288243, NP\_002277.3, 206486.at  
 Figure 1516: PRO36451  
 Figure 1517: DNA268333, NP\_001260.1, 206499.s.at  
 Figure 1518: PRO57322  
 Figure 1519: DNA344382, NP\_003826.1, 206518.s.at  
 Figure 1520: PRO95082  
 Figure 1521A-B: DNA334589, NP\_055073.1, 206546.at  
 Figure 1522: PRO89073  
 Figure 1523: DNA327663, NP\_006771.1, 206565.x.at  
 Figure 1524: PRO83654  
 Figure 1525: DNA330103, NP\_056179.1, 206584.at  
 Figure 1526: PRO19671  
 Figure 1527: DNA329172, NP\_005254.1, 206589.at  
 Figure 1528: PRO84796  
 Figure 1529: DNA344383, NP\_003846.1, 206618.at  
 Figure 1530: PRO4778  
 Figure 1531A-C: DNA328331, NP\_004645.1, 206624.at  
 Figure 1532: PRO84195  
 Figure 1533: DNA227709, NP\_000947.1, 206631.at  
 Figure 1534: PRO38172  
 Figure 1535: DNA335452, NP\_004891.3, 206632.s.at  
 Figure 1536: PRO89808  
 Figure 1537: DNA327666, 7688312.1, 206653.at  
 Figure 1538: PRO83656  
 Figure 1539: DNA88374, NP\_002095.1, 206666.at  
 Figure 1540: PRO2768  
 Figure 1541: DNA334470, NP\_536859.1, 206687.s.at  
 Figure 1542: PRO88974  
 Figure 1543: DNA328590, NP\_056948.2, 206707.x.at  
 Figure 1544: PRO84375  
 Figure 1545: DNA340145, NP\_036439.1, 206710.s.at  
 Figure 1546: PRO91644  
 Figure 1547: DNA340152, NP\_055300.1, 206726.at  
 Figure 1548: PRO91651  
 Figure 1549: DNA226427, NP\_002251.1, 206785.s.at  
 Figure 1550: PRO36890  
 Figure 1551: DNA88195, NP\_000064.1, 206804.at  
 Figure 1552: PRO2693  
 Figure 1553: DNA272165, NP\_003319.1, 206828.at

WO 2005/019258

PCT/US2004/025788

Figure 1554: PRO60433  
Figure 1555: DNA339650, NP\_079465.1, 206829.x.at  
Figure 1556: PRO91399  
Figure 1557: DNA256561, NP\_062550.1, 206914.at  
Figure 1558: PRO51592  
Figure 1559: DNA344384, NP\_005659.1, 206925.at  
Figure 1560: PRO59592  
Figure 1561: DNA83130, NP\_002665.1, 206942.s.at  
Figure 1562: PRO2096  
Figure 1563: DNA93439, NP\_006555.1, 206974.at  
Figure 1564: PRO4515  
Figure 1565: DNA35629, NP\_000586.2, 206975.at  
Figure 1566: PRO7  
Figure 1567: DNA331493, NP\_000638.1, 206978.at  
Figure 1568: PRO84690  
Figure 1569: DNA188346, NP\_001450.1, 206980.s.at  
Figure 1570: PRO21766  
Figure 1571A-B: DNA227659, NP\_000570.1, 206991.s.at  
Figure 1572: PRO38122  
Figure 1573A-B: DNA344385, NP\_001550.1, 206999.at  
Figure 1574: PRO23394  
Figure 1575: DNA328295, NP\_004154.2, 207017.at  
Figure 1576: PRO84168  
Figure 1577: DNA344386, NP\_003830.1, 207037.at  
Figure 1578: PRO20114  
Figure 1579: DNA344387, NP\_003844.1, 207072.at  
Figure 1580: PRO36013  
Figure 1581: DNA334102, NM\_020481, 207087.x.at  
Figure 1582: PRO88662  
Figure 1583: DNA344388, NM\_000594, 207113.s.at  
Figure 1584: PRO6  
Figure 1585: DNA344389, NP\_060113.1, 207115.x.at  
Figure 1586: PRO95083  
Figure 1587A-B: DNA327674, NP\_002739.1, 207121.s.at  
Figure 1588: PRO83661  
Figure 1589: DNA331323, NP\_001250.1, 207143.at  
Figure 1590: PRO86412  
Figure 1591: DNA344390, NP\_000873.2, 207160.at  
Figure 1592: PRO82  
Figure 1593: DNA103418, NP\_036616.1, 207165.at  
Figure 1594: PRO4746  
Figure 1595: DNA344391, NP\_004450.1, 207186.s.at  
Figure 1596: PRO95084  
Figure 1597A-B: DNA151879, NP\_055463.1, 207231.at  
Figure 1598: PRO12743  
Figure 1599A-B: DNA151879, NM\_014648, 207232.s.at  
Figure 1600: PRO12743  
Figure 1601: DNA330024, NP\_058521.1, 207266.x.at  
Figure 1602: PRO85309  
Figure 1603: DNA226045, NP\_006728.1, 207313.x.at  
Figure 1604: PRO36508  
Figure 1605: DNA226045, NM\_006737, 207314.x.at  
Figure 1606: PRO36508  
Figure 1607: DNA227751, NP\_006557.1, 207315.at  
Figure 1608: PRO38214  
Figure 1609A-B: DNA226536, NP\_003225.1, 207332.s.at  
Figure 1610: PRO36999  
Figure 1611: DNA88656, NP\_003233.3, 207334.s.at  
Figure 1612: PRO2461  
Figure 1613: DNA331497, NP\_002332.1, 207339.s.at  
Figure 1614: PRO11604  
Figure 1615: DNA330117, NP\_003966.1, 207351.s.at  
Figure 1616: PRO85379  
Figure 1617: DNA225961, NP\_005308.1, 207460.at  
Figure 1618: PRO36424  
Figure 1619: DNA274829, NP\_003653.1, 207469.s.at  
Figure 1620: PRO62588  
Figure 1621: DNA344392, AK000231, 207474.at  
Figure 1622: PRO95085  
Figure 1623: DNA344393, Y07827, 207485.x.at  
Figure 1624: PRO95086  
Figure 1625A-B: DNA344394, NP\_777613.1, 207521.s.at  
Figure 1626: PRO95087  
Figure 1627A-B: DNA344395, NM\_174954, 207522.s.at  
Figure 1628: PRO95088  
Figure 1629: DNA216508, NP\_002972.1, 207533.at  
Figure 1630: PRO34260  
Figure 1631: DNA344396, NP\_001552.2, 207536.s.at  
Figure 1632: PRO2023  
Figure 1633: DNA344397, NP\_000580.1, 207538.at  
Figure 1634: PRO68  
Figure 1635: DNA344398, NM\_000589, 207539.s.at  
Figure 1636: PRO68  
Figure 1637: DNA344399, NP\_523353.1, 207551.s.at  
Figure 1638: PRO95089  
Figure 1639: DNA328600, NP\_004839.1, 207571.x.at  
Figure 1640: PRO84383  
Figure 1641: DNA328601, NP\_056490.1, 207574.s.at  
Figure 1642: PRO84384  
Figure 1643: DNA330121, NP\_004171.2, 207616.s.at  
Figure 1644: PRO85383  
Figure 1645: DNA228010, NP\_003679.1, 207620.s.at  
Figure 1646: PRO38473  
Figure 1647: DNA344400, NP\_005683.2, 207622.s.at  
Figure 1648: PRO36800  
Figure 1649: DNA227606, NP\_001872.2, 207630.s.at  
Figure 1650: PRO38069  
Figure 1651: DNA196426, NP\_037440.1, 207651.at  
Figure 1652: PRO24924  
Figure 1653: DNA328554, NM\_013416, 207677.s.at  
Figure 1654: PRO84354  
Figure 1655: DNA227752, NP\_001495.1, 207681.at  
Figure 1656: PRO38215  
Figure 1657: DNA328763, NP\_001219.2, 207686.s.at

WO 2005/019258

PCT/US2004/025788

Figure 1658: PRO84511  
 Figure 1659: DNA336246, NP\_001767.2, 207691.x.at  
 Figure 1660: PRO90415  
 Figure 1661A-B: DNA226405, NP\_006525.1, 207700.s.at  
 Figure 1662: PRO36868  
 Figure 1663: DNA333631, NP\_031359.1, 207723.s.at  
 Figure 1664: PRO88273  
 Figure 1665: DNA329064, NP\_060301.1, 207735.at  
 Figure 1666: PRO84724  
 Figure 1667: DNA325654, NP\_054752.1, 207761.s.at  
 Figure 1668: PRO4348  
 Figure 1669A-B: DNA329179, NP\_056958.1, 207785.s.at  
 Figure 1670: PRO84802  
 Figure 1671: DNA329180, NP\_004428.1, 207793.s.at  
 Figure 1672: PRO84803  
 Figure 1673: DNA329000, NM\_000648, 207794.at  
 Figure 1674: PRO84690  
 Figure 1675: DNA227722, NP\_002253.1, 207795.s.at  
 Figure 1676: PRO38185  
 Figure 1677: DNA329181, NM\_007334, 207796.x.at  
 Figure 1678: PRO84804  
 Figure 1679: DNA227494, NP\_002158.1, 207826.s.at  
 Figure 1680: PRO37957  
 Figure 1681A-C: DNA335409, NP\_057427.2, 207828.s.at  
 Figure 1682: PRO89771  
 Figure 1683: DNA329182, NP\_065385.2, 207838.x.at  
 Figure 1684: PRO84805  
 Figure 1685: DNA330123, NP\_008984.1, 207840.at  
 Figure 1686: PRO35080  
 Figure 1687: DNA344401, NP\_002179.2, 207844.at  
 Figure 1688: PRO95090  
 Figure 1689: DNA217244, U25676, 207849.at  
 Figure 1690: PRO34286  
 Figure 1691: DNA330124, NP\_002981.2, 207861.at  
 Figure 1692: PRO34107  
 Figure 1693: DNA109234, NP\_000065.1, 207892.at  
 Figure 1694: PRO6517  
 Figure 1695: DNA344402, NP\_002978.1, 207900.at  
 Figure 1696: PRO1717  
 Figure 1697A-B: DNA150910, NP\_005566.1, 207904.s.at  
 Figure 1698: PRO12536  
 Figure 1699: DNA344403, NP\_000579.2, 207906.at  
 Figure 1700: PRO95091  
 Figure 1701: DNA344404, NP\_000870.1, 207952.at  
 Figure 1702: PRO69  
 Figure 1703: DNA227067, X06318, 207957.s.at  
 Figure 1704: PRO37530  
 Figure 1705A-B: DNA344405, NP\_008912.1, 207978.s.at  
 Figure 1706: PRO85386  
 Figure 1707A-C: DNA254145, NP\_004329.1, 207996.s.at

Figure 1708: PRO49260  
 Figure 1709A-B: DNA226403, NP\_000711.1, 207998.s.at  
 Figure 1710: PRO36866  
 Figure 1711: DNA344406, NM\_012411, 208010.s.at  
 Figure 1712: PRO95092  
 Figure 1713: DNA324249, NM\_004510, 208012.x.at  
 Figure 1714: PRO80933  
 Figure 1715: DNA333763, NM\_021708, 208071.s.at  
 Figure 1716: PRO88387  
 Figure 1717A-C: DNA331500, NP\_003307.2, 208073.x.at  
 Figure 1718: PRO86537  
 Figure 1719: DNA331501, D84212, 208079.s.at  
 Figure 1720: PRO58855  
 Figure 1721A-B: DNA344407, NP\_110384.1, 208082.x.at  
 Figure 1722: PRO95093  
 Figure 1723: DNA344408, NP\_112182.1, 208103.s.at  
 Figure 1724: PRO80638  
 Figure 1725A-B: DNA335356, NP\_000952.1, 208131.s.at  
 Figure 1726: PRO25026  
 Figure 1727: DNA325329, NP\_004719.1, 208152.s.at  
 Figure 1728: PRO81872  
 Figure 1729: DNA344409, NP\_002177.1, 208164.s.at  
 Figure 1730: PRO64957  
 Figure 1731: DNA210622, NP\_057009.1, 208190.s.at  
 Figure 1732: PRO35016  
 Figure 1733: DNA36717, NP\_000581.1, 208193.at  
 Figure 1734: PRO72  
 Figure 1735: DNA328611, NP\_005816.2, 208206.s.at  
 Figure 1736: PRO84393  
 Figure 1737: DNA344410, NP\_071431.2, 208303.s.at  
 Figure 1738: PRO28725  
 Figure 1739: DNA196361, NP\_001828.1, 208304.at  
 Figure 1740: PRO24864  
 Figure 1741: DNA344411, X12544, 208306.x.at  
 Figure 1742: PRO95094  
 Figure 1743A-B: DNA344412, NP\_006776.1, 208309.s.at  
 Figure 1744: PRO9824  
 Figure 1745A-C: DNA344413, NP\_006729.3, 208325.s.at  
 Figure 1746: PRO95095  
 Figure 1747: DNA344414, NP\_003813.1, 208337.s.at  
 Figure 1748: PRO62964  
 Figure 1749: DNA344415, NM\_003822, 208343.s.at  
 Figure 1750: PRO62964  
 Figure 1751: DNA329576, NM\_002745, 208351.s.at  
 Figure 1752: PRO64127  
 Figure 1753: DNA344416, NM\_020480, 208353.x.at  
 Figure 1754: PRO95096  
 Figure 1755: DNA344417, NP\_008999.2, 208382.s.at  
 Figure 1756: PRO95097  
 Figure 1757: DNA324250, NP\_536349.1, 208392.x.at

WO 2005/019258

PCT/US2004/025788

Figure 1758: PRO80934  
 Figure 1759A-B: DNA344418, NP\_005723.2, 208393.s.at  
 Figure 1760: PRO86236  
 Figure 1761: DNA344419, NP\_004801.1, 208406.s.at  
 Figure 1762: PRO12190  
 Figure 1763A-B: DNA331315, NP\_004622.1, 208433.s.at  
 Figure 1764: PRO70090  
 Figure 1765: DNA327690, NP\_004022.1, 208436.s.at  
 Figure 1766: PRO83673  
 Figure 1767A-C: DNA331504, NP\_000042.2, 208442.s.at  
 Figure 1768: PRO86540  
 Figure 1769: DNA331327, NP\_036382.2, 208456.s.at  
 Figure 1770: PRO86414  
 Figure 1771: DNA326738, NP\_004315.1, 208478.s.at  
 Figure 1772: PRO38101  
 Figure 1773: DNA344420, NM\_006260, 208499.s.at  
 Figure 1774: PRO11602  
 Figure 1775: DNA344421, NP\_005281.1, 208524.at  
 Figure 1776: PRO54695  
 Figure 1777: DNA344422, NP\_619527.1, 208536.s.at  
 Figure 1778: PRO95098  
 Figure 1779: DNA330045, NP\_005943.1, 208581.x.at  
 Figure 1780: PRO82583  
 Figure 1781: DNA225836, NP\_006716.1, 208602.x.at  
 Figure 1782: PRO36299  
 Figure 1783: DNA344423, NP\_066301.1, 208608.s.at  
 Figure 1784: PRO23346  
 Figure 1785: DNA281431, NP\_004550.1, 208628.s.at  
 Figure 1786: PRO66271  
 Figure 1787: DNA324641, NP\_005608.1, 208646.at  
 Figure 1788: PRO10849  
 Figure 1789: DNA344424, NP\_006007.2, 208653.s.at  
 Figure 1790: PRO95099  
 Figure 1791: DNA344425, U87954, 208676.s.at  
 Figure 1792: PRO95100  
 Figure 1793: DNA304686, NP\_002565.1, 208680.at  
 Figure 1794: PRO71112  
 Figure 1795A-B: DNA328619, BC001188, 208691.at  
 Figure 1796: PRO84401  
 Figure 1797: DNA287189, NP\_002038.1, 208693.s.at  
 Figure 1798: PRO69475  
 Figure 1799: DNA344426, NP\_036205.1, 208696.at  
 Figure 1800: PRO81195  
 Figure 1801: DNA325127, NP\_001559.1, 208697.s.at  
 Figure 1802: PRO81699  
 Figure 1803A-B: DNA325944, NP\_001960.2, 208708.x.at  
 Figure 1804: PRO82391  
 Figure 1805: DNA344427, NP\_061899.1, 208716.s.at  
 Figure 1806: PRO177  
 Figure 1807: DNA344428, NP\_003899.1, 208726.s.at  
 Figure 1808: PRO95101  
 Figure 1809: DNA344429, NP\_004879.1, 208737.at

Figure 1810: PRO61194  
 Figure 1811: DNA344430, NM\_006476, 208745.at  
 Figure 1812: PRO95102  
 Figure 1813: DNA287285, NP\_005794.1, 208748.s.at  
 Figure 1814: PRO69556  
 Figure 1815: DNA344431, NP\_631946.1, 208754.s.at  
 Figure 1816: PRO71113  
 Figure 1817: DNA324217, NP\_004035.2, 208758.at  
 Figure 1818: PRO80908  
 Figure 1819: DNA344432, NP\_060877.1, 208767.s.at  
 Figure 1820: PRO37687  
 Figure 1821: DNA344433, NP\_002806.2, 208777.s.at  
 Figure 1822: PRO95103  
 Figure 1823: DNA287219, NP\_110379.1, 208778.s.at  
 Figure 1824: PRO69498  
 Figure 1825: DNA329189, NP\_009139.1, 208787.at  
 Figure 1826: PRO4911  
 Figure 1827: DNA225671, NP\_001822.1, 208791.at  
 Figure 1828: PRO36134  
 Figure 1829A-B: DNA344434, NP\_055818.2, 208798.x.at  
 Figure 1830: PRO95104  
 Figure 1831: DNA330145, NP\_002788.1, 208799.at  
 Figure 1832: PRO84403  
 Figure 1833A-C: DNA330146, 1397486.26, 208806.at  
 Figure 1834: PRO85404  
 Figure 1835: DNA273521, NP\_002070.1, 208813.at  
 Figure 1836: PRO61502  
 Figure 1837: DNA327699, BAA75062.1, 208815.x.at  
 Figure 1838: PRO83682  
 Figure 1839: DNA344435, NP\_002789.1, 208827.at  
 Figure 1840: PRO82662  
 Figure 1841A-B: DNA83031, NP\_001737.1, 208852.s.at  
 Figure 1842: PRO2564  
 Figure 1843: DNA227874, NP\_003320.1, 208864.s.at  
 Figure 1844: PRO38337  
 Figure 1845: DNA344436, NP\_113600.1, 208869.s.at  
 Figure 1846: PRO95105  
 Figure 1847: DNA328624, BC003562, 208891.at  
 Figure 1848: PRO59076  
 Figure 1849: DNA270713, NP\_001937.1, 208892.s.at  
 Figure 1850: PRO59076  
 Figure 1851: DNA328625, NM\_022652, 208893.s.at  
 Figure 1852: PRO84404  
 Figure 1853: DNA329221, NP\_061984.1, 208894.at  
 Figure 1854: PRO4555  
 Figure 1855A-B: DNA324910, NP\_061820.1, 208905.at  
 Figure 1856: PRO81514  
 Figure 1857: DNA326260, NP\_001203.1, 208910.s.at  
 Figure 1858: PRO82667  
 Figure 1859: DNA226500, NP\_005619.1, 208916.at  
 Figure 1860: PRO36963  
 Figure 1861: DNA325473, NP\_006353.2, 208922.s.at  
 Figure 1862: PRO81996

WO 2005/019258

PCT/US2004/025788

Figure 1863: DNA329552, NP\_063948.1, 208925.at  
 Figure 1864: PRO85097  
 Figure 1865: DNA326233, NP\_000968.2, 208929.x.at  
 Figure 1866: PRO82645  
 Figure 1867: DNA327702, NP\_006490.2, 208934.s.at  
 Figure 1868: PRO83684  
 Figure 1869: DNA327702, NM\_006499, 208936.x.at  
 Figure 1870: PRO83684  
 Figure 1871: DNA344437, NP\_036379.1, 208941.s.at  
 Figure 1872: PRO70339  
 Figure 1873A-B: DNA344438, D50683, 208944.at  
 Figure 1874: PRO95106  
 Figure 1875: DNA325900, NP\_002297.1, 208949.s.at  
 Figure 1876: PRO82356  
 Figure 1877: DNA327661, NP\_005522.1, 208966.x.at  
 Figure 1878: PRO83652  
 Figure 1879A-B: DNA344439, NP\_002256.2, 208974.x.at  
 Figure 1880: PRO82739  
 Figure 1881A-B: DNA330153, L38951, 208975.s.at  
 Figure 1882: PRO82739  
 Figure 1883: DNA328629, NP\_006079.1, 208977.x.at  
 Figure 1884: PRO84407  
 Figure 1885: DNA329522, NP\_000433.2, 208981.at  
 Figure 1886: PRO85080  
 Figure 1887: DNA330155, 7692317.2, 208982.at  
 Figure 1888: PRO85407  
 Figure 1889: DNA329522, NM\_000442, 208983.s.at  
 Figure 1890: PRO85080  
 Figure 1891: DNA330156, NP\_003749.1, 208985.s.at  
 Figure 1892: PRO85408  
 Figure 1893: DNA344440, NP\_644805.1, 208991.at  
 Figure 1894: PRO95107  
 Figure 1895: DNA331514, NM\_003150, 208992.s.at  
 Figure 1896: PRO86548  
 Figure 1897: DNA227552, NP\_003346.2, 208997.s.at  
 Figure 1898: PRO38015  
 Figure 1899A-B: DNA344441, AAG09407.1, 208999.at  
 Figure 1900: PRO95108  
 Figure 1901: DNA328630, NP\_036293.1, 209004.s.at  
 Figure 1902: PRO84408  
 Figure 1903: DNA328631, AK027318, 209006.s.at  
 Figure 1904: PRO84409  
 Figure 1905: DNA328632, NP\_064713.2, 209007.s.at  
 Figure 1906: PRO84410  
 Figure 1907: DNA328633, NP\_004784.2, 209017.s.at  
 Figure 1908: PRO84411  
 Figure 1909: DNA327706, NP\_006363.3, 209024.s.at  
 Figure 1910: PRO83688  
 Figure 1911: DNA344442, AF279899, 209034.at  
 Figure 1912: PRO95109  
 Figure 1913: DNA274967, AF233453, 209049.s.at  
 Figure 1914: PRO62700  
 Figure 1915A-C: DNA344443, NP\_579890.1, 209052.s.at

Figure 1916: PRO81109  
 Figure 1917A-B: DNA331518, NM\_133336, 209053.s.at  
 Figure 1918: PRO86550  
 Figure 1919A-B: DNA226405, NM\_006534, 209060.x.at  
 Figure 1920: PRO36868  
 Figure 1921A-C: DNA344444, 1394903.34, 209061.at  
 Figure 1922: PRO95110  
 Figure 1923A-B: DNA226405, AF036892, 209062.x.at  
 Figure 1924: PRO36868  
 Figure 1925: DNA330160, NP\_006285.1, 209066.x.at  
 Figure 1926: PRO85412  
 Figure 1927: DNA329194, NP\_112740.1, 209067.s.at  
 Figure 1928: PRO84814  
 Figure 1929A-B: DNA324473, NP\_002904.2, 209084.s.at  
 Figure 1930: PRO81135  
 Figure 1931A-B: DNA273483, AB007960, 209090.s.at  
 Figure 1932: DNA324318, NP\_006755.2, 209100.at  
 Figure 1933: PRO80995  
 Figure 1934: DNA330118, NP\_036389.2, 209102.s.at  
 Figure 1935: PRO85380  
 Figure 1936: DNA330163, NP\_060308.1, 209104.s.at  
 Figure 1937: PRO85415  
 Figure 1938A-B: DNA344445, 104805.26, 209105.at  
 Figure 1939: PRO95111  
 Figure 1940: DNA344446, NP\_004055.1, 209112.at  
 Figure 1941: PRO95112  
 Figure 1942: DNA344447, BC005127, 209122.at  
 Figure 1943: PRO95113  
 Figure 1944: DNA344448, NM\_176895, 209147.s.at  
 Figure 1945: PRO95114  
 Figure 1946: DNA330166, NP\_004688.2, 209161.at  
 Figure 1947: PRO85418  
 Figure 1948: DNA344449, 1448768.1, 209163.at  
 Figure 1949: PRO95115  
 Figure 1950: DNA344450, NP\_001906.1, 209164.s.at  
 Figure 1951: PRO57071  
 Figure 1952A-C: DNA270403, NM\_016343, 209172.s.at  
 Figure 1953: PRO58786  
 Figure 1954: DNA329196, NP\_004573.2, 209181.s.at  
 Figure 1955: PRO84815  
 Figure 1956A-B: DNA344451, NP\_733765.1, 209186.at  
 Figure 1957: PRO84419  
 Figure 1958: DNA189700, NP\_005243.1, 209189.at  
 Figure 1959: PRO25619  
 Figure 1960: DNA226176, NP\_003458.1, 209201.x.at  
 Figure 1961: PRO36639  
 Figure 1962: DNA326267, NP\_004861.1, 209208.at  
 Figure 1963: PRO82674  
 Figure 1964: DNA103439, NP\_001111.2, 209215.at



WO 2005/019258

PCT/US2004/025788

Figure 1965: PRO4766  
Figure 1966: DNA330168, NP\_006322.1, 209233.at  
Figure 1967: PRO85420  
Figure 1968: DNA344452, NM\_007189, 209247.s.at  
Figure 1969: PRO95116  
Figure 1970: DNA344453, BC004949, 209251.x.at  
Figure 1971: PRO84424  
Figure 1972: DNA255255, NP\_071437.3, 209267.s.at  
Figure 1973: PRO50332  
Figure 1974: DNA328650, DNA328650, 209286.at  
Figure 1975: PRO84425  
Figure 1976A-B: DNA344454, NP\_006440.2, 209288.s.at  
Figure 1977: PRO95117  
Figure 1978: DNA328651, AF087853, 209304.x.at  
Figure 1979: PRO82889  
Figure 1980: DNA344455, BC024654, 209305.s.at  
Figure 1981: PRO95118  
Figure 1982: DNA344456, NP\_001216.1, 209310.s.at  
Figure 1983: PRO37559  
Figure 1984: DNA344457, U65585, 209312.x.at  
Figure 1985: PRO95119  
Figure 1986A-B: DNA344458, NP\_006611.1, 209316.s.at  
Figure 1987: PRO12057  
Figure 1988: DNA344459, U94829, 209325.s.at  
Figure 1989: PRO95120  
Figure 1990: DNA329200, NP\_005040.1, 209336.at  
Figure 1991: PRO84817  
Figure 1992: DNA275106, NP\_005058.2, 209339.at  
Figure 1993: PRO62821  
Figure 1994: DNA328655, 346677.3, 209341.s.at  
Figure 1995: PRO84429  
Figure 1996: DNA227208, NM\_005360, 209347.s.at  
Figure 1997: PRO37671  
Figure 1998A-B: DNA328658, AF055376, 209348.s.at  
Figure 1999: PRO84432  
Figure 2000: DNA330170, AF109161, 209357.at  
Figure 2001: PRO84807  
Figure 2002A-B: DNA344460, NP\_001745.2, 209360.s.at  
Figure 2003: PRO95121  
Figure 2004A-C: DNA344461, NP\_061872.1, 209379.s.at  
Figure 2005: PRO95122  
Figure 2006: DNA330173, NP\_006200.2, 209392.at  
Figure 2007: PRO85423  
Figure 2008: DNA339326, NP\_004273.1, 209406.at  
Figure 2009: PRO91131  
Figure 2010: DNA330175, NP\_006836.1, 209408.at  
Figure 2011: PRO59681  
Figure 2012A-B: DNA344462, NM\_133650, 209447.at  
Figure 2013: PRO95123  
Figure 2014: DNA330121, NM\_004180, 209451.at  
Figure 2015: PRO85383  
Figure 2016: DNA344463, NP\_065737.1, 209459.s.at  
Figure 2017: PRO95124  
Figure 2018: DNA344464, NM\_020686, 209460.at  
Figure 2019: PRO95125  
Figure 2020: DNA287304, AAH00040.1, 209461.x.at  
Figure 2021: PRO69571  
Figure 2022A-B: DNA344465, 347965.2, 209473.at  
Figure 2023: PRO95126  
Figure 2024: DNA336246, NM\_001776, 209474.s.at  
Figure 2025: PRO90415  
Figure 2026: DNA324976, NP\_005828.1, 209482.at  
Figure 2027: PRO81571  
Figure 2028: DNA324899, NP\_002938.1, 209507.at  
Figure 2029: PRO81503  
Figure 2030: DNA274027, NP\_004571.2, 209514.s.at  
Figure 2031: PRO61971  
Figure 2032A-B: DNA344466, NM\_144767, 209534.x.at  
Figure 2033: PRO95127  
Figure 2034: DNA344467, NM\_139265, 209536.s.at  
Figure 2035: PRO82426  
Figure 2036: DNA274949, NP\_008904.1, 209538.at  
Figure 2037: PRO62684  
Figure 2038A-B: DNA344468, NP\_004831.1, 209539.at  
Figure 2039: PRO83388  
Figure 2040A-C: DNA335383, NP\_000609.1, 209540.at  
Figure 2041: PRO19618  
Figure 2042A-C: DNA335383, NM\_000618, 209541.at  
Figure 2043: PRO19618  
Figure 2044: DNA329201, NP\_055984.1, 209567.at  
Figure 2045: PRO84818  
Figure 2046: DNA344469, NP\_003788.2, 209572.s.at  
Figure 2047: PRO40888  
Figure 2048A-C: DNA254145, NM\_004338, 209573.s.at  
Figure 2049: PRO49260  
Figure 2050: DNA344470, NP\_002060.3, 209576.at  
Figure 2051: PRO95128  
Figure 2052: DNA304797, NP\_005935.3, 209582.s.at  
Figure 2053: PRO71209  
Figure 2054: DNA304797, NM\_005944, 209583.s.at  
Figure 2055: PRO71209  
Figure 2056: DNA344471, NP\_004119.1, 209595.at  
Figure 2057: PRO95129  
Figure 2058: DNA270689, NP\_002042.1, 209602.s.at  
Figure 2059: PRO59053  
Figure 2060: DNA344472, 412986.6, 209603.at  
Figure 2061: PRO95130  
Figure 2062: DNA270689, NM\_002051, 209604.s.at  
Figure 2063: PRO59053  
Figure 2064: DNA330186, NP\_004327.1, 209642.at  
Figure 2065: PRO85434

WO 2005/019258

PCT/US2004/025788

Figure 2066: DNA323856, NP\_056455.1, 209669.s.at  
 Figure 2067: PRO80599  
 Figure 2068A-B: DNA344473, NP\_008927.1, 209681.at  
 Figure 2069: PRO23299  
 Figure 2070A-B: DNA344474, NM\_170662, 209682.at  
 Figure 2071: PRO95131  
 Figure 2072: DNA328264, NP\_005183.2, 209714.s.at  
 Figure 2073: PRO12087  
 Figure 2074A-B: DNA328594, M37435, 209716.at  
 Figure 2075: PRO84379  
 Figure 2076A-C: DNA254412, NP\_005656.2, 209717.at  
 Figure 2077: PRO49522  
 Figure 2078: DNA227124, NP\_005118.1, 209732.at  
 Figure 2079: PRO37587  
 Figure 2080: DNA344475, AF113682, 209753.s.at  
 Figure 2081: PRO95132  
 Figure 2082: DNA344476, U09088, 209754.s.at  
 Figure 2083: PRO95133  
 Figure 2084: DNA324250, NM\_080424, 209761.s.at  
 Figure 2085: PRO80934  
 Figure 2086A-B: DNA328675, NM\_033274, 209765.at  
 Figure 2087: PRO84447  
 Figure 2088: DNA329178, NP\_008979.2, 209770.at  
 Figure 2089: PRO84801  
 Figure 2090: DNA275195, NP\_001025.1, 209773.s.at  
 Figure 2091: PRO62893  
 Figure 2092A-B: DNA255050, NP\_065165.1, 209780.at  
 Figure 2093: PRO50138  
 Figure 2094A-B: DNA344477, AF222340, 209788.s.at  
 Figure 2095: PRO95134  
 Figure 2096: DNA336284, NP\_001217.2, 209790.s.at  
 Figure 2097: PRO90442  
 Figure 2098: DNA226436, NP\_001772.1, 209795.at  
 Figure 2099: PRO36899  
 Figure 2100: DNA327731, NP\_003302.1, 209803.s.at  
 Figure 2101: PRO83707  
 Figure 2102: DNA271384, AAA61110.1, 209813.x.at  
 Figure 2103: PRO59683  
 Figure 2104: DNA326100, NP\_006444.2, 209820.s.at  
 Figure 2105: PRO82528  
 Figure 2106: DNA225992, NP\_003374.1, 209822.s.at  
 Figure 2107: PRO36455  
 Figure 2108: DNA344478, M17955, 209823.x.at  
 Figure 2109: PRO95135  
 Figure 2110: DNA336282, NP\_001169.2, 209824.s.at  
 Figure 2111: PRO61686  
 Figure 2112: DNA327732, NP\_036606.2, 209825.s.at  
 Figure 2113: PRO61801  
 Figure 2114A-B: DNA196499, AB002384, 209829.at  
 Figure 2115: PRO24988

Figure 2116: DNA344479, L05424, 209835.x.at  
 Figure 2117: DNA344480, AAH35133.1, 209840.s.at  
 Figure 2118: PRO95136  
 Figure 2119: DNA329207, NM\_018334, 209841.s.at  
 Figure 2120: PRO220  
 Figure 2121: DNA344481, BC012398, 209845.at  
 Figure 2122: PRO95137  
 Figure 2123: DNA324805, NP\_008978.1, 209846.s.at  
 Figure 2124: PRO81419  
 Figure 2125: DNA272753, NP\_005780.1, 209853.s.at  
 Figure 2126: PRO60864  
 Figure 2127: DNA344482, NP\_006829.1, 209861.s.at  
 Figure 2128: PRO61513  
 Figure 2129A-B: DNA325767, NP\_476510.1, 209876.at  
 Figure 2130: PRO82238  
 Figure 2131: DNA226120, NP\_002997.1, 209879.at  
 Figure 2132: PRO36583  
 Figure 2133A-C: DNA194808, NP\_003606.2, 209884.s.at  
 Figure 2134: PRO24078  
 Figure 2135A-B: DNA344483, NP\_056305.1, 209889.at  
 Figure 2136: PRO95138  
 Figure 2137: DNA334335, NP\_065726.1, 209891.at  
 Figure 2138: PRO80882  
 Figure 2139: DNA254936, NP\_009164.1, 209917.s.at  
 Figure 2140: PRO50026  
 Figure 2141: DNA299884, AB040875, 209921.at  
 Figure 2142: PRO70858  
 Figure 2143: DNA226887, NP\_002529.1, 209925.at  
 Figure 2144: PRO37350  
 Figure 2145: DNA150133, AAD01646.1, 209933.s.at  
 Figure 2146: PRO12219  
 Figure 2147: DNA336245, AF005775, 209939.x.at  
 Figure 2148: PRO91070  
 Figure 2149: DNA344484, NM\_139266, 209969.s.at  
 Figure 2150: PRO83711  
 Figure 2151: DNA344485, AF116615, 209971.x.at  
 Figure 2152: DNA226658, NP\_003736.1, 209999.x.at  
 Figure 2153: PRO37121  
 Figure 2154: DNA226658, NM\_003745, 210001.s.at  
 Figure 2155: PRO37121  
 Figure 2156A-B: DNA344486, NM\_173844, 210017.at  
 Figure 2157: PRO95140  
 Figure 2158A-B: DNA344487, NM\_006785, 210018.x.at  
 Figure 2159: PRO9824  
 Figure 2160: DNA255921, NP\_000725.1, 210031.at  
 Figure 2161: PRO50974  
 Figure 2162: DNA344488, NP\_002159.1, 210046.s.at  
 Figure 2163: PRO82489  
 Figure 2164: DNA326809, NP\_036244.2, 210052.s.at  
 Figure 2165: PRO83142  
 Figure 2166: DNA328285, NP\_002745.1, 210059.s.at

WO 2005/019258

PCT/US2004/025788

Figure 2167: PRO84161  
 Figure 2168: DNA344489, NP\_057580.1, 210075.at  
 Figure 2169: PRO50605  
 Figure 2170: DNA334812, NP\_002028.1, 210105.s.at  
 Figure 2171: PRO4624  
 Figure 2172A-C: DNA344490, 348003.19, 210108.at  
 Figure 2173: PRO95141  
 Figure 2174: DNA254310, NP\_055226.1, 210109.at  
 Figure 2175: PRO49421  
 Figure 2176: DNA270010, NP\_002342.1, 210116.at  
 Figure 2177: PRO58405  
 Figure 2178: DNA344491, 7763479.63, 210136.at  
 Figure 2179: PRO95142  
 Figure 2180: DNA333697, NP\_003641.2, 210140.at  
 Figure 2181: PRO88328  
 Figure 2182: DNA256015, NP\_002182.1, 210141.s.at  
 Figure 2183: PRO51063  
 Figure 2184: DNA344492, NP\_077734.1, 210145.at  
 Figure 2185: PRO90384  
 Figure 2186: DNA340737, NM\_172390, 210162.s.at  
 Figure 2187: PRO92688  
 Figure 2188: DNA330202, NP\_005400.1, 210163.at  
 Figure 2189: PRO19838  
 Figure 2190: DNA287620, NP\_004122.1, 210164.at  
 Figure 2191: PRO2081  
 Figure 2192: DNA335084, 233354.1, 210174.at  
 Figure 2193: PRO89492  
 Figure 2194: DNA330203, NP\_003755.1, 210190.at  
 Figure 2195: PRO85449  
 Figure 2196: DNA186230, NP\_006599.1, 210191.s.at  
 Figure 2197: PRO21476  
 Figure 2198: DNA344493, NP\_003773.1, 210205.at  
 Figure 2199: PRO1756  
 Figure 2200: DNA344494, NP\_000749.2, 210229.s.at  
 Figure 2201: PRO2055  
 Figure 2202: DNA344495, NM\_134470, 210233.at  
 Figure 2203: PRO88491  
 Figure 2204: DNA328690, NP\_524145.1, 210240.s.at  
 Figure 2205: PRO59660  
 Figure 2206: DNA287333, NP\_005283.1, 210279.at  
 Figure 2207: PRO69597  
 Figure 2208A-B: DNA270015, NP\_003444.1, 210281.s.at  
 Figure 2209: PRO58410  
 Figure 2210A-C: DNA194808, NM\_003615, 210286.s.at  
 Figure 2211: PRO24078  
 Figure 2212: DNA272137, NP\_000309.1, 210296.s.at  
 Figure 2213: PRO60406  
 Figure 2214A-B: DNA188419, NP\_002011.1, 210316.at  
 Figure 2215: PRO21767  
 Figure 2216: DNA329213, NP\_219491.1, 210321.at  
 Figure 2217: PRO2313  
 Figure 2218: DNA225528, NP\_000610.1, 210354.at  
 Figure 2219: PRO35991  
 Figure 2220: DNA330207, BC001131, 210387.at  
 Figure 2221: PRO85451  
 Figure 2222A-B: DNA330208, AF164622, 210425.x.at  
 Figure 2223: PRO85452  
 Figure 2224: DNA344496, NP\_599022.1, 210426.x.at  
 Figure 2225: PRO95143  
 Figure 2226: DNA329215, NP\_036224.1, 210439.at  
 Figure 2227: PRO7424  
 Figure 2228: DNA344497, NP\_002552.2, 210448.s.at  
 Figure 2229: PRO95144  
 Figure 2230: DNA344498, NM\_133484, 210458.s.at  
 Figure 2231: PRO86554  
 Figure 2232: DNA326589, NP\_060192.1, 210463.x.at  
 Figure 2233: PRO82947  
 Figure 2234: DNA323856, NM\_015640, 210466.s.at  
 Figure 2235: PRO80599  
 Figure 2236A-B: DNA274461, M37712, 210473.s.at  
 Figure 2237: PRO62367  
 Figure 2238: DNA344499, NM\_134262, 210479.s.at  
 Figure 2239: PRO95145  
 Figure 2240: DNA256385, NP\_004470.1, 210506.at  
 Figure 2241: PRO51426  
 Figure 2242: DNA344500, NP\_003367.2, 210512.s.at  
 Figure 2243: PRO84827  
 Figure 2244: DNA344501, NP\_002118.1, 210514.x.at  
 Figure 2245: PRO50891  
 Figure 2246: DNA270066, AF078844, 210524.x.at  
 Figure 2247: PRO58459  
 Figure 2248: DNA344502, AF010447, 210528.at  
 Figure 2249: PRO95146  
 Figure 2250: DNA344503, NP\_003769.1, 210540.s.at  
 Figure 2251: PRO1109  
 Figure 2252A-B: DNA344504, NP\_004546.1, 210555.s.at  
 Figure 2253: PRO82622  
 Figure 2254A-B: DNA344505, NM\_173164, 210556.at  
 Figure 2255: PRO95147  
 Figure 2256: DNA344506, NM\_172211, 210557.x.at  
 Figure 2257: PRO95148  
 Figure 2258: DNA344507, NM\_033379, 210559.s.at  
 Figure 2259: PRO70806  
 Figure 2260: DNA344508, U97075, 210563.x.at  
 Figure 2261: PRO95149  
 Figure 2262: DNA329217, AAH03406.1, 210571.s.at  
 Figure 2263: PRO84828  
 Figure 2264: DNA344509, AF241788, 210574.s.at  
 Figure 2265: PRO95150  
 Figure 2266: DNA327808, NM\_002970, 210592.s.at  
 Figure 2267: PRO83769  
 Figure 2268: DNA227722, NM\_002262, 210606.x.at  
 Figure 2269: PRO38185  
 Figure 2270: DNA330210, U03858, 210607.at  
 Figure 2271: PRO126  
 Figure 2272: DNA150511, AF000425, 210629.x.at

WO 2005/019258

PCT/US2004/025788

- Figure 2273: PRO11557  
 Figure 2274: DNA344510, NP\_003692.1, 210643.at  
 Figure 2275: PRO1292  
 Figure 2276: DNA227153, NP\_002278.1, 210644.s.at  
 Figure 2277: PRO37616  
 Figure 2278A-C: DNA330214, D83077, 210645.s.at  
 Figure 2279: PRO12135  
 Figure 2280: DNA290260, NP\_036555.1, 210646.x.at  
 Figure 2281: PRO70385  
 Figure 2282: DNA256521, NP\_038459.1, 210690.at  
 Figure 2283: PRO51556  
 Figure 2284: DNA329218, NM\_014412, 210691.s.at  
 Figure 2285: PRO84829  
 Figure 2286A-B: DNA335356, NM\_000961, 210702.s.at  
 Figure 2287: PRO25026  
 Figure 2288: DNA329023, NP\_066925.1, 210715.s.at  
 Figure 2289: PRO209  
 Figure 2290: DNA344511, BC015818, 210732.s.at  
 Figure 2291: PRO95151  
 Figure 2292: DNA103245, NM\_002350, 210754.s.at  
 Figure 2293: PRO4575  
 Figure 2294: DNA194819, NP\_667341.1, 210763.x.at  
 Figure 2295: PRO24086  
 Figure 2296: DNA344512, NP\_001307.2, 210766.s.at  
 Figure 2297: PRO83174  
 Figure 2298: DNA103572, D14705, 210844.x.at  
 Figure 2299: PRO4896  
 Figure 2300: DNA344513, Y09392, 210847.x.at  
 Figure 2301A-C: DNA329220, NM\_000051, 210858.x.at  
 Figure 2302: PRO84830  
 Figure 2303: DNA188234, NP\_000630.1, 210865.at  
 Figure 2304: PRO21942  
 Figure 2305: DNA228132, NM\_024090, 210868.s.at  
 Figure 2306: PRO38595  
 Figure 2307: DNA344514, AF098641, 210916.s.at  
 Figure 2308: PRO95153  
 Figure 2309: DNA344515, NP\_000061.1, 210944.s.at  
 Figure 2310: PRO38022  
 Figure 2311: DNA344516, NM\_003711, 210946.at  
 Figure 2312: PRO95154  
 Figure 2313: DNA344517, AF294627, 210948.s.at  
 Figure 2314: PRO95155  
 Figure 2315: DNA344518, NP\_004453.1, 210950.s.at  
 Figure 2316: PRO81644  
 Figure 2317: DNA274027, NM\_004580, 210951.x.at  
 Figure 2318: PRO61971  
 Figure 2319: DNA336282, NM\_001178, 210971.s.at  
 Figure 2320: PRO61686  
 Figure 2321A-B: DNA344519, NP\_000595.1, 210973.s.at  
 Figure 2322: PRO34231  
 Figure 2323: DNA344520, U47674, 210980.s.at  
 Figure 2324: PRO95156  
 Figure 2325: DNA269888, NP\_002073.1, 210981.s.at  
 Figure 2326: PRO58286  
 Figure 2327: DNA329221, NM\_019111, 210982.s.at  
 Figure 2328: PRO4555  
 Figure 2329: DNA238565, NP\_005907.2, 210983.s.at  
 Figure 2330: PRO39210  
 Figure 2331: DNA151825, NP\_005891.1, 210993.s.at  
 Figure 2332: PRO12900  
 Figure 2333: DNA344521, NM\_002184, 211000.s.at  
 Figure 2334: PRO85478  
 Figure 2335: DNA150135, NP\_055202.1, 211005.at  
 Figure 2336: PRO12232  
 Figure 2337: DNA273498, L12723, 211015.s.at  
 Figure 2338: PRO61480  
 Figure 2339: DNA344522, BC002526, 211016.x.at  
 Figure 2340: PRO95157  
 Figure 2341A-C: DNA344523, NP\_000480.2, 211022.s.at  
 Figure 2342: PRO95158  
 Figure 2343: DNA287198, NP\_006073.1, 211058.x.at  
 Figure 2344: PRO69484  
 Figure 2345: DNA328698, NM\_006153, 211063.s.at  
 Figure 2346: PRO12168  
 Figure 2347: DNA326974, NM\_000967, 211073.x.at  
 Figure 2348: PRO83285  
 Figure 2349A-B: DNA235639, NP\_000206.1, 211108.s.at  
 Figure 2350: PRO38866  
 Figure 2351: DNA304765, M30894, 211144.x.at  
 Figure 2352: PRO71178  
 Figure 2353: DNA196439, NM\_003874, 211190.x.at  
 Figure 2354: PRO24934  
 Figure 2355: DNA344524, U96627, 211192.s.at  
 Figure 2356: PRO95159  
 Figure 2357: DNA330221, NP\_056071.1, 211207.s.at  
 Figure 2358: PRO85460  
 Figure 2359: DNA270010, NM\_002351, 211209.x.at  
 Figure 2360: PRO58405  
 Figure 2361: DNA344525, AF100539, 211210.x.at  
 Figure 2362: PRO95160  
 Figure 2363: DNA344526, AF100542, 211211.x.at  
 Figure 2364: PRO95161  
 Figure 2365: DNA151022, NM\_001345, 211272.s.at  
 Figure 2366: PRO12096  
 Figure 2367: DNA344527, NM\_004130, 211275.s.at  
 Figure 2368: PRO95162  
 Figure 2369A-B: DNA344528, NM\_002600, 211302.s.at  
 Figure 2370: PRO10691  
 Figure 2371A-C: DNA328811, NM\_002222, 211323.s.at  
 Figure 2372: PRO84551  
 Figure 2373A-B: DNA339333, NP\_005537.3, 211339.s.at  
 Figure 2374: PRO91137  
 Figure 2375: DNA103395, U80737, 211352.s.at  
 Figure 2376: PRO4723

WO 2005/019258

PCT/US2004/025788

Figure 2377: DNA327754, NP\_150634.1, 211367.s.at  
 Figure 2378: PRO4526  
 Figure 2379A-B: DNA339371, NP\_054742.1, 211383.s.at  
 Figure 2380: PRO91176  
 Figure 2381: DNA327755, NP\_115957.1, 211458.s.at  
 Figure 2382: PRO83725  
 Figure 2383: DNA93439, NM\_006564, 211469.s.at  
 Figure 2384: PRO4515  
 Figure 2385: DNA324183, NM\_001935, 211478.s.at  
 Figure 2386: PRO80881  
 Figure 2387: DNA344529, BC001173, 211501.s.at  
 Figure 2388: PRO62214  
 Figure 2389: DNA344530, NM\_003376, 211527.x.at  
 Figure 2390: PRO69153  
 Figure 2391: DNA344531, NP\_001005.1, 211542.x.at  
 Figure 2392: PRO95163  
 Figure 2393: DNA269888, NM\_002082, 211543.s.at  
 Figure 2394: PRO58286  
 Figure 2395: DNA226578, NM\_004354, 211559.s.at  
 Figure 2396: PRO37041  
 Figure 2397: DNA329031, NP\_004890.2, 211566.x.at  
 Figure 2398: PRO84699  
 Figure 2399: DNA226255, NP\_003047.1, 211576.s.at  
 Figure 2400: PRO36718  
 Figure 2401: DNA331572, AF000426, 211581.x.at  
 Figure 2402: PRO86585  
 Figure 2403: DNA196752, AF031136, 211583.x.at  
 Figure 2404: PRO25202  
 Figure 2405: DNA344532, NP\_631958.1, 211597.s.at  
 Figure 2406: PRO95164  
 Figure 2407: DNA275389, M30448, 211623.s.at  
 Figure 2408: PRO63052  
 Figure 2409: DNA344533, M24668, 211633.x.at  
 Figure 2410: PRO95165  
 Figure 2411: DNA344534, L06101, 211641.x.at  
 Figure 2412: DNA344535, M17565, 211654.x.at  
 Figure 2413A-B: DNA103553, NM\_000176, 211671.s.at  
 Figure 2414: PRO4880  
 Figure 2415A-B: DNA255619, AF054589, 211675.s.at  
 Figure 2416: PRO50682  
 Figure 2417: DNA188293, NP\_000407.1, 211676.s.at  
 Figure 2418: PRO21787  
 Figure 2419: DNA327760, NP\_114430.1, 211685.s.at  
 Figure 2420: PRO83729  
 Figure 2421: DNA88515, L41270, 211688.x.at  
 Figure 2422: PRO2390  
 Figure 2423: DNA344536, NM\_000968, 211710.x.at  
 Figure 2424: PRO95168  
 Figure 2425: DNA344537, NM\_178014, 211714.x.at  
 Figure 2426: PRO10347  
 Figure 2427A-B: DNA274117, NP\_612356.1, 211721.s.at  
 Figure 2428: PRO62054

Figure 2429: DNA329225, NP\_006486.2, 211742.s.at  
 Figure 2430: PRO84833  
 Figure 2431: DNA344538, NM\_148976, 211746.x.at  
 Figure 2432: PRO81959  
 Figure 2433: DNA344539, NP\_036454.1, 211747.s.at  
 Figure 2434: PRO95169  
 Figure 2435: DNA344540, BC021088, 211750.x.at  
 Figure 2436: PRO84424  
 Figure 2437: DNA324147, NP\_005774.2, 211758.x.at  
 Figure 2438: PRO80848  
 Figure 2439: DNA344541, BC005974, 211760.s.at  
 Figure 2440: PRO95170  
 Figure 2441: DNA254725, NM\_002266, 211762.s.at  
 Figure 2442: PRO49824  
 Figure 2443: DNA340145, NM\_012307, 211776.s.at  
 Figure 2444: PRO91644  
 Figure 2445: DNA344542, NM\_001561, 211786.at  
 Figure 2446: PRO2023  
 Figure 2447: DNA344543, NP\_003627.1, 211791.s.at  
 Figure 2448: PRO62306  
 Figure 2449: DNA331536, AAA60662.1, 211796.s.at  
 Figure 2450: PRO86563  
 Figure 2451: DNA344544, NM\_052827, 211804.s.at  
 Figure 2452: PRO95171  
 Figure 2453A-B: DNA225940, NP\_000144.1, 211810.s.at  
 Figure 2454: PRO36403  
 Figure 2455A-B: DNA328707, AAF03782.1, 211828.s.at  
 Figure 2456: PRO84466  
 Figure 2457: DNA344545, NM\_138763, 211833.s.at  
 Figure 2458: PRO95172  
 Figure 2459: DNA344546, NP\_757351.1, 211839.s.at  
 Figure 2460: PRO95173  
 Figure 2461A-B: DNA188192, NP\_006130.1, 211856.x.at  
 Figure 2462: PRO21704  
 Figure 2463A-B: DNA188192, NM\_006139, 211861.x.at  
 Figure 2464: PRO21704  
 Figure 2465: DNA225836, NM\_006725, 211893.x.at  
 Figure 2466: PRO36299  
 Figure 2467: DNA344547, U66146, 211900.x.at  
 Figure 2468: PRO95174  
 Figure 2469: DNA226176, NM\_003467, 211919.s.at  
 Figure 2470: PRO36639  
 Figure 2471: DNA272286, NM\_001752, 211922.s.at  
 Figure 2472: PRO60544  
 Figure 2473: DNA344548, 7762146.13, 211929.at  
 Figure 2474: PRO95175  
 Figure 2475A-B: DNA272195, D21262, 211951.at  
 Figure 2476: DNA325941, NP\_005339.1, 211969.at  
 Figure 2477: PRO82388  
 Figure 2478: DNA344549, 474771.15, 211974.x.at  
 Figure 2479: PRO95176  
 Figure 2480A-B: DNA344550, BC047523, 211984.at

WO 2005/019258

PCT/US2004/025788

Figure 2481: PRO4904  
Figure 2482A-B: DNA344551, 7698619.16, 211985.s.at  
Figure 2483: PRO95177  
Figure 2484A-C: DNA327765, 1390535.1, 211986.at  
Figure 2485: PRO83732  
Figure 2486: DNA344552, NP\_291032.1, 211990.at  
Figure 2487: PRO85469  
Figure 2488: DNA324768, NM\_033554, 211991.s.at  
Figure 2489: PRO4884  
Figure 2490: DNA326406, NP\_005315.1, 211999.at  
Figure 2491: PRO11403  
Figure 2492: DNA287433, NP\_006810.1, 212009.s.at  
Figure 2493: PRO69690  
Figure 2494: DNA88197, X66733, 212014.x.at  
Figure 2495: PRO2694  
Figure 2496A-D: DNA103461, NP\_002408.2, 212020.s.at  
Figure 2497: PRO4788  
Figure 2498A-D: DNA103461, NM\_002417, 212022.s.at  
Figure 2499: PRO4788  
Figure 2500A-D: DNA226463, X65551, 212023.s.at  
Figure 2501: PRO36926  
Figure 2502: DNA328709, BC004151, 212048.s.at  
Figure 2503: PRO37676  
Figure 2504A-B: DNA344553, 7697666.18, 212063.at  
Figure 2505: PRO95178  
Figure 2506A-D: DNA344554, BAA25496.2, 212065.s.at  
Figure 2507: PRO95179  
Figure 2508: DNA344555, NP\_065800.1, 212096.s.at  
Figure 2509: PRO95180  
Figure 2510: DNA325009, NP\_001744.2, 212097.at  
Figure 2511: PRO81600  
Figure 2512: DNA344556, AF055029, 212098.at  
Figure 2513: PRO95181  
Figure 2514: DNA344557, 7763517.13, 212099.at  
Figure 2515: PRO95182  
Figure 2516A-B: DNA150956, BAA06685.1, 212110.at  
Figure 2517: PRO12560  
Figure 2518: DNA344558, AF070622, 212124.at  
Figure 2519: PRO95183  
Figure 2520: DNA151008, BC014044, 212125.at  
Figure 2521: PRO12837  
Figure 2522: DNA330242, BC007034, 212185.x.at  
Figure 2523: PRO85477  
Figure 2524: DNA330243, NP\_006207.1, 212190.at  
Figure 2525: PRO2584  
Figure 2526: DNA326233, NM\_000977, 212191.x.at  
Figure 2527: PRO82645  
Figure 2528A-C: DNA330244, 253946.17, 212195.at  
Figure 2529: PRO85478  
Figure 2530: DNA328437, NM\_005801, 212227.x.at  
Figure 2531: PRO84271  
Figure 2532: DNA151120, M61906, 212240.s.at  
Figure 2533: PRO12179  
Figure 2534A-B: DNA329229, 1345070.7, 212249.at  
Figure 2535: PRO84835  
Figure 2536: DNA329182, NM\_020524, 212259.s.at  
Figure 2537: PRO84805  
Figure 2538A-B: DNA344559, 332723.7, 212290.at  
Figure 2539: PRO95184  
Figure 2540: DNA344560, AL833829, 212291.at  
Figure 2541: DNA328719, BC012895, 212295.s.at  
Figure 2542: PRO84475  
Figure 2543A-B: DNA344561, AL832633, 212299.at  
Figure 2544: PRO95186  
Figure 2545A-B: DNA344562, 319543.9, 212314.at  
Figure 2546: PRO95187  
Figure 2547A-B: DNA124122, NP\_005602.2, 212331.at  
Figure 2548: PRO6323  
Figure 2549A-B: DNA124122, NM\_005611, 212332.at  
Figure 2550: PRO6323  
Figure 2551: DNA287190, CAB43217.1, 212333.at  
Figure 2552: PRO69476  
Figure 2553: DNA344563, BC017742, 212334.at  
Figure 2554: PRO95188  
Figure 2555A-B: DNA344564, 254170.1, 212335.at  
Figure 2556: PRO2759  
Figure 2557A-B: DNA255527, D50525, 212337.at  
Figure 2558: DNA344565, BC040726, 212359.s.at  
Figure 2559A-B: DNA269762, BAA25456.1, 212368.at  
Figure 2560: PRO58171  
Figure 2561A-B: DNA344566, BAA25518.1, 212370.x.at  
Figure 2562: PRO95190  
Figure 2563A-C: DNA330249, AAA99177.1, 212372.at  
Figure 2564: PRO85482  
Figure 2565A-C: DNA344567, 020294.13, 212386.at  
Figure 2566: PRO95191  
Figure 2567A-C: DNA328725, AB007923, 212390.at  
Figure 2568A-B: DNA328549, NP\_002897.1, 212397.at  
Figure 2569: PRO84350  
Figure 2570A-B: DNA328549, NM\_002906, 212398.at  
Figure 2571: PRO84350  
Figure 2572A-B: DNA344568, AK074108, 212400.at  
Figure 2573A-B: DNA330250, NP\_060727.1, 212406.s.at  
Figure 2574: PRO85483  
Figure 2575: DNA254828, NP\_056417.1, 212408.at  
Figure 2576: PRO49923  
Figure 2577: DNA344569, 1454838.10, 212412.at  
Figure 2578: PRO95192  
Figure 2579: DNA330251, NP\_059965.1, 212430.at

WO 2005/019258

PCT/US2004/025788

Figure 2580: PRO85484  
 Figure 2581: DNA304655, NP\_079472.1, 212434.at  
 Figure 2582: PRO71082  
 Figure 2583A-B: DNA344570, 481983.1, 212446.s.at  
 Figure 2584: PRO95193  
 Figure 2585: DNA344571, AF052178, 212458.at  
 Figure 2586: PRO95194  
 Figure 2587: DNA151348, DNA151348, 212463.at  
 Figure 2588: PRO11726  
 Figure 2589: DNA344572, 226098.35, 212472.at  
 Figure 2590: PRO95195  
 Figure 2591A-B: DNA330252, NP\_055447.1, 212473.s.at  
 Figure 2592: PRO85485  
 Figure 2593A-B: DNA344573, D26069, 212476.at  
 Figure 2594A-C: DNA344574, NP\_597677.1, 212483.at  
 Figure 2595: PRO95197  
 Figure 2596: DNA344575, 7762745.4, 212498.at  
 Figure 2597: PRO95198  
 Figure 2598: DNA344576, NP\_005185.2, 212501.at  
 Figure 2599: PRO91094  
 Figure 2600A-B: DNA344577, NP\_116193.1, 212502.at  
 Figure 2601: PRO84485  
 Figure 2602: DNA344578, 1307005.1, 212511.at  
 Figure 2603: PRO95199  
 Figure 2604A-B: DNA344579, BC036190, 212522.at  
 Figure 2605: PRO95200  
 Figure 2606: DNA328733, AF038183, 212527.at  
 Figure 2607: PRO84486  
 Figure 2608: DNA344580, AL080111, 212530.at  
 Figure 2609: PRO95201  
 Figure 2610A-C: DNA344581, NP\_056111.1, 212538.at  
 Figure 2611: PRO95202  
 Figure 2612: DNA65407, DNA65407, 212558.at  
 Figure 2613: PRO1276  
 Figure 2614A-D: DNA328737, 148650.1, 212560.at  
 Figure 2615: PRO84490  
 Figure 2616A-B: DNA254958, AL117448, 212561.at  
 Figure 2617: DNA344582, NP\_056016.1, 212563.at  
 Figure 2618: PRO81715  
 Figure 2619: DNA344583, BC039084, 212568.s.at  
 Figure 2620: PRO95203  
 Figure 2621A-C: DNA331128, NP\_065892.1, 212582.at  
 Figure 2622: PRO84841  
 Figure 2623A-B: DNA333749, NP\_002829.2, 212587.s.at  
 Figure 2624: PRO88374  
 Figure 2625: DNA275100, DNA275100, 212589.at  
 Figure 2626: DNA331327, NM\_012250, 212590.at  
 Figure 2627: PRO86414  
 Figure 2628: DNA331298, NM\_014456, 212593.s.at  
 Figure 2629: PRO81909

Figure 2630: DNA272928, NP\_055579.1, 212595.s.at  
 Figure 2631: PRO61012  
 Figure 2632: DNA344584, 253648.3, 212613.at  
 Figure 2633: PRO95204  
 Figure 2634A-B: DNA330258, BAA22955.2, 212619.at  
 Figure 2635: PRO85490  
 Figure 2636A-B: DNA344585, AL833311, 212621.at  
 Figure 2637: PRO95205  
 Figure 2638: DNA194679, BAA05062.1, 212623.at  
 Figure 2639: PRO23989  
 Figure 2640: DNA344586, AL050082, 212637.s.at  
 Figure 2641: PRO95206  
 Figure 2642A-C: DNA344587, NP\_006725.2, 212641.at  
 Figure 2643: PRO95207  
 Figure 2644A-C: DNA344588, NM\_006734, 212642.s.at  
 Figure 2645: PRO95208  
 Figure 2646: DNA329031, NM\_004899, 212645.x.at  
 Figure 2647: PRO84699  
 Figure 2648: DNA344589, NP\_000568.1, 212657.s.at  
 Figure 2649: PRO83789  
 Figure 2650A-B: DNA344590, D87076, 212660.at  
 Figure 2651: DNA344591, L34089, 212671.s.at  
 Figure 2652A-D: DNA344592, 032872.20, 212672.at  
 Figure 2653: PRO84830  
 Figure 2654: DNA344593, AF515797, 212681.at  
 Figure 2655A-B: DNA329901, BAA32291.2, 212683.at  
 Figure 2656: PRO85218  
 Figure 2657: DNA272355, L38935, 212697.at  
 Figure 2658: DNA326234, NM\_033251, 212734.x.at  
 Figure 2659: PRO82646  
 Figure 2660: DNA290267, NP\_005000.1, 212739.s.at  
 Figure 2661: PRO70399  
 Figure 2662A-B: DNA327779, 363462.9, 212741.at  
 Figure 2663: PRO83744  
 Figure 2664A-B: DNA273398, NM\_015568, 212750.at  
 Figure 2665: PRO61398  
 Figure 2666A-B: DNA344594, NP\_751911.1, 212757.s.at  
 Figure 2667: PRO95212  
 Figure 2668: DNA344595, AAH34232.1, 212771.at  
 Figure 2669: PRO95213  
 Figure 2670A-C: DNA344596, AB029032, 212779.at  
 Figure 2671: DNA290260, NM\_012423, 212790.x.at  
 Figure 2672: PRO70385  
 Figure 2673A-B: DNA150479, BAA74900.1, 212792.at  
 Figure 2674: PRO12281  
 Figure 2675A-B: DNA344597, NP\_055894.1, 212796.s.at  
 Figure 2676: PRO95215  
 Figure 2677: DNA328750, 7689361.1, 212812.at

WO 2005/019258

PCT/US2004/025788

Figure 2678: PRO84500  
 Figure 2679A-C: DNA336121, AB020663, 212820.at  
 Figure 2680A-B: DNA344598, BAB84995.1, 212823.s.at  
 Figure 2681: PRO95216  
 Figure 2682: DNA330171, CAA34971.1, 212827.at  
 Figure 2683: PRO85421  
 Figure 2684: DNA344599, 234498.36, 212847.at  
 Figure 2685: PRO95217  
 Figure 2686: DNA344600, AL713742, 212886.at  
 Figure 2687: PRO95218  
 Figure 2688: DNA344601, 989341.96, 212906.at  
 Figure 2689: PRO85986  
 Figure 2690: DNA271630, DNA271630, 212907.at  
 Figure 2691: DNA272939, NP\_064582.1, 212922.s.at  
 Figure 2692: PRO61023  
 Figure 2693: DNA344602, BC045715, 212923.s.at  
 Figure 2694A-B: DNA344603, AB011164, 212929.s.at  
 Figure 2695A-B: DNA272008, BAA06684.1, 212932.at  
 Figure 2696: PRO60283  
 Figure 2697: DNA344604, NP\_056156.2, 212949.at  
 Figure 2698: PRO80842  
 Figure 2699: DNA255330, AL359588, 212959.s.at  
 Figure 2700: DNA344605, U66042, 212961.x.at  
 Figure 2701: PRO50485  
 Figure 2702: DNA325417, NP\_001742.1, 212971.at  
 Figure 2703: PRO69635  
 Figure 2704A-B: DNA344606, 474311.10, 212985.at  
 Figure 2705: PRO95220  
 Figure 2706: DNA344607, NM\_147156, 212989.at  
 Figure 2707: PRO50467  
 Figure 2708: DNA344608, BC038387, 213010.at  
 Figure 2709A-C: DNA327783, DNA327783, 213015.at  
 Figure 2710: PRO83747  
 Figure 2711A-B: DNA253815, BAA20833.2, 213035.at  
 Figure 2712: PRO49218  
 Figure 2713A-B: DNA344609, NM\_174953, 213036.x.at  
 Figure 2714: PRO95221  
 Figure 2715: DNA344610, NP\_699172.1, 213038.at  
 Figure 2716: PRO95222  
 Figure 2717A-B: DNA329242, BAA76857.1, 213056.at  
 Figure 2718: PRO84847  
 Figure 2719: DNA323879, NP\_003991.1, 213060.s.at  
 Figure 2720: PRO80622  
 Figure 2721A-C: DNA328757, 475076.9, 213069.at  
 Figure 2722: PRO84506  
 Figure 2723: DNA150837, CAA06743.1, 213083.at  
 Figure 2724: PRO12495  
 Figure 2725: DNA344611, NP\_000975.2, 213084.x.at  
 Figure 2726: PRO95223

Figure 2727A-B: DNA331353, BAA76818.1, 213092.x.at  
 Figure 2728: PRO60758  
 Figure 2729: DNA270466, M12996, 213093.at  
 Figure 2730A-B: DNA339968, BAA76825.1, 213111.at  
 Figure 2731: PRO91476  
 Figure 2732: DNA330215, NP\_060081.1, 213113.s.at  
 Figure 2733: PRO24295  
 Figure 2734: DNA326217, NP\_004474.1, 213129.s.at  
 Figure 2735: PRO82630  
 Figure 2736: DNA344612, NM\_006806, 213134.x.at  
 Figure 2737: PRO95224  
 Figure 2738: DNA287230, AAA36325.1, 213138.at  
 Figure 2739: PRO69509  
 Figure 2740: DNA330277, CAB45152.1, 213142.x.at  
 Figure 2741: PRO85506  
 Figure 2742A-B: DNA344613, 1330122.30, 213164.at  
 Figure 2743: PRO95225  
 Figure 2744: DNA344614, X17568, 213175.s.at  
 Figure 2745: PRO95226  
 Figure 2746: DNA344615, AF279370, 213186.at  
 Figure 2747: DNA344616, NP\_705833.1, 213188.s.at  
 Figure 2748: PRO95227  
 Figure 2749: DNA339710, NP\_116167.3, 213189.at  
 Figure 2750: PRO91439  
 Figure 2751: DNA344617, K02885, 213193.x.at  
 Figure 2752: DNA344618, 1501943.6, 213206.at  
 Figure 2753: PRO95229  
 Figure 2754: DNA344619, 1398007.8, 213226.at  
 Figure 2755: PRO95230  
 Figure 2756A-B: DNA344620, NP\_065186.2, 213238.at  
 Figure 2757: PRO95231  
 Figure 2758A-B: DNA194850, BAA25458.1, 213243.at  
 Figure 2759: PRO24112  
 Figure 2760A-C: DNA344621, BAA20800.2, 213261.at  
 Figure 2761: PRO59767  
 Figure 2762A-B: DNA344622, AY217548, 213281.at  
 Figure 2763: PRO4671  
 Figure 2764: DNA260974, NP\_006065.1, 213293.s.at  
 Figure 2765: PRO54720  
 Figure 2766A-B: DNA329248, BAA20816.1, 213302.at  
 Figure 2767: PRO84850  
 Figure 2768A-B: DNA331295, NM\_002719, 213305.s.at  
 Figure 2769: PRO86394  
 Figure 2770A-B: DNA344623, NP\_055999.1, 213309.at  
 Figure 2771: PRO95232  
 Figure 2772: DNA344624, AY074889, 213315.x.at  
 Figure 2773: PRO95233  
 Figure 2774: DNA344625, BC020923, 213317.at



WO 2005/019258

PCT/US2004/025788

Figure 2775: PRO95234  
 Figure 2776: DNA344626, AAH19339.1, 213320.at  
 Figure 2777: PRO95235  
 Figure 2778A-B: DNA344627, AF022789, 213327.s.at  
 Figure 2779: DNA287433, NM\_006819, 213330.s.at  
 Figure 2780: PRO69690  
 Figure 2781A-B: DNA274793, BAA96028.1, 213365.at  
 Figure 2782: PRO62559  
 Figure 2783: DNA324853, NP\_001007.2, 213377.x.at  
 Figure 2784: PRO81462  
 Figure 2785: DNA344628, 222320.2, 213385.at  
 Figure 2786: PRO95237  
 Figure 2787A-B: DNA344629, 7697344.6, 213416.at  
 Figure 2788: PRO95238  
 Figure 2789A-B: DNA331398, DNA331398, 213457.at  
 Figure 2790: PRO83924  
 Figure 2791A-B: DNA330285, 241020.1, 213469.at  
 Figure 2792: PRO85513  
 Figure 2793A-B: DNA344630, NP\_055917.1, 213471.at  
 Figure 2794: PRO95239  
 Figure 2795: DNA328766, NP\_006077.1, 213476.x.at  
 Figure 2796: PRO84514  
 Figure 2797A-B: DNA344631, NM\_002265, 213507.s.at  
 Figure 2798: PRO82739  
 Figure 2799: DNA326639, NP\_001229.1, 213523.at  
 Figure 2800: PRO82992  
 Figure 2801: DNA324005, NP\_056529.1, 213524.s.at  
 Figure 2802: PRO11582  
 Figure 2803: DNA344632, BC022977, 213530.at  
 Figure 2804A-B: DNA344633, 062042.23, 213531.s.at  
 Figure 2805: PRO95240  
 Figure 2806: DNA254264, NP\_689960.1, 213546.at  
 Figure 2807: PRO49375  
 Figure 2808: DNA344634, NM\_144781, 213581.at  
 Figure 2809: PRO95241  
 Figure 2810: DNA344635, AAH15899.1, 213587.s.at  
 Figure 2811: PRO95242  
 Figure 2812: DNA326426, NP\_004300.1, 213606.s.at  
 Figure 2813: PRO61246  
 Figure 2814A-C: DNA330292, NP\_056045.2, 213618.at  
 Figure 2815: PRO85519  
 Figure 2816: DNA344636, BC045542, 213623.at  
 Figure 2817: PRO95243  
 Figure 2818: DNA344637, NP\_005940.1, 213629.x.at  
 Figure 2819: PRO95244  
 Figure 2820: DNA326239, NP\_006752.1, 213655.at  
 Figure 2821: PRO39530  
 Figure 2822: DNA325704, NM\_004990, 213671.s.at  
 Figure 2823: PRO82188

Figure 2824: DNA344638, AK057596, 213703.at  
 Figure 2825: PRO95245  
 Figure 2826: DNA328629, NM\_006088, 213726.x.at  
 Figure 2827: PRO84407  
 Figure 2828: DNA334387, NP\_075563.2, 213727.x.at  
 Figure 2829: PRO88903  
 Figure 2830A-B: DNA344639, NP\_036467.2, 213733.at  
 Figure 2831: PRO95246  
 Figure 2832: DNA326273, NM\_001970, 213757.at  
 Figure 2833: PRO82678  
 Figure 2834: DNA327804, AF442151, 213797.at  
 Figure 2835: PRO69493  
 Figure 2836A-B: DNA344640, 7684018.188, 213803.at  
 Figure 2837: PRO95247  
 Figure 2838: DNA344641, 233172.5, 213852.at  
 Figure 2839: PRO95248  
 Figure 2840: DNA344642, 026641.16, 213888.s.at  
 Figure 2841: PRO95249  
 Figure 2842: DNA272347, NP\_001011.1, 213890.x.at  
 Figure 2843: PRO60603  
 Figure 2844: DNA151041, X66087, 213906.at  
 Figure 2845: DNA333671, NP\_005592.1, 213915.at  
 Figure 2846: PRO37543  
 Figure 2847: DNA327806, 242985.1, 213929.at  
 Figure 2848: PRO83767  
 Figure 2849: DNA344643, 1454455.7, 213931.at  
 Figure 2850: PRO95250  
 Figure 2851A-D: DNA339387, NM\_014810, 213956.at  
 Figure 2852: PRO91192  
 Figure 2853: DNA344644, BC033755, 213958.at  
 Figure 2854: PRO95251  
 Figure 2855: DNA226014, NP\_000230.1, 213975.s.at  
 Figure 2856: PRO36477  
 Figure 2857: DNA344645, AL050290, 213988.s.at  
 Figure 2858: PRO95252  
 Figure 2859: DNA344646, AF305069, 213996.at  
 Figure 2860: PRO86433  
 Figure 2861: DNA329136, NM\_016391, 214011.s.at  
 Figure 2862: PRO84772  
 Figure 2863: DNA150990, NM\_003641, 214022.s.at  
 Figure 2864: PRO12570  
 Figure 2865: DNA344647, BC013297, 214049.x.at  
 Figure 2866: PRO84853  
 Figure 2867: DNA330298, NP\_005403.2, 214095.at  
 Figure 2868: PRO83772  
 Figure 2869: DNA330298, NM\_005412, 214096.s.at  
 Figure 2870: PRO83772  
 Figure 2871: DNA344648, L43578, 214112.s.at  
 Figure 2872: DNA344649, NP\_005096.1, 214113.s.at  
 Figure 2873: PRO37600  
 Figure 2874: DNA344650, 127586.127, 214129.at  
 Figure 2875: PRO95254  
 Figure 2876: DNA344651, 1500085.15, 214163.at

WO 2005/019258

PCT/US2004/025788

Figure 2877: PRO95255  
 Figure 2878: DNA344652, 236569.38, 214169.at  
 Figure 2879: PRO95256  
 Figure 2880: DNA329182, BC016852, 214177.s.at  
 Figure 2881: PRO84805  
 Figure 2882A-B: DNA269826, NP\_003195.1, 214179.s.at  
 Figure 2883: PRO58228  
 Figure 2884: DNA344653, NM\_000391, 214196.s.at  
 Figure 2885: PRO95257  
 Figure 2886: DNA331361, NP\_003318.1, 214228.x.at  
 Figure 2887: PRO2398  
 Figure 2888: DNA344654, 264912.4, 214241.at  
 Figure 2889: PRO95258  
 Figure 2890: DNA344655, 202212.8, 214329.x.at  
 Figure 2891: PRO95259  
 Figure 2892: DNA344656, NP\_203524.1, 214352.s.at  
 Figure 2893: PRO95260  
 Figure 2894: DNA304680, NM\_007355, 214359.s.at  
 Figure 2895: PRO71106  
 Figure 2896: DNA273138, NP\_005495.1, 214390.s.at  
 Figure 2897: PRO61182  
 Figure 2898: DNA344657, AK097004, 214402.s.at  
 Figure 2899: PRO95261  
 Figure 2900: DNA287630, NP\_000160.1, 214430.at  
 Figure 2901: PRO2154  
 Figure 2902: DNA344658, BC039858, 214435.x.at  
 Figure 2903: PRO12184  
 Figure 2904A-B: DNA344659, NP\_036213.1, 214446.at  
 Figure 2905: PRO37794  
 Figure 2906: DNA331744, NP\_001326.2, 214450.at  
 Figure 2907: PRO1574  
 Figure 2908: DNA327812, NP\_006408.2, 214453.s.at  
 Figure 2909: PRO83773  
 Figure 2910: DNA150971, NP\_002249.1, 214470.at  
 Figure 2911: PRO12564  
 Figure 2912: DNA329253, NP\_006128.1, 214551.s.at  
 Figure 2913: PRO84853  
 Figure 2914: DNA80218, U23772, 214567.s.at  
 Figure 2915: PRO1610  
 Figure 2916: DNA344660, AF001892, 214657.s.at  
 Figure 2917: PRO95262  
 Figure 2918: DNA330303, BAA05499.1, 214662.at  
 Figure 2919: PRO85528  
 Figure 2920: DNA328785, NP\_004062.1, 214683.s.at  
 Figure 2921: PRO84531  
 Figure 2922: DNA344661, NP\_006622.1, 214686.at  
 Figure 2923: PRO95263  
 Figure 2924A-B: DNA344662, AB002326, 214707.x.at  
 Figure 2925: DNA344663, AB046861, 214723.x.at  
 Figure 2926A-B: DNA334132, BAB21826.1, 214724.at  
 Figure 2927: PRO88686  
 Figure 2928A-B: DNA344664, 350410.3, 214787.at

Figure 2929: PRO95266  
 Figure 2930: DNA339733, NP\_612411.2, 214791.at  
 Figure 2931: PRO91461  
 Figure 2932A-B: DNA344665, AAH42045.1, 214855.s.at  
 Figure 2933: PRO95267  
 Figure 2934A-E: DNA344666, L39064, 214950.at  
 Figure 2935: DNA344667, NP\_009198.3, 214958.s.at  
 Figure 2936: PRO95269  
 Figure 2937A-B: DNA344668, NP\_003023.1, 214971.s.at  
 Figure 2938: PRO54745  
 Figure 2939: DNA344669, NP\_003819.1, 214975.s.at  
 Figure 2940: PRO95270  
 Figure 2941: DNA327532, NM\_002065, 215001.s.at  
 Figure 2942: PRO71134  
 Figure 2943: DNA344670, U90551, 215071.s.at  
 Figure 2944: PRO85534  
 Figure 2945: DNA344671, 212023.3, 215100.at  
 Figure 2946: PRO23679  
 Figure 2947: DNA344672, 350922.19, 215133.s.at  
 Figure 2948: PRO95271  
 Figure 2949: DNA344673, AAH20773.1, 215136.s.at  
 Figure 2950: PRO84861  
 Figure 2951: DNA273371, NP\_000364.1, 215165.x.at  
 Figure 2952: PRO61373  
 Figure 2953: DNA324015, NM\_006335, 215171.s.at  
 Figure 2954: PRO80735  
 Figure 2955: DNA344674, NP\_056420.1, 215172.at  
 Figure 2956: PRO95272  
 Figure 2957A-B: DNA150496, AB023212, 215175.at  
 Figure 2958: DNA324269, NP\_006345.1, 215273.s.at  
 Figure 2959: PRO80952  
 Figure 2960A-B: DNA255050, NM\_020432, 215286.s.at  
 Figure 2961: PRO50138  
 Figure 2962: DNA254588, AL049782, 215318.at  
 Figure 2963: DNA344675, 7763519.36, 215338.s.at  
 Figure 2964: PRO95273  
 Figure 2965: DNA336791, BC027954, 215345.x.at  
 Figure 2966: PRO90861  
 Figure 2967: DNA327831, NP\_076956.1, 215380.s.at  
 Figure 2968: PRO83783  
 Figure 2969: DNA331570, AAH15794.1, 215440.s.at  
 Figure 2970: PRO84545  
 Figure 2971: DNA344676, NM\_152876, 215719.x.at  
 Figure 2972: PRO95274  
 Figure 2973: DNA273821, X98258, 215731.s.at  
 Figure 2974: DNA344677, NP\_000944.1, 215894.at  
 Figure 2975: PRO95275  
 Figure 2976: DNA330324, NP\_002720.1, 215933.s.at  
 Figure 2977: PRO58034  
 Figure 2978: DNA344678, 1452291.4, 216133.at  
 Figure 2979: PRO23844  
 Figure 2980: DNA344679, AAA61033.1, 216191.s.at  
 Figure 2981: PRO95276

WO 2005/019258

PCT/US2004/025788

Figure 2982A-B: DNA344680, NM\_015184, 216218.s.at  
 Figure 2983: PRO95277  
 Figure 2984: DNA344681, NM\_173172, 216248.s.at  
 Figure 2985: PRO95278  
 Figure 2986: DNA326994, NP\_055955.1, 216251.s.at  
 Figure 2987: PRO83301  
 Figure 2988: DNA344682, NM\_152873, 216252.s.at  
 Figure 2989: PRO95279  
 Figure 2990A-C: DNA270933, NM\_006766, 216361.s.at  
 Figure 2991: PRO59265  
 Figure 2992: DNA344683, X80821, 216563.at  
 Figure 2993: DNA287243, NP\_004452.1, 216602.s.at  
 Figure 2994: PRO69518  
 Figure 2995A-C: DNA150435, NP\_055444.1, 216620.s.at  
 Figure 2996: PRO12247  
 Figure 2997: DNA226699, NM\_000022, 216705.s.at  
 Figure 2998: PRO37162  
 Figure 2999: DNA344684, BC026029, 216804.s.at  
 Figure 3000: PRO95280  
 Figure 3001: DNA329135, NP\_002913.2, 216834.at  
 Figure 3002: PRO58102  
 Figure 3003: DNA227597, NP\_000627.1, 216841.s.at  
 Figure 3004: PRO38060  
 Figure 3005: DNA344685, L76665, 216907.x.at  
 Figure 3006: PRO95281  
 Figure 3007: DNA328810, NM\_001779, 216942.s.at  
 Figure 3008: PRO2557  
 Figure 3009A-C: DNA103378, U23850, 216944.s.at  
 Figure 3010: PRO4708  
 Figure 3011: DNA275181, NM\_003090, 216977.x.at  
 Figure 3012: PRO62882  
 Figure 3013: DNA344686, NP\_543157.1, 217025.s.at  
 Figure 3014: PRO95282  
 Figure 3015: DNA331366, L06797, 217028.at  
 Figure 3016: PRO4516  
 Figure 3017: DNA329073, NP\_004830.1, 217080.s.at  
 Figure 3018: PRO84731  
 Figure 3019A-B: DNA328813, BAA76774.1, 217118.s.at  
 Figure 3020: PRO84553  
 Figure 3021: DNA227752, NM\_001504, 217119.s.at  
 Figure 3022: PRO38215  
 Figure 3023A-B: DNA329269, BAA32292.2, 217122.s.at  
 Figure 3024: PRO84865  
 Figure 3025: DNA340209, NP\_114093.1, 217123.x.at  
 Figure 3026: PRO91704  
 Figure 3027: DNA344687, NP\_001893.2, 217127.at  
 Figure 3028: PRO84866  
 Figure 3029: DNA103549, M21624, 217143.s.at  
 Figure 3030: PRO4876  
 Figure 3031: DNA227786, NP\_057472.1, 217147.s.at  
 Figure 3032: PRO38249

Figure 3033: DNA344688, NM\_005949, 217165.x.at  
 Figure 3034: PRO95283  
 Figure 3035: DNA344689, NM\_176786, 217212.s.at  
 Figure 3036: PRO95284  
 Figure 3037: DNA344690, D84140, 217235.x.at  
 Figure 3038: DNA151105, NP\_005601.1, 217301.x.at  
 Figure 3039: PRO12857  
 Figure 3040: DNA344691, X69383, 217381.s.at  
 Figure 3041: PRO95286  
 Figure 3042: DNA344692, D13079, 217394.at  
 Figure 3043: PRO95287  
 Figure 3044: DNA344693, BC047570, 217403.s.at  
 Figure 3045: PRO95288  
 Figure 3046: DNA344694, 7697666.21, 217523.at  
 Figure 3047: PRO95289  
 Figure 3048: DNA344695, 023453.1, 217540.at  
 Figure 3049: PRO95290  
 Figure 3050: DNA344696, 346253.1, 217550.at  
 Figure 3051: PRO95291  
 Figure 3052: DNA344697, AK074970, 217724.at  
 Figure 3053: PRO95292  
 Figure 3054: DNA323856, AL080119, 217725.x.at  
 Figure 3055: PRO80599  
 Figure 3056: DNA325832, NP\_068839.1, 217731.s.at  
 Figure 3057: PRO1869  
 Figure 3058: DNA325832, NM\_021999, 217732.s.at  
 Figure 3059: PRO1869  
 Figure 3060A-B: DNA327847, 142131.14, 217738.at  
 Figure 3061: PRO2834  
 Figure 3062: DNA88541, NP\_005737.1, 217739.s.at  
 Figure 3063: PRO2834  
 Figure 3064: DNA227205, NP\_071404.1, 217744.s.at  
 Figure 3065: PRO37668  
 Figure 3066: DNA344698, NP\_057001.1, 217751.at  
 Figure 3067: PRO95293  
 Figure 3068: DNA325910, NP\_057110.2, 217776.at  
 Figure 3069: PRO82365  
 Figure 3070: DNA328819, NP\_057145.1, 217783.s.at  
 Figure 3071: PRO84557  
 Figure 3072: DNA325873, NP\_006100.2, 217786.at  
 Figure 3073: PRO82331  
 Figure 3074A-B: DNA254292, NP\_004472.1, 217787.s.at  
 Figure 3075: PRO49403  
 Figure 3076A-B: DNA254292, NM\_004481, 217788.s.at  
 Figure 3077: PRO49403  
 Figure 3078: DNA344699, NP\_005709.1, 217818.s.at  
 Figure 3079: PRO80955  
 Figure 3080: DNA344700, BC032643, 217832.at  
 Figure 3081: PRO95294  
 Figure 3082: DNA344701, BC040844, 217834.s.at  
 Figure 3083: PRO95295  
 Figure 3084: DNA328823, NP\_057421.1, 217838.s.at  
 Figure 3085: PRO84561  
 Figure 3086: DNA344702, NP\_066952.1, 217848.s.at

WO 2005/019258

PCT/US2004/025788

Figure 3087: PRO11669  
Figure 3088A-B: DNA324921, NP\_073585.6, 217853.at  
Figure 3089: PRO81523  
Figure 3090: DNA344703, NP\_002686.2, 217854.s.at  
Figure 3091: PRO95296  
Figure 3092: DNA344704, NP\_060904.1, 217865.at  
Figure 3093: PRO95297  
Figure 3094: DNA335592, NP\_036237.2, 217867.x.at  
Figure 3095: PRO852  
Figure 3096: DNA344705, NP\_001247.2, 217879.at  
Figure 3097: PRO95298  
Figure 3098: DNA255145, NP\_060917.1, 217882.at  
Figure 3099: PRO50225  
Figure 3100A-B: DNA325652, NP\_057441.1, 217892.s.at  
Figure 3101: PRO82143  
Figure 3102: DNA330345, NP\_055130.1, 217906.at  
Figure 3103: PRO85566  
Figure 3104: DNA328826, NP\_004272.2, 217911.s.at  
Figure 3105: PRO84564  
Figure 3106: DNA344706, NP\_751918.1, 217919.s.at  
Figure 3107: PRO95299  
Figure 3108: DNA287241, NP\_056991.1, 217933.s.at  
Figure 3109: PRO69516  
Figure 3110A-B: DNA225648, NP\_061165.1, 217941.s.at  
Figure 3111: PRO36111  
Figure 3112: DNA326730, NP\_057037.1, 217950.at  
Figure 3113: PRO83072  
Figure 3114: DNA329273, NP\_037374.1, 217957.at  
Figure 3115: PRO84869  
Figure 3116A-B: DNA272661, NP\_443198.1, 217966.s.at  
Figure 3117: PRO60787  
Figure 3118A-B: DNA272661, NM\_052966, 217967.s.at  
Figure 3119: PRO60787  
Figure 3120: DNA329546, NP\_055214.1, 217979.at  
Figure 3121: PRO296  
Figure 3122: DNA227218, NP\_003721.2, 217983.s.at  
Figure 3123: PRO37681  
Figure 3124: DNA227218, NM\_003730, 217984.at  
Figure 3125: PRO37681  
Figure 3126: DNA328831, NP\_057329.1, 217989.at  
Figure 3127: PRO233  
Figure 3128: DNA344707, NP\_663768.1, 217991.x.at  
Figure 3129: PRO95300  
Figure 3130: DNA328832, NP\_067022.1, 217995.at  
Figure 3131: PRO84568  
Figure 3132: DNA328833, BC018929, 217996.at  
Figure 3133: PRO84569  
Figure 3134: DNA328834, AF220656, 217997.at  
Figure 3135: DNA287364, NP\_031376.1, 218000.s.at  
Figure 3136: PRO69625  
Figure 3137: DNA326005, NP\_057004.1, 218007.s.at  
Figure 3138: PRO82446  
Figure 3139: DNA273008, NP\_003972.1, 218009.s.at  
Figure 3140: PRO61079  
Figure 3141: DNA339506, NP\_060589.1, 218016.s.at  
Figure 3142: PRO91277  
Figure 3143: DNA325094, NP\_079346.1, 218017.s.at  
Figure 3144: PRO81671  
Figure 3145: DNA328836, NP\_054894.1, 218027.at  
Figure 3146: PRO84572  
Figure 3147A-B: DNA255183, NP\_061900.1, 218035.s.at  
Figure 3148: PRO50262  
Figure 3149: DNA325978, NM\_016359, 218039.at  
Figure 3150: PRO82423  
Figure 3151: DNA329276, NP\_077001.1, 218069.at  
Figure 3152: PRO12104  
Figure 3153: DNA287261, NP\_060344.1, 218081.at  
Figure 3154: PRO69533  
Figure 3155: DNA325169, NP\_057494.2, 218085.at  
Figure 3156: PRO81734  
Figure 3157: DNA344708, NP\_056207.2, 218086.at  
Figure 3158: PRO95301  
Figure 3159: DNA329278, NP\_004495.1, 218092.s.at  
Figure 3160: PRO84871  
Figure 3161: DNA225639, NP\_060831.1, 218096.at  
Figure 3162: PRO36102  
Figure 3163: DNA344709, NP\_004540.1, 218101.s.at  
Figure 3164: PRO82036  
Figure 3165: DNA344710, NP\_666499.1, 218105.s.at  
Figure 3166: PRO62669  
Figure 3167: DNA344711, NP\_060699.2, 218139.s.at  
Figure 3168: PRO95302  
Figure 3169: DNA327857, NP\_057386.1, 218142.s.at  
Figure 3170: PRO83799  
Figure 3171: DNA287235, NP\_060598.1, 218156.s.at  
Figure 3172: PRO69514  
Figure 3173: DNA151377, NP\_057132.1, 218170.at  
Figure 3174: PRO11754  
Figure 3175: DNA304470, NP\_061100.1, 218172.s.at  
Figure 3176: PRO71046  
Figure 3177A-D: DNA340174, NP\_064630.1, 218184.at  
Figure 3178: PRO91669  
Figure 3179: DNA344712, NP\_036590.1, 218188.s.at  
Figure 3180: PRO82887  
Figure 3181A-C: DNA330360, NP\_078789.1, 218204.s.at  
Figure 3182: PRO85576  
Figure 3183: DNA344713, NP\_060641.2, 218218.at  
Figure 3184: PRO95303  
Figure 3185: DNA225650, NP\_057246.1, 218234.at  
Figure 3186: PRO36113  
Figure 3187: DNA327858, NP\_036473.1, 218238.at  
Figure 3188: PRO83800  
Figure 3189: DNA327858, NM\_012341, 218239.s.at  
Figure 3190: PRO83800

WO 2005/019258

PCT/US2004/025788

Figure 3191A-B: DNA344714, NP\_037367.2,  
218269.at  
Figure 3192: PRO95304  
Figure 3193: DNA329074, NP\_064524.1, 218285.s.at  
Figure 3194: PRO21326  
Figure 3195A-B: DNA328853, NP\_065702.2,  
218319.at  
Figure 3196: PRO84584  
Figure 3197: DNA329281, NP\_036526.2, 218336.at  
Figure 3198: PRO84874  
Figure 3199A-B: DNA344715, BAB47444.2,  
218342.s.at  
Figure 3200: PRO95305  
Figure 3201: DNA328854, NP\_056979.1, 218350.s.at  
Figure 3202: PRO84585  
Figure 3203A-B: DNA273415, NP\_036442.2,  
218355.at  
Figure 3204: PRO61414  
Figure 3205: DNA344716, NP\_071921.1, 218373.at  
Figure 3206: PRO95306  
Figure 3207A-B: DNA330366, NP\_073602.2,  
218376.s.at  
Figure 3208: PRO85581  
Figure 3209: DNA328856, NP\_068376.1, 218380.at  
Figure 3210: PRO84586  
Figure 3211: DNA327863, NP\_055131.1, 218384.at  
Figure 3212: PRO83804  
Figure 3213: DNA255340, NP\_060154.1, 218396.at  
Figure 3214: PRO50409  
Figure 3215: DNA344717, NP\_663747.1, 218399.s.at  
Figure 3216: PRO95307  
Figure 3217A-B: DNA287192, NP\_006178.1,  
218400.at  
Figure 3218: PRO69478  
Figure 3219: DNA333245, NP\_037454.2, 218404.at  
Figure 3220: PRO87952  
Figure 3221A-B: DNA344718, NP\_076414.2,  
218456.at  
Figure 3222: PRO95308  
Figure 3223: DNA328861, NP\_057030.2, 218472.s.at  
Figure 3224: PRO84589  
Figure 3225: DNA327943, NP\_055399.1, 218498.s.at  
Figure 3226: PRO865  
Figure 3227: DNA150648, NP\_037464.1, 218507.at  
Figure 3228: PRO11576  
Figure 3229: DNA326550, NP\_057663.1, 218529.at  
Figure 3230: PRO224  
Figure 3231: DNA327868, NP\_060601.2, 218542.at  
Figure 3232: PRO83809  
Figure 3233: DNA255113, NP\_073587.1, 218543.s.at  
Figure 3234: PRO50195  
Figure 3235: DNA330373, NP\_060751.1, 218552.at  
Figure 3236: PRO85587  
Figure 3237: DNA344719, NP\_059142.1, 218558.s.at  
Figure 3238: PRO85588  
Figure 3239: DNA329587, NP\_036256.1, 218566.s.at

Figure 3240: PRO85121  
Figure 3241: DNA325036, NP\_060708.1, 218568.at  
Figure 3242: PRO81625  
Figure 3243A-B: DNA273435, NP\_057532.1,  
218585.s.at  
Figure 3244: PRO61430  
Figure 3245: DNA93548, NP\_005758.1, 218589.at  
Figure 3246: PRO4929  
Figure 3247: DNA326916, NP\_149061.1, 218592.s.at  
Figure 3248: PRO83235  
Figure 3249: DNA287642, NP\_060934.1, 218597.s.at  
Figure 3250: PRO9902  
Figure 3251A-B: DNA254789, NP\_057301.1,  
218603.at  
Figure 3252: PRO49887  
Figure 3253A-B: DNA344720, NP\_073600.2,  
218618.s.at  
Figure 3254: PRO95309  
Figure 3255A-B: DNA339409, NP\_057257.1,  
218620.s.at  
Figure 3256: PRO91214  
Figure 3257: DNA327869, NP\_057672.1, 218625.at  
Figure 3258: PRO1898  
Figure 3259: DNA339537, NP\_060864.1, 218633.x.at  
Figure 3260: PRO91303  
Figure 3261: DNA344721, NP\_057303.1, 218636.s.at  
Figure 3262: PRO1477  
Figure 3263A-B: DNA344722, NP\_073606.1,  
218648.at  
Figure 3264: PRO95310  
Figure 3265: DNA330378, NP\_071741.2, 218663.at  
Figure 3266: PRO81126  
Figure 3267: DNA339660, NP\_079491.1, 218670.at  
Figure 3268: PRO91402  
Figure 3269: DNA287291, NP\_067036.1, 218676.s.at  
Figure 3270: PRO69561  
Figure 3271: DNA330379, NP\_073562.1, 218689.at  
Figure 3272: PRO85591  
Figure 3273: DNA328873, NP\_057041.1, 218698.at  
Figure 3274: PRO84600  
Figure 3275: DNA344723, NP\_060320.1, 218712.at  
Figure 3276: PRO95311  
Figure 3277: DNA328874, NP\_054778.1, 218723.s.at  
Figure 3278: PRO84601  
Figure 3279: DNA324251, NP\_060880.2, 218726.at  
Figure 3280: PRO80935  
Figure 3281: DNA330382, NP\_005724.1, 218755.at  
Figure 3282: PRO61907  
Figure 3283A-B: DNA344724, NP\_054828.2,  
218782.s.at  
Figure 3284: PRO95312  
Figure 3285: DNA335239, NP\_060158.1, 218792.s.at  
Figure 3286: PRO89625  
Figure 3287: DNA344725, NP\_060854.2, 218805.at  
Figure 3288: PRO95313  
Figure 3289: DNA256846, NP\_059985.1, 218826.at

WO 2005/019258

PCT/US2004/025788

Figure 3290: PRO51777  
 Figure 3291: DNA255213, AK000364, 218829.s.at  
 Figure 3292: PRO50292  
 Figure 3293: DNA328879, NP\_064570.1, 218845.at  
 Figure 3294: PRO84606  
 Figure 3295A-B: DNA344726, NP\_004821.2, 218846.at  
 Figure 3296: PRO95314  
 Figure 3297: DNA330385, NP\_057733.2, 218859.s.at  
 Figure 3298: PRO85594  
 Figure 3299: DNA330386, NP\_057394.1, 218866.s.at  
 Figure 3300: PRO85595  
 Figure 3301: DNA344727, NP\_060930.2, 218870.at  
 Figure 3302: PRO95315  
 Figure 3303: DNA330387, NP\_036309.1, 218875.s.at  
 Figure 3304: PRO85596  
 Figure 3305: DNA327874, BC022791, 218880.at  
 Figure 3306: PRO4805  
 Figure 3307: DNA344728, NP\_078806.1, 218881.s.at  
 Figure 3308: PRO95316  
 Figure 3309: DNA226633, NP\_060376.1, 218886.at  
 Figure 3310: PRO37096  
 Figure 3311A-B: DNA335042, NP\_060562.3, 218888.s.at  
 Figure 3312: PRO4401  
 Figure 3313: DNA344729, AK026953, 218889.at  
 Figure 3314: PRO95317  
 Figure 3315: DNA254380, NP\_065112.1, 218918.at  
 Figure 3316: PRO49490  
 Figure 3317: DNA328364, NP\_068577.1, 218921.at  
 Figure 3318: PRO84223  
 Figure 3319: DNA329333, NP\_054886.1, 218936.s.at  
 Figure 3320: PRO84917  
 Figure 3321A-B: DNA344730, NP\_055129.1, 218943.s.at  
 Figure 3322: PRO69459  
 Figure 3323: DNA334561, NP\_068572.1, 218976.at  
 Figure 3324: PRO89050  
 Figure 3325: DNA329050, NP\_057053.1, 218982.s.at  
 Figure 3326: PRO84712  
 Figure 3327A-B: DNA344731, NP\_060101.1, 218986.s.at  
 Figure 3328: PRO51309  
 Figure 3329: DNA327211, NP\_075053.2, 218989.x.at  
 Figure 3330: PRO71052  
 Figure 3331: DNA227194, NP\_060765.1, 218999.at  
 Figure 3332: PRO37657  
 Figure 3333: DNA328884, NP\_054884.1, 219006.at  
 Figure 3334: PRO84609  
 Figure 3335: DNA227187, NP\_057703.1, 219014.at  
 Figure 3336: PRO37650  
 Figure 3337: DNA328885, NP\_061108.2, 219017.at  
 Figure 3338: PRO50294  
 Figure 3339: DNA329293, NP\_057136.1, 219037.at  
 Figure 3340: PRO84883  
 Figure 3341: DNA333718, NP\_068595.2, 219066.at

Figure 3342: PRO88346  
 Figure 3343A-B: DNA344732, NP\_060254.2, 219073.s.at  
 Figure 3344: PRO90806  
 Figure 3345: DNA327877, NP\_065108.1, 219099.at  
 Figure 3346: PRO83816  
 Figure 3347: DNA344733, NP\_079204.1, 219100.at  
 Figure 3348: PRO95318  
 Figure 3349: DNA287242, NP\_127460.1, 219110.at  
 Figure 3350: PRO69517  
 Figure 3351: DNA304472, NP\_057678.1, 219117.s.at  
 Figure 3352: PRO535  
 Figure 3353: DNA297191, NP\_060962.2, 219148.at  
 Figure 3354: PRO70808  
 Figure 3355: DNA329295, NP\_036549.1, 219155.at  
 Figure 3356: PRO84885  
 Figure 3357A-B: DNA331610, NM\_025085, 219158.s.at  
 Figure 3358: PRO86609  
 Figure 3359: DNA328892, NM\_021630, 219165.at  
 Figure 3360: PRO84616  
 Figure 3361: DNA330400, NP\_078796.1, 219176.at  
 Figure 3362: PRO85608  
 Figure 3363A-B: DNA344734, NP\_078914.1, 219178.at  
 Figure 3364: PRO95319  
 Figure 3365: DNA329223, NP\_037517.1, 219183.s.at  
 Figure 3366: PRO84831  
 Figure 3367: DNA330401, NP\_057377.1, 219191.s.at  
 Figure 3368: PRO85609  
 Figure 3369: DNA344735, NP\_071451.1, 219209.at  
 Figure 3370: PRO83818  
 Figure 3371: DNA344736, NP\_057614.1, 219210.s.at  
 Figure 3372: PRO95320  
 Figure 3373: DNA330403, NP\_059110.1, 219211.at  
 Figure 3374: PRO85611  
 Figure 3375: DNA339627, NP\_079000.1, 219221.at  
 Figure 3376: PRO91378  
 Figure 3377: DNA333832, NP\_071411.1, 219222.at  
 Figure 3378: PRO88449  
 Figure 3379: DNA225594, NP\_037404.1, 219229.at  
 Figure 3380: PRO36057  
 Figure 3381: DNA252224, NM\_022073, 219232.s.at  
 Figure 3382: PRO48216  
 Figure 3383: DNA344737, NP\_060796.1, 219243.at  
 Figure 3384: PRO84617  
 Figure 3385: DNA344738, NP\_061195.2, 219255.x.at  
 Figure 3386: PRO19612  
 Figure 3387: DNA329296, NP\_060328.1, 219258.at  
 Figure 3388: PRO84886  
 Figure 3389: DNA328895, NP\_071762.2, 219259.at  
 Figure 3390: PRO1317  
 Figure 3391: DNA255020, NP\_061918.1, 219297.at  
 Figure 3392: PRO50109  
 Figure 3393: DNA255939, NP\_078876.1, 219315.s.at  
 Figure 3394: PRO50991

WO 2005/019258

PCT/US2004/025788

Figure 3395: DNA227784, NP\_060383.1, 219343.at  
 Figure 3396: PRO38247  
 Figure 3397: DNA254710, NP\_060382.1, 219352.at  
 Figure 3398: PRO49810  
 Figure 3399: DNA287174, AF161525, 219356.s.at  
 Figure 3400: PRO69464  
 Figure 3401A-B: DNA327885, NP\_075601.1, 219369.s.at  
 Figure 3402: PRO82377  
 Figure 3403: DNA188342, NP\_064510.1, 219386.s.at  
 Figure 3404: PRO21718  
 Figure 3405: DNA344739, NP\_683866.1, 219423.x.at  
 Figure 3406: PRO95321  
 Figure 3407: DNA329014, NP\_005746.2, 219424.at  
 Figure 3408: PRO9998  
 Figure 3409: DNA328902, NP\_071750.1, 219452.at  
 Figure 3410: PRO84623  
 Figure 3411: DNA328367, NP\_079108.2, 219456.s.at  
 Figure 3412: PRO84226  
 Figure 3413: DNA328367, NM\_024832, 219457.s.at  
 Figure 3414: PRO84226  
 Figure 3415A-B: DNA199058, NP\_060319.1, 219460.s.at  
 Figure 3416: PRO28533  
 Figure 3417: DNA325850, NP\_076994.1, 219479.at  
 Figure 3418: PRO82312  
 Figure 3419: DNA344740, NP\_079021.2, 219493.at  
 Figure 3420: PRO95322  
 Figure 3421A-B: DNA344741, NP\_059120.2, 219505.at  
 Figure 3422: PRO95323  
 Figure 3423A-C: DNA330409, NM\_022898, 219528.s.at  
 Figure 3424: PRO85617  
 Figure 3425: DNA329299, NP\_004660.1, 219529.at  
 Figure 3426: PRO84888  
 Figure 3427: DNA334311, NP\_073563.1, 219532.at  
 Figure 3428: PRO50477  
 Figure 3429: DNA344742, NP\_003405.2, 219540.at  
 Figure 3430: PRO95324  
 Figure 3431: DNA256737, NP\_060276.1, 219541.at  
 Figure 3432: PRO51671  
 Figure 3433: DNA330410, NP\_060925.1, 219555.s.at  
 Figure 3434: PRO85618  
 Figure 3435: DNA225636, NP\_065696.1, 219557.s.at  
 Figure 3436: PRO36099  
 Figure 3437: DNA336133, NP\_078852.1, 219582.at  
 Figure 3438: PRO90333  
 Figure 3439: DNA325053, NP\_060230.2, 219588.s.at  
 Figure 3440: PRO81637  
 Figure 3441: DNA344743, NP\_006125.2, 219600.s.at  
 Figure 3442: PRO193  
 Figure 3443: DNA331601, NP\_071915.1, 219628.at  
 Figure 3444: PRO85620  
 Figure 3445: DNA327892, NP\_060470.1, 219648.at  
 Figure 3446: PRO83828

Figure 3447: DNA328915, NP\_055056.2, 219654.at  
 Figure 3448: PRO84634  
 Figure 3449: DNA344744, NP\_079352.1, 219675.s.at  
 Figure 3450: PRO95325  
 Figure 3451: DNA255161, NP\_071430.1, 219684.at  
 Figure 3452: PRO50241  
 Figure 3453: DNA339552, NP\_061922.1, 219696.at  
 Figure 3454: PRO91318  
 Figure 3455A-B: DNA330297, NP\_065138.2, 219700.at  
 Figure 3456: PRO85524  
 Figure 3457A-B: DNA227762, NP\_060169.1, 219734.at  
 Figure 3458: PRO38225  
 Figure 3459: DNA256481, NP\_060269.1, 219757.s.at  
 Figure 3460: PRO51518  
 Figure 3461: DNA344745, NP\_078896.1, 219765.at  
 Figure 3462: PRO95326  
 Figure 3463: DNA344746, NP\_078987.2, 219777.at  
 Figure 3464: PRO95327  
 Figure 3465A-B: DNA330418, NP\_060568.3, 219787.s.at  
 Figure 3466: PRO85623  
 Figure 3467: DNA344747, NP\_690049.1, 219793.at  
 Figure 3468: PRO95328  
 Figure 3469: DNA324981, NP\_076975.1, 219812.at  
 Figure 3470: PRO81575  
 Figure 3471: DNA331378, NP\_079020.12, 219834.at  
 Figure 3472: PRO86449  
 Figure 3473: DNA287295, NP\_078784.1, 219836.at  
 Figure 3474: PRO69564  
 Figure 3475: DNA344748, NP\_066358.1, 219854.at  
 Figure 3476: PRO95329  
 Figure 3477: DNA255255, NM\_022154, 219869.s.at  
 Figure 3478: PRO50332  
 Figure 3479: DNA344749, NP\_079273.1, 219870.at  
 Figure 3480: PRO95330  
 Figure 3481: DNA254838, NP\_078904.1, 219874.at  
 Figure 3482: PRO49933  
 Figure 3483: DNA328923, NP\_075379.1, 219892.at  
 Figure 3484: PRO84640  
 Figure 3485: DNA330421, NP\_057438.2, 219911.s.at  
 Figure 3486: PRO85626  
 Figure 3487A-C: DNA344750, NP\_060606.2, 219918.s.at  
 Figure 3488: PRO95331  
 Figure 3489: DNA328924, NP\_057150.2, 219933.at  
 Figure 3490: PRO84641  
 Figure 3491: DNA344751, NP\_037396.2, 219945.at  
 Figure 3492: PRO95332  
 Figure 3493: DNA256345, AK000925, 219957.at  
 Figure 3494: PRO51387  
 Figure 3495: DNA218280, NP\_068570.1, 219971.at  
 Figure 3496: PRO34332  
 Figure 3497: DNA325979, NP\_060924.4, 219978.s.at  
 Figure 3498: PRO82424

WO 2005/019258

PCT/US2004/025788

Figure 3499: DNA330425, NP\_078956.1, 219990.at  
 Figure 3500: PRO85630  
 Figure 3501: DNA333765, AK000812, 219994.at  
 Figure 3502: PRO88389  
 Figure 3503: DNA256141, NP\_060893.1, 220030.at  
 Figure 3504: PRO51189  
 Figure 3505A-B: DNA344752, NP\_037389.3, 220038.at  
 Figure 3506: PRO95333  
 Figure 3507A-B: DNA221079, NP\_071445.1, 220066.at  
 Figure 3508: PRO34753  
 Figure 3509: DNA256091, NP\_071385.1, 220094.s.at  
 Figure 3510: PRO51141  
 Figure 3511: DNA330431, NP\_055198.1, 220118.at  
 Figure 3512: PRO85635  
 Figure 3513: DNA256803, AK001445, 220121.at  
 Figure 3514: PRO51734  
 Figure 3515: DNA227302, NP\_037401.1, 220132.s.at  
 Figure 3516: PRO37765  
 Figure 3517: DNA344753, AK000388, 220161.s.at  
 Figure 3518: PRO95334  
 Figure 3519: DNA335568, NP\_076927.1, 220177.s.at  
 Figure 3520: PRO89910  
 Figure 3521: DNA330434, NP\_060842.1, 220235.s.at  
 Figure 3522: PRO85637  
 Figure 3523: DNA344754, NP\_036551.3, 220334.at  
 Figure 3524: PRO95335  
 Figure 3525: DNA287186, NP\_061134.1, 220358.at  
 Figure 3526: PRO69472  
 Figure 3527: DNA255964, NP\_079113.1, 220416.at  
 Figure 3528: PRO51015  
 Figure 3529: DNA339549, NP\_061834.1, 220418.at  
 Figure 3530: PRO91315  
 Figure 3531: DNA330438, NP\_061026.1, 220485.s.at  
 Figure 3532: PRO50795  
 Figure 3533: DNA327214, NP\_078991.2, 220495.s.at  
 Figure 3534: PRO83483  
 Figure 3535: DNA344755, NP\_620591.1, 220558.x.at  
 Figure 3536: PRO95336  
 Figure 3537: DNA255798, NP\_079265.1, 220576.at  
 Figure 3538: PRO50853  
 Figure 3539: DNA344756, NP\_079282.1, 220577.at  
 Figure 3540: PRO95337  
 Figure 3541: DNA344757, NP\_071767.2, 220587.s.at  
 Figure 3542: PRO95338  
 Figure 3543A-B: DNA334963, NP\_116561.1, 220613.s.at  
 Figure 3544: PRO89395  
 Figure 3545: DNA227368, NP\_057371.1, 220633.s.at  
 Figure 3546: PRO37831  
 Figure 3547A-B: DNA327908, NP\_060988.2, 220651.s.at  
 Figure 3548: PRO83843  
 Figure 3549: DNA329306, NP\_079149.2, 220655.at  
 Figure 3550: PRO84895

Figure 3551A-B: DNA327909, NP\_064568.2, 220658.s.at  
 Figure 3552: PRO83844  
 Figure 3553: DNA329307, NP\_037483.1, 220684.at  
 Figure 3554: PRO84896  
 Figure 3555: DNA323756, NP\_057267.2, 220688.s.at  
 Figure 3556: PRO80512  
 Figure 3557: DNA330443, NP\_061086.1, 220702.at  
 Figure 3558: PRO85644  
 Figure 3559: DNA344758, NP\_061033.1, 220704.at  
 Figure 3560: PRO88381  
 Figure 3561A-B: DNA329308, NP\_065705.2, 220735.s.at  
 Figure 3562: PRO84897  
 Figure 3563: DNA344759, NP\_065857.1, 220773.s.at  
 Figure 3564: PRO50495  
 Figure 3565: DNA344760, NP\_065089.1, 220888.s.at  
 Figure 3566: PRO95339  
 Figure 3567: DNA288247, NP\_478059.1, 220892.s.at  
 Figure 3568: PRO70011  
 Figure 3569: DNA338124, NP\_079419.1, 220918.at  
 Figure 3570: PRO90989  
 Figure 3571: DNA328940, NP\_078893.1, 220933.s.at  
 Figure 3572: PRO84653  
 Figure 3573: DNA344761, NP\_065126.1, 220944.at  
 Figure 3574: PRO95340  
 Figure 3575: DNA324246, NP\_112188.1, 221004.s.at  
 Figure 3576: PRO80930  
 Figure 3577: DNA336778, NP\_110407.2, 221020.s.at  
 Figure 3578: PRO90848  
 Figure 3579: DNA254520, NP\_060952.1, 221039.s.at  
 Figure 3580: PRO49627  
 Figure 3581: DNA328945, NP\_079177.2, 221081.s.at  
 Figure 3582: PRO84657  
 Figure 3583: DNA344762, NP\_036613.1, 221092.at  
 Figure 3584: PRO89669  
 Figure 3585: DNA226227, NP\_060872.1, 221111.at  
 Figure 3586: PRO36690  
 Figure 3587: DNA344763, NP\_659508.1, 221223.x.at  
 Figure 3588: PRO86458  
 Figure 3589A-C: DNA332533, NP\_068585.1, 221234.s.at  
 Figure 3590: PRO87347  
 Figure 3591: DNA328948, NP\_110437.1, 221253.s.at  
 Figure 3592: PRO84659  
 Figure 3593: DNA330452, NP\_112494.2, 221258.s.at  
 Figure 3594: PRO85653  
 Figure 3595: DNA344764, BC000158, 221267.s.at  
 Figure 3596: PRO95341  
 Figure 3597: DNA295327, NP\_068575.1, 221271.at  
 Figure 3598: PRO70773  
 Figure 3599: DNA329312, NP\_005205.2, 221331.x.at  
 Figure 3600: PRO84901  
 Figure 3601: DNA256061, NP\_112183.1, 221428.s.at  
 Figure 3602: PRO51109  
 Figure 3603: DNA344765, NP\_112487.1, 221434.s.at



WO 2005/019258

PCT/US2004/025788

Figure 3604: PRO70013  
Figure 3605: DNA344766, 1163161.25, 221471.at  
Figure 3606: PRO12237  
Figure 3607: DNA324282, NP\_002939.2, 221475.s.at  
Figure 3608: PRO6360  
Figure 3609: DNA227303, NP\_004322.1, 221479.s.at  
Figure 3610: PRO37766  
Figure 3611A-B: DNA344767, NP\_004767.1, 221484.at  
Figure 3612: PRO59982  
Figure 3613: DNA330456, NP\_060571.1, 221520.s.at  
Figure 3614: PRO85657  
Figure 3615: DNA328952, NP\_067067.1, 221524.s.at  
Figure 3616: PRO84663  
Figure 3617: DNA328953, NP\_004086.1, 221539.at  
Figure 3618: PRO70296  
Figure 3619: DNA327526, NM\_020676, 221552.at  
Figure 3620: PRO83574  
Figure 3621: DNA304486, NP\_115497.1, 221553.at  
Figure 3622: PRO71055  
Figure 3623: DNA329317, NP\_057353.1, 221558.s.at  
Figure 3624: PRO81157  
Figure 3625: DNA329095, NP\_057000.2, 221565.s.at  
Figure 3626: PRO77352  
Figure 3627: DNA334699, NP\_003937.1, 221567.at  
Figure 3628: PRO89166  
Figure 3629: DNA329319, NP\_005440.1, 221601.s.at  
Figure 3630: PRO1607  
Figure 3631: DNA329319, NM\_005449, 221602.s.at  
Figure 3632: PRO1607  
Figure 3633: DNA344768, NP\_057059.2, 221618.s.at  
Figure 3634: PRO95342  
Figure 3635: DNA344769, NP\_036464.1, 221641.s.at  
Figure 3636: PRO95343  
Figure 3637: DNA218280, NM\_021798, 221658.s.at  
Figure 3638: PRO34332  
Figure 3639: DNA327927, NP\_037390.2, 221666.s.at  
Figure 3640: PRO57311  
Figure 3641A-B: DNA344770, NP\_055140.1, 221676.s.at  
Figure 3642: PRO49875  
Figure 3643: DNA194468, AF225418, 221679.s.at  
Figure 3644: PRO23835  
Figure 3645: DNA344771, AF094508, 221681.s.at  
Figure 3646: DNA330460, NP\_060255.2, 221685.s.at  
Figure 3647: PRO85660  
Figure 3648: DNA324690, NP\_002511.1, 221691.x.at  
Figure 3649: PRO58993  
Figure 3650: DNA256141, NM\_018423, 221696.s.at  
Figure 3651: PRO51189  
Figure 3652: DNA344772, NP\_078943.1, 221704.s.at  
Figure 3653: PRO90809  
Figure 3654A-C: DNA328664, NM\_007200, 221718.s.at  
Figure 3655: PRO84437  
Figure 3656A-B: DNA344773, 1505701.34, 221727.at  
Figure 3657: PRO95345  
Figure 3658: DNA328961, NP\_443112.1, 221756.at  
Figure 3659: PRO84667  
Figure 3660: DNA328961, NM\_052880, 221757.at  
Figure 3661: PRO84667  
Figure 3662A-C: DNA328965, BAB21809.1, 221778.at  
Figure 3663: PRO51878  
Figure 3664A-B: DNA344774, AL833316, 221824.s.at  
Figure 3665: PRO95346  
Figure 3666: DNA344775, NP\_689501.1, 221864.at  
Figure 3667: PRO95347  
Figure 3668: DNA344776, 299937.3, 221897.at  
Figure 3669: PRO95348  
Figure 3670: DNA327933, 1452741.11, 221899.at  
Figure 3671: PRO83865  
Figure 3672A-B: DNA344777, AB020656, 221905.at  
Figure 3673: DNA328971, AK000472, 221923.s.at  
Figure 3674: PRO84674  
Figure 3675: DNA329321, NP\_112493.1, 221931.s.at  
Figure 3676: PRO84906  
Figure 3677A-B: DNA336655, BAB85561.1, 221971.x.at  
Figure 3678: PRO90728  
Figure 3679: DNA344778, 7696429.33, 221973.at  
Figure 3680: PRO95350  
Figure 3681: DNA331384, AK026326, 221985.at  
Figure 3682: PRO86454  
Figure 3683: DNA254739, NP\_068766.1, 221987.s.at  
Figure 3684: PRO49837  
Figure 3685: DNA344779, AF218023, 221989.at  
Figure 3686: PRO95351  
Figure 3687: DNA344780, 127586.70, 222001.x.at  
Figure 3688: PRO95352  
Figure 3689A-C: DNA344781, NM\_006738, 222024.s.at  
Figure 3690: PRO95353  
Figure 3691: DNA344782, AAH44933.1, 222039.at  
Figure 3692: PRO95354  
Figure 3693: DNA325036, NM\_018238, 222132.s.at  
Figure 3694: PRO81625  
Figure 3695A-B: DNA339979, BAA95990.1, 222139.at  
Figure 3696: PRO91487  
Figure 3697: DNA329916, 338326.15, 222142.at  
Figure 3698: PRO85231  
Figure 3699A-B: DNA344783, 027987.100, 222145.at  
Figure 3700: PRO95355  
Figure 3701: DNA331386, AL079297, 222150.s.at  
Figure 3702: DNA328975, NP\_078807.1, 222155.s.at  
Figure 3703: PRO47688  
Figure 3704: DNA256784, NP\_075069.1, 222209.s.at  
Figure 3705: PRO51716  
Figure 3706: DNA323915, NP\_077306.1, 222217.s.at  
Figure 3707: PRO703

WO 2005/019258

PCT/US2004/025788

Figure 3708: DNA287425, NP\_060979.1, 222231.s.at  
 Figure 3709: PRO69682  
 Figure 3710: DNA344784, AAB26149.1, 222247.at  
 Figure 3711: PRO95356  
 Figure 3712: DNA344785, AL137750, 222262.s.at  
 Figure 3713: PRO95357  
 Figure 3714: DNA344786, 405457.25, 222303.at  
 Figure 3715: PRO95358  
 Figure 3716: DNA330470, 096828.1, 222307.at  
 Figure 3717: PRO85668  
 Figure 3718: DNA344787, 016338.1, 222371.at  
 Figure 3719: PRO95359  
 Figure 3720A-B: DNA324364, NP\_037468.1, 222385.x.at  
 Figure 3721: PRO1314  
 Figure 3722: DNA335675, AJ251830, 222392.x.at  
 Figure 3723: PRO90003  
 Figure 3724: DNA227358, NP\_057479.1, 222404.x.at  
 Figure 3725: PRO37821  
 Figure 3726: DNA344788, AK074898, 222405.at  
 Figure 3727: PRO95360  
 Figure 3728A-B: DNA344789, NM\_014325, 222409.at  
 Figure 3729: PRO49875  
 Figure 3730: DNA327939, NP\_060654.1, 222442.s.at  
 Figure 3731: PRO83869  
 Figure 3732: DNA344790, NM\_005105, 222443.s.at  
 Figure 3733: PRO37600  
 Figure 3734A-B: DNA325652, NM\_016357, 222457.s.at  
 Figure 3735: PRO82143  
 Figure 3736A-B: DNA256489, NP\_079110.1, 222464.s.at  
 Figure 3737: PRO51526  
 Figure 3738: DNA331089, NP\_057143.1, 222500.at  
 Figure 3739: PRO4984  
 Figure 3740: DNA329370, NP\_060611.2, 222522.x.at  
 Figure 3741: PRO84949  
 Figure 3742A-B: DNA344791, AL834191, 222603.at  
 Figure 3743: PRO95361  
 Figure 3744: DNA330483, AK001472, 222608.s.at  
 Figure 3745: PRO85679  
 Figure 3746: DNA329330, NP\_057130.1, 222609.s.at  
 Figure 3747: PRO84914  
 Figure 3748: DNA344792, BC035985, 222622.at  
 Figure 3749: PRO95362  
 Figure 3750: DNA329331, NP\_005763.2, 222666.s.at  
 Figure 3751: PRO84915  
 Figure 3752: DNA344793, 1454336.17, 222669.s.at  
 Figure 3753: PRO95363  
 Figure 3754: DNA344794, NP\_079170.1, 222684.s.at  
 Figure 3755: PRO95364  
 Figure 3756A-B: DNA344795, AF537091, 222685.at  
 Figure 3757: PRO95365  
 Figure 3758A-B: DNA344796, 998337.2, 222689.at  
 Figure 3759: PRO95366

Figure 3760: DNA339537, NM\_018394, 222697.s.at  
 Figure 3761: PRO91303  
 Figure 3762: DNA323797, NP\_078916.1, 222703.s.at  
 Figure 3763: PRO80547  
 Figure 3764: DNA344797, BC044575, 222734.at  
 Figure 3765: PRO95367  
 Figure 3766: DNA333586, 295181.4, 222735.at  
 Figure 3767: PRO84603  
 Figure 3768A-B: DNA344798, NM\_014109, 222740.at  
 Figure 3769: PRO95368  
 Figure 3770: DNA335239, NM\_017688, 222746.s.at  
 Figure 3771: PRO89625  
 Figure 3772A-B: DNA340168, NP\_060163.2, 222761.at  
 Figure 3773: PRO91663  
 Figure 3774: DNA344799, BC005401, 222763.s.at  
 Figure 3775: PRO95369  
 Figure 3776A-B: DNA335042, NM\_018092, 222774.s.at  
 Figure 3777: PRO4401  
 Figure 3778A-B: DNA344800, BC033901, 222787.s.at  
 Figure 3779: PRO95370  
 Figure 3780: DNA255044, DNA255044, 222833.at  
 Figure 3781A-B: DNA329438, NP\_476516.1, 222837.s.at  
 Figure 3782: PRO85008  
 Figure 3783: DNA339367, NP\_037469.1, 222841.s.at  
 Figure 3784: PRO91172  
 Figure 3785: DNA344801, AL834387, 222843.at  
 Figure 3786: PRO95371  
 Figure 3787A-B: DNA333626, DNA333626, 222846.at  
 Figure 3788: PRO88268  
 Figure 3789: DNA335638, NP\_203130.1, 222847.s.at  
 Figure 3790: PRO48216  
 Figure 3791: DNA331389, NP\_071428.2, 222848.at  
 Figure 3792: PRO81238  
 Figure 3793A-B: DNA344802, NP\_064547.2, 222875.at  
 Figure 3794: PRO95372  
 Figure 3795: DNA344803, 321334.4, 222900.at  
 Figure 3796: PRO95373  
 Figure 3797: DNA344804, NP\_005012.1, 222938.x.at  
 Figure 3798: PRO95374  
 Figure 3799: DNA330501, AK022792, 222958.s.at  
 Figure 3800: PRO85694  
 Figure 3801: DNA330503, NP\_038466.2, 222991.s.at  
 Figure 3802: PRO85696  
 Figure 3803: DNA330504, NP\_057575.2, 222993.at  
 Figure 3804: PRO84923  
 Figure 3805: DNA324548, NP\_110409.2, 223020.at  
 Figure 3806: PRO81202  
 Figure 3807A-B: DNA344805, NP\_057308.1, 223027.at

WO 2005/019258

PCT/US2004/025788

Figure 3808: PRO84924  
Figure 3809A-B: DNA344806, NM.016224, 223028.s.at  
Figure 3810: PRO84924  
Figure 3811: DNA324707, NP.037369.1, 223032.x.at  
Figure 3812: PRO81339  
Figure 3813A-B: DNA256347, NP.065801.1, 223055.s.at  
Figure 3814: PRO51389  
Figure 3815A-B: DNA256347, NM.020750, 223056.s.at  
Figure 3816: PRO51389  
Figure 3817: DNA325295, NP.113641.1, 223058.at  
Figure 3818: PRO81841  
Figure 3819: DNA287216, NM.021154, 223062.s.at  
Figure 3820: PRO69496  
Figure 3821: DNA304492, NP.114405.1, 223065.s.at  
Figure 3822: PRO1864  
Figure 3823A-B: DNA328934, NP.061936.2, 223068.at  
Figure 3824: PRO84649  
Figure 3825A-B: DNA328934, NM.019063, 223069.s.at  
Figure 3826: PRO84649  
Figure 3827: DNA344807, NP.036609.1, 223072.s.at  
Figure 3828: PRO95375  
Figure 3829: DNA227294, NP.060225.1, 223076.s.at  
Figure 3830: PRO37757  
Figure 3831A-B: DNA329316, AF158555, 223079.s.at  
Figure 3832: PRO84904  
Figure 3833: DNA329349, NP.054861.1, 223100.s.at  
Figure 3834: PRO84931  
Figure 3835A-C: DNA339662, NP.110433.1, 223125.s.at  
Figure 3836: PRO91404  
Figure 3837: DNA330445, NP.112174.1, 223132.s.at  
Figure 3838: PRO85646  
Figure 3839: DNA325557, NP.115675.1, 223151.at  
Figure 3840: PRO82060  
Figure 3841: DNA329352, NP.057154.2, 223156.at  
Figure 3842: PRO84932  
Figure 3843A-B: DNA339969, BAA86461.1, 223162.s.at  
Figure 3844: PRO91477  
Figure 3845: DNA324924, NP.113631.1, 223164.at  
Figure 3846: PRO81525  
Figure 3847A-B: DNA344808, NP.067028.1, 223168.at  
Figure 3848: PRO1200  
Figure 3849A-B: DNA344809, AAH23525.1, 223176.at  
Figure 3850: PRO95376  
Figure 3851: DNA344810, NP.113665.1, 223179.at  
Figure 3852: PRO84933  
Figure 3853: DNA254276, NP.054896.1, 223180.s.at  
Figure 3854: PRO49387  
Figure 3855: DNA344811, NP.113675.2, 223182.s.at  
Figure 3856: PRO95377  
Figure 3857: DNA344812, AF201944, 223193.x.at  
Figure 3858: PRO95378  
Figure 3859: DNA323792, NP.113647.1, 223195.s.at  
Figure 3860: PRO80542  
Figure 3861: DNA339535, NP.060855.1, 223200.s.at  
Figure 3862: PRO91301  
Figure 3863A-B: DNA257461, NP.113607.1, 223217.s.at  
Figure 3864: PRO52040  
Figure 3865A-B: DNA257461, NM.031419, 223218.s.at  
Figure 3866: PRO52040  
Figure 3867: DNA327954, NP.113646.1, 223220.s.at  
Figure 3868: PRO83879  
Figure 3869: DNA340182, NP.068380.1, 223222.at  
Figure 3870: PRO91677  
Figure 3871: DNA344813, NP.114091.2, 223227.at  
Figure 3872: PRO95379  
Figure 3873: DNA344814, NP.060019.1, 223253.at  
Figure 3874: PRO95380  
Figure 3875: DNA330517, NP.115879.1, 223273.at  
Figure 3876: PRO85707  
Figure 3877: DNA344815, NP.116565.1, 223276.at  
Figure 3878: PRO12050  
Figure 3879A-B: DNA330522, NP.116071.2, 223287.s.at  
Figure 3880: PRO85712  
Figure 3881: DNA326962, NP.064711.1, 223290.at  
Figure 3882: PRO83275  
Figure 3883: DNA330523, BC001220, 223294.at  
Figure 3884: PRO85713  
Figure 3885: DNA257363, NP.115691.1, 223296.at  
Figure 3886: PRO51950  
Figure 3887: DNA329355, NP.150596.1, 223299.at  
Figure 3888: PRO50434  
Figure 3889: DNA329356, NP.115671.1, 223304.at  
Figure 3890: PRO84935  
Figure 3891: DNA330454, NP.112589.1, 223307.at  
Figure 3892: PRO85655  
Figure 3893: DNA344816, NM.020806, 223319.at  
Figure 3894: PRO50495  
Figure 3895: DNA329358, NP.115649.1, 223334.at  
Figure 3896: PRO84937  
Figure 3897A-B: DNA255756, L12052, 223358.s.at  
Figure 3898: PRO50812  
Figure 3899: DNA344817, NM.145071, 223377.x.at  
Figure 3900: PRO86458  
Figure 3901A-B: DNA344818, NP.055387.1, 223380.s.at  
Figure 3902: PRO95381  
Figure 3903: DNA344819, NP.663735.1, 223381.at  
Figure 3904: PRO38881  
Figure 3905A-B: DNA344820, NP.115644.1,

WO 2005/019258

PCT/US2004/025788

223382.s.at  
Figure 3906: PRO84939  
Figure 3907A-B: DNA344821, NM\_032268, 223383.at  
Figure 3908: PRO84939  
Figure 3909: DNA340216, NP\_115686.2, 223398.at  
Figure 3910: PRO91711  
Figure 3911: DNA339511, NP\_060635.1, 223400.s.at  
Figure 3912: PRO91282  
Figure 3913: DNA324156, NP\_115588.1, 223403.s.at  
Figure 3914: PRO80856  
Figure 3915: DNA344822, NP\_115514.2, 223412.at  
Figure 3916: PRO95382  
Figure 3917: DNA329362, NP\_060286.1, 223413.s.at  
Figure 3918: PRO84941  
Figure 3919: DNA329362, NM\_017816, 223414.s.at  
Figure 3920: PRO84941  
Figure 3921: DNA255676, NP\_060754.1, 223434.at  
Figure 3922: PRO50738  
Figure 3923: DNA330533, NP\_058647.1, 223451.s.at  
Figure 3924: PRO772  
Figure 3925: DNA344823, BAA92078.1, 223457.at  
Figure 3926: PRO95383  
Figure 3927: DNA273418, AAG01157.1, 223480.s.at  
Figure 3928: DNA327958, NP\_115789.1, 223484.at  
Figure 3929: PRO23554  
Figure 3930: DNA329456, NP\_057126.1, 223490.s.at  
Figure 3931: PRO85023  
Figure 3932: DNA338084, NP\_006564.1, 223502.s.at  
Figure 3933: PRO738  
Figure 3934: DNA344824, AF255647, 223503.at  
Figure 3935: PRO95384  
Figure 3936: DNA333656, NP\_115646.2, 223533.at  
Figure 3937: PRO88295  
Figure 3938: DNA330536, NP\_115666.1, 223542.at  
Figure 3939: PRO85722  
Figure 3940A-B: DNA339971, BAA86587.1, 223617.x.at  
Figure 3941: PRO91479  
Figure 3942: DNA327028, NP\_005291.1, 223620.at  
Figure 3943: PRO37083  
Figure 3944: DNA344825, BC002724, 223666.at  
Figure 3945: PRO83126  
Figure 3946: DNA344826, NP\_006548.1, 223704.s.at  
Figure 3947: PRO51385  
Figure 3948: DNA344827, AF176013, 223722.at  
Figure 3949: PRO95385  
Figure 3950: DNA344828, NM\_146388, 223743.s.at  
Figure 3951: PRO95386  
Figure 3952: DNA188735, NP\_001506.1, 223758.s.at  
Figure 3953: PRO26224  
Figure 3954: DNA287253, NP\_444268.1, 223774.at  
Figure 3955: PRO69527  
Figure 3956: DNA331132, NP\_115524.1, 223798.at  
Figure 3957: PRO86273  
Figure 3958: DNA332645, NP\_570138.1, 223809.at

Figure 3959: PRO61997  
Figure 3960: DNA327200, NP\_114156.1, 223836.at  
Figure 3961: PRO1065  
Figure 3962: DNA344829, NP\_683699.1, 223851.s.at  
Figure 3963: PRO95387  
Figure 3964: DNA335398, AF132202, 223940.x.at  
Figure 3965A-B: DNA344830, NM\_004830, 223947.s.at  
Figure 3966: PRO95388  
Figure 3967: DNA335568, NM\_024022, 223948.s.at  
Figure 3968: PRO89910  
Figure 3969: DNA327213, NM\_032405, 223949.at  
Figure 3970: PRO83482  
Figure 3971: DNA344831, NM\_013324, 223961.s.at  
Figure 3972: PRO37588  
Figure 3973: DNA324248, NM\_004509, 223980.s.at  
Figure 3974: PRO80932  
Figure 3975: DNA344832, AF130059, 223991.s.at  
Figure 3976: PRO95389  
Figure 3977: DNA344833, NP\_002594.1, 224046.s.at  
Figure 3978: PRO95390  
Figure 3979: DNA344834, NM\_172234, 224156.x.at  
Figure 3980: PRO95391  
Figure 3981A-C: DNA227619, NP\_054831.1, 224218.s.at  
Figure 3982: PRO38082  
Figure 3983: DNA324707, NM\_013237, 224232.s.at  
Figure 3984: PRO81339  
Figure 3985: DNA329370, NM\_018141, 224247.s.at  
Figure 3986: PRO84949  
Figure 3987: DNA344835, NP\_115942.1, 224285.at  
Figure 3988: PRO78450  
Figure 3989: DNA330558, NP\_057588.1, 224330.s.at  
Figure 3990: PRO84950  
Figure 3991: DNA344836, NP\_115868.1, 224331.s.at  
Figure 3992: PRO84951  
Figure 3993: DNA344837, BC015060, 224345.x.at  
Figure 3994: PRO86616  
Figure 3995: DNA344838, NM\_018725, 224361.s.at  
Figure 3996: PRO19612  
Figure 3997: DNA335328, NP\_116010.1, 224367.at  
Figure 3998: PRO89703  
Figure 3999: DNA330334, NP\_114402.1, 224368.s.at  
Figure 4000: PRO85557  
Figure 4001: DNA328323, NP\_114148.2, 224428.s.at  
Figure 4002: PRO69531  
Figure 4003: DNA344839, NP\_113668.2, 224450.s.at  
Figure 4004: PRO95392  
Figure 4005: DNA328885, NM\_018638, 224453.s.at  
Figure 4006: PRO50294  
Figure 4007: DNA344840, NP\_116186.1, 224461.s.at  
Figure 4008: PRO95393  
Figure 4009: DNA329373, NP\_115722.1, 224467.s.at  
Figure 4010: PRO84952  
Figure 4011: DNA323732, NP\_057260.2, 224472.x.at  
Figure 4012: PRO80490

WO 2005/019258

PCT/US2004/025788

Figure 4013: DNA344841, BC006236, 224480.s\_at  
 Figure 4014: PRO95394  
 Figure 4015A-C: DNA344842, AJ314646, 224482.s\_at  
 Figure 4016: DNA344843, BC006384, 224507.s\_at  
 Figure 4017: PRO95396  
 Figure 4018: DNA344844, 242250.1, 224508.at  
 Figure 4019: PRO95397  
 Figure 4020: DNA327977, NP\_115886.1, 224518.s\_at  
 Figure 4021: PRO83898  
 Figure 4022: DNA329374, NP\_115735.1, 224523.s\_at  
 Figure 4023: PRO84953  
 Figure 4024: DNA344845, NM\_148902, 224553.s\_at  
 Figure 4025: PRO95398  
 Figure 4026: DNA344846, 1453417.19, 224559.at  
 Figure 4027: PRO95399  
 Figure 4028A-E: DNA344847, AF001893, 224566.at  
 Figure 4029: PRO95400  
 Figure 4030: DNA334965, D87666, 224567.x\_at  
 Figure 4031: DNA330569, BC020516, 224572.s\_at  
 Figure 4032: DNA344848, NP\_066972.1, 224583.at  
 Figure 4033: PRO82633  
 Figure 4034A-B: DNA334919, NP\_536856.2, 224596.at  
 Figure 4035: PRO89354  
 Figure 4036: DNA344849, 1383705.7, 224601.at  
 Figure 4037: PRO95401  
 Figure 4038: DNA331396, 1357555.1, 224603.at  
 Figure 4039: PRO86461  
 Figure 4040: DNA255362, DNA255362, 224604.at  
 Figure 4041: DNA344850, BC017399, 224605.at  
 Figure 4042: PRO95402  
 Figure 4043: DNA344851, AF070636, 224609.at  
 Figure 4044: PRO95403  
 Figure 4045: DNA344852, 348196.115, 224610.at  
 Figure 4046: PRO95404  
 Figure 4047: DNA329376, BAA91036.1, 224632.at  
 Figure 4048: PRO84954  
 Figure 4049A-B: DNA344853, 361207.5, 224634.at  
 Figure 4050: PRO95405  
 Figure 4051: DNA344854, AK093442, 224654.at  
 Figure 4052: PRO95406  
 Figure 4053A-B: DNA344855, BAB21782.1, 224674.at  
 Figure 4054: PRO49364  
 Figure 4055A-B: DNA344856, AL161973, 224685.at  
 Figure 4056A-B: DNA330574, BAA86542.2, 224698.at  
 Figure 4057: PRO85755  
 Figure 4058: DNA329378, BC022990, 224714.at  
 Figure 4059: PRO84956  
 Figure 4060: DNA330577, NP\_443076.1, 224715.at  
 Figure 4061: PRO85758  
 Figure 4062: DNA330579, NP\_612434.1, 224719.s\_at  
 Figure 4063: PRO85760  
 Figure 4064: DNA344857, NP\_653202.1, 224733.at  
 Figure 4065: PRO95408  
 Figure 4066: DNA257352, DNA257352, 224739.at  
 Figure 4067: PRO51940  
 Figure 4068: DNA344858, 887619.58, 224741.x\_at  
 Figure 4069: PRO95409  
 Figure 4070: DNA330581, NP\_542399.1, 224753.at  
 Figure 4071: PRO82014  
 Figure 4072A-B: DNA344859, NP\_065875.1, 224764.at  
 Figure 4073: PRO95410  
 Figure 4074: DNA336077, BC035511, 224783.at  
 Figure 4075: PRO90299  
 Figure 4076A-B: DNA333692, AB033075, 224790.at  
 Figure 4077: DNA228087, DNA228087, 224793.s\_at  
 Figure 4078: PRO38550  
 Figure 4079A-B: DNA287330, BAA86479.1, 224799.at  
 Figure 4080: PRO69594  
 Figure 4081A-B: DNA330584, NP\_065881.1, 224800.at  
 Figure 4082: PRO85764  
 Figure 4083A-B: DNA287330, AB032991, 224801.at  
 Figure 4084: DNA331397, AK001723, 224802.at  
 Figure 4085: PRO23259  
 Figure 4086: DNA344860, NP\_699164.1, 224819.at  
 Figure 4087: PRO95411  
 Figure 4088A-B: DNA330559, BAB21791.1, 224832.at  
 Figure 4089: PRO85741  
 Figure 4090A-B: DNA330809, 336997.1, 224837.at  
 Figure 4091: PRO85973  
 Figure 4092A-B: DNA330522, NM\_032682, 224838.at  
 Figure 4093: PRO85712  
 Figure 4094A-B: DNA344861, NP\_597700.1, 224839.s\_at  
 Figure 4095: PRO95412  
 Figure 4096A-B: DNA324748, NP\_004108.1, 224840.at  
 Figure 4097: PRO36841  
 Figure 4098A-B: DNA344862, AF141346, 224841.x\_at  
 Figure 4099: DNA344863, BC027989, 224847.at  
 Figure 4100: PRO95414  
 Figure 4101A-C: DNA329379, 010205.2, 224848.at  
 Figure 4102: PRO84957  
 Figure 4103: DNA344864, NP\_116199.1, 224850.at  
 Figure 4104: PRO95415  
 Figure 4105A-B: DNA324748, NM\_004117, 224856.at  
 Figure 4106: PRO36841  
 Figure 4107: DNA329381, D28589, 224870.at  
 Figure 4108A-B: DNA344865, NP\_065871.1, 224909.s\_at  
 Figure 4109: PRO95416  
 Figure 4110: DNA344866, AAH10736.1, 224913.s\_at  
 Figure 4111: PRO95417

WO 2005/019258

PCT/US2004/025788

Figure 4112: DNA330591, NP\_115865.1, 224919.at  
Figure 4113: PRO85771  
Figure 4114A-B: DNA344867, BC009948, 224925.at  
Figure 4115: PRO95418  
Figure 4116A-B: DNA228196, BAA92674.1, 224937.at  
Figure 4117: PRO38661  
Figure 4118: DNA336269, 346724.14, 224944.at  
Figure 4119: PRO90430  
Figure 4120: DNA344868, 7769724.1, 224989.at  
Figure 4121: PRO95419  
Figure 4122: DNA329384, NP\_777581.1, 224990.at  
Figure 4123: PRO84960  
Figure 4124: DNA344869, BC034247, 225036.at  
Figure 4125: PRO95420  
Figure 4126: DNA344870, NP\_061189.1, 225081.s.at  
Figure 4127: PRO95421  
Figure 4128: DNA330598, 1384569.2, 225086.at  
Figure 4129: PRO85776  
Figure 4130A-E: DNA329391, 233747.10, 225097.at  
Figure 4131: PRO84967  
Figure 4132A-B: DNA327993, 898436.7, 225133.at  
Figure 4133: PRO81138  
Figure 4134: DNA344871, BC037573, 225148.at  
Figure 4135: PRO95422  
Figure 4136: DNA344872, NP\_079272.4, 225158.at  
Figure 4137: PRO84969  
Figure 4138: DNA344873, NM\_024996, 225161.at  
Figure 4139: PRO84969  
Figure 4140: DNA330604, NP\_277050.1, 225171.at  
Figure 4141: PRO85782  
Figure 4142: DNA330604, NM\_033515, 225173.at  
Figure 4143: PRO85782  
Figure 4144: DNA344874, BC040556, 225175.s.at  
Figure 4145: PRO95423  
Figure 4146: DNA344875, AAH27990.1, 225178.at  
Figure 4147: PRO83914  
Figure 4148A-B: DNA344876, 335186.18, 225195.at  
Figure 4149: PRO95424  
Figure 4150: DNA336053, NP\_110438.1, 225196.s.at  
Figure 4151: PRO90282  
Figure 4152: DNA344877, 233597.34, 225220.at  
Figure 4153: PRO95425  
Figure 4154: DNA344878, NP\_542763.1, 225252.at  
Figure 4155: PRO95426  
Figure 4156A-B: DNA330605, 233102.7, 225265.at  
Figure 4157: PRO85783  
Figure 4158A-B: DNA258863, DNA258863, 225266.at  
Figure 4159A-B: DNA344879, 7771332.17, 225285.at  
Figure 4160: PRO95427  
Figure 4161A-B: DNA330606, 475590.1, 225290.at  
Figure 4162: PRO85784  
Figure 4163: DNA344880, NP\_149100.1, 225291.at  
Figure 4164: PRO95428  
Figure 4165: DNA339708, NP\_116147.1, 225309.at  
Figure 4166: PRO91438  
Figure 4167: DNA344881, 1455093.11, 225315.at  
Figure 4168: PRO95429  
Figure 4169: DNA324422, DNA324422, 225331.at  
Figure 4170: PRO81086  
Figure 4171A-B: DNA344882, 331507.16, 225342.at  
Figure 4172: PRO95430  
Figure 4173: DNA344883, 475538.46, 225351.at  
Figure 4174: PRO95431  
Figure 4175: DNA344884, 475309.4, 225356.at  
Figure 4176: PRO95432  
Figure 4177A-B: DNA330742, 476805.1, 225363.at  
Figure 4178: PRO85910  
Figure 4179: DNA327965, NP\_060760.1, 225367.at  
Figure 4180: PRO83888  
Figure 4181: DNA329401, NP\_612403.2, 225386.s.at  
Figure 4182: PRO84976  
Figure 4183: DNA344885, NM\_173647, 225414.at  
Figure 4184: PRO95433  
Figure 4185: DNA344886, NP\_116258.1, 225439.at  
Figure 4186: PRO52516  
Figure 4187A-B: DNA330617, 336147.2, 225447.at  
Figure 4188: PRO59923  
Figure 4189: DNA330618, CAB55990.1, 225458.at  
Figure 4190: PRO85793  
Figure 4191: DNA344887, BC022333, 225470.at  
Figure 4192: PRO95434  
Figure 4193A-B: DNA328006, 234824.7, 225478.at  
Figure 4194: PRO83924  
Figure 4195A-B: DNA334963, NM\_032943, 225496.s.at  
Figure 4196: PRO89395  
Figure 4197A-B: DNA344888, AL833216, 225519.at  
Figure 4198: PRO95435  
Figure 4199: DNA331675, NP\_056255.1, 225520.at  
Figure 4200: PRO86670  
Figure 4201A-B: DNA344889, BAB33341.1, 225525.at  
Figure 4202: PRO95436  
Figure 4203: DNA330621, AAF71051.1, 225535.s.at  
Figure 4204: PRO85795  
Figure 4205: DNA328010, NP\_149016.1, 225557.at  
Figure 4206: PRO83928  
Figure 4207A-B: DNA344890, NM\_057170, 225558.at  
Figure 4208: PRO95437  
Figure 4209A-B: DNA344891, AL832362, 225570.at  
Figure 4210: PRO95438  
Figure 4211A-B: DNA329407, 234687.2, 225606.at  
Figure 4212: PRO84980  
Figure 4213A-B: DNA344892, AK074072, 225608.at  
Figure 4214A-C: DNA344893, 197240.1, 225611.at  
Figure 4215: PRO95440  
Figure 4216: DNA331399, 994419.37, 225622.at  
Figure 4217: PRO86463  
Figure 4218A-B: DNA340041, AK024473, 225624.at

WO 2005/019258

PCT/US2004/025788

Figure 4219A-B: DNA331400, NP\_060910.2, 225626.at  
 Figure 4220: PRO86464  
 Figure 4221A-B: DNA344894, BAA96062.2, 225629.s.at  
 Figure 4222: PRO95441  
 Figure 4223: DNA344895, 473880.39, 225636.at  
 Figure 4224: PRO95442  
 Figure 4225: DNA344896, NM\_148170, 225647.s.at  
 Figure 4226: PRO95443  
 Figure 4227A-B: DNA288261, NP\_037414.2, 225655.at  
 Figure 4228: PRO70021  
 Figure 4229: DNA344897, NP\_612496.1, 225657.at  
 Figure 4230: PRO81096  
 Figure 4231A-B: DNA344898, NM\_133646, 225662.at  
 Figure 4232: PRO95444  
 Figure 4233A-B: DNA344899, AF480462, 225665.at  
 Figure 4234: PRO95445  
 Figure 4235: DNA332522, 235504.1, 225685.at  
 Figure 4236: PRO87339  
 Figure 4237: DNA328012, BC017873, 225686.at  
 Figure 4238: PRO83930  
 Figure 4239: DNA329410, DNA329410, 225699.at  
 Figure 4240: PRO84982  
 Figure 4241: DNA304821, AAH11254.1, 225706.at  
 Figure 4242: PRO71227  
 Figure 4243: DNA344900, NP\_689735.1, 225707.at  
 Figure 4244: PRO95446  
 Figure 4245: DNA344901, 1383664.3, 225710.at  
 Figure 4246: PRO95447  
 Figure 4247: DNA344902, 040422.37, 225711.at  
 Figure 4248: PRO95448  
 Figure 4249A-B: DNA330634, 243208.1, 225725.at  
 Figure 4250: PRO85806  
 Figure 4251A-B: DNA255834, BAA86514.1, 225727.at  
 Figure 4252: PRO50889  
 Figure 4253: DNA325290, NP\_116294.1, 225751.at  
 Figure 4254: PRO81837  
 Figure 4255A-B: DNA344903, 232693.1, 225752.at  
 Figure 4256: PRO95449  
 Figure 4257A-B: DNA344904, 344455.25, 225766.s.at  
 Figure 4258: PRO60223  
 Figure 4259: DNA344905, BC044244, 225775.at  
 Figure 4260: PRO95450  
 Figure 4261: DNA328016, NP\_542409.1, 225783.at  
 Figure 4262: PRO83934  
 Figure 4263: DNA344906, 033730.20, 225796.at  
 Figure 4264: PRO95451  
 Figure 4265: DNA344907, BC009508, 225799.at  
 Figure 4266: PRO84986  
 Figure 4267A-B: DNA328001, 246799.1, 225801.at  
 Figure 4268: PRO83920

Figure 4269: DNA330637, NP\_478136.1, 225803.at  
 Figure 4270: PRO85809  
 Figure 4271: DNA344908, BC046199, 225834.at  
 Figure 4272: PRO95452  
 Figure 4273: DNA335325, 199593.7, 225835.at  
 Figure 4274: PRO89700  
 Figure 4275: DNA329417, 411336.1, 225842.at  
 Figure 4276: PRO84989  
 Figure 4277: DNA329418, NP\_660152.1, 225850.at  
 Figure 4278: PRO19906  
 Figure 4279: DNA344909, 001697.17, 225857.s.at  
 Figure 4280: PRO95453  
 Figure 4281A-B: DNA258903, DNA258903, 225864.at  
 Figure 4282: DNA344910, BC035314, 225866.at  
 Figure 4283: PRO81453  
 Figure 4284A-B: DNA344911, NP\_733837.1, 225887.at  
 Figure 4285: PRO95454  
 Figure 4286: DNA330642, NP\_115494.1, 225898.at  
 Figure 4287: PRO85814  
 Figure 4288A-B: DNA331403, NP\_150601.1, 225912.at  
 Figure 4289: PRO86467  
 Figure 4290: DNA344912, 232561.20, 225922.at  
 Figure 4291: PRO95455  
 Figure 4292A-B: DNA328790, 481415.9, 225927.at  
 Figure 4293: PRO84535  
 Figure 4294A-B: DNA344913, AL833201, 225929.s.at  
 Figure 4295: PRO95456  
 Figure 4296: DNA344914, BC032220, 225931.s.at  
 Figure 4297: PRO95457  
 Figure 4298A-B: DNA344915, AL390144, 225959.s.at  
 Figure 4299: PRO95458  
 Figure 4300: DNA344916, 202205.5, 225967.s.at  
 Figure 4301: PRO95459  
 Figure 4302A-B: DNA344917, BC037303, 225984.at  
 Figure 4303: PRO95460  
 Figure 4304A-B: DNA329423, BAB21799.1, 226003.at  
 Figure 4305: PRO84994  
 Figure 4306A-B: DNA335463, 246054.6, 226021.at  
 Figure 4307: PRO89818  
 Figure 4308A-B: DNA344918, 347857.19, 226025.at  
 Figure 4309: PRO95461  
 Figure 4310: DNA335659, 027830.2, 226034.at  
 Figure 4311: PRO89988  
 Figure 4312A-B: DNA344919, 331817.1, 226039.at  
 Figure 4313: PRO95462  
 Figure 4314: DNA344920, NP\_079382.2, 226075.at  
 Figure 4315: PRO95463  
 Figure 4316A-B: DNA344921, 1500207.3, 226085.at  
 Figure 4317: PRO95464  
 Figure 4318A-B: DNA344922, NM\_012081,

WO 2005/019258

PCT/US2004/025788

226099.at  
Figure 4319: PRO37794  
Figure 4320: DNA329425, BC008294, 226117.at  
Figure 4321A-B: DNA344923, AK027859, 226118.at  
Figure 4322: PRO95465  
Figure 4323: DNA257557, DNA257557, 226123.at  
Figure 4324: DNA330657, 198409.1, 226140.s.at  
Figure 4325: PRO85829  
Figure 4326: DNA344924, 243488.38, 226150.at  
Figure 4327: PRO95466  
Figure 4328A-B: DNA344925, BAB67795.1, 226184.at  
Figure 4329: PRO95467  
Figure 4330: DNA344926, 128514.91, 226193.x.at  
Figure 4331: PRO95468  
Figure 4332: DNA344927, NP\_659489.1, 226199.at  
Figure 4333: PRO91821  
Figure 4334: DNA344928, AF306698, 226214.at  
Figure 4335: PRO95469  
Figure 4336A-B: DNA329428, 1446144.8, 226218.at  
Figure 4337: PRO84999  
Figure 4338A-B: DNA344929, 1445835.2, 226225.at  
Figure 4339: PRO95470  
Figure 4340: DNA344930, 7761926.1, 226233.at  
Figure 4341: PRO95471  
Figure 4342: DNA344931, BX248749, 226241.s.at  
Figure 4343A-C: DNA344932, 987122.2, 226251.at  
Figure 4344: PRO95473  
Figure 4345: DNA344933, NP\_071931.1, 226264.at  
Figure 4346: PRO95474  
Figure 4347: DNA330666, 199829.14, 226272.at  
Figure 4348: PRO85838  
Figure 4349: DNA344934, BC036402, 226275.at  
Figure 4350: DNA344935, 347831.7, 226282.at  
Figure 4351: PRO95476  
Figure 4352: DNA328028, NP\_005773.1, 226319.s.at  
Figure 4353: PRO83945  
Figure 4354: DNA328028, NM\_005782, 226320.at  
Figure 4355: PRO83945  
Figure 4356: DNA344936, 7696668.2, 226333.at  
Figure 4357: PRO95477  
Figure 4358: DNA344937, 218237.1, 226350.at  
Figure 4359: PRO95478  
Figure 4360A-B: DNA331407, 198233.1, 226352.at  
Figure 4361: PRO86471  
Figure 4362: DNA329430, NP\_116191.2, 226353.at  
Figure 4363: PRO38524  
Figure 4364A-B: DNA330675, 177663.2, 226372.at  
Figure 4365: PRO85847  
Figure 4366A-B: DNA344938, AL832599, 226390.at  
Figure 4367: DNA335613, NP\_116178.1, 226401.at  
Figure 4368: PRO89948  
Figure 4369: DNA344939, BC044951, 226410.at  
Figure 4370: DNA344940, 407605.1, 226431.at  
Figure 4371: PRO95480  
Figure 4372A-B: DNA344941, 474795.3, 226438.at

Figure 4373: PRO95481  
Figure 4374: DNA330678, 401430.1, 226444.at  
Figure 4375: PRO85850  
Figure 4376: DNA344942, AL390172, 226517.at  
Figure 4377: PRO95482  
Figure 4378: DNA344943, 334193.1, 226528.at  
Figure 4379: PRO95483  
Figure 4380: DNA304794, NP\_115521.2, 226541.at  
Figure 4381: PRO71206  
Figure 4382: DNA344944, 978789.5, 226545.at  
Figure 4383: PRO95484  
Figure 4384A-B: DNA344945, 237667.2, 226568.at  
Figure 4385: PRO95485  
Figure 4386A-B: DNA328031, 331264.1, 226587.at  
Figure 4387: PRO83948  
Figure 4388: DNA344946, AK098194, 226609.at  
Figure 4389: PRO95486  
Figure 4390: DNA344947, AAM76703.1, 226610.at  
Figure 4391: PRO95487  
Figure 4392: DNA344948, AF514992, 226611.s.at  
Figure 4393: DNA328033, 1446419.1, 226625.at  
Figure 4394: PRO83949  
Figure 4395: DNA344949, NP\_689775.1, 226661.at  
Figure 4396: PRO95489  
Figure 4397: DNA338349, NM\_173626, 226679.at  
Figure 4398: PRO91021  
Figure 4399A-B: DNA328035, 336832.2, 226682.at  
Figure 4400: PRO83951  
Figure 4401A-B: DNA344950, 239418.7, 226683.at  
Figure 4402: PRO95490  
Figure 4403A-C: DNA329129, NM\_007203, 226694.at  
Figure 4404: PRO84288  
Figure 4405: DNA328037, AAH16969.1, 226702.at  
Figure 4406: PRO83952  
Figure 4407: DNA344951, NP\_660202.1, 226707.at  
Figure 4408: PRO95491  
Figure 4409: DNA344952, 7762613.1, 226736.at  
Figure 4410: PRO95492  
Figure 4411A-B: DNA344953, NP\_689561.1, 226738.at  
Figure 4412: PRO95493  
Figure 4413A-B: DNA344954, 7762967.1, 226756.at  
Figure 4414: PRO95494  
Figure 4415: DNA338085, NP\_001538.2, 226757.at  
Figure 4416: PRO90963  
Figure 4417: DNA344955, 232416.1, 226759.at  
Figure 4418: PRO95495  
Figure 4419A-B: DNA344956, 898708.1, 226760.at  
Figure 4420: PRO95496  
Figure 4421A-B: DNA344957, AL832206, 226782.at  
Figure 4422: PRO95497  
Figure 4423A-B: DNA332574, 1383798.8, 226789.at  
Figure 4424: PRO87370  
Figure 4425A-B: DNA330694, 481455.4, 226810.at  
Figure 4426: PRO85865



WO 2005/019258

PCT/US2004/025788

Figure 4427: DNA328038, 216863.2, 226811.at  
 Figure 4428: PRO83953  
 Figure 4429A-B: DNA344958, NP\_115939.1, 226829.at  
 Figure 4430: PRO95498  
 Figure 4431: DNA344959, 221888.1, 226832.at  
 Figure 4432: PRO95499  
 Figure 4433: DNA344960, 999400.45, 226864.at  
 Figure 4434: PRO95500  
 Figure 4435: DNA344961, 255540.3, 226867.at  
 Figure 4436: PRO95501  
 Figure 4437: DNA344962, Z99705, 226878.at  
 Figure 4438: DNA344963, 366261.31, 226883.at  
 Figure 4439: PRO95503  
 Figure 4440: DNA330564, NP\_115885.1, 226906.s.at  
 Figure 4441: PRO85746  
 Figure 4442: DNA328044, DNA328044, 226936.at  
 Figure 4443: PRO83958  
 Figure 4444: DNA154627, DNA154627, 226976.at  
 Figure 4445: DNA344964, 7696742.1, 226982.at  
 Figure 4446: PRO95504  
 Figure 4447: DNA344965, 7769585.1, 226991.at  
 Figure 4448: PRO95505  
 Figure 4449: DNA339717, NP\_150281.1, 227006.at  
 Figure 4450: PRO91445  
 Figure 4451A-B: DNA275168, DNA275168, 227013.at  
 Figure 4452: PRO62870  
 Figure 4453: DNA344966, NP\_065170.1, 227014.at  
 Figure 4454: PRO86261  
 Figure 4455A-B: DNA330705, 198782.1, 227020.at  
 Figure 4456: PRO85876  
 Figure 4457: DNA344967, 350955.33, 227030.at  
 Figure 4458: PRO95506  
 Figure 4459A-C: DNA344968, AB055890, 227039.at  
 Figure 4460: PRO95507  
 Figure 4461: DNA344969, 7769752.1, 227052.at  
 Figure 4462: PRO95508  
 Figure 4463: DNA336061, NP\_660322.1, 227066.at  
 Figure 4464: PRO90288  
 Figure 4465: DNA344970, 7698705.3, 227074.at  
 Figure 4466: PRO95509  
 Figure 4467A-B: DNA344971, 7697931.24, 227110.at  
 Figure 4468: PRO95510  
 Figure 4469: DNA330709, 7692923.1, 227117.at  
 Figure 4470: PRO85880  
 Figure 4471: DNA344972, 7698297.2, 227124.at  
 Figure 4472: PRO95511  
 Figure 4473: DNA333713, 407443.5, 227125.at  
 Figure 4474: PRO88341  
 Figure 4475: DNA344973, AK098237, 227141.at  
 Figure 4476: PRO95512  
 Figure 4477: DNA340090, AAH07902.1, 227161.at  
 Figure 4478: PRO91590  
 Figure 4479A-B: DNA344974, NP\_689899.1, 227166.at

Figure 4480: PRO38669  
 Figure 4481: DNA344975, NP\_612350.1, 227172.at  
 Figure 4482: PRO95513  
 Figure 4483: DNA344976, 332013.1, 227177.at  
 Figure 4484: PRO95514  
 Figure 4485: DNA267411, NP\_659443.1, 227182.at  
 Figure 4486: PRO57098  
 Figure 4487A-B: DNA344977, 408890.1, 227210.at  
 Figure 4488: PRO95515  
 Figure 4489: DNA344978, AL834179, 227237.x.at  
 Figure 4490: PRO95516  
 Figure 4491A-B: DNA344979, AL833296, 227239.at  
 Figure 4492: PRO95517  
 Figure 4493: DNA330717, 232831.10, 227290.at  
 Figure 4494: PRO85888  
 Figure 4495: DNA344980, BC042036, 227291.s.at  
 Figure 4496: PRO95518  
 Figure 4497A-B: DNA344981, 337195.1, 227318.at  
 Figure 4498: PRO95519  
 Figure 4499: DNA329446, NM\_078468, 227322.s.at  
 Figure 4500: PRO85014  
 Figure 4501: DNA344982, AK097987, 227353.at  
 Figure 4502: PRO95520  
 Figure 4503: DNA336553, AK095177, 227354.at  
 Figure 4504: PRO90632  
 Figure 4505: DNA344983, 211443.3, 227357.at  
 Figure 4506: PRO95521  
 Figure 4507: DNA344984, 163230.9, 227361.at  
 Figure 4508: PRO95522  
 Figure 4509: DNA344985, BC036414, 227369.at  
 Figure 4510: PRO95523  
 Figure 4511: DNA344986, BC045695, 227379.at  
 Figure 4512: PRO95524  
 Figure 4513: DNA344987, 244251.8, 227383.at  
 Figure 4514: PRO95525  
 Figure 4515: DNA332679, 335037.7, 227396.at  
 Figure 4516: PRO87464  
 Figure 4517: DNA226872, NP\_001955.1, 227404.s.at  
 Figure 4518: PRO37335  
 Figure 4519: DNA344988, 200338.2, 227410.at  
 Figure 4520: PRO95526  
 Figure 4521: DNA344989, NP\_659486.1, 227413.at  
 Figure 4522: PRO95527  
 Figure 4523A-C: DNA344990, 410523.22, 227426.at  
 Figure 4524: PRO12910  
 Figure 4525A-B: DNA340206, NP\_079420.2, 227438.at  
 Figure 4526: PRO91701  
 Figure 4527A-B: DNA328054, 233014.1, 227458.at  
 Figure 4528: PRO83968  
 Figure 4529: DNA344991, NP\_005222.2, 227473.at  
 Figure 4530: PRO95528  
 Figure 4531A-B: DNA344992, AL832945, 227478.at  
 Figure 4532: PRO95529  
 Figure 4533: DNA344993, 221804.1, 227489.at  
 Figure 4534: PRO95530

WO 2005/019258

PCT/US2004/025788

Figure 4535: DNA344994, 197788.1, 227491.at  
 Figure 4536: PRO95531  
 Figure 4537: DNA344995, 1449825.8, 227503.at  
 Figure 4538: PRO95532  
 Figure 4539: DNA344996, 887619.55, 227517.s.at  
 Figure 4540: PRO95533  
 Figure 4541A-B: DNA331401, 336865.4, 227525.at  
 Figure 4542: PRO86465  
 Figure 4543: DNA340229, NP\_443070.1, 227552.at  
 Figure 4544: PRO91724  
 Figure 4545: DNA344997, AAM09645.1, 227560.at  
 Figure 4546: PRO95534  
 Figure 4547A-B: DNA287193, BAA92611.1, 227606.s.at  
 Figure 4548: PRO69479  
 Figure 4549: DNA330730, BC010846, 227607.at  
 Figure 4550: PRO85899  
 Figure 4551A-B: DNA344998, NM\_170709, 227627.at  
 Figure 4552: PRO95535  
 Figure 4553A-B: DNA344999, BC028212, 227645.at  
 Figure 4554: PRO95536  
 Figure 4555A-B: DNA345000, 1081047.29, 227670.at  
 Figure 4556: PRO95537  
 Figure 4557: DNA330734, NP\_116143.2, 227686.at  
 Figure 4558: PRO85903  
 Figure 4559: DNA345001, 020646.23, 227697.at  
 Figure 4560: PRO95538  
 Figure 4561: DNA323723, NP\_060658.1, 227700.x.at  
 Figure 4562: PRO80483  
 Figure 4563: DNA345002, AJ420488, 227708.at  
 Figure 4564: PRO95539  
 Figure 4565A-B: DNA333658, 1454272.17, 227755.at  
 Figure 4566: PRO88297  
 Figure 4567A-B: DNA345003, 232924.7, 227767.at  
 Figure 4568: PRO95540  
 Figure 4569: DNA332527, 028115.17, 227769.at  
 Figure 4570: PRO87344  
 Figure 4571: DNA339728, NP\_542382.1, 227787.s.at  
 Figure 4572: PRO91456  
 Figure 4573: DNA345004, 196714.3, 227798.at  
 Figure 4574: PRO95541  
 Figure 4575: DNA345005, AL137420, 227818.at  
 Figure 4576: DNA345006, NP\_689613.1, 227856.at  
 Figure 4577: PRO95543  
 Figure 4578: DNA260485, DNA260485, 227867.at  
 Figure 4579: PRO54411  
 Figure 4580: DNA336725, AY032883, 227877.at  
 Figure 4581: PRO90794  
 Figure 4582: DNA345007, 198947.2, 227889.at  
 Figure 4583: PRO95544  
 Figure 4584: DNA329481, NP\_057234.2, 227915.at  
 Figure 4585: PRO60949  
 Figure 4586: DNA329456, NM\_016042, 227916.x.at  
 Figure 4587: PRO85023  
 Figure 4588: DNA345008, 199363.8, 227930.at

Figure 4589: PRO95545  
 Figure 4590: DNA345009, 040316.1, 227944.at  
 Figure 4591: PRO95546  
 Figure 4592: DNA345010, 1101718.57, 227984.at  
 Figure 4593: PRO95547  
 Figure 4594: DNA150660, NP\_057151.1, 228019.s.at  
 Figure 4595: PRO12397  
 Figure 4596: DNA345011, 241960.67, 228030.at  
 Figure 4597: PRO95548  
 Figure 4598: DNA345012, 156397.1, 228032.s.at  
 Figure 4599: PRO95549  
 Figure 4600: DNA334778, 1383803.1, 228049.x.at  
 Figure 4601: PRO89231  
 Figure 4602: DNA331655, 1449874.3, 228053.s.at  
 Figure 4603: PRO86651  
 Figure 4604: DNA330745, NP\_612428.1, 228069.at  
 Figure 4605: PRO85913  
 Figure 4606: DNA345013, NP\_694968.1, 228071.at  
 Figure 4607: PRO23647  
 Figure 4608: DNA345014, AAH25407.1, 228080.at  
 Figure 4609: PRO95550  
 Figure 4610: DNA345015, NP\_694938.1, 228094.at  
 Figure 4611: PRO95551  
 Figure 4612: DNA330436, NP\_037394.1, 228098.s.at  
 Figure 4613: PRO85639  
 Figure 4614: DNA151725, DNA151725, 228107.at  
 Figure 4615: PRO12014  
 Figure 4616A-C: DNA330747, 200650.1, 228109.at  
 Figure 4617: PRO85915  
 Figure 4618: DNA340579, BC040547, 228113.at  
 Figure 4619: PRO92247  
 Figure 4620A-B: DNA334022, NP\_569713.1, 228167.at  
 Figure 4621: PRO88589  
 Figure 4622: DNA345016, CAD38596.1, 228245.s.at  
 Figure 4623: PRO95552  
 Figure 4624: DNA260948, DNA260948, 228273.at  
 Figure 4625: PRO54700  
 Figure 4626: DNA330755, BC020784, 228280.at  
 Figure 4627: PRO85923  
 Figure 4628: DNA345017, NP\_659455.2, 228281.at  
 Figure 4629: PRO95553  
 Figure 4630: DNA340370, DNA340370, 228283.at  
 Figure 4631: PRO91834  
 Figure 4632: DNA339731, NP\_612380.1, 228298.at  
 Figure 4633: PRO91459  
 Figure 4634: DNA345018, 333338.2, 228314.at  
 Figure 4635: PRO95554  
 Figure 4636A-B: DNA345019, 1453154.2, 228324.at  
 Figure 4637: PRO95555  
 Figure 4638: DNA345020, NM\_174889, 228355.s.at  
 Figure 4639: PRO95556  
 Figure 4640: DNA336744, BC007609, 228361.at  
 Figure 4641: PRO90814  
 Figure 4642: DNA345021, 7769848.1, 228363.at  
 Figure 4643: PRO95557

WO 2005/019258

PCT/US2004/025788

Figure 4644: DNA345022, AF378122, 228376.at  
 Figure 4645: PRO95558  
 Figure 4646: DNA330759, 337444.1, 228390.at  
 Figure 4647: PRO85926  
 Figure 4648A-B: DNA330760, 330900.8, 228401.at  
 Figure 4649: PRO85927  
 Figure 4650A-B: DNA339727, NP\_542179.1, 228410.at  
 Figure 4651: PRO91455  
 Figure 4652: DNA345023, NM\_015975, 228483.s.at  
 Figure 4653: PRO95559  
 Figure 4654A-C: DNA330761, 388991.1, 228487.s.at  
 Figure 4655: PRO85928  
 Figure 4656A-B: DNA328454, NP\_057525.1, 228496.s.at  
 Figure 4657: PRO4330  
 Figure 4658: DNA345024, 412954.22, 228532.at  
 Figure 4659: PRO95560  
 Figure 4660: DNA336376, 234038.1, 228560.at  
 Figure 4661: PRO91061  
 Figure 4662: DNA345025, 1453417.9, 228582.x.at  
 Figure 4663: PRO95561  
 Figure 4664: DNA150004, DNA150004, 228592.at  
 Figure 4665: PRO4644  
 Figure 4666: DNA345026, BC035088, 228654.at  
 Figure 4667: PRO95562  
 Figure 4668A-B: DNA345027, 7698079.3, 228658.at  
 Figure 4669: PRO95563  
 Figure 4670: DNA335393, 025911.1, 228708.at  
 Figure 4671: PRO89758  
 Figure 4672A-B: DNA345028, 7695185.17, 228722.at  
 Figure 4673: PRO95564  
 Figure 4674: DNA330772, 286623.2, 228729.at  
 Figure 4675: PRO85937  
 Figure 4676: DNA257559, NP\_116272.1, 228737.at  
 Figure 4677: PRO52129  
 Figure 4678: DNA328082, BC014851, 228762.at  
 Figure 4679: PRO83994  
 Figure 4680: DNA345029, 998974.45, 228809.at  
 Figure 4681: PRO95565  
 Figure 4682: DNA260010, DNA260010, 228812.at  
 Figure 4683: DNA330777, DNA330777, 228869.at  
 Figure 4684: PRO85941  
 Figure 4685: DNA345030, 7693726.1, 228879.at  
 Figure 4686: PRO95566  
 Figure 4687: DNA345031, 021903.1, 228910.at  
 Figure 4688: PRO95567  
 Figure 4689: DNA345032, 1087130.10, 228931.at  
 Figure 4690: PRO95568  
 Figure 4691: DNA329447, BC016981, 228948.at  
 Figure 4692: PRO85015  
 Figure 4693A-B: DNA345033, AY198415, 228964.at  
 Figure 4694: PRO95569  
 Figure 4695A-B: DNA340099, BC028424, 228980.at  
 Figure 4696: PRO91599  
 Figure 4697: DNA345034, AL137573, 229007.at

Figure 4698: PRO95570  
 Figure 4699A-B: DNA336693, NP\_277037.1, 229016.s.at  
 Figure 4700: PRO90766  
 Figure 4701: DNA330786, 233085.1, 229029.at  
 Figure 4702: PRO85950  
 Figure 4703: DNA336085, DNA336085, 229041.s.at  
 Figure 4704: PRO90304  
 Figure 4705: DNA330777, 330848.1, 229045.at  
 Figure 4706: PRO85941  
 Figure 4707: DNA345035, BAC04479.1, 229065.at  
 Figure 4708: PRO95571  
 Figure 4709: DNA330790, NP\_116133.1, 229070.at  
 Figure 4710: PRO85954  
 Figure 4711: DNA330791, 7697349.2, 229072.at  
 Figure 4712: PRO85955  
 Figure 4713: DNA332520, 344561.1, 229101.at  
 Figure 4714: PRO87337  
 Figure 4715A-B: DNA345036, 468481.1, 229116.at  
 Figure 4716: PRO95572  
 Figure 4717A-D: DNA345037, 903479.18, 229287.at  
 Figure 4718: PRO95573  
 Figure 4719: DNA333664, 237320.4, 229295.at  
 Figure 4720: PRO88303  
 Figure 4721A-B: DNA255352, AB033060, 229354.at  
 Figure 4722: DNA345038, NM\_024711, 229367.s.at  
 Figure 4723: PRO95574  
 Figure 4724: DNA345039, 199232.2, 229390.at  
 Figure 4725: PRO57551  
 Figure 4726: DNA255197, DNA255197, 229391.s.at  
 Figure 4727: PRO50276  
 Figure 4728: DNA335178, AF402776, 229437.at  
 Figure 4729: PRO69678  
 Figure 4730: DNA330797, 211332.1, 229442.at  
 Figure 4731: PRO85961  
 Figure 4732: DNA328090, 007911.2, 229450.at  
 Figure 4733: PRO84001  
 Figure 4734A-B: DNA237810, DNA237810, 229490.s.at  
 Figure 4735: PRO38918  
 Figure 4736: DNA338094, AK093350, 229521.at  
 Figure 4737: PRO90970  
 Figure 4738: DNA330799, 481875.1, 229551.x.at  
 Figure 4739: PRO85963  
 Figure 4740: DNA334937, BAB71227.1, 229553.at  
 Figure 4741: PRO89370  
 Figure 4742A-B: DNA345040, 451858.13, 229572.at  
 Figure 4743: PRO95575  
 Figure 4744A-B: DNA345041, AL834393, 229594.at  
 Figure 4745: DNA345042, NP\_689831.1, 229603.at  
 Figure 4746: PRO95577  
 Figure 4747: DNA345043, 401253.39, 229604.at  
 Figure 4748: PRO95578  
 Figure 4749: DNA345044, BC025714, 229606.at  
 Figure 4750: PRO95579  
 Figure 4751: DNA333760, 098138.1, 229629.at

WO 2005/019258

PCT/US2004/025788

Figure 4752: PRO88384  
 Figure 4753: DNA345045, BC034328, 229638.at  
 Figure 4754: DNA345046, AL833184, 229686.at  
 Figure 4755: PRO95581  
 Figure 4756: DNA334491, 428695.5, 229725.at  
 Figure 4757: PRO88993  
 Figure 4758A-B: DNA227985, NP\_055107.1, 229733.s.at  
 Figure 4759: PRO38448  
 Figure 4760: DNA345047, 979808.6, 229764.at  
 Figure 4761: PRO95582  
 Figure 4762: DNA330807, 334422.1, 229814.at  
 Figure 4763: PRO85971  
 Figure 4764: DNA345048, 7683061.1, 229841.at  
 Figure 4765: PRO95583  
 Figure 4766: DNA345049, NP\_694579.1, 229901.at  
 Figure 4767: PRO81858  
 Figure 4768: DNA333743, 243761.3, 229937.x.at  
 Figure 4769: PRO88368  
 Figure 4770: DNA345050, 221062.1, 229954.at  
 Figure 4771: PRO95584  
 Figure 4772A-B: DNA345051, NP\_722579.1, 229971.at  
 Figure 4773: PRO6017  
 Figure 4774: DNA345052, NP\_689413.1, 229980.s.at  
 Figure 4775: PRO69560  
 Figure 4776: DNA330811, 1382987.2, 230000.at  
 Figure 4777: PRO85975  
 Figure 4778: DNA338348, BAC03808.1, 230012.at  
 Figure 4779: PRO91019  
 Figure 4780: DNA345053, AL834186, 230060.at  
 Figure 4781: PRO95585  
 Figure 4782: DNA332487, DNA332487, 230110.at  
 Figure 4783: PRO87315  
 Figure 4784: DNA345054, 064937.11, 230141.at  
 Figure 4785: PRO95586  
 Figure 4786: DNA345055, NP\_065391.1, 230170.at  
 Figure 4787: PRO88  
 Figure 4788: DNA345056, AL831898, 230179.at  
 Figure 4789: PRO95587  
 Figure 4790A-B: DNA345057, AL713763, 230180.at  
 Figure 4791: PRO95588  
 Figure 4792: DNA345058, AL832695, 230192.at  
 Figure 4793: DNA345059, 229293.16, 230206.at  
 Figure 4794: PRO95590  
 Figure 4795: DNA345060, 7692383.1, 230226.s.at  
 Figure 4796: PRO95591  
 Figure 4797: DNA345061, AK058039, 230292.at  
 Figure 4798: PRO95592  
 Figure 4799: DNA330818, 212282.1, 230304.at  
 Figure 4800: PRO85982  
 Figure 4801: DNA345062, 403834.1, 230383.x.at  
 Figure 4802: PRO95593  
 Figure 4803: DNA330822, 332195.1, 230391.at  
 Figure 4804: PRO85986  
 Figure 4805A-B: DNA345063, 234102.72, 230425.at

Figure 4806: PRO95594  
 Figure 4807: DNA345064, NP\_653312.1, 230434.at  
 Figure 4808: PRO95595  
 Figure 4809: DNA330712, 1452648.12, 230466.s.at  
 Figure 4810: PRO85883  
 Figure 4811A-B: DNA330824, 333480.5, 230489.at  
 Figure 4812: PRO85988  
 Figure 4813: DNA332672, 335924.1, 230494.at  
 Figure 4814: PRO87457  
 Figure 4815: DNA332827, NP\_660356.1, 230563.at  
 Figure 4816: PRO87594  
 Figure 4817: DNA345065, 234921.2, 230570.at  
 Figure 4818: PRO95596  
 Figure 4819A-C: DNA254793, NP\_055987.1, 230618.s.at  
 Figure 4820: PRO49890  
 Figure 4821: DNA328098, 402974.1, 230653.at  
 Figure 4822: PRO84008  
 Figure 4823: DNA257789, NP\_116219.1, 230656.s.at  
 Figure 4824: PRO52338  
 Figure 4825: DNA340247, DNA340247, 230753.at  
 Figure 4826: PRO91742  
 Figure 4827: DNA345066, AAH29505.1, 230756.at  
 Figure 4828: PRO95597  
 Figure 4829: DNA336379, 401125.10, 230795.at  
 Figure 4830: PRO90514  
 Figure 4831: DNA345067, 1132645.25, 230805.at  
 Figure 4832: PRO95598  
 Figure 4833: DNA332685, 234194.1, 230836.at  
 Figure 4834: PRO87470  
 Figure 4835: DNA338109, 211204.3, 230866.at  
 Figure 4836: PRO90980  
 Figure 4837: DNA336019, DNA336019, 230970.at  
 Figure 4838: DNA345068, 407233.3, 231093.at  
 Figure 4839: PRO95599  
 Figure 4840: DNA329405, AL117452, 231094.s.at  
 Figure 4841: DNA345069, 895820.1, 231106.at  
 Figure 4842: PRO95600  
 Figure 4843: DNA329473, 370473.13, 231124.x.at  
 Figure 4844: PRO85038  
 Figure 4845A-B: DNA226303, DNA226303, 231259.s.at  
 Figure 4846: PRO36766  
 Figure 4847A-B: DNA339703, NP\_115970.2, 231396.s.at  
 Figure 4848: PRO91433  
 Figure 4849: DNA338354, DNA338354, 231576.at  
 Figure 4850: PRO91025  
 Figure 4851: DNA150808, M55542, 231577.s.at  
 Figure 4852: PRO12478  
 Figure 4853: DNA345070, NP\_006630.1, 231747.at  
 Figure 4854: PRO34958  
 Figure 4855: DNA330839, NP\_060908.1, 231769.at  
 Figure 4856: PRO86002  
 Figure 4857: DNA331119, NP\_005433.2, 231776.at  
 Figure 4858: PRO50745

WO 2005/019258

PCT/US2004/025788

Figure 4859: DNA335123, AK027521, 231837.at  
Figure 4860: PRO89526  
Figure 4861: DNA345071, 1512952.7, 231866.at  
Figure 4862: PRO95601  
Figure 4863A-C: DNA339989, BAB21817.1, 231899.at  
Figure 4864: PRO91497  
Figure 4865A-B: DNA329476, 205127.1, 231929.at  
Figure 4866: PRO85040  
Figure 4867A-B: DNA256267, BAB13444.1, 231956.at  
Figure 4868: PRO51311  
Figure 4869: DNA345072, 978672.3, 232000.at  
Figure 4870: PRO95602  
Figure 4871: DNA345073, NP\_056475.1, 232024.at  
Figure 4872: PRO95603  
Figure 4873: DNA323732, NM\_016176, 232032.x.at  
Figure 4874: PRO80490  
Figure 4875: DNA330852, 1383611.1, 232138.at  
Figure 4876: PRO86015  
Figure 4877: DNA329094, NP\_077285.1, 232160.s.at  
Figure 4878: PRO84746  
Figure 4879: DNA345074, 1077685.1, 232230.at  
Figure 4880: PRO95604  
Figure 4881: DNA345075, AJ278112, 232278.s.at  
Figure 4882: PRO95605  
Figure 4883: DNA329393, AF367998, 232296.s.at  
Figure 4884: PRO84969  
Figure 4885: DNA330862, 339154.9, 232304.at  
Figure 4886: PRO86025  
Figure 4887A-B: DNA340232, NP\_443169.1, 232382.s.at  
Figure 4888: PRO91727  
Figure 4889: DNA328117, U25029, 232431.at  
Figure 4890: PRO84024  
Figure 4891: DNA340435, DNA340435, 232504.at  
Figure 4892: DNA329286, NP\_005691.2, 232510.s.at  
Figure 4893: PRO69644  
Figure 4894: DNA330868, 337037.1, 232584.at  
Figure 4895: PRO86031  
Figure 4896: DNA340361, DNA340361, 232615.at  
Figure 4897: DNA345076, 143540.3, 232682.at  
Figure 4898: PRO95606  
Figure 4899: DNA330869, 406591.1, 232687.at  
Figure 4900: PRO86032  
Figure 4901: DNA270329, DNA270329, 232737.s.at  
Figure 4902: PRO58716  
Figure 4903: DNA330870, 227719.1, 232883.at  
Figure 4904: PRO86033  
Figure 4905: DNA325531, NM\_032379, 232914.s.at  
Figure 4906: PRO82038  
Figure 4907: DNA345077, AK022251, 233089.at  
Figure 4908: PRO95607  
Figure 4909: DNA336161, NP\_060857.2, 233252.s.at  
Figure 4910: PRO90356  
Figure 4911A-B: DNA340168, NM\_017693, 233255.s.at  
Figure 4912: PRO91663  
Figure 4913: DNA324156, NM\_032212, 233341.s.at  
Figure 4914: PRO80856  
Figure 4915: DNA331423, AF176071, 233467.s.at  
Figure 4916A-B: DNA331391, NP\_065947.1, 233734.s.at  
Figure 4917: PRO49998  
Figure 4918: DNA335477, 209190.1, 233800.at  
Figure 4919: PRO89830  
Figure 4920A-B: DNA345078, 474673.14, 233849.s.at  
Figure 4921: PRO95608  
Figure 4922: DNA329481, NM\_016150, 233857.s.at  
Figure 4923: PRO60949  
Figure 4924A-B: DNA338110, 1382987.31, 233880.at  
Figure 4925: PRO90981  
Figure 4926: DNA345079, NP\_057023.2, 233970.s.at  
Figure 4927: PRO84916  
Figure 4928: DNA331687, D13078, 234013.at  
Figure 4929: PRO86682  
Figure 4930: DNA333607, 211626.1, 234151.at  
Figure 4931: PRO88251  
Figure 4932: DNA345080, 401293.1, 234260.at  
Figure 4933: PRO95609  
Figure 4934A-B: DNA345081, NP\_057422.2, 234304.s.at  
Figure 4935: PRO95610  
Figure 4936: DNA330881, NP\_067004.3, 234306.s.at  
Figure 4937: PRO1138  
Figure 4938: DNA329312, NM\_005214, 234362.s.at  
Figure 4939: PRO84901  
Figure 4940: DNA345082, 1452291.29, 234398.at  
Figure 4941: PRO95611  
Figure 4942: DNA345083, S60795, 234402.at  
Figure 4943: PRO95612  
Figure 4944: DNA345084, NP\_443104.1, 234408.at  
Figure 4945: PRO20110  
Figure 4946: DNA345085, AAA61109.1, 234440.at  
Figure 4947: PRO95613  
Figure 4948A-C: DNA339394, NP\_055768.2, 234660.s.at  
Figure 4949: PRO91199  
Figure 4950: DNA345086, BAB15056.1, 234785.at  
Figure 4951: PRO95614  
Figure 4952: DNA345087, X04937, 234819.at  
Figure 4953: PRO95615  
Figure 4954: DNA345088, CAA29554.1, 234849.at  
Figure 4955: PRO95616  
Figure 4956A-C: DNA345089, AJ238394, 234928.x.at  
Figure 4957: PRO95617  
Figure 4958: DNA330882, 406739.1, 234974.at  
Figure 4959: PRO86044  
Figure 4960: DNA345090, NM\_052913, 234994.at  
Figure 4961: PRO95618

WO 2005/019258

PCT/US2004/025788

Figure 4962: DNA258761, DNA258761, 235019.at  
 Figure 4963A-B: DNA345091, 135369.13, 235020.at  
 Figure 4964: PRO95619  
 Figure 4965: DNA339413, DNA339413, 235046.at  
 Figure 4966A-B: DNA345092, 292261.1, 235048.at  
 Figure 4967: PRO95620  
 Figure 4968A-B: DNA340485, BAC56923.1, 235085.at  
 Figure 4969: PRO92206  
 Figure 4970: DNA345093, 337920.2, 235104.at  
 Figure 4971: PRO95621  
 Figure 4972: DNA328146, BC025376, 235117.at  
 Figure 4973: PRO84051  
 Figure 4974: DNA333752, 200228.1, 235199.at  
 Figure 4975: PRO88377  
 Figure 4976: DNA345094, 1384081.2, 235203.at  
 Figure 4977: PRO95622  
 Figure 4978: DNA330896, 250896.1, 235213.at  
 Figure 4979: PRO86057  
 Figure 4980: DNA345095, 131102.1, 235230.at  
 Figure 4981: PRO95623  
 Figure 4982: DNA324093, NP\_620156.1, 235256.s.at  
 Figure 4983: PRO80802  
 Figure 4984: DNA336016, DNA336016, 235291.s.at  
 Figure 4985: DNA345096, 237100.26, 235292.at  
 Figure 4986: PRO95624  
 Figure 4987: DNA330898, 227608.1, 235299.at  
 Figure 4988: PRO86059  
 Figure 4989A-B: DNA345097, NP\_783161.1, 235306.at  
 Figure 4990: PRO86060  
 Figure 4991: DNA328151, 982500.1, 235352.at  
 Figure 4992: PRO84056  
 Figure 4993A-C: DNA345098, AL832877, 235410.at  
 Figure 4994: PRO95625  
 Figure 4995A-B: DNA345099, AF133211, 235421.at  
 Figure 4996: PRO95626  
 Figure 4997A-B: DNA345100, NP\_689737.1, 235425.at  
 Figure 4998: PRO95627  
 Figure 4999A-B: DNA345101, 979268.1, 235440.at  
 Figure 5000: PRO95628  
 Figure 5001: DNA257872, DNA257872, 235457.at  
 Figure 5002: DNA330906, NP\_116171.2, 235458.at  
 Figure 5003: PRO86067  
 Figure 5004A-B: DNA345102, AAH30800.1, 235463.s.at  
 Figure 5005: PRO95629  
 Figure 5006: DNA345103, NP\_689629.1, 235509.at  
 Figure 5007: PRO95630  
 Figure 5008: DNA330912, 984873.1, 235609.at  
 Figure 5009: PRO86073  
 Figure 5010A-B: DNA336026, AB095926, 235643.at  
 Figure 5011: DNA345104, 1448915.1, 235680.at  
 Figure 5012: PRO95631  
 Figure 5013: DNA336165, AF368463, 235706.at  
 Figure 5014: PRO84371  
 Figure 5015: DNA345105, NP\_689674.1, 235745.at  
 Figure 5016: PRO95632  
 Figure 5017A-B: DNA335175, DNA335175, 235971.at  
 Figure 5018: PRO89566  
 Figure 5019A-B: DNA345106, 244378.1, 236125.at  
 Figure 5020: PRO49375  
 Figure 5021: DNA336348, 1512910.2, 236203.at  
 Figure 5022: PRO90492  
 Figure 5023: DNA331211, 392245.1, 236226.at  
 Figure 5024: PRO86341  
 Figure 5025: DNA335691, DNA335691, 236280.at  
 Figure 5026: PRO12646  
 Figure 5027: DNA345107, AF488410, 236313.at  
 Figure 5028A-B: DNA345108, AF318353, 236322.at  
 Figure 5029: PRO95634  
 Figure 5030: DNA329312, AF414120, 236341.at  
 Figure 5031: PRO84901  
 Figure 5032: DNA333653, 325998.1, 236435.at  
 Figure 5033: PRO88292  
 Figure 5034: DNA345109, 7763130.1, 236471.at  
 Figure 5035: PRO95635  
 Figure 5036: DNA328168, 179804.1, 236474.at  
 Figure 5037: PRO84071  
 Figure 5038: DNA345110, 7691553.11, 236488.s.at  
 Figure 5039: PRO95636  
 Figure 5040: DNA330934, DNA330934, 236595.at  
 Figure 5041: PRO86095  
 Figure 5042: DNA330935, 229915.1, 236610.at  
 Figure 5043: PRO86096  
 Figure 5044: DNA345111, 414146.8, 236717.at  
 Figure 5045: PRO95637  
 Figure 5046: DNA329491, DNA329491, 236787.at  
 Figure 5047: DNA330939, 214517.1, 236796.at  
 Figure 5048: PRO86100  
 Figure 5049: DNA345112, AK074237, 236984.at  
 Figure 5050: PRO95638  
 Figure 5051: DNA330943, 1042935.2, 237009.at  
 Figure 5052: PRO86104  
 Figure 5053: DNA345113, 7762795.1, 237105.at  
 Figure 5054: PRO95639  
 Figure 5055A-B: DNA226536, NM\_003234, 237215.s.at  
 Figure 5056: PRO36999  
 Figure 5057: DNA345114, BC032694, 237559.at  
 Figure 5058: PRO78081  
 Figure 5059: DNA328178, 985267.1, 237839.at  
 Figure 5060: PRO84081  
 Figure 5061: DNA330950, 983684.2, 237953.at  
 Figure 5062: PRO86111  
 Figure 5063A-B: DNA345115, 062186.18, 238002.at  
 Figure 5064: PRO60111  
 Figure 5065: DNA345116, BC033490, 238018.at  
 Figure 5066: PRO95640  
 Figure 5067A-B: DNA330952, 333610.10,

WO 2005/019258

PCT/US2004/025788

238021.s.at  
 Figure 5068: PRO86113  
 Figure 5069: DNA345117, 333610.2, 238022.at  
 Figure 5070: PRO95641  
 Figure 5071: DNA345118, 337083.5, 238075.at  
 Figure 5072: PRO95642  
 Figure 5073: DNA329492, 017295.1, 238156.at  
 Figure 5074: PRO85053  
 Figure 5075: DNA345119, 331249.6, 238520.at  
 Figure 5076: PRO95643  
 Figure 5077: DNA329495, 1447201.1, 238581.at  
 Figure 5078: PRO85056  
 Figure 5079: DNA329497, 232064.1, 238619.at  
 Figure 5080: PRO85058  
 Figure 5081A-B: DNA345120, 1400266.11, 238649.at  
 Figure 5082: PRO95644  
 Figure 5083: DNA334895, 172305.1, 238787.at  
 Figure 5084: PRO89333  
 Figure 5085: DNA328188, 7688626.1, 238875.at  
 Figure 5086: PRO84091  
 Figure 5087: DNA345121, 255109.1, 238900.at  
 Figure 5088: PRO95645  
 Figure 5089: DNA329500, 214454.1, 238950.at  
 Figure 5090: PRO85061  
 Figure 5091A-C: DNA345122, NM\_018136, 239002.at  
 Figure 5092: PRO95646  
 Figure 5093A-B: DNA345123, 086440.4, 239151.at  
 Figure 5094: PRO95647  
 Figure 5095: DNA335753, 408088.2, 239179.at  
 Figure 5096: PRO90062  
 Figure 5097: DNA345124, 7685093.8, 239237.at  
 Figure 5098: PRO95648  
 Figure 5099: DNA345125, 401336.15, 239288.at  
 Figure 5100: PRO95649  
 Figure 5101: DNA333746, 332697.1, 239294.at  
 Figure 5102: PRO88371  
 Figure 5103: DNA345126, AL713733, 239412.at  
 Figure 5104: PRO95650  
 Figure 5105: DNA329502, 210572.1, 239427.at  
 Figure 5106: PRO85063  
 Figure 5107: DNA330983, 305289.1, 239448.at  
 Figure 5108: PRO86142  
 Figure 5109: DNA345127, 1397901.50, 239629.at  
 Figure 5110: PRO95651  
 Figure 5111: DNA333632, 247565.1, 240064.at  
 Figure 5112: PRO88274  
 Figure 5113: DNA330314, 026641.5, 240265.at  
 Figure 5114: PRO85538  
 Figure 5115: DNA340269, DNA340269, 240572.s.at  
 Figure 5116: PRO91765  
 Figure 5117A-B: DNA345128, NM\_175571, 240646.at  
 Figure 5118: PRO86060  
 Figure 5119: DNA345129, 217952.1, 240789.at  
 Figure 5120: PRO95652

Figure 5121: DNA345130, 231676.2, 240951.at  
 Figure 5122: PRO95653  
 Figure 5123: DNA345131, NM\_139273, 240983.s.at  
 Figure 5124: PRO95654  
 Figure 5125: DNA345132, 227682.1, 241393.at  
 Figure 5126: PRO95655  
 Figure 5127: DNA345133, BC016950, 241682.at  
 Figure 5128: PRO95656  
 Figure 5129: DNA345134, 212515.1, 241819.at  
 Figure 5130: PRO24261  
 Figure 5131: DNA331011, 979953.1, 241859.at  
 Figure 5132: PRO86169  
 Figure 5133: DNA345135, AK074645, 241869.at  
 Figure 5134: PRO95657  
 Figure 5135: DNA329506, NP\_387510.1, 241937.s.at  
 Figure 5136: PRO85067  
 Figure 5137: DNA345136, 264653.1, 241956.at  
 Figure 5138: PRO95658  
 Figure 5139: DNA331015, 109159.1, 242031.at  
 Figure 5140: PRO86173  
 Figure 5141: DNA345137, 072859.8, 242146.at  
 Figure 5142: PRO95659  
 Figure 5143: DNA345138, 1502644.28, 242520.s.at  
 Figure 5144: PRO95660  
 Figure 5145A-B: DNA345139, AB067489, 242665.at  
 Figure 5146: DNA331031, 405967.1, 242669.at  
 Figure 5147: PRO86189  
 Figure 5148A-B: DNA345140, NM\_015979, 242706.s.at  
 Figure 5149: PRO85734  
 Figure 5150: DNA345141, 7698324.1, 242939.at  
 Figure 5151: PRO95662  
 Figure 5152: DNA329507, 407430.1, 242943.at  
 Figure 5153: PRO85068  
 Figure 5154: DNA335321, 350834.1, 243049.at  
 Figure 5155: PRO89696  
 Figure 5156: DNA345142, 011019.14, 243124.at  
 Figure 5157: PRO95663  
 Figure 5158: DNA345143, AL833716, 243166.at  
 Figure 5159: PRO95664  
 Figure 5160A-B: DNA329508, 142131.16, 243296.at  
 Figure 5161: PRO85069  
 Figure 5162: DNA345144, 407288.1, 243386.at  
 Figure 5163: PRO95665  
 Figure 5164: DNA345145, 994948.45, 243405.at  
 Figure 5165: PRO95666  
 Figure 5166: DNA331051, 306804.1, 243469.at  
 Figure 5167: PRO86209  
 Figure 5168A-B: DNA345146, 331965.1, 243495.s.at  
 Figure 5169: PRO52796  
 Figure 5170: DNA333748, 394811.1, 243602.at  
 Figure 5171: PRO88373  
 Figure 5172: DNA345147, 315972.1, 243788.at  
 Figure 5173: PRO95667  
 Figure 5174: DNA345148, 086440.19, 243937.x.at  
 Figure 5175: PRO95668

WO 2005/019258

PCT/US2004/025788

Figure 5176A-B: DNA329494, 978990.1, 243999.at  
 Figure 5177: PRO85055  
 Figure 5178: DNA345149, 1009940.1, 244042.x.at  
 Figure 5179: PRO95669  
 Figure 5180: DNA335678, 432509.1, 244044.at  
 Figure 5181: PRO90006  
 Figure 5182: DNA334339, DNA334339, 244267.at  
 Figure 5183: PRO86220  
 Figure 5184: DNA345150, 333325.3, 244308.at  
 Figure 5185: PRO95670  
 Figure 5186: DNA328237, 337066.49, 244383.at  
 Figure 5187: PRO84140  
 Figure 5188A-B: DNA345151, NP\_689742.2, 244509.at  
 Figure 5189: PRO95671  
 Figure 5190: DNA334446, 207194.3, 244579.at  
 Figure 5191: PRO88952  
 Figure 5192: DNA333766, 215245.1, 244598.at  
 Figure 5193: PRO88390  
 Figure 5194: DNA345152, 032035.3, 244764.at  
 Figure 5195: PRO95672  
 Figure 5196: DNA331069, DNA331069, 244798.at  
 Figure 5197: PRO86226  
 Figure 5198A-B: DNA328729, BAA11496.1, D80001.at  
 Figure 5199: PRO38526  
 Figure 5200: DNA328961, BC011049, DNA36995.at  
 Figure 5201: PRO84667  
 Figure 5202: DNA304492, NM\_032016, DNA45409.at  
 Figure 5203: PRO1864  
 Figure 5204: DNA327200, NM\_031950, DNA59602.at  
 Figure 5205: PRO1065  
 Figure 5206: DNA345153, BC031639, DNA61875.at  
 Figure 5207: PRO83478  
 Figure 5208: DNA345154, NP\_002174.1, DNA82348.at  
 Figure 5209: PRO2021  
 Figure 5210: DNA327667, NP\_065392.1, DNA84141.at  
 Figure 5211: PRO83135  
 Figure 5212: DNA325850, NM\_024089, DNA84917.at  
 Figure 5213: PRO82312  
 Figure 5214: DNA325654, NM\_014033, DNA92232.at  
 Figure 5215: PRO4348  
 Figure 5216A-B: DNA345155, NM\_153837, DNA96860.at  
 Figure 5217: PRO6017  
 Figure 5218: DNA96866, DNA96866, DNA96866.at  
 Figure 5219: PRO6015  
 Figure 5220: DNA331073, NP\_112184.1, DNA101926.at  
 Figure 5221: PRO86229

Figure 5222: DNA108681, DNA108681, DNA108681.at  
 Figure 5223: PRO6492  
 Figure 5224: DNA329215, NM\_012092, DNA108917.at  
 Figure 5225: PRO7424  
 Figure 5226: DNA345156, BC047595, DNA119482.at  
 Figure 5227: PRO9850  
 Figure 5228A-B: DNA345157, BAA86515.1, DNA132162.at  
 Figure 5229: PRO95673  
 Figure 5230: DNA345158, BC044246, DNA139546.at  
 Figure 5231: PRO95674  
 Figure 5232: DNA324246, NM\_030926, DNA143288.at  
 Figure 5233: PRO80930  
 Figure 5234A-B: DNA150956, D31887, DNA150956.at  
 Figure 5235: DNA304833, NP\_443163.1, DNA161000.at  
 Figure 5236: PRO71240  
 Figure 5237: DNA330417, NP\_085144.1, DNA164989.at  
 Figure 5238: PRO21341  
 Figure 5239: DNA345159, BC050675, P\_Z93700.at  
 Figure 5240: PRO95675  
 Figure 5241: DNA329207, AL442092, P\_X52226.at  
 Figure 5242: PRO220  
 Figure 5243: DNA345160, BC025407, P\_X52238.at  
 Figure 5244: PRO95676  
 Figure 5245: DNA345161, BC009955, P\_Z34109.at  
 Figure 5246A-B: DNA330610, BAB15739.1, P\_A37063.at  
 Figure 5247: PRO85787  
 Figure 5248: DNA328250, NP\_443164.1, P\_Z65107.at  
 Figure 5249: PRO82061  
 Figure 5250: DNA304469, NP\_149078.1, P\_A37079.at  
 Figure 5251: PRO71045  
 Figure 5252: DNA345162, NM\_153206, P\_Z65110.at  
 Figure 5253: PRO95678  
 Figure 5254: DNA345163, NM\_171846, P\_A37128.at  
 Figure 5255: PRO95679  
 Figure 5256A-C: DNA345164, NM\_020477, NM\_000037.at  
 Figure 5257: PRO95680  
 Figure 5258: DNA109234, NM\_000074, NM\_000074.at  
 Figure 5259: PRO6517  
 Figure 5260: DNA325711, NM\_000075, NM\_000075.at  
 Figure 5261: PRO4873  
 Figure 5262: DNA227514, NP\_000152.1, NM\_000161.at  
 Figure 5263: PRO37977  
 Figure 5264: DNA287630, NM\_000169, NM\_000169.at



WO 2005/019258

PCT/US2004/025788

Figure 5265: PRO2154  
 Figure 5266: DNA328612, NP\_000166.2, NM\_000175.at  
 Figure 5267: PRO84394  
 Figure 5268: DNA76511, NP\_000197.1, NM\_000206.at  
 Figure 5269: PRO2539  
 Figure 5270A-B: DNA220748, NM\_000210, NM\_000210.at  
 Figure 5271: PRO34726  
 Figure 5272: DNA88450, NM\_000235, NM\_000235.at  
 Figure 5273: PRO2795  
 Figure 5274: DNA226014, NM\_000239, NM\_000239.at  
 Figure 5275: PRO36477  
 Figure 5276: DNA227071, NM\_000269, NM\_000269.at  
 Figure 5277: PRO37534  
 Figure 5278: DNA226078, NP\_000296.1, NM\_000305.at  
 Figure 5279: PRO36541  
 Figure 5280: DNA226082, NP\_000301.1, NM\_000310.at  
 Figure 5281: PRO36545  
 Figure 5282A-B: DNA226395, NM\_000321, NM\_000321.at  
 Figure 5283: PRO36858  
 Figure 5284A-C: DNA345165, AF039704, NM\_000391.at  
 Figure 5285: DNA227081, NP\_000390.2, NM\_000399.at  
 Figure 5286: PRO37544  
 Figure 5287: DNA76514, NM\_000418, NM\_000418.at  
 Figure 5288: PRO2540  
 Figure 5289: DNA88549, M28526, NM\_000442.at  
 Figure 5290: PRO2408  
 Figure 5291A-E: DNA226238, NM\_000540, NM\_000540.at  
 Figure 5292A-B: PRO36701  
 Figure 5293: DNA83046, M31516, NM\_000574.at  
 Figure 5294: PRO2569  
 Figure 5295A-B: DNA227659, NM\_000579, NM\_000579.at  
 Figure 5296: PRO38122  
 Figure 5297: DNA345166, NM\_000584, NM\_000584.at  
 Figure 5298: PRO74  
 Figure 5299: DNA345167, NM\_000588, NM\_000588.at  
 Figure 5300: PRO95682  
 Figure 5301: DNA36717, NM\_000590, NM\_000590.at  
 Figure 5302: PRO72  
 Figure 5303: DNA345168, NM\_000593, NM\_000593.at  
 Figure 5304: PRO36996  
 Figure 5305: DNA218655, M10988, NM\_000594.at

Figure 5306: PRO34451  
 Figure 5307: DNA35629, NM\_000595, NM\_000595.at  
 Figure 5308: PRO7  
 Figure 5309: DNA225829, M59040, NM\_000610.at  
 Figure 5310: PRO36292  
 Figure 5311: DNA345169, NP\_000607.1, NM\_000616.at  
 Figure 5312: PRO2222  
 Figure 5313: DNA225528, NM\_000619, NM\_000619.at  
 Figure 5314: PRO35991  
 Figure 5315: DNA227597, NM\_000636, NM\_000636.at  
 Figure 5316: PRO38060  
 Figure 5317: DNA188234, NM\_000639, NM\_000639.at  
 Figure 5318: PRO21942  
 Figure 5319: DNA331493, NM\_000647, NM\_000647.at  
 Figure 5320: PRO84690  
 Figure 5321: DNA225993, NM\_000655, NM\_000655.at  
 Figure 5322: PRO36456  
 Figure 5323: DNA89242, NM\_000700, NM\_000700.at  
 Figure 5324: PRO2907  
 Figure 5325: DNA88194, NM\_000733, NM\_000733.at  
 Figure 5326: PRO2220  
 Figure 5327: DNA90631, NM\_000756, NM\_000756.at  
 Figure 5328: PRO2519  
 Figure 5329: DNA345170, NM\_000758, NM\_000758.at  
 Figure 5330: PRO2055  
 Figure 5331A-B: DNA226870, DNA226870, NM\_000791.at  
 Figure 5332: PRO37333  
 Figure 5333: DNA151820, NM\_000860, NM\_000860.at  
 Figure 5334: PRO12194  
 Figure 5335A-B: DNA345171, NP\_000868.1, NM\_000877.at  
 Figure 5336: PRO2590  
 Figure 5337A-B: DNA331484, NM\_000878, NM\_000878.at  
 Figure 5338: PRO3276  
 Figure 5339: DNA345172, NM\_000879, NM\_000879.at  
 Figure 5340: PRO69  
 Figure 5341A-B: DNA220746, NM\_000885, NM\_000885.at  
 Figure 5342: PRO34724  
 Figure 5343: DNA220761, NM\_000889, NM\_000889.at  
 Figure 5344: PRO34739  
 Figure 5345A-B: DNA345173, NM\_138822, NM\_000919.at  
 Figure 5346: PRO95683

WO 2005/019258

PCT/US2004/025788

Figure 5347: DNA326011, NP\_000933.1, NM\_000942.at  
 Figure 5348: PRO2720  
 Figure 5349: DNA227709, NM\_000956, NM\_000956.at  
 Figure 5350: PRO38172  
 Figure 5351: DNA226195, NM\_000958, NM\_000958.at  
 Figure 5352: PRO36658  
 Figure 5353A-B: DNA226070, NM\_000963, NM\_000963.at  
 Figure 5354: PRO36533  
 Figure 5355A-B: DNA333708, NM\_001066, NM\_001066.at  
 Figure 5356: PRO21928  
 Figure 5357A-B: DNA150748, NM\_001114, NM\_001114.at  
 Figure 5358: PRO12446  
 Figure 5359: DNA225584, NM\_001154, NM\_001154.at  
 Figure 5360: PRO36047  
 Figure 5361A-B: DNA325972, NM\_001211, NM\_001211.at  
 Figure 5362: PRO82417  
 Figure 5363: DNA327718, NM\_033307, NM\_001225.at  
 Figure 5364: PRO83697  
 Figure 5365: DNA287267, NP\_001228.1, NM\_001237.at  
 Figure 5366: PRO37015  
 Figure 5367: DNA226177, NM\_001295, NM\_001295.at  
 Figure 5368: PRO36640  
 Figure 5369: DNA331744, NM\_001335, NM\_001335.at  
 Figure 5370: PRO1574  
 Figure 5371: DNA226182, NP\_001391.2, NM\_001400.at  
 Figure 5372: PRO36645  
 Figure 5373: DNA227344, NP\_001403.1, NM\_001412.at  
 Figure 5374: PRO37807  
 Figure 5375: DNA97300, NP\_001407.1, NM\_001416.at  
 Figure 5376: PRO3647  
 Figure 5377: DNA188346, NM\_001459, NM\_001459.at  
 Figure 5378: PRO21766  
 Figure 5379: DNA227752, X95876, NM\_001504.at  
 Figure 5380: PRO38215  
 Figure 5381: DNA329941, NM\_001552, NM\_001552.at  
 Figure 5382: PRO85249  
 Figure 5383A-B: DNA345174, NM\_001558, NM\_001558.at  
 Figure 5384: PRO2536

Figure 5385A-B: DNA345175, NM\_001559, NM\_001559.at  
 Figure 5386: PRO23394  
 Figure 5387: DNA218677, L12964, NM\_001561.at  
 Figure 5388: PRO34455  
 Figure 5389: DNA82362, NM\_001565, NM\_001565.at  
 Figure 5390: PRO1718  
 Figure 5391A-B: DNA226364, NP\_001612.1, NM\_001621.at  
 Figure 5392: PRO36827  
 Figure 5393: DNA88076, NM\_001637, NM\_001637.at  
 Figure 5394: PRO2640  
 Figure 5395: DNA188736, U00115, NM\_001706.at  
 Figure 5396: PRO26296  
 Figure 5397A-B: DNA83031, NM\_001746, NM\_001746.at  
 Figure 5398: PRO2564  
 Figure 5399: DNA150725, NM\_001747, NM\_001747.at  
 Figure 5400: PRO12792  
 Figure 5401: DNA227480, NP\_001739.1, NM\_001748.at  
 Figure 5402: PRO37943  
 Figure 5403: DNA345176, 348151.15, NM\_001759.at  
 Figure 5404: PRO95684  
 Figure 5405: DNA103588, L27706, NM\_001762.at  
 Figure 5406: PRO4912  
 Figure 5407: DNA75526, NM\_001767, NM\_001767.at  
 Figure 5408: PRO2013  
 Figure 5409: DNA328387, NM\_001769, NM\_001769.at  
 Figure 5410: PRO4769  
 Figure 5411: DNA226380, NM\_001774, NM\_001774.at  
 Figure 5412: PRO4695  
 Figure 5413: DNA226234, NM\_001775, NM\_001775.at  
 Figure 5414: PRO36697  
 Figure 5415: DNA328522, NM\_001778, NM\_001778.at  
 Figure 5416: PRO2696  
 Figure 5417: DNA226436, NM\_001781, NM\_001781.at  
 Figure 5418: PRO36899  
 Figure 5419: DNA227573, NP\_001780.1, NM\_001789.at  
 Figure 5420: PRO38036  
 Figure 5421: DNA329940, NM\_001814, NM\_001814.at  
 Figure 5422: PRO2679  
 Figure 5423: DNA225671, NM\_001831, NM\_001831.at  
 Figure 5424: PRO36134  
 Figure 5425: DNA196361, NM\_001837, NM\_001837.at  
 Figure 5426: PRO24864

WO 2005/019258

PCT/US2004/025788

Figure 5427: DNA88224, NM\_001838, NM\_001838.at  
 Figure 5428: PRO2236  
 Figure 5429: DNA227606, NM\_001881, NM\_001881.at  
 Figure 5430: PRO38069  
 Figure 5431: DNA225804, DNA225804, NM\_001908.at  
 Figure 5432: PRO3344  
 Figure 5433: DNA225661, NP\_001944.1, NM\_001953.at  
 Figure 5434: PRO36124  
 Figure 5435: DNA226872, NM\_001964, NM\_001964.at  
 Figure 5436: PRO37335  
 Figure 5437: DNA325595, NP\_001966.1, NM\_001975.at  
 Figure 5438: PRO38010  
 Figure 5439: DNA226133, NM\_001992, NM\_001992.at  
 Figure 5440: PRO36596  
 Figure 5441: DNA226892, DNA226892, NM\_002053.at  
 Figure 5442: PRO12478  
 Figure 5443: DNA88352, NM\_002076, NM\_002076.at  
 Figure 5444: PRO2759  
 Figure 5445: DNA88374, NM\_002104, NM\_002104.at  
 Figure 5446: PRO2768  
 Figure 5447: DNA151752, NM\_002133, NM\_002133.at  
 Figure 5448: PRO12886  
 Figure 5449: DNA228014, NM\_002162, NM\_002162.at  
 Figure 5450: PRO38477  
 Figure 5451A-B: DNA345177, NP\_002173.1, NM\_002182.at  
 Figure 5452: PRO6177  
 Figure 5453: DNA345178, NM\_002185, NM\_002185.at  
 Figure 5454: PRO95685  
 Figure 5455: DNA345179, NM\_002186, NM\_002186.at  
 Figure 5456: PRO64957  
 Figure 5457: DNA345180, NM\_002188, NM\_002188.at  
 Figure 5458: PRO95686  
 Figure 5459A-B: DNA220744, NP\_002194.1, NM\_002203.at  
 Figure 5460: PRO34722  
 Figure 5461A-B: DNA88423, NP\_002200.1, NM\_002209.at  
 Figure 5462: PRO2784  
 Figure 5463A-B: DNA325306, NM\_002211, NM\_002211.at  
 Figure 5464: PRO81851  
 Figure 5465: DNA345181, NP\_689926.1, NM\_002219.at  
 Figure 5466: PRO95687  
 Figure 5467A-C: DNA328811, D26070, NM\_002222.at  
 Figure 5468: PRO84551  
 Figure 5469: DNA226359, DNA226359, NM\_002228.at  
 Figure 5470: PRO36822  
 Figure 5471: DNA103320, NM\_002229, NM\_002229.at  
 Figure 5472: PRO4650  
 Figure 5473: DNA345182, NM\_002250, NM\_002250.at  
 Figure 5474: PRO4787  
 Figure 5475: DNA150971, NM\_002258, NM\_002258.at  
 Figure 5476: PRO12564  
 Figure 5477: DNA226427, NM\_002260, NM\_002260.at  
 Figure 5478: PRO36890  
 Figure 5479A-B: DNA345183, AJ000673, NM\_002262.at  
 Figure 5480: DNA345184, BC036703, NM\_002265.at  
 Figure 5481: PRO82739  
 Figure 5482: DNA288243, NM\_002286, NM\_002286.at  
 Figure 5483: PRO36451  
 Figure 5484A-B: DNA188301, NM\_002309, NM\_002309.at  
 Figure 5485: PRO21834  
 Figure 5486: DNA151012, NM\_009588, NM\_002341.at  
 Figure 5487: PRO11604  
 Figure 5488A-B: DNA196641, NM\_002349, NM\_002349.at  
 Figure 5489: PRO25114  
 Figure 5490: DNA103245, M16038, NM\_002350.at  
 Figure 5491: PRO4575  
 Figure 5492: DNA227033, NM\_002371, NM\_002371.at  
 Figure 5493: PRO37496  
 Figure 5494: DNA345185, NP\_002380.3, NM\_002389.at  
 Figure 5495: PRO95689  
 Figure 5496: DNA103554, J03569, NM\_002394.at  
 Figure 5497: PRO4881  
 Figure 5498: DNA97290, NM\_002512, NM\_002512.at  
 Figure 5499: PRO3637  
 Figure 5500: DNA88035, NM\_002526, NM\_002526.at  
 Figure 5501: PRO2135  
 Figure 5502: DNA345186, NM\_175080, NM\_002561.at  
 Figure 5503: PRO95690  
 Figure 5504A-B: DNA329120, NM\_002569, NM\_002569.at  
 Figure 5505: PRO2752  
 Figure 5506: DNA83130, NM\_002674, NM\_002674.at

WO 2005/019258

PCT/US2004/025788

Figure 5507: PRO2096  
Figure 5508: DNA345187, NP\_002698.1, NM\_002707.at  
Figure 5509: DNA227090, NP\_002750.1, NM\_002759.at  
Figure 5510: PRO37553  
Figure 5511: DNA345188, NP\_002795.2, NM\_002804.at  
Figure 5512: PRO81979  
Figure 5513A-B: DNA345189, NM\_002844, NM\_002844.at  
Figure 5514: PRO95691  
Figure 5515: DNA227063, NM\_002858, NM\_002858.at  
Figure 5516: PRO37526  
Figure 5517: DNA219225, NP\_002874.1, NM\_002883.at  
Figure 5518: PRO34531  
Figure 5519: DNA88607, NP\_002892.1, NM\_002901.at  
Figure 5520: PRO2863  
Figure 5521: DNA103281, NM\_002908, NM\_002908.at  
Figure 5522: PRO4611  
Figure 5523: DNA216508, NM\_002981, NM\_002981.at  
Figure 5524: PRO34260  
Figure 5525: DNA192060, NM\_002983, NM\_002983.at  
Figure 5526: PRO21960  
Figure 5527: DNA216689, NM\_002984, NM\_002984.at  
Figure 5528: PRO34276  
Figure 5529: DNA329241, NP\_003002.1, NM\_003011.at  
Figure 5530: PRO84846  
Figure 5531: DNA329005, NM\_003037, NM\_003037.at  
Figure 5532: PRO12612  
Figure 5533A-B: DNA326573, NP\_003063.2, NM\_003072.at  
Figure 5534: PRO82935  
Figure 5535: DNA345190, NM\_139276, NM\_003150.at  
Figure 5536: PRO95692  
Figure 5537: DNA227447, X59871, NM\_003202.at  
Figure 5538: PRO37910  
Figure 5539A-B: DNA226536, X01060, NM\_003234.at  
Figure 5540: PRO36999  
Figure 5541A-B: DNA83176, NM\_003243, NM\_003243.at  
Figure 5542: PRO2620  
Figure 5543: DNA227874, NM\_003329, NM\_003329.at  
Figure 5544: PRO38337

Figure 5545: DNA103421, NP\_003366.1, NM\_003375.at  
Figure 5546: PRO4749  
Figure 5547: DNA345191, X71635, NM\_003467.at  
Figure 5548: PRO4516  
Figure 5549: DNA304489, NM\_003504, NM\_003504.at  
Figure 5550: PRO71058  
Figure 5551: DNA227239, NM\_003506, NM\_003506.at  
Figure 5552: PRO37702  
Figure 5553: DNA150990, X84958, NM\_003641.at  
Figure 5554: PRO12570  
Figure 5555: DNA333697, NM\_003650, NM\_003650.at  
Figure 5556: PRO88328  
Figure 5557: DNA151802, AB004066, NM\_003670.at  
Figure 5558: PRO12890  
Figure 5559: DNA227213, NP\_003671.1, NM\_003680.at  
Figure 5560: PRO37676  
Figure 5561: DNA228010, NM\_003688, NM\_003688.at  
Figure 5562: PRO38473  
Figure 5563: DNA345192, U88326, NM\_003745.at  
Figure 5564: PRO12771  
Figure 5565: DNA345193, NM\_148974, NM\_003790.at  
Figure 5566: PRO95693  
Figure 5567: DNA227921, NM\_003798, NM\_003798.at  
Figure 5568: PRO38384  
Figure 5569: DNA345194, NP\_003798.2, NM\_003807.at  
Figure 5570: PRO5810  
Figure 5571: DNA84130, U37518, NM\_003810.at  
Figure 5572: PRO1096  
Figure 5573A-B: DNA200236, NP\_003807.1, NM\_003816.at  
Figure 5574: PRO34137  
Figure 5575: DNA345195, NM\_003839, NM\_003839.at  
Figure 5576: PRO20114  
Figure 5577: DNA345196, NM\_003853, NM\_003853.at  
Figure 5578: PRO36013  
Figure 5579: DNA345197, NM\_003855, NM\_003855.at  
Figure 5580: PRO4778  
Figure 5581: DNA325749, NP\_003868.1, NM\_003877.at  
Figure 5582: PRO12839  
Figure 5583: DNA331776, NM\_003897, NM\_003897.at  
Figure 5584: PRO84760  
Figure 5585: DNA227329, NP\_004031.1,

WO 2005/019258

PCT/US2004/025788

NM\_004040.at  
 Figure 5586: PRO37792  
 Figure 5587: DNA328570, NM\_004049, NM\_004049.at  
 Figure 5588: PRO37843  
 Figure 5589: DNA88173, S93414, NM\_004079.at  
 Figure 5590: PRO2210  
 Figure 5591: DNA103208, NM\_004099, NM\_004099.at  
 Figure 5592: PRO4538  
 Figure 5593: DNA287620, NM\_004131, NM\_004131.at  
 Figure 5594: PRO2081  
 Figure 5595: DNA227562, NP\_004139.1, NM\_004148.at  
 Figure 5596: PRO38025  
 Figure 5597: DNA331392, NM\_004195, NM\_004195.at  
 Figure 5598: PRO364  
 Figure 5599: DNA103394, U81800, NM\_004207.at  
 Figure 5600: PRO4722  
 Figure 5601: DNA345198, NP\_004212.3, NM\_004221.at  
 Figure 5602: PRO95694  
 Figure 5603: DNA345199, NP\_004224.1, NM\_004233.at  
 Figure 5604: PRO2225  
 Figure 5605: DNA329130, NP\_004286.2, NM\_004295.at  
 Figure 5606: PRO20124  
 Figure 5607: DNA287240, NM\_004335, NM\_004335.at  
 Figure 5608: PRO29371  
 Figure 5609: DNA329008, NP\_004337.2, NM\_004346.at  
 Figure 5610: PRO12832  
 Figure 5611: DNA226578, U47414, NM\_004354.at  
 Figure 5612: PRO37041  
 Figure 5613: DNA345200, NP\_620599.1, NM\_004357.at  
 Figure 5614: PRO95695  
 Figure 5615A-B: DNA151420, NM\_004430, NM\_004430.at  
 Figure 5616: PRO12876  
 Figure 5617: DNA328541, NM\_004512, NM\_004512.at  
 Figure 5618: PRO4843  
 Figure 5619A-C: DNA345201, NP\_757366.1, NM\_004513.at  
 Figure 5620: PRO95696  
 Figure 5621: DNA328262, U57094, NM\_004580.at  
 Figure 5622: PRO84153  
 Figure 5623: DNA226737, NM\_004585, NM\_004585.at  
 Figure 5624: PRO37200  
 Figure 5625A-B: DNA345202, NM\_033300,

NM\_004631.at  
 Figure 5626: PRO95697  
 Figure 5627: DNA227700, NM\_004778, NM\_004778.at  
 Figure 5628: PRO38163  
 Figure 5629: DNA151675, NM\_004800, NM\_004800.at  
 Figure 5630: PRO11975  
 Figure 5631: DNA345203, NM\_004810, NM\_004810.at  
 Figure 5632: PRO12190  
 Figure 5633: DNA345204, AJ420587, NM\_004830.at  
 Figure 5634: PRO95698  
 Figure 5635: DNA345205, AL117422, NM\_004844.at  
 Figure 5636: PRO95699  
 Figure 5637: DNA329010, NM\_004951, NM\_004951.at  
 Figure 5638: PRO23370  
 Figure 5639: DNA227563, NP\_004946.1, NM\_004955.at  
 Figure 5640: PRO38026  
 Figure 5641A-B: DNA103316, M54968, NM\_004985.at  
 Figure 5642: PRO4646  
 Figure 5643: DNA151043, NP\_005004.1, NM\_005013.at  
 Figure 5644: PRO12099  
 Figure 5645: DNA227909, NP\_005024.1, NM\_005033.at  
 Figure 5646: PRO38372  
 Figure 5647: DNA227124, NM\_005127, NM\_005127.at  
 Figure 5648: PRO37587  
 Figure 5649: DNA328264, NM\_005192, NM\_005192.at  
 Figure 5650: PRO12087  
 Figure 5651: DNA329159, NP\_005195.2, NM\_005204.at  
 Figure 5652: PRO4660  
 Figure 5653: DNA88259, L15006, NM\_005214.at  
 Figure 5654: PRO2254  
 Figure 5655: DNA189700, NM\_005252, NM\_005252.at  
 Figure 5656: PRO25619  
 Figure 5657: DNA325989, NP\_005304.3, NM\_005313.at  
 Figure 5658: PRO2732  
 Figure 5659: DNA225961, NM\_005317, NM\_005317.at  
 Figure 5660: PRO36424  
 Figure 5661: DNA196628, NM\_005327, NM\_005327.at  
 Figure 5662: PRO25105  
 Figure 5663: DNA227208, AF055377, NM\_005360.at  
 Figure 5664: PRO37671  
 Figure 5665: DNA103269, NP\_005366.1,

WO 2005/019258

PCT/US2004/025788

NM\_005375.at  
 Figure 5666: PRO4599  
 Figure 5667: DNA188207, D28124, NM\_005380.at  
 Figure 5668: PRO21719  
 Figure 5669: DNA153752, NP\_005372.1, NM\_005381.at  
 Figure 5670: PRO12926  
 Figure 5671: DNA227376, NP\_005393.1, NM\_005402.at  
 Figure 5672: PRO37839  
 Figure 5673A-B: DNA331302, NP\_005424.1, NM\_005433.at  
 Figure 5674: PRO12922  
 Figure 5675: DNA88410, NM\_005534, NM\_005534.at  
 Figure 5676: PRO2778  
 Figure 5677: DNA226262, NM\_005563, NM\_005563.at  
 Figure 5678: PRO36725  
 Figure 5679: DNA333671, NM\_005601, NM\_005601.at  
 Figure 5680: PRO37543  
 Figure 5681: DNA150427, NM\_005608, NM\_005608.at  
 Figure 5682: PRO12243  
 Figure 5683: DNA345206, NM\_005627, NM\_005627.at  
 Figure 5684: PRO86741  
 Figure 5685: DNA226500, NM\_005628, NM\_005628.at  
 Figure 5686: PRO36963  
 Figure 5687: DNA329013, NM\_005658, NM\_005658.at  
 Figure 5688: PRO20128  
 Figure 5689: DNA226610, M80254, NM\_005729.at  
 Figure 5690: PRO37073  
 Figure 5691A-B: DNA345207, NM\_133482, NM\_005732.at  
 Figure 5692: PRO95700  
 Figure 5693: DNA88541, NM\_005746, NM\_005746.at  
 Figure 5694: PRO2834  
 Figure 5695: DNA93548, NM\_005767, NM\_005767.at  
 Figure 5696: PRO4929  
 Figure 5697: DNA227695, AF097358, NM\_005810.at  
 Figure 5698: PRO38158  
 Figure 5699: DNA150959, NM\_005822, NM\_005822.at  
 Figure 5700: PRO11599  
 Figure 5701: DNA328516, NM\_005842, NM\_005842.at  
 Figure 5702: PRO12323  
 Figure 5703: DNA151825, NM\_005900, NM\_005900.at  
 Figure 5704: PRO12900  
 Figure 5705: DNA345208, NM\_130439, NM\_005962.at  
 Figure 5706: PRO95701  
 Figure 5707: DNA328266, NM\_006002, NM\_006002.at  
 Figure 5708: PRO12125  
 Figure 5709: DNA225959, NM\_006144, NM\_006144.at  
 Figure 5710: PRO36422  
 Figure 5711: DNA28759, NM\_006159, NM\_006159.at  
 Figure 5712: PRO2520  
 Figure 5713: DNA329015, NP\_006155.2, NM\_006164.at  
 Figure 5714: PRO84691  
 Figure 5715A-B: DNA151841, M59465, NM\_006290.at  
 Figure 5716: PRO12904  
 Figure 5717: DNA103371, NP\_006361.1, NM\_006370.at  
 Figure 5718: PRO4701  
 Figure 5719: DNA189708, AF155568, NM\_006372.at  
 Figure 5720: PRO23166  
 Figure 5721: DNA150430, NM\_006396, NM\_006396.at  
 Figure 5722: PRO12770  
 Figure 5723: DNA227112, NM\_006406, NM\_006406.at  
 Figure 5724: PRO37575  
 Figure 5725: DNA227795, NM\_006429, NM\_006429.at  
 Figure 5726: PRO38258  
 Figure 5727: DNA329225, NM\_006495, NM\_006495.at  
 Figure 5728: PRO84833  
 Figure 5729: DNA226277, X91790, NM\_006499.at  
 Figure 5730: PRO36740  
 Figure 5731: DNA103253, NP\_006507.1, NM\_006516.at  
 Figure 5732: PRO4583  
 Figure 5733A-B: DNA331802, AF012108, NM\_006534.at  
 Figure 5734: PRO86743  
 Figure 5735: DNA93439, Y13248, NM\_006564.at  
 Figure 5736: PRO4515  
 Figure 5737: DNA227751, NM\_006566, NM\_006566.at  
 Figure 5738: PRO38214  
 Figure 5739A-B: DNA345209, NP\_006697.2, NM\_006706.at  
 Figure 5740: PRO95702  
 Figure 5741: DNA225836, U66142, NM\_006725.at  
 Figure 5742: PRO36299  
 Figure 5743: DNA226260, NP\_006760.1, NM\_006769.at  
 Figure 5744: PRO36723  
 Figure 5745: DNA227190, NP\_006830.1, NM\_006839.at  
 Figure 5746: PRO37653  
 Figure 5747: DNA324897, NM\_006854,

WO 2005/019258

PCT/US2004/025788

NM\_006854.at  
Figure 5748: PRO12468  
Figure 5749A-B: DNA103449, NM\_006931, NM\_006931.at  
Figure 5750: PRO4776  
Figure 5751: DNA324805, NM\_007047, NM\_007047.at  
Figure 5752: PRO81419  
Figure 5753: DNA328271, NM\_007057, NM\_007057.at  
Figure 5754: PRO81868  
Figure 5755: DNA329189, NM\_007208, NM\_007208.at  
Figure 5756: PRO4911  
Figure 5757: DNA103440, NM\_007360, NM\_007360.at  
Figure 5758: PRO4767  
Figure 5759A-B: DNA345210, BC028412, NM\_012081.at  
Figure 5760: PRO37794  
Figure 5761: DNA326809, NM\_012112, NM\_012112.at  
Figure 5762: PRO83142  
Figure 5763A-B: DNA151707, NP\_036273.1, NM\_012141.at  
Figure 5764: PRO12884  
Figure 5765: DNA345211, NM\_012449, NM\_012449.at  
Figure 5766: PRO28528  
Figure 5767: DNA150621, NM\_012463, NM\_012463.at  
Figure 5768: PRO12374  
Figure 5769: DNA331485, NM\_012483, NM\_012483.at  
Figure 5770: PRO86529  
Figure 5771: DNA331519, NM\_012485, NM\_012484.at  
Figure 5772: PRO86551  
Figure 5773: DNA227302, NM\_013269, NM\_013269.at  
Figure 5774: PRO37765  
Figure 5775: DNA225594, NM\_013272, NM\_013272.at  
Figure 5776: PRO36057  
Figure 5777: DNA103481, NP\_037417.1, NM\_013285.at  
Figure 5778: PRO4808  
Figure 5779: DNA196426, NM\_013308, NM\_013308.at  
Figure 5780: PRO24924  
Figure 5781: DNA227125, AF132297, NM\_013324.at  
Figure 5782: PRO37588  
Figure 5783: DNA150648, NM\_013332, NM\_013332.at  
Figure 5784: PRO11576  
Figure 5785: DNA345212, AB025219, NM\_013416.at

Figure 5786: PRO84354  
Figure 5787: DNA345213, NM\_014044, NM\_014044.at  
Figure 5788: PRO95703  
Figure 5789A-C: DNA227619, NM\_014112, NM\_014112.at  
Figure 5790: PRO38082  
Figure 5791: DNA331817, NM\_014339, NM\_014339.at  
Figure 5792: PRO86240  
Figure 5793: DNA227351, AF191020, NM\_014367.at  
Figure 5794: PRO37814  
Figure 5795: DNA329546, NM\_014399, NM\_014399.at  
Figure 5796: PRO296  
Figure 5797: DNA330084, NM\_014450, NM\_014450.at  
Figure 5798: PRO9895  
Figure 5799: DNA227252, U96628, NM\_014456.at  
Figure 5800: PRO37715  
Figure 5801A-B: DNA277809, D87465, NM\_014767.at  
Figure 5802: PRO64556  
Figure 5803A-B: DNA151685, NP\_055610.1, NM\_014795.at  
Figure 5804: PRO12883  
Figure 5805A-B: DNA227353, NM\_014822, NM\_014822.at  
Figure 5806: PRO37816  
Figure 5807: DNA150805, NM\_014888, NM\_014888.at  
Figure 5808: PRO11583  
Figure 5809: DNA103333, NM\_014890, NM\_014890.at  
Figure 5810: PRO4663  
Figure 5811: DNA328274, NM\_014891, NM\_014891.at  
Figure 5812: PRO12912  
Figure 5813A-B: DNA304464, NM\_014918, NM\_014918.at  
Figure 5814: PRO71042  
Figure 5815A-B: DNA345214, NP\_619520.1, NM\_014966.at  
Figure 5816: PRO12282  
Figure 5817: DNA330103, NM\_015364, NM\_015364.at  
Figure 5818: PRO19671  
Figure 5819: DNA345215, NM\_015392, NM\_015392.at  
Figure 5820: PRO95704  
Figure 5821: DNA226662, NP\_057043.1, NM\_015959.at  
Figure 5822: PRO37125  
Figure 5823: DNA330096, NM\_015967, NM\_015967.at  
Figure 5824: PRO37163

WO 2005/019258

PCT/US2004/025788

Figure 5825A-B: DNA345216, AF077041,  
NM\_016081.at  
Figure 5826: PRO95705  
Figure 5827: DNA328831, NM\_016245,  
NM\_016245.at  
Figure 5828: PRO233  
Figure 5829: DNA227352, AF110777, NM\_016283.at  
Figure 5830: PRO37815  
Figure 5831: DNA330421, NM\_016354,  
NM\_016354.at  
Figure 5832: PRO85626  
Figure 5833A-B: DNA328454, NM\_016441,  
NM\_016441.at  
Figure 5834: PRO4330  
Figure 5835: DNA345217, NP\_057546.1,  
NM\_016462.at  
Figure 5836: PRO23604  
Figure 5837: DNA227364, NP\_057635.1,  
NM\_016551.at  
Figure 5838: PRO37827  
Figure 5839: DNA326550, NM\_016579,  
NM\_016579.at  
Figure 5840: PRO224  
Figure 5841: DNA327869, NM\_016588,  
NM\_016588.at  
Figure 5842: PRO1898  
Figure 5843: DNA227187, NM\_016619,  
NM\_016619.at  
Figure 5844: PRO37650  
Figure 5845: DNA326078, NM\_016641,  
NM\_016641.at  
Figure 5846: PRO38464  
Figure 5847: DNA227294, NM\_017755,  
NM\_017755.at  
Figure 5848: PRO37757  
Figure 5849: DNA226633, NM\_017906,  
NM\_017906.at  
Figure 5850: PRO37096  
Figure 5851: DNA336491, AK027630, NM\_018092.at  
Figure 5852: PRO4401  
Figure 5853A-B: DNA345218, BC034607,  
NM\_018123.at  
Figure 5854: PRO95706  
Figure 5855: DNA227194, NM\_018295,  
NM\_018295.at  
Figure 5856: PRO37657  
Figure 5857: DNA226227, NM\_018402,  
NM\_018402.at  
Figure 5858: PRO36690  
Figure 5859: DNA287642, NM\_018464,  
NM\_018464.at  
Figure 5860: PRO9902  
Figure 5861: DNA345219, AF116708, NM\_018630.at  
Figure 5862: DNA304494, AF212365, NM\_018725.at  
Figure 5863: PRO71061  
Figure 5864: DNA227929, NP\_061932.1,

NM\_019059.at  
Figure 5865: PRO38392  
Figure 5866: DNA227268, NP\_061955.1,  
NM\_019082.at  
Figure 5867: PRO37731  
Figure 5868: DNA226256, J00194, NM\_019111.at  
Figure 5869: PRO36719  
Figure 5870: DNA329552, NM\_019895,  
NM\_019895.at  
Figure 5871: PRO85097  
Figure 5872: DNA329074, NM\_020139,  
NM\_020139.at  
Figure 5873: PRO21326  
Figure 5874: DNA329553, NM\_020150,  
NM\_020150.at  
Figure 5875: PRO38313  
Figure 5876: DNA227280, NP\_064615.1,  
NM\_020230.at  
Figure 5877: PRO37743  
Figure 5878: DNA227720, NP\_065161.1,  
NM\_020428.at  
Figure 5879: PRO38183  
Figure 5880: DNA225636, NM\_020645,  
NM\_020645.at  
Figure 5881: PRO36099  
Figure 5882: DNA150992, NP\_066362.1,  
NM\_021034.at  
Figure 5883: PRO12572  
Figure 5884: DNA329023, NM\_021102,  
NM\_021102.at  
Figure 5885: PRO209  
Figure 5886: DNA227121, NM\_021105,  
NM\_021105.at  
Figure 5887: PRO37584  
Figure 5888: DNA345220, NM\_021129,  
NM\_021129.at  
Figure 5889: PRO11669  
Figure 5890A-B: DNA333179, AF231512,  
NM\_021618.at  
Figure 5891: PRO87901  
Figure 5892: DNA326379, NP\_067639.1,  
NM\_021626.at  
Figure 5893: PRO302  
Figure 5894: DNA345221, BC004348, NM\_021798.at  
Figure 5895: PRO10273  
Figure 5896: DNA331834, AF246221, NM\_021999.at  
Figure 5897: PRO86760  
Figure 5898: DNA304835, NP\_071327.1,  
NM\_022044.at  
Figure 5899: PRO71242  
Figure 5900: DNA330378, NM\_022346,  
NM\_022346.at  
Figure 5901: PRO81126  
Figure 5902: DNA328902, NM\_022355,  
NM\_022355.at  
Figure 5903: PRO84623



WO 2005/019258

PCT/US2004/025788

Figure 5904: DNA328895, NM\_022367, NM\_022367.at  
 Figure 5905: PRO1317  
 Figure 5906A-B: DNA329024, BAA25532.2, AB011178.at  
 Figure 5907: PRO84696  
 Figure 5908: DNA345222, NP\_612213.2, AF007152.at  
 Figure 5909: PRO95708  
 Figure 5910: DNA66487, NM\_002467, HSMYC1.at  
 Figure 5911: PRO1213  
 Figure 5912A-B: DNA325227, NP\_005338.1, HSRNABIP.at  
 Figure 5913: PRO81785  
 Figure 5914: DNA345223, Y00790, HSTCRGR.at  
 Figure 5915: PRO95709  
 Figure 5916: DNA103258, DNA103258, HSINTASA.at  
 Figure 5917: PRO4588  
 Figure 5918: DNA288259, NP\_114172.1, HUMCYCB.at  
 Figure 5919: PRO4676  
 Figure 5920A-B: DNA227134, NP\_000918.1, HUMMDR1.at  
 Figure 5921: PRO37597  
 Figure 5922: DNA329025, NM\_006208, HUMPC1Q1.at  
 Figure 5923: PRO4860  
 Figure 5924: DNA345224, X15260, HUMTCRGC.at  
 Figure 5925: DNA150552, AAB97011.1, AF040965.at  
 Figure 5926: PRO12326  
 Figure 5927: DNA331095, NP\_005216.1, HUME2F.at  
 Figure 5928: PRO86245  
 Figure 5929: DNA151041, DNA151041, P\_V84330.at  
 Figure 5930: PRO12849  
 Figure 5931: DNA329276, NM\_024096, AK024843.at  
 Figure 5932: PRO12104  
 Figure 5933: DNA151120, DNA151120, HUMP13KIN.at  
 Figure 5934: PRO12179  
 Figure 5935: DNA345225, NM\_138341, P\_Z29229.at  
 Figure 5936: PRO95710  
 Figure 5937: DNA345226, NP\_663781.1, AK024570.at  
 Figure 5938: PRO11652  
 Figure 5939: DNA287190, AL049943, HSM800284.at  
 Figure 5940: DNA345227, NP\_005660.1, HUMPOLLA.at  
 Figure 5941: PRO95711  
 Figure 5942: DNA151434, DNA151434, P\_X04382.at  
 Figure 5943: PRO11802  
 Figure 5944: DNA345228, NP\_079522.1, P\_V61478.at  
 Figure 5945: PRO95712  
 Figure 5946A-C: DNA345229, NM\_015293, AB018339.at  
 Figure 5947: PRO95713  
 Figure 5948: DNA345230, M12886, HUMTCBYY.at  
 Figure 5949: PRO95714  
 Figure 5950A-C: DNA302013, NM\_023037, HSU50534.at  
 Figure 5951: PRO71030  
 Figure 5952A-B: DNA328284, NP\_056356.1, P\_X37553.at  
 Figure 5953: PRO84160  
 Figure 5954A-B: DNA345231, 331792.1, HSM801131.at  
 Figure 5955: PRO24965  
 Figure 5956: DNA151774, DNA151774, P\_X85042.at  
 Figure 5957: PRO12052  
 Figure 5958A-B: DNA169926, DNA169926, AB032991.at  
 Figure 5959: PRO23259  
 Figure 5960A-B: DNA345232, NM\_006996, HSA237724.at  
 Figure 5961: PRO23299  
 Figure 5962A-B: DNA329269, AB007916, AB007916.at  
 Figure 5963A-B: DNA193917, AL050367, HSM800541.at  
 Figure 5964: DNA330906, NM\_032782, P\_A51904.at  
 Figure 5965: PRO86067  
 Figure 5966: DNA193996, DNA193996, P\_A40502.at  
 Figure 5967: PRO23400  
 Figure 5968: DNA194141, DNA194141, P\_X37431.at  
 Figure 5969: PRO23535  
 Figure 5970: DNA228132, AK027031, AK027031.at  
 Figure 5971: PRO38595  
 Figure 5972: DNA345233, AL136919, P\_Z51682.at  
 Figure 5973: PRO95715  
 Figure 5974: DNA328288, BC020517, AK022938.at  
 Figure 5975: PRO69876  
 Figure 5976: DNA345234, AK026962, AK026962.at  
 Figure 5977: PRO95716  
 Figure 5978: DNA331098, AY052405, AX047348.at  
 Figure 5979: PRO86248  
 Figure 5980: DNA345235, 221966.14, AI984778\_RC.at  
 Figure 5981: PRO95717  
 Figure 5982: DNA345236, 330869.67, AV762213.at  
 Figure 5983: PRO95718  
 Figure 5984: DNA210194, DNA210194, HSM802254.at  
 Figure 5985: DNA331856, BC022522, 237658.8.at  
 Figure 5986: PRO71209  
 Figure 5987: DNA194527, DNA194527, 399617.1.at  
 Figure 5988: PRO23884  
 Figure 5989: DNA345237, 196714.4, 196714.2.at  
 Figure 5990: PRO95719  
 Figure 5991: DNA345238, 001697.46, 001697.5.at  
 Figure 5992: PRO95720  
 Figure 5993: DNA345239, AAH35779.1, 399901.2.at

WO 2005/019258

PCT/US2004/025788

Figure 5994: PRO95721  
 Figure 5995: DNA338349, BC035900, 428335.22.at  
 Figure 5996: PRO91021  
 Figure 5997: DNA164635, DNA164635,  
 DNA164635.at  
 Figure 5998: DNA326749, NP\_116101.1,  
 DNA167237.at  
 Figure 5999: PRO23238  
 Figure 6000: DNA210622, NM\_015925,  
 NM\_015925.at  
 Figure 6001: PRO35016  
 Figure 6002: DNA345240, 098138.2, P\_Q74306.at  
 Figure 6003: PRO95722  
 Figure 6004: DNA330438, NM\_018556,  
 NM\_018556.at  
 Figure 6005: PRO50795  
 Figure 6006: DNA345241, NM\_018384,  
 NM\_018384.at  
 Figure 6007: PRO95723  
 Figure 6008: DNA254520, NM\_018482,  
 NM\_018482.at  
 Figure 6009: PRO49627  
 Figure 6010: DNA254470, NM\_002497,  
 NM\_002497.at  
 Figure 6011: PRO49578  
 Figure 6012A-B: DNA331400, NM\_018440,  
 NM\_018440.at  
 Figure 6013: PRO86464  
 Figure 6014: DNA254414, NP\_054898.1,  
 NM\_014179.at  
 Figure 6015: PRO49524  
 Figure 6016: DNA255340, NM\_017684,  
 NM\_017684.at  
 Figure 6017: PRO50409  
 Figure 6018: DNA253811, NP\_004410.2,  
 NM\_004419.at  
 Figure 6019: PRO49214  
 Figure 6020: DNA255921, NM\_000734,  
 NM\_000734.at  
 Figure 6021: PRO50974  
 Figure 6022: DNA345242, BC002342, NM\_014325.at  
 Figure 6023: PRO49875  
 Figure 6024: DNA255161, NM\_022147,  
 NM\_022147.at  
 Figure 6025: PRO50241  
 Figure 6026: DNA330123, NM\_007053,  
 NM\_007053.at  
 Figure 6027: PRO35080  
 Figure 6028: DNA327812, NM\_006417,  
 NM\_006417.at  
 Figure 6029: PRO83773  
 Figure 6030: DNA304717, NM\_000389,  
 NM\_000389.at  
 Figure 6031: PRO71143  
 Figure 6032: DNA328431, NM\_001826,  
 NM\_001826.at

Figure 6033: PRO45093  
 Figure 6034A-B: DNA333574, NM\_002829,  
 NM\_002829.at  
 Figure 6035: PRO88221  
 Figure 6036: DNA345243, L38616, NM\_004899.at  
 Figure 6037: PRO95724  
 Figure 6038: DNA287207, NM\_006325,  
 NM\_006325.at  
 Figure 6039: PRO39268  
 Figure 6040: DNA329172, NM\_005263,  
 NM\_005263.at  
 Figure 6041: PRO84796  
 Figure 6042: DNA345244, NP\_036229.1,  
 NM\_012097.at  
 Figure 6043: PRO71114  
 Figure 6044: DNA256257, NM\_014398,  
 NM\_014398.at  
 Figure 6045: PRO51301  
 Figure 6046A-B: DNA221079, NM\_022162,  
 NM\_022162.at  
 Figure 6047: PRO34753  
 Figure 6048: DNA255454, NP\_060834.1,  
 NM\_018364.at  
 Figure 6049: PRO50521  
 Figure 6050A-B: DNA254789, NM\_016217,  
 NM\_016217.at  
 Figure 6051: PRO49887  
 Figure 6052A-B: DNA254376, NM\_014963,  
 NM\_014963.at  
 Figure 6053: PRO49486  
 Figure 6054: DNA254214, NM\_001698,  
 NM\_001698.at  
 Figure 6055: PRO49326  
 Figure 6056: DNA345245, BC015815, NM\_006994.at  
 Figure 6057: PRO49242  
 Figure 6058: DNA253802, NP\_055569.1,  
 NM\_014754.at  
 Figure 6059: PRO49207  
 Figure 6060: DNA255269, AL110271, NM\_015462.at  
 Figure 6061: PRO50346  
 Figure 6062: DNA256521, NM\_013431,  
 NM\_013431.at  
 Figure 6063: PRO51556  
 Figure 6064A-B: DNA345246, NM\_138292,  
 NM\_000051.at  
 Figure 6065: PRO95725  
 Figure 6066: DNA256533, NM\_006114,  
 NM\_006114.at  
 Figure 6067: PRO51565  
 Figure 6068A-B: DNA287273, NM\_006444,  
 NM\_006444.at  
 Figure 6069: PRO69545  
 Figure 6070: DNA330223, NP\_001790.1,  
 NM\_001799.at  
 Figure 6071: PRO49730  
 Figure 6072: DNA254350, NM\_004052,

WO 2005/019258

PCT/US2004/025788

NM\_004052.at  
 Figure 6073: PRO49461  
 Figure 6074: DNA254163, S73813, NM\_001776.at  
 Figure 6075: PRO49277  
 Figure 6076: DNA328876, NP\_060582.1, NM\_018112.at  
 Figure 6077: PRO84603  
 Figure 6078: DNA329900, M87338, NM\_002914.at  
 Figure 6079: PRO81549  
 Figure 6080: DNA330040, NM\_078626, NM\_001262.at  
 Figure 6081: PRO59546  
 Figure 6082: DNA339592, NP\_071401.2, NM\_022118.at  
 Figure 6083: PRO91353  
 Figure 6084: DNA329575, NP\_004699.1, NM\_004708.at  
 Figure 6085: PRO61403  
 Figure 6086: DNA277083, M84489, NM\_002745.at  
 Figure 6087: PRO64127  
 Figure 6088: DNA327690, NM\_004031, NM\_004031.at  
 Figure 6089: PRO83673  
 Figure 6090: DNA272066, NM\_002940, NM\_002940.at  
 Figure 6091: PRO60337  
 Figure 6092: DNA345247, BC012125, NM\_022154.at  
 Figure 6093: PRO50332  
 Figure 6094A-B: DNA254616, NM\_004482, NM\_004482.at  
 Figure 6095: PRO49718  
 Figure 6096: DNA255402, NM\_014473, NM\_014473.at  
 Figure 6097: PRO50469  
 Figure 6098: DNA328296, NP\_061059.1, NM\_018589.at  
 Figure 6099: PRO51817  
 Figure 6100: DNA345248, NM\_006639, NM\_006639.at  
 Figure 6101: PRO34958  
 Figure 6102: DNA287241, NM\_015907, NM\_015907.at  
 Figure 6103: PRO69516  
 Figure 6104: DNA254380, NM\_020379, NM\_020379.at  
 Figure 6105: PRO49490  
 Figure 6106A-B: DNA345249, AAH38115.1, NM\_017631.at  
 Figure 6107: PRO95726  
 Figure 6108: DNA287221, NP\_057407.1, NM\_016323.at  
 Figure 6109: PRO69500  
 Figure 6110: DNA252224, AK025273, NM\_022073.at  
 Figure 6111: PRO48216  
 Figure 6112A-B: DNA254218, NP\_001914.2, NM\_001923.at

Figure 6113: PRO49330  
 Figure 6114: DNA329033, NM\_005384, NM\_005384.at  
 Figure 6115: PRO84700  
 Figure 6116A-C: DNA345250, NP\_002751.1, NM\_002760.at  
 Figure 6117: PRO59148  
 Figure 6118: DNA273060, NM\_001255, NM\_001255.at  
 Figure 6119: PRO61125  
 Figure 6120: DNA345251, NP\_694858.1, NM\_002270.at  
 Figure 6121: PRO60223  
 Figure 6122: DNA269750, NP\_002919.1, NM\_002928.at  
 Figure 6123: PRO58159  
 Figure 6124: DNA327927, NM\_013258, NM\_013258.at  
 Figure 6125: PRO57311  
 Figure 6126: DNA330057, NM\_005950, NM\_005950.at  
 Figure 6127: PRO85337  
 Figure 6128A-B: DNA345252, AL136911, NM\_016357.at  
 Figure 6129: PRO82143  
 Figure 6130: DNA329118, NM\_021874, NM\_021874.at  
 Figure 6131: PRO83123  
 Figure 6132A-B: DNA345253, NM\_174956, NM\_005173.at  
 Figure 6133: PRO95727  
 Figure 6134: DNA256737, NM\_017806, NM\_017806.at  
 Figure 6135: PRO51671  
 Figure 6136: DNA329253, NM\_006137, NM\_006137.at  
 Figure 6137: PRO84853  
 Figure 6138: DNA254570, NP\_055484.1, NM\_014669.at  
 Figure 6139: PRO49673  
 Figure 6140: DNA254416, NP\_060915.1, NM\_018445.at  
 Figure 6141: PRO49526  
 Figure 6142A-C: DNA328497, NM\_005502, NM\_005502.at  
 Figure 6143: PRO84319  
 Figure 6144A-B: DNA330366, NM\_022765, NM\_022765.at  
 Figure 6145: PRO85581  
 Figure 6146: DNA328471, NP\_005848.2, NM\_005857.at  
 Figure 6147: PRO84297  
 Figure 6148: DNA324742, NM\_001760, NM\_001760.at  
 Figure 6149: PRO81367  
 Figure 6150A-B: DNA255183, NM\_019027,

WO 2005/019258

PCT/US2004/025788

NM_019027.at	NM_005508.at
Figure 6151: PRO50262	Figure 6191: PRO85119
Figure 6152: DNA256141, AL353940, NM_018423.at	Figure 6192: DNA345261, NM_005290,
Figure 6153: PRO51189	NM_005290.at
Figure 6154: DNA255145, NM_018447,	Figure 6193: PRO54695
NM_018447.at	Figure 6194: DNA328915, NM_014241,
Figure 6155: PRO50225	NM_014241.at
Figure 6156: DNA256762, AK022882, NM_022451.at	Figure 6195: PRO84634
Figure 6157: PRO51695	Figure 6196: DNA256089, D88308, NM_003645.at
Figure 6158: DNA345254, NM_020437,	Figure 6197: PRO51139
NM_020437.at	Figure 6198: DNA255215, AF207600, NM_018638.at
Figure 6159: PRO86261	Figure 6199: PRO50294
Figure 6160: DNA329584, NP_005032.1,	Figure 6200A-B: DNA256807, NM_016255,
NM_005041.at	NM_016255.at
Figure 6161: PRO85118	Figure 6201: PRO51738
Figure 6162: DNA345255, AY184205, NM_015180.at	Figure 6202: DNA255213, DNA255213,
Figure 6163: PRO95728	NM_017780.at
Figure 6164: DNA327521, NM_002201,	Figure 6203: PRO50292
NM_002201.at	Figure 6204: DNA255386, NP_037518.1,
Figure 6165: PRO58320	NM_013386.at
Figure 6166: DNA331323, NM_001259,	Figure 6205: PRO50454
NM_001259.at	Figure 6206A-B: DNA254292, DNA254292,
Figure 6167: PRO86412	NM_004481.at
Figure 6168: DNA272655, NM_001827,	Figure 6207: PRO49403
NM_001827.at	Figure 6208: DNA260974, NM_006074,
Figure 6169: PRO60781	NM_006074.at
Figure 6170A-B: DNA345256, NP_665702.1,	Figure 6209: PRO54720
NM_004619.at	Figure 6210: DNA345262, NP_055118.1,
Figure 6171: PRO20111	NM_014303.at
Figure 6172: DNA345257, NM_003835,	Figure 6211: PRO49256
NM_003835.at	Figure 6212: DNA331119, NM_005442,
Figure 6173: PRO95729	NM_005442.at
Figure 6174: DNA345258, NM_002925,	Figure 6213: PRO50745
NM_002925.at	Figure 6214: DNA345263, NM_022468,
Figure 6175: PRO63255	NM_022468.at
Figure 6176: DNA345259, NM_006538,	Figure 6215: PRO51432
NM_006538.at	Figure 6216: DNA254543, NP_006799.1,
Figure 6177: PRO84980	NM_006808.at
Figure 6178: DNA270717, U31382, NM_004485.at	Figure 6217: PRO49648
Figure 6179: PRO59080	Figure 6218: DNA255088, NP_003249.1,
Figure 6180: DNA152786, NP_057215.1,	NM_003258.at
NM_016131.at	Figure 6219: PRO50174
Figure 6181: PRO10928	Figure 6220: DNA253798, NP_002632.1,
Figure 6182: DNA345260, NM_022168,	NM_002641.at
NM_022168.at	Figure 6221: PRO49203
Figure 6183: PRO95730	Figure 6222: DNA287425, NM_018509,
Figure 6184A-B: DNA327674, NM_002748,	NM_018509.at
NM_002748.at	Figure 6223: PRO69682
Figure 6185: PRO83661	Figure 6224: DNA295327, NM_021803,
Figure 6186: DNA325648, NP_037409.2,	NM_021803.at
NM_013277.at	Figure 6225: PRO70773
Figure 6187: PRO82139	Figure 6226: DNA273523, NP_002154.1,
Figure 6188: DNA256561, NM_019604,	NM_002163.at
NM_019604.at	Figure 6227: PRO61504
Figure 6189: PRO51592	Figure 6228: DNA271189, L22075, NM_006572.at
Figure 6190: DNA329585, NP_005499.1,	Figure 6229: PRO59506

WO 2005/019258

PCT/US2004/025788

Figure 6230: DNA333731, NP\_055165.1, NM\_014350.at  
 Figure 6231: PRO88357  
 Figure 6232: DNA325507, NP\_005842.1, NM\_005851.at  
 Figure 6233: PRO69461  
 Figure 6234: DNA294794, NM\_002870, NM\_002870.at  
 Figure 6235: PRO70754  
 Figure 6236: DNA328303, NP\_056525.1, NM\_015710.at  
 Figure 6237: PRO84173  
 Figure 6238: DNA345264, AL137399, NM\_006785.at  
 Figure 6239: DNA327858, AF120334, NM\_012341.at  
 Figure 6240: PRO83800  
 Figure 6241: DNA331122, NP\_005728.2, NM\_005737.at  
 Figure 6242: PRO86265  
 Figure 6243: DNA289528, NM\_004311, NM\_004311.at  
 Figure 6244: PRO70286  
 Figure 6245: DNA329123, NM\_002882, NM\_002882.at  
 Figure 6246: PRO84765  
 Figure 6247: DNA339428, NP\_057604.1, NM\_016520.at  
 Figure 6248: PRO91233  
 Figure 6249: DNA329038, NP\_055704.1, NM\_014889.at  
 Figure 6250: PRO84705  
 Figure 6251: DNA345265, NP\_004216.1, NM\_004225.at  
 Figure 6252: PRO95732  
 Figure 6253: DNA329587, NM\_012124, NM\_012124.at  
 Figure 6254: PRO85121  
 Figure 6255A-B: DNA329248, AB002359, AB002359.at  
 Figure 6256A-B: DNA255619, DNA255619, AF054589.at  
 Figure 6257: PRO50682  
 Figure 6258A-B: DNA330255, AK025499, HSM800958.at  
 Figure 6259: PRO85488  
 Figure 6260A-B: DNA255050, AL136883, HSM801851.at  
 Figure 6261: PRO50138  
 Figure 6262: DNA328529, NM\_001629, P\_Z36336.at  
 Figure 6263: PRO49814  
 Figure 6264A-B: DNA329039, NP\_056250.2, AK027070.at  
 Figure 6265: PRO84706  
 Figure 6266: DNA328509, NM\_006748, HSU44403.at  
 Figure 6267: PRO57996  
 Figure 6268: DNA345266, AF067023, NM\_001363.at  
 Figure 6269A-B: DNA345267, NM\_020453, AB040920.at  
 Figure 6270: PRO95734  
 Figure 6271A-B: DNA331898, AF058925, AF058925.at  
 Figure 6272: PRO86787  
 Figure 6273: DNA345268, NM\_032479, AF151109.at  
 Figure 6274: PRO84951  
 Figure 6275: DNA331901, AL117515, AB029015.at  
 Figure 6276: DNA256422, AJ227900, HSA227900.at  
 Figure 6277: DNA254610, Z48633, HSHRTPSN.at  
 Figure 6278: DNA345269, NM\_015660, HSM800796.at  
 Figure 6279: PRO95735  
 Figure 6280: DNA256846, NM\_017515, AK023080.at  
 Figure 6281: PRO51777  
 Figure 6282: DNA331902, NP\_619634.1, HSSOM172M.at  
 Figure 6283: PRO86790  
 Figure 6284: DNA329040, NP\_005524.1, HSU72882.at  
 Figure 6285: PRO84707  
 Figure 6286: DNA256796, AF083127, AF083127.at  
 Figure 6287: DNA345270, AAH06437.1, AK024476.at  
 Figure 6288: PRO82523  
 Figure 6289A-B: DNA256299, BAB21793.1, AB051489.at  
 Figure 6290: PRO51343  
 Figure 6291: DNA330259, NP\_008944.1, HSM801707.at  
 Figure 6292: PRO49366  
 Figure 6293: DNA331132, NM\_032148, HSM801796.at  
 Figure 6294: PRO86273  
 Figure 6295: DNA255964, NM\_024837, AK025125.at  
 Figure 6296: PRO51015  
 Figure 6297: DNA256061, NM\_030921, AF267864.at  
 Figure 6298: PRO51109  
 Figure 6299: DNA329078, NP\_112200.2, HSM801679.at  
 Figure 6300: PRO23253  
 Figure 6301: DNA345271, NP\_001275.1, NM\_001284.at  
 Figure 6302: PRO22838  
 Figure 6303: DNA304710, NM\_001540, NM\_001540.at  
 Figure 6304: PRO71136  
 Figure 6305: DNA330023, NM\_001924, NM\_001924.at  
 Figure 6306: PRO85308  
 Figure 6307: DNA275385, NM\_002094, NM\_002094.at  
 Figure 6308: PRO63048  
 Figure 6309: DNA328418, NM\_003407, NM\_003407.at  
 Figure 6310: PRO84261

WO 2005/019258

PCT/US2004/025788

Figure 6311: DNA345272, NM\_004128, NM\_004128.at  
 Figure 6312: PRO95736  
 Figure 6313: DNA331133, U63830, NM\_004180.at  
 Figure 6314: PRO86274  
 Figure 6315: DNA287203, NP\_006182.1, NM\_006191.at  
 Figure 6316: PRO69487  
 Figure 6317: DNA325920, NM\_012111, NM\_012111.at  
 Figure 6318: PRO82373  
 Figure 6319: DNA253807, NM\_020529, NM\_020529.at  
 Figure 6320: PRO49210  
 Figure 6321: DNA329925, NM\_001537, NM\_001537.at  
 Figure 6322: PRO85239  
 Figure 6323: DNA289526, NM\_004024, NM\_004024.at  
 Figure 6324: PRO70282  
 Figure 6325: DNA269766, NP\_005646.1, NM\_005655.at  
 Figure 6326: PRO58175  
 Figure 6327: DNA329047, NM\_006399, NM\_006399.at  
 Figure 6328: PRO58425  
 Figure 6329: DNA274167, AF026166, NM\_006431.at  
 Figure 6330: PRO62097  
 Figure 6331: DNA254572, NM\_006585, NM\_006585.at  
 Figure 6332: PRO49675  
 Figure 6333: DNA328591, NP\_006635.1, NM\_006644.at  
 Figure 6334: PRO84376  
 Figure 6335: DNA255289, NM\_014791, NM\_014791.at  
 Figure 6336: PRO50363  
 Figure 6337: DNA345273, X15183, HSHSP90R.at  
 Figure 6338: PRO95737  
 Figure 6339: DNA271847, NM\_001539, NM\_001539.at  
 Figure 6340: PRO60127  
 Figure 6341: DNA270929, M88279, NM\_002014.at  
 Figure 6342: PRO59262  
 Figure 6343: DNA329106, AF042081, NM\_003022.at  
 Figure 6344: PRO83360  
 Figure 6345: DNA345274, NM\_174886, NM\_003244.at  
 Figure 6346: PRO95738  
 Figure 6347: DNA253585, NM\_004418, NM\_004418.at  
 Figure 6348: PRO49183  
 Figure 6349A-B: DNA275334, NP\_112162.1, NM\_004749.at  
 Figure 6350: PRO63009  
 Figure 6351A-B: DNA270923, NM\_004817, NM\_004817.at  
 Figure 6352: PRO59256  
 Figure 6353: DNA345275, NM\_005572, NM\_005572.at  
 Figure 6354: PRO80660  
 Figure 6355A-B: DNA328473, NP\_006473.1, NM\_006482.at  
 Figure 6356: PRO84299  
 Figure 6357: DNA326736, NM\_006666, NM\_006666.at  
 Figure 6358: PRO83076  
 Figure 6359: DNA290235, NP\_057121.1, NM\_016037.at  
 Figure 6360: PRO70335  
 Figure 6361: DNA331135, D43950, HUMKG1DD.at  
 Figure 6362: DNA273498, DNA273498, HUMHSP70H.at  
 Figure 6363: PRO61480  
 Figure 6364: DNA270689, X58072, NM\_002051.at  
 Figure 6365: PRO59053  
 Figure 6366: DNA271973, NM\_002731, NM\_002731.at  
 Figure 6367: PRO60248  
 Figure 6368A-B: DNA345276, S65186, NM\_005546.at  
 Figure 6369: PRO95739  
 Figure 6370: DNA274202, NP\_006804.1, NM\_006813.at  
 Figure 6371: PRO62131  
 Figure 6372: DNA328601, NM\_015675, NM\_015675.at  
 Figure 6373: PRO84384  
 Figure 6374: DNA329050, NM\_015969, NM\_015969.at  
 Figure 6375: PRO84712  
 Figure 6376: DNA326116, NM\_016292, NM\_016292.at  
 Figure 6377: PRO82542  
 Figure 6378A-B: DNA329122, D87119, NM\_021643.at  
 Figure 6379: PRO84764  
 Figure 6380: DNA255418, L43575, HUMUNKN.at  
 Figure 6381: DNA345277, AK026038, AB046774.at  
 Figure 6382: PRO95740  
 Figure 6383: DNA339707, NP\_116119.1, P\_T31854.at  
 Figure 6384: PRO91437  
 Figure 6385: DNA328923, NM\_023003, AF255922.at  
 Figure 6386: PRO84640  
 Figure 6387: DNA345278, NM\_025006, AK023435.at  
 Figure 6388: PRO95741  
 Figure 6389: DNA255219, NP\_078936.1, AK026226.at  
 Figure 6390: PRO50298  
 Figure 6391: DNA345279, AAH14655.1, IR1875335.at  
 Figure 6392: PRO84549

WO 2005/019258

PCT/US2004/025788

Figure 6393: DNA256091, NM\_022102, AK024611.at  
 Figure 6394: PRO51141  
 Figure 6395: DNA254838, NM\_024628, AK026841.at  
 Figure 6396: PRO49933  
 Figure 6397: DNA330548, AK025645, AK025645.at  
 Figure 6398: PRO85732  
 Figure 6399: DNA329355, NM\_033280, P\_V40521.at  
 Figure 6400: PRO50434  
 Figure 6401A-B: DNA256267, AB046838, AB046838.at  
 Figure 6402: DNA327954, NM\_031458, P\_D00629.at  
 Figure 6403: PRO83879  
 Figure 6404: DNA255798, NM\_024989, AK022439.at  
 Figure 6405: PRO50853  
 Figure 6406: DNA329384, NM\_174921, P\_Z33372.at  
 Figure 6407: PRO84960  
 Figure 6408: DNA345280, AB089319, P\_Z24893.at  
 Figure 6409: PRO95742  
 Figure 6410: DNA255913, AL050125, HSM800425.at  
 Figure 6411: PRO50966  
 Figure 6412: DNA325379, NP\_116136.1, HSM800835.at  
 Figure 6413: PRO81913  
 Figure 6414: DNA254596, DNA254596, AF026941.at  
 Figure 6415: PRO49699  
 Figure 6416A-B: DNA254801, AL080209, HSM800735.at  
 Figure 6417: PRO49897  
 Figure 6418: DNA255700, DNA255700, HSM801128.at  
 Figure 6419A-B: DNA328853, NM\_020651, AF302505.at  
 Figure 6420: PRO84584  
 Figure 6421: DNA330854, AK023113, AK023113.at  
 Figure 6422: PRO86017  
 Figure 6423A-B: DNA345281, 198947.4, AK023271.at  
 Figure 6424: PRO6012  
 Figure 6425: DNA345282, 154551.19, 154551.10.at  
 Figure 6426: PRO95743  
 Figure 6427A-B: DNA345283, 1327517.49, 994387.65.at  
 Figure 6428: PRO95744  
 Figure 6429: DNA257363, NM\_032315, 203633.4.at  
 Figure 6430: PRO51950  
 Figure 6431: DNA345284, NM\_145810, 475113.7.at  
 Figure 6432: PRO69531  
 Figure 6433: DNA345285, 200333.3, 200333.3.CON.at  
 Figure 6434: PRO95745  
 Figure 6435: DNA304068, NP\_653250.1, 1091656.1.at  
 Figure 6436: PRO71035  
 Figure 6437A-B: DNA338079, AL831953, 337352.17.at  
 Figure 6438: PRO90959  
 Figure 6439: DNA258677, DNA258677, 404505.1.at  
 Figure 6440: DNA345286, 1452432.11, 359193.13.at  
 Figure 6441: PRO95746  
 Figure 6442A-B: DNA345287, NM\_032550, 481857.16.at  
 Figure 6443: PRO95747  
 Figure 6444: DNA259902, DNA259902, 475431.4.at  
 Figure 6445: PRO53832  
 Figure 6446: DNA345288, 1499607.2, 210883.2.at  
 Figure 6447: PRO95748  
 Figure 6448: DNA345289, 1449133.1, 109254.1.at  
 Figure 6449: PRO95749  
 Figure 6450: DNA345290, 332730.8, 332730.8.at  
 Figure 6451: PRO95750  
 Figure 6452: DNA345291, 407233.2, 407233.2.at  
 Figure 6453: PRO95751  
 Figure 6454: DNA345292, NM\_144601, 197670.7.at  
 Figure 6455: PRO95752  
 Figure 6456: DNA259663, DNA259663, 215119.2.at  
 Figure 6457: DNA345293, 408339.15, 221433.12.at  
 Figure 6458: PRO95753  
 Figure 6459: DNA287258, NP\_542786.1, 228321.19.at  
 Figure 6460: PRO52174  
 Figure 6461: DNA329626, 1089565.1, 1089565.1.at  
 Figure 6462: PRO85155  
 Figure 6463: DNA259852, DNA259852, 099349.1.at  
 Figure 6464: PRO53782

What is claimed:

1. Isolated nucleic acid comprising at least 80% nucleic acid sequence identity to a nucleotide sequence encoding the polypeptide as shown in any one of the SEQ ID NOs 1-6464.
2. Isolated nucleic acid comprising at least 80% nucleic acid sequence identity to a nucleotide sequence comprising the full-length coding sequence of the nucleotide sequence as shown in any one of the SEQ ID NOs 1-6464.
3. A vector comprising the nucleic acid of Claim 1.
4. The vector of Claim 3 operably linked to control sequences recognized by a host cell transformed with the vector.
5. A host cell comprising the vector of Claim 3.
6. The host cell of Claim 5, wherein said cell is a CHO cell, an *E.coli* cell or a yeast cell.
7. A process for producing a PRO polypeptide comprising culturing the host cell of Claim 6 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
8. An isolated polypeptide comprising at least 80% amino acid sequence identity to an amino acid sequence of the polypeptide as shown in any one of the SEQ ID NOs 1-6464.
9. A chimeric molecule comprising a polypeptide according to Claim 8 fused to a heterologous amino acid sequence.
10. The chimeric molecule of Claim 9, wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.
11. An antibody which specifically binds to a polypeptide according to Claim 8.
12. The antibody of Claim 11, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.
13. A composition of matter comprising (a) a polypeptide of Claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, in combination with a carrier.



14. The composition of matter of Claim 13, wherein said carrier is a pharmaceutically acceptable carrier.

15. The composition of matter of Claim 14 comprising a therapeutically effective amount of  
5 (a), (b), (c) or (d).

16. An article of manufacture, comprising:  
a container;  
a label on said container; and  
10 a composition of matter comprising (a) a polypeptide of Claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide, contained within said container; wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

17. A method of treating an immune related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of (a) a polypeptide of Claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide.

18. The method of Claim 17, wherein the immune related disorder is systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an idiopathic inflammatory myopathy, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, a demyelinating disease of the central or peripheral nervous system,  
25 idiopathic demyelinating polyneuropathy, Guillain-Barré syndrome, a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary disease, infectious or autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's disease, an autoimmune or immune-mediated skin disease, a bullous skin disease, erythema multiforme, contact dermatitis, psoriasis, an allergic disease, asthma, allergic rhinitis, atopic  
30 dermatitis, food hypersensitivity, urticaria, an immunologic disease of the lung, eosinophilic pneumonias, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, a transplantation associated disease, graft rejection or graft-versus-host-disease.

19. A method for determining the presence of a PRO polypeptide of the invention as described  
35 in any one of SEQ ID NOs 1-6464, in a sample suspected of containing said polypeptide, said method comprising exposing said sample to an anti-PRO antibody, where the and determining binding of said antibody to a component of said sample.

20. A method of diagnosing an immune related disease in a mammal, said method comprising  
40 detecting the level of expression of a gene encoding a PRO polypeptide of the invention as described in any

WO 2005/019258

PCT/US2004/025788

one of SEQ ID NOs 1-6464, (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of an immune related disease in the mammal from which the test tissue cells were obtained.

5

21. A method of diagnosing an immune related disease in a mammal, said method comprising (a) contacting a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of an immune related disease in the mammal from which the test tissue cells were obtained.

10

22. A method of identifying a compound that inhibits the activity of a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, said method comprising contacting cells which normally respond to said polypeptide with (a) said polypeptide and (b) a candidate compound, and determining the lack responsiveness by said cell to (a).

15

23. A method of identifying a compound that inhibits the expression of a gene encoding a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, said method comprising contacting cells which normally express said polypeptide with a candidate compound, and determining the lack of expression said gene.

20

24. The method of Claim 23, wherein said candidate compound is an antisense nucleic acid.

25

25. A method of identifying a compound that mimics the activity of a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, said method comprising contacting cells which normally respond to said polypeptide with a candidate compound, and determining the responsiveness by said cell to said candidate compound.

30

26. A method of stimulating the immune response in a mammal, said method comprising administering to said mammal an effective amount of a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, antagonist, wherein said immune response is stimulated.

27. A method of diagnosing an inflammatory immune response in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide of the invention as described in any one of SEQ ID NOs 1-6464, (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of an inflammatory immune response in the mammal from which the test tissue cells were obtained.

40